- 1 DIRECT EXAMINATION
- 2 BY MS. KASULIS:
- 3 Q Good morning, Mr. Richardson.
- 4 A Good morning.
- 5 Q So yesterday we spoke about Retrophin and the 2012 time
- 6 | period, now we'll talk about Retrophin in the 2013 time
- 7 period. During that time period, 2012 to 2013, who was
- 8 | controlling Retrophin?
- 9 A Martin Shkreli was certainly leading the company.
- 10 Q Who had access to Retrophin's bank accounts during that
- 11 time period?
- 12 A Martin.
- 13 Q Following the reverse merger that we spoke about
- 14 | yesterday, did you have any discussions with the defendant
- 15 | regarding the status of your investment in Retrophin?
- 16 A Yes, I did.
- 17 | Q So I'm showing you what is marked for identification as
- 18 | Government's Exhibit 122-38, tab 49 of your binder. It's --
- 19 | 122-39, I'm sorry.
- 20 A Bear with me. It's tab? I'm sorry.
- 21 Q Tab 49 of your binder.
- 22 A Thank you.
- 23 Q Do you recognize this document?
- 24 A Yes.
- 25 Q What is it?

- 1 A It is an e-mail from Martin telling us that our stock
- 2 certificates are available.
- 3 Q What is the date on this e-mail?
- 4 A Dated January 24, 2013.
- 5 MS. KASULIS: The Government moves this exhibit into
- 6 evidence.
- 7 MR. AGNIFILO: No objection.
- 8 THE COURT: We'll receive 122-39.
- 9 (Government Exhibit 122-39, was received in
- 10 evidence.)
- 11 Q This appears to be an e-mail from Mr. Shkreli to a number
- of receipts including yourself, Mr. Richardson?
- 13 A Yes.
- 14 Q The date is January 24, 2013?
- 15 A Yes.
- 16 Q It's regarding Retrophin stock certificates?
- 17 A Yes.
- 18 Q The first sentence reads, "You may now call our transfer
- 19 agent Standard Registrar and Transfer Company" -- with the
- 20 phone number -- "and request the FedEx of your stock
- 21 | certificates. Once you receive your certificates you may
- 22 deposit them at a brokerage of your choice at your
- 23 | convenience. The shares will be restricted from trading until
- 24 a registration statement is filed."
- 25 What does that mean to you, that the shares will be

- 1 restricted from trading?
- 2 A That there was a period of time that we, as investors,
- 3 have to hold them, not able to trade them.
- 4 Q If you look at the next paragraph, he states, "Of course
- 5 I trust there will not be any sellers whatsoever." Then goes
- 6 on to say, "In all seriousness, thank you for your support."
- 7 Did you feel any pressure from the defendant to not
- 8 | sell your Retrophin stock?
- 9 MR. AGNIFILO: Objection to the form of the
- 10 question.
- 11 THE COURT: Try to rephrase it Ms. Kasulis.
- 12 BY MS. KASULIS:
- 13 Q During this time period did you have any discussions with
- 14 | the defendant regarding selling your Retrophin stock?
- 15 A No, I did not.
- 16 Q Now I'm showing you what's been marked for identification
- 17 | as Government's Exhibit 122-97, it's tab 50 of your binder.
- 18 A Yes.
- 19 Q Do you recognize this document?
- 20 A Yes.
- 21 Q What is it?
- 22 A An e-mail exchange between myself and Martin.
- 23 Q What is the date on the exchange?
- 24 A Starts on the 7th of March, 2013.
- MS. KASULIS: The Government moves this exhibit into

- 1 evidence.
- 2 MR. AGNIFILO: It's one of new exhibits, I just have
- 3 to -- no objection.
- 4 THE COURT: We will receive Government's Exhibit
- 5 122-97.
- 6 (Government Exhibit 122-97, was received in
- 7 evidence.)
- 8 BY MS. KASULIS:
- 9 Q Mr. Richardson, if we could start with the first email
- 10 chronologically in the chain, March 7, 2013, from you to
- 11 Mr. Shkreli with a title, "clarify headline numbers." Can you
- 12 | read this, what you wrote in this e-mail to the jury?
- 13 A "Hi again M. I know you are sending me the
- 14 reconciliation of my monies with you from MSMB Capital through
- 15 to the present day. But I need to submit my Form 4 for the
- 16 | recent stock purchases is adding more urgency. Evan's team
- 17 | sent me back the Form 4 saying I hold 99,055 shares after the
- 18 1,000 I had purchased. Is that the common stock? I am
- 19 | holding preferred stock as well, but I don't have to record on
- 20 | the Form 4. I'm trying to see where my total value sits,
- 21 | knowing how well it grew from the MSMB fund and through the
- 22 | private Retrophin holding, where I know you kindly gave me an
- 23 extra stock along the way. I clearly have a lot more of the
- 24 99,000. I don't want to sign the Form 4 until I know the
- 25 | accurate picture. Please give me the overall picture so I

- 1 know how to submit the Form 4 correctly."
- 2 Q What is a Form 4?
- 3 A A Securities Exchange requirement to log how many, what
- 4 my shareholding is.
- 5 Q Had you just made another purchase of Retrophin stock, is
- 6 that what you're discussing, in part, in this e-mail?
- 7 A Yes. I additionally just purchased 1,000 shares myself.
- 8 Q If we go to the Mr. Shkreli's response.
- 9 A He says, "Yes, it is a lot more, let me do some work."
- 10 Q Do you respond to this e-mail?
- 11 A Yes. I say, "Good. I know I have north of 5 percent
- 12 | when it was 8 million shares. I know that was diluted when
- 13 the financing took us to 12 million. Look forward to
- 14 confirmation."
- 15 Q When you say, "I know I had north of 5 percent," what are
- 16 | you referring to there?
- 17 A Both verbal commitments that Martin had given me and the
- 18 | Capitalization Table, which said I would be getting 5 percent
- 19 of the company stock.
- 20 | Q When you refer to, "when the financing took us to
- 21 | 12 million, " what are you referring to there?
- 22 A We initially were operating with 8 million shares. And
- 23 | as you go out and sell more shares we went from 8 million to
- 24 | 12 million. So whatever percent I had will be slightly
- 25 diluted, slightly smaller, a piece of 12 million instead of a

SIDEBAR CONFERENCE

1 THE COURT: Can you work it out? 2 MR. AGNIFILO: We might be able to. So the 3 objection is, this is one of -- the format is different, one 4 of the Jackson Su emails that's been our position he stole. 5 But, so what we're going to do is this, I don't want to 6 interrupt the direct. It's harmless. But I don't want to 7 waive the objection by letting this in. What we'll do is put 8 it in then substitute, you probably have another one. 9 MS. SMITH: Just so it's clear, when Mr. Su was 10 copying and printing out these e-mails, obviously the MSMB 11 Capital e-mail address is one that, as we discussed early on, 12 was on the Retrophin servers. However, Mr. Shkreli, after he was terminated went back into the servers and deleted 13 14 documents. And not all of the documents with that e-mail 15 address remain on the server. I don't know whether or not we 16 are going to be able to get this off of the Retrophin server. 17 It's our position that this is an authentic 18 document. And Mr. Richardson can testify that he actually 19 received this document. It has his e-mail address on it. 20 understood the objection with Mr. Su, in part, because Mr. Su himself didn't send or receive this e-mail. He was watching 21 22 them pop up and printed them out. But whether or not we are 23 going to get this off of Retrophin servers is another question 24 because of the actions that the defendant himself took.

What about Mr. Richardson, does he have

THE COURT:

25

SIDEBAR CONFERENCE

1 | this e-mail change?

- 2 MS. KASULIS: I have to go back and look.
- MR. AGNIFILO: Here is what I'm happy to do. The

 only reason I'm objecting, I've made a legal objection and I

 don't want to waive it by letting it in but I also don't want

6 to interrupt the flow of the direct.

What I'm happy to do is, if you have another version of this, and you can swap it out later, you'll do that. If you don't have another version of it, without waiving my objection overall to the proprietary of the Su e-mails, I don't want to interrupt the trial obviously. We'll just let it come in with that understanding.

THE COURT: Well, all right. I don't know how you would propose to authentic this Su e-mail. The Government does have a difficult position if this fact what they say is correct, that Mr. Shkreli deleted e-mails from the servers where you would have otherwise not have an objection.

MR. AGNIFILO: I don't know that that's true. I'll work with them. I'm not going to object. I'm putting my objection here.

MS. SMITH: It may be that we can find another version.

MR. AGNIFILO: If you can, great; if you can't, without waiving the overall objection.

MS. KASULIS: This is the version that was clearest

RICHARDSON - DIRECT - KASULIS

- 1 (In open court.)
- 2 MR. AGNIFILO: With the understanding that we
- 3 discussed at sidebar, I waive the objection to this one
- 4 document.

7

- 5 THE COURT: All right. We will admit Government's
- 6 Exhibit 122-41.
- 8 BY MS. KASULIS:
- 9 Q Mr. Richardson if we could start with the earliest e-mail
- 10 | in this chain. This e-mail chain is between yourself and
- 11 Mr. Shkreli; is that right?
- 12 A Yes.
- 13 Q So it appears that this you sent an e-mail on March 13,
- 14 2013, to Mr. Shkreli and it's regarding candidate, you say,
- 15 | "Hi M. Hope the trip and presentation go well. I'm now back
- 16 | in NYC and had a good call with Marc Panoff. Let me know when
- 17 | you're back in NYC so I can debrief you on my thoughts. Save
- 18 travels S."
- 19 Who is Marc Panoff?
- 20 A One of the candidates I was interviewing for our Chief
- 21 | Financial Officer position.
- 22 Q If we go to Mr. Shkreli's response starting on the prior
- 23 page, the first page of the document.
- 24 A Yes.
- 25 Q Dated March 13, 2013, he states, "Just a reminder, we

- 1 have never given options or stock to anyone, something we are
- 2 | sorely overdue for." On the bottom he lists out you're first
- 3 MSMB Capital Management investment?
- 4 A Yes.
- 5 Q If you go to the top of the next page, zoom in on this
- 6 whole e-mail.
- 7 A Yes.
- 8 Q Mr. Shkreli appears to list out his accounting of your
- 9 various investments in MSMB Capital, and then Retrophin LLC do
- 10 you see that at the top portion here of the page?
- 11 A Yes.
- 12 | Q Is he states, "Total cash invested 460,000," and then
- 13 referring to the units of Retrophin owned, then in bold
- 14 | states, "122,916 total shares post conversion times \$4.90
- 15 | stock price equals \$602,288.40." Do you see that there?
- 16 A Yes.
- 17 Q So underneath that he writes, "So according to my math,
- 18 | you're missing about 25,000 shares." When he was referring to
- 19 | shares is he referring to Retrophin shares?
- 20 A Yes, he is.
- 21 Q He then write, "The company has never given stock out to
- 22 you, which I think is something overdue, perhaps even owed to
- 23 | you, and that we should discuss ASAP." What is your reaction
- 24 to seeing that the company had never given stock out to you?
- 25 A A little surprised, a little surprised. I'd been a Board

- 1 | member for a period of time. I was expecting some recognition
- 2 as a Board member, but we hadn't discussed it as a specific
- 3 number at that point.
- 4 Q And then you respond to this e-mail; is that correct,
- 5 Mr. Richardson?
- 6 A Yes.
- 7 Q What is the subject line here of this e-mail?
- 8 A "Major concern".
- 9 Q Was that actually different than the subject line for the
- 10 e-mail that Mr. Shkreli sent you that you're responding to?
- 11 A Yes, I had changed it.
- 12 Q Why did thank you change it to major concern?
- 13 A Because I felt the response here just given me, the one
- 14 | we reviewed, was significantly different than what he said to
- 15 | me even a few days earlier in talking about the 5 percent of
- 16 the company and talking about the aspects of the
- 17 | Capitalization Table.
- 18 Q Can you please read your e-mail that you sent to
- 19 Mr. Shkreli in response to his e-mail.
- 20 A "M, this is exactly why I had been asking for an accurate
- 21 | accounting for months. Your summary below is well off the
- 22 | mark, even at a factual level, and that's pushing the verbal
- 23 | and written commitments to the side for the moment. If your
- 24 | numbers below are to believe, then you're asking me to accept
- 25 | an actual loss on my investment since MSMB, and then have the

RICHARDSON - DIRECT - KASULIS

news compounded with zero upside from getting Retrophin from 1 2 day one, where I signed papers telling me we have potential 3 stock pricing before we went public" -- excuse me, 4 "preferential stock pricing before we went public. Also any 5 calculation of my investments into Retrophin as a public stock 6 would be need to be assessed at agreed initial strike price 7 which I recall was \$2 or 2.50 not 4.90. As a founding 8 investor how can there be no accurate record of my accumulated 9 investments? I'm at a dinner with friends but will send a 10 list of facts back to you in the morning, which will then need 11 to be tracked back to the market pricing decisions taken been 12 Retrophin each step of the way. This is a huge disappointment 13 to me and a lesson to me letting friendship drive blind faith. 14 And no, I haven't spoken with the transfer agent. I wanted an 15 accurate reconciliation of my stockholding before I did, 16 fearing you didn't have an accurate record." 17 When you write here, "This is a huge disappointment to me 18 and a lesson to me letting friendship drive blind faith," what 19 do you mean there? 20 I had raised this issue back at the point of our 21 Capitalization Table coming out when I first raised the 22 subject of Martin saying I really want to have a clear picture 23 of what my stockholdings are and the value of them. And so I 24 was blindly waiting from, I think November through to March, 25 expecting he'd give me an accurate response at this point.

- 1 | Q When you say not, "letting friendship drive blind faith,"
- 2 what do you mean by that?
- 3 A Again, trusting that he would be coming back to me at
- 4 this point with an accurate reflection of the stock I was
- 5 | holding per the Capitalization Table from late 2012.
- 6 Q Let's look at -- did Mr. Shkreli in fact respond to this
- 7 e-mail?
- 8 A Yes.
- 9 Q Let's look at that response.
- 10 A Yes, do you want me to read it?
- 11 Q I can read the first couple of sentences. "Yes,
- 12 Retrophin has not been a good investment in the last six
- 13 | months. There wasn't much we could do other than what we did.
- 14 There is some good news, we should be able to transfer some
- 15 | stock from Marek and myself to make sure everyone ends up a
- 16 | winner." When you saw the "Retrophin has not been a good
- 17 | investment in the last six months," what was your response to
- 18 that?
- 19 A I certainly knew given the strategic direction, that we
- 20 | had to move in a different direction, but I was surprised to
- 21 | see it written like that.
- 22 | Q Did you in fact send in your own accounting of your
- 23 | holdings in Retrophin to the defendant?
- 24 A Yes, I did.
- 25 Q I'm showing you what's been marked for identification as

- 1 Government's Exhibit 122-42, and it's tab 52 of your binder.
- 2 Do you recognize this exhibit, Mr. Richardson?
- 3 A Yes.
- 4 Q What is it?
- 5 A It is my own reconciliation starting to layout my
- 6 assessment of the facts on my stockholding in an e-mail
- 7 exchange with Martin.
- 8 MS. KASULIS: Government moves this exhibit into
- 9 evidence.
- MR. AGNIFILO: No objection.
- 11 THE COURT: We will receive Government's Exhibit
- 12 122-42.
- 13 (Government Exhibit 122-42, was received in
- 14 evidence.)
- 15 BY MS. KASULIS:
- 16 Q If we can start on the last page of this exhibit, ending
- 17 | 505, the earliest e-mail in this chain, the bottom, this is if
- 18 | we scroll up, does this appear to be the prior e-mails that we
- 19 | saw in Government's Exhibit 122-41?
- 20 A Yes, it's the same e-mail exchange.
- 21 Q Okay. If we could go to the prior page, you submit a
- 22 | fairly lengthy e-mail to Mr. Shkreli. Why don't we focus on
- 23 the first half of that e-mail.
- 24 A Yes.
- 25 Q Does it appear to be your response to Mr. Shkreli

- 1 | outlining what you believe your holdings are in Retrophin?
- 2 A Yes, I had gone back to my files and my emails to pull
- 3 out of facts as I saw them.
- 4 Q So you write Martin, "Here are the facts that I have on
- 5 | file." Your first point is entitled "my investments into
- 6 MSMB; " is that correct?
- 7 A Yes.
- 8 Q Then you then list your \$400,000 and the dates of those
- 9 investments into MSMB Capital?
- 10 A Yes.
- 11 Q That last line, the last section here, what do you write
- 12 "This 400,000"?
- 13 A "This 400,000, thanks to you and your team's performance,
- 14 | stood \$583,482 as of February 2012, the last MSMB performance
- 15 | summary I've access to. All of which was moved into
- Retrophin. So a total of 583,482 invested into Retrophin at
- 17 | the deeply discounted preferred stock rate."
- 18 Q Your second point, "My additional investments into
- 19 Retrophin," and you then list out your additional investments
- 20 and the dates of those investments; is that right?
- 21 A Yes.
- 22 | Q Then you write, "So an additional 75,000 invested into
- 23 Retrophin, again at the preferred stock rate; " is that
- 24 correct?
- 25 A Yes.

- 1 Q The third point is regarding what we had spoken about
- 2 | yesterday entitled "My investments in MSMB consumer and
- 3 Surepoint."
- 4 A Yes.
- 5 Q What do you write?
- 6 A "Of the \$100,000 I invested, I was refunded \$86,967, a
- 7 loss of \$13,033. You committed to cover these losses and
- 8 | rather than receiving a check I asked you to invest the 13,033
- 9 into Retrophin on my behalf."
- 10 Q Then write below that it appears that you then tally
- 11 | points one, two, three; is that correct?
- 12 A That's correct.
- 13 Q What do you state there?
- 14 A "Running total, so I have invested 671,515 into Retrophin
- 15 | all at the preferred discounted rate, which while private was
- 16 | \$20 and \$25, while the valuation set at \$80 per e-mails from
- 17 vou and Jackson."
- 18 Q Then section four below that is entitled, "the multiplier
- 19 | factors and conversations." You then write, "You have said to
- 20 | me a number of times that you had added to my portfolio in
- 21 recognition of my sustaining role and being a board member."
- 22 Then right below that you state, "You shared the
- 23 | Capitalization Table, which showed my shares moving from
- $24 \mid 14,361, (2\%)$ to 264,361 (5%). As Aselage, Tim and others
- 25 | received stock, I was left with the clear impression this new

- 1 | allocution was made effective."
- Who is Tim?
- 3 A This is Tim Pierotti.
- 4 Q Below that you wrote, "In sharing news of the final
- 5 | financing deal you verbally reaffirmed to me that I had
- 6 | 5 percent before the move to 12 million shares and that my
- 7 stake was worth between 1.5 and 3 million; " is that correct
- 8 there, sir?
- 9 A Yes.
- 10 Q If we go to the next page, just look at the rest of your
- 11 response. The fifth point is entitled, "critical calculation
- 12 points," then why don't we go to the last sentence in this
- 13 | section starting, "Which ever way," read that?
- 14 A "Which ever way I look at it, I was expecting my stake to
- 15 be worth north of 1.5 million entering this phase of our
- 16 | evolution and before the market price took hold."
- 17 | Q You have a section entitled, "key actions," can you read
- 18 | those key actions that you list there?
- 19 A "Somebody needs to do a forensic accounting review of any
- 20 | investments and the transactions pricing decisions taken at
- 21 | each decision action point. You need to clarify where/when
- 22 | the new capitalization takes or took effect, and whether I was
- 23 included."
- 24 | Q Why are you asking for a forensic accounting review of
- 25 your investments?

- 1 A Because I was disappointed by, as per the earlier e-mail
- 2 | we reviewed, disappointed by Martin's first response to this
- 3 discussion around reconciling my investments.
- 4 Q Did Mr. Shkreli then respond to your e-mail?
- 5 A Yes.
- 6 Q Let's look further up in this chain. It appears his
- 7 response starts at the bottom of the first page of this
- 8 exhibit ending in 503, from Mr. Shkreli to you Mr. Richardson
- 9 on March 14, 2013, do you see that?
- 10 A Yes.
- 11 Q If we go to the next page, can you please read that first
- 12 paragraph there to the jury?
- 13 A "I agree that you should have about 400,000 shares, which
- 14 | would have been 5 percent of the company post DGTE" -- Desert
- 15 | Gateway -- "the company had \$88 million post DGTE."
- 16 Q Keep going.
- 17 | A "So we owe you 300,000 shares. I think we can
- 18 | accommodate this painlessly. I think my accounting was
- 19 | accurate. I think there was some miscommunication on my part,
- 20 | but also some great fault on my part for not being clear. I
- 21 | probably assumed an options grant would be done when it
- 22 | wasn't. I will try to be more clear and direct in the
- 23 future."
- 24 Q So in terms of this paragraph, did you at this point in
- 25 | time believe you were owed 300,000 shares of Retrophin?

- 1 A Yes.
- 2 Q If we read the next paragraph.
- 3 A "I have a call with Evan to see what the best path
- 4 | forward is. The biggest two deltas here are the perception of
- 5 a deeply discounted rate, that was not the case. We always
- 6 had looked Retrophin valuations of 20 and \$40 million, both of
- 7 | which proved to be heavily optimistic as we raised the 10
- 8 | million at a 24 million valuation."
- 9 Q Just to stop you there, when he said, "we raised the
- 10 | 10 million," what is that a reference to?
- 11 A One of our financing.
- 12 Q When you say financing, what do you mean?
- 13 A One of the investment pipes calling for more investments.
- 14 Q Just what is a pipe?
- 15 A A pipe is a private investment in public equity.
- 16 Q What does that mean when you say, this is one of the
- 17 pipes?
- 18 A When we go out to the market looking to attract new funds
- 19 and bringing investors in. When you do a pipe, normally it's
- 20 at a discounted rate on the stock price so that it becomes an
- 21 | attractive way to attract new dollars for the company.
- 22 Q So looking back on this e-mail, when Mr. Shkreli writes,
- 23 | "we raised 910 million," is that a separate pipe that had
- 24 recently occurred with respect to Retrophin?
- 25 A Yes.

- 1 Q Then can you continue, please?
- 2 A "The second misunderstanding is the added stock for your
- 3 recognition. This was repeatedly said but frankly never done
- 4 for any of us on the Board. I have been pushing Evan for a
- 5 grant but it simply hasn't happened given all we've tried to
- 6 accomplish."
- 7 Q The Evan references who you are referring to, who Evan
- 8 is?
- 9 A Evan Greebel, who again, is the outside counsel and
- 10 acting internal counsel.
- 11 Q If you could proceed with the last paragraph.
- 12 A "The good news is, it is all fixable. I certainly feel
- 13 that without any top up, the number you have now is still shy
- 14 | but not terribly shy of accurate. The top up is obviously the
- 15 | big part and a lot of people got topped up with the DGTE
- 16 | transaction, which should have been handled very differently.
- 17 I'm apologetic for the way this was handled. We can go over
- 18 | that in person. In the meantime I will discuss the solution
- 19 | with Evan tonight. I hope we can secure your signature
- 20 | tomorrow, as penalties kick in if we don't all sign it."
- 21 Q "I hope we can secure your signature tomorrow, as
- 22 | penalties kick in if we don't all sign it, " do you know what
- 23 he's referring to there?
- 24 A He's referring to the S1 form that was the subject to my
- 25 | earlier e-mail that had to be submitted by a concern deadline,

- 1 otherwise the company would be held liable for not meeting
- 2 registry deadlines.
- 3 Q Your understanding is you had to sign that form as part
- 4 of your role in the company?
- 5 A Yes.
- 6 Q Did you respond to this e-mail, Mr. Richardson?
- 7 A Yes.
- 8 Q Why don't we take a look at that. Can you please read
- 9 your response to the jury?
- 10 A "I appreciate the spirit of your response and I hate
- 11 | finding myself in this situation. I never fueled this vision
- 12 | with you having money at the center. I always knew I would
- 13 lose it all, or do amazingly well. But I always proceeded
- 14 | with your endorsing words believing that my core investment
- 15 was accumulating well through these early stages and my
- 16 | jumping in early each time to invest would be recognized. You
- 17 | are right, we need to get this fixed and behind us and commit
- 18 | that we never get far apart in understanding again. Knowing
- 19 | we have to go over the details in my investment journey, I
- 20 | don't yet agree that the accounting you laid out is accurate.
- 21 My summary to you highlighted a number of discrepancies that
- 22 | you are not -- that are not to do with any top up or options.
- 23 I can't sign the filing with the current data in it. As I
- 24 | speak with Evan perhaps there is a way to footnote this as an
- 25 open issue being worked on. We will need to move forward in

- 1 good faith that the right resolution is locked. Let me know
- 2 | what your recommendation is after you discussed with Evan."
- 3 Q Why did you feel you couldn't be followed with signed the
- 4 S1 form?
- 5 A Because to me there was some factual errors on the
- 6 initial list that Martin shared with me about my
- 7 stockholdings. He missed one or two of my of contributions.
- 8 Q If we look at the response from Mr. Shkreli.
- 9 A "Just so we're transparent, the issue with the S1 is it
- 10 | needs to be filed with the SEC by tomorrow, by tomorrow night,
- 11 or there are punitive damages that they begin in favor of the
- 12 | investors who just invested. I personally swear to you that
- 13 | my assessment is that it is largely irrelevant what number is
- 14 | written there. You are right to be wanting to be accurate.
- 15 So as long as you get to where you want through our
- 16 discussions, which I have no reason to think that you
- 17 | shouldn't, have the faith we can arrive at it in the very near
- 18 | future."
- 19 Q You respond to Mr. Shkreli; is that correct,
- 20 Mr. Richardson?
- 21 A Yes.
- 22 | Q Let's look at your response. If we can scroll up, can
- 23 | you please read your response?
- 24 A "The way you forward your outline is fine. And yes, I
- 25 | have trust of that it being fulfilled, although it pains me

- 1 | that I would be sourcing shares from you and Marek. I agree
- 2 that option grant should be issued to a select few. Are you
- 3 therefore to sign the filing as is, or is Evan making any
- 4 changes?"
- 5 Q So your understanding, when you say the "sourcing," that
- 6 | it would be sourcing shares from you and Marek, what do you
- 7 mean by that?
- 8 A Again, in the earlier communication to me he said that
- 9 part of making sure I got to the accurate number, i.e. the
- 10 | 300,000 shares, that Marek and he would be contributing to
- 11 | those shares that were owed to me.
- 12 Q So those were Marek and Martin's shares in Retrophin that
- 13 he would be giving you?
- 14 A Yes.
- 15 Q If we of go to Mr. Shkreli's response, the last e-mail in
- 16 this chain.
- 17 A Yes.
- 18 Q What does he write there?
- 19 A "He will make the changes that will indicate a large
- 20 | share count. I would not feel pained at all. We had intend
- 21 | to do this for sometime. We apologize for not having our act
- 22 | together. With everything in the air I hope you understand
- 23 | why we overlooked it. It is because we do in fact do trust
- 24 and love you, not because we thought we could avoid this. I
- 25 | thank you for holding me accountable. I dread giving anyone a

- 1 | feeling that I'm abusing a friendship."
- 2 Q Did you have any further discussions with the defendant
- 3 about him giving you some of his Retrophin shares?
- 4 A Yes. There was a follow up, I think a few days after
- 5 this, where I met with him in the office and talked through
- 6 the subject in person with him.
- 7 Q What do you recall discussing in that conversation?
- 8 A I was, again you can tell from these e-mail exchanges, I
- 9 was pretty upset. I asked him to get me more background on
- 10 | why exactly this happened. He shared with me, he said that he
- 11 did have a problem with the MSMB funds in the period from when
- 12 | it was, in the period from when it was winding down before the
- 13 | monies were moved into Retrophin for any of the investors that
- 14 chose to do that.
- 15 Q What else did he discuss with you in that meeting?
- 16 A He said that he diluted to that in these e-mails, there
- 17 were a number of investors that chose to move their founds
- 18 | over to Retrophin, that indeed he had to top up. I was not
- 19 the only one that indeed he was going to have to top up.
- 20 Q Your understanding was that those investors were
- 21 | similarly situated to you, meaning they had chosen to role
- 22 | their investment in MSMB Capital, or any other fund, into
- 23 Retrophin?
- 24 MR. AGNIFILO: I object to leading, Judge.
- 25 THE COURT: Overruled.

- 1 A Yes, yes, that's certainly the way he expressed it to me.
- 2 Q What did he say with respect to giving you shares from
- 3 his own Retrophin holdings?
- 4 A He had shared with me, because it was going to represent
- 5 | a sizeable number of shares, that he would be passing to me
- 6 and to some other investors that as he was the regarded CEO it
- 7 | wouldn't look good if these shares all came down dramatically,
- 8 quickly. It could be viewed by the investment market as a
- 9 negative signal and would I mind waiting to get my shares as
- 10 he worked through some of other ones he was going to do. So
- 11 | it didn't have a dramatic impact on reducing his personal
- 12 | shares, which the market could view negatively. I said I
- 13 | would be willing to wait.
- 14 Q Did you have a sense of how long you were being -- what
- 15 was your understanding of how long you were being asked to
- 16 wait?
- 17 A There was no precise timeline that we agreed. I got the
- 18 impression it was a matter of months.
- 19 Q Did you ever see a finalized Capitalization Table for
- 20 Retrophin?
- 21 A No.
- 22 | Q Did you ultimately sign this S1 registration form that's
- 23 the being discussed in the e-mail chain at 122-42?
- 24 A Yes, I did, on the basis that I clarified that when my
- 25 | stock was changed we would send a revision of that form in.

- 1 | So I did sign the S1 at that point.
- 2 Q Did the defendant ever give you shares from his Retrophin
- 3 | holdings, the ones that he had stated he would give you?
- 4 A No.
- 5 Q Did you ever file a revised S1 statement?
- 6 A No.
- 7 Q I wanted to next discuss with you Retrophin in the 2013
- 8 into 2014 time period after the reverse merger. Immediately
- 9 following Retrophin becoming a public company, at the end of
- 10 December 2012, what was your position or role at Retrophin?
- 11 A I continued on the Board of Directors.
- 12 Q In that role, did you have an understanding of
- 13 Retrophin's financial state at this point in time?
- 14 A Generally, yes. I know we were very, very tight on cash
- 15 available to us at that point.
- 16 Q Did you have access to the bank accounts of Retrophin?
- 17 A No.
- 18 Q After Retrophin became public, what was your
- 19 understanding as to what the plan was for Retrophin in the
- 20 first half of 2013?
- 21 A Well, the decision we made at the end of 2012 not to go
- 22 to the merger route or the venture capital route, meant now we
- 23 | were determined, having done the reverse merger with Desert
- 24 | Gateway, established us on the over-the-counter markets. That
- 25 | now we would be a stand-alone company. Now we needed to

- 1 | seriously build out our capability and really look at bringing
- 2 drugs on board, building up a management team and bringing in
- 3 expertise we needed. And as the year progressed, building up
- 4 the Board of Directors as well. Now we were no longer
- 5 thinking of merging with someone else, we had to build those
- 6 capabilities ourselves.
- 7 Q When you were talking about building out the management,
- 8 were you part of the process of helping to build out the
- 9 management at Retrophin?
- 10 A Yes, because again, with my HR background Martin asked me
- 11 to interview some of key senior positions as candidates that
- 12 were identified.
- 13 Q Did you in fact participate in those interviews?
- 14 A I did, for the Chief Medical Officer position and for the
- 15 Chief Financial Officer position.
- 16 Q Were those two positions filled?
- 17 A They were, around mid-year.
- 18 Q Mid-year, which year?
- 19 A 2013.
- 20 Q With respect to the Chief Financial Officer position, who
- 21 | obtained that position?
- 22 A The final candidate that was selected was Mark Panoff.
- 23 Q With respect to the Chief Medical Officer position, who
- 24 | filled that role?
- 25 A A gentleman called Horacio Plotkin.

- 1 | Q What, if any role, did Steve Aselage play in the first
- 2 half of 2013?
- 3 A At this point, given the fact that we had changed
- 4 strategy, he had vacated the CEO role that he had assumed in
- 5 late 2012 for the company, and Martin had retaken, resumed the
- 6 CEO rolled, and Aselage continued on the Board of Directors.
- 7 Q You had said that in the first half of 2013 Mr. Shkreli
- 8 was the CEO of Retrophin?
- 9 A Yes.
- 10 Q What about Evan Greebel? What was his role, if any, with
- 11 respect to Retrophin in the first half of 2013?
- 12 A Continuing as both external legal counsel and acting as
- 13 | internal counsel.
- 14 Q Do you know who Ron Tilles is?
- 15 A Ron is someone that Martin had accessed who was very good
- 16 | at building future investors and attracting that, and looking
- 17 at the financing options.
- 18 Q Who did Ron Tilles work for?
- 19 A He worked directly with Martin.
- 20 Q Did you know for which entities?
- 21 A Not at that point, no, I assumed it was Retrophin.
- 22 Q Now, you were on the Board of Directors in the first half
- 23 of 2013 you had testified; is that right?
- 24 A Yes.
- 25 Q What was the status of the Board of Directors at that

- 1 point in time?
- 2 A It was just myself, Martin, and Steve Aselage, the three
- 3 of us at the start of the year.
- 4 Q Were you having face-to-face regular board meetings at
- 5 that point in time?
- 6 A No.
- 7 Q What, generally speaking, were the meetings like?
- 8 A They were either telephonic or individual discussions
- 9 with Martin.
- 10 Q As part of these meetings, was it your understanding that
- 11 there were supposed to be minutes taken of the meetings?
- 12 A Yes, if there was no unanimous written consent recorded.
- 13 Q And what was your understanding as to who was responsible
- 14 for taking those minutes?
- 15 A Evan Greebel as our acting counsel, internal counsel.
- 16 Q When Mr. Greebel was acting as internal counsel and
- 17 | responsible for those minutes, did you receive those minutes
- 18 after each board meeting to review?
- 19 A No.
- 20 Q Did you ever receive Board of Directors meeting minutes
- 21 to review?
- 22 A In 2014.
- 23 0 Who circulated those minutes?
- 24 A The first minutes we received came in approximately July,
- 25 | I believe of 2014, from a new colleague Margaret

- 1 | Valeur-Jensen, who was appointed as our internal general
- 2 | counsel for the company in the middle of 2014.
- 3 Q So you received -- the first board minutes you ever
- 4 received to review was in July 2014 from Ms. Valeur-Jensen?
- 5 A Yes.
- 6 Q Did you ever receive board minutes that had been drafted
- 7 by Mr. Greebel?
- 8 A Yes. He sent a whole batch to us I believe around in
- 9 September of 2014.
- 10 Q So September 2014?
- 11 A '14.
- 12 Q Now directing your attention to the July 2013 time
- 13 period, did you have a telephonic Board of Directors meeting
- 14 that month?
- 15 A Yes, I believe we did.
- 16 Q I'm showing you what is marked for identification as
- 17 Government's Exhibit 122-43, it's tab 53 of your binder.
- 18 A Yes.
- 19 Q Do you recognize this document?
- 20 A Yes.
- 21 Q What is it?
- 22 A It is an e-mail from Marc Panoff, who is our recently
- 23 appointed Chief Financial Officer, talking about the subjects
- 24 to be covered on the Board call.
- MS. KASULIS: Government moves this exhibit into

- 23 followed up and sends some attachments to you prior to this 24 meeting?
- 25 Yes.

Then if we zoom in it appears that he actually then

- 1 Q So let's look at the next page of this exhibit, do you
- 2 recognize this document?
- 3 A Yes.
- 4 Q What is it?
- 5 A It's a summary cash flow for the Retrophin company
- 6 through to the middle of June 2013.
- 7 Q If we look at the very first line, did you review this
- 8 document?
- 9 A Yes, it was discussed on the Board call.
- 10 Q The very first line of this document, does it state,
- 11 | "Cash balance as of December 31, 2012 is that \$11,388?
- 12 A Yes.
- 13 Q That's for the company?
- 14 A Yes.
- 15 Q If we look, if we scroll down, there is financing
- 16 proceeds and then it says, "Amounts raised, gross Q1, and
- 17 | that's \$9,954,451," what does this line reference?
- 18 A That's talking about the external financing that we
- 19 referenced earlier that we had just secured.
- 20 Q That was what you referred to as a pipe?
- 21 A Referred to as a pipe. I call it, \$10 million, it was
- 22 close to that.
- 23 Q With some deduction of legal fees then the net financing
- 24 | is around 9.275 million; is that right?
- 25 A Yes.

- 1 Q And then if we could zoom out and look at the operating
- 2 expenses section for quarter 1 and quarter 2.
- 3 A Yes.
- 4 Q If we can just go -- thank you. Perfect.
- 5 So does it appear here that under operating expenses
- 6 it's broken out by each quarter, quarter 1 and quarter 2?
- 7 A Yes.
- 8 Q And under quarter 2 the cash balance as of June 30, 2013,
- 9 what is the number listed there?
- 10 A Excuse me. Which?
- 11 Q It says -- I'm sorry. The very bottom, the very last
- 12 line, cash balance as of June 30, 2013.
- 13 A Oh, yes. \$303,247.
- 14 Q And one of the line items in this quarter 2 section, do
- 15 | you see there MSMB settlement, (Spencer Spielberg, Sarah
- 16 | Hassan, Trachtenberg & Rodes), do you see that?
- 17 A Yes.
- 18 Q And it's quarter 2 and it's listing as a deduction
- 19 \$548,711?
- 20 A Yes.
- 21 Q Do you recall this line item at all, Mr. Richardson, in
- 22 this financial flow?
- 23 A I believe I -- I believe, because I read the page, I had
- 24 recognized it but there was no discussion.
- 25 Q Do you know who Spencer Spielberg, Sarah Hassan and

- 1 | Trachtenberg & Rodes, who those people are?
- 2 A No.
- 3 Q So this \$303,247 cash balance as of June 30, 2013, what
- 4 was your understanding of the financial state of the company
- 5 at this point in time?
- 6 A Again, as I mentioned at the start of the year because we
- 7 | were going to a new strategy, we knew that we were very tight
- 8 and we had to raise funds. The discussion we had on this call
- 9 was recognizing that we were spending money very rapidly, and
- 10 | that we had to come up with a sustained funding strategy. And
- 11 | we also had to get on top of expenses because we were burning
- 12 expenses very rapidly. That was what the discussion was on
- 13 this board call. Particularly with Marc Panoff, as our new
- 14 CFO, as one of first priorities he had when he came onboard.
- 15 Q And so that's what your recollection was the focus of
- 16 this call?
- 17 A That's my recollection of the focus of the call.
- 18 Q And so now directing your attention to the September 2013
- 19 time period. We can put this aside.
- 20 Do you recall having any board of directors meeting
- 21 in that month?
- 22 A Which month?
- 23 Q September 2013 time period.
- 24 A Yes, I do.
- 25 Q Was that a telephonic meeting?

- 1 A Yes.
- 2 Q I'm showing you what's been marked for identification as
- 3 Government's Exhibits 48 -- 122-48, 122-49 and 122-50.
- 4 | They're tabs 54 through 56 of your binder. If you can just
- 5 take a minute to look at those three exhibits and let me know
- 6 | if you recognize them.
- 7 A Yes.
- 8 0 What are these documents?
- 9 A These are documents attached for the subjects that we're
- 10 going to be reviewing as a board on this call.
- 11 MS. KASULIS: The government moves these exhibits
- 12 into evidence.
- MR. AGNIFILO: No objection.
- 14 THE COURT: We will receive 122-48, 122-49 and
- 15 122-50.
- 16 (Government Exhibit 122-48, 122-49, 122-50, was
- 17 received in evidence.)
- 18 Q We can start with 122-48. I'm sorry, 122-49.
- And what is this document, Mr. Richardson?
- 20 A This is the agenda for the call and the subjects that
- 21 they intended for us to cover.
- 22 Q Did you, in fact, participate in this board of directors
- 23 | call?
- 24 A Yes, I did.
- 25 Q And there are a number of items listed here as agenda

- 1 items. Which of these items do you remember discussing on
- 2 this call?
- 3 A I believe, because part of the issue is a lot of the
- 4 documents have come out rather late and we only got to a
- 5 | number of the items on this list. I believe we covered 2
- 6 | through 7. Yeah, 2 through 7 I believe we covered on the
- 7 available time.
- 8 Q And what about the rest of the items?
- 9 A The rest of the items, which were the more administrative
- 10 ones, Martin said he'd bring back to us as a board.
- 11 Q Now, item number 2 there states "Review and approve
- 12 | amendments to the 2012 10K and the 10Q for the quarter ended
- 13 | March 31, 2013."
- 14 What was your understanding as to why these two SEC
- 15 | filings needed to be amended?
- 16 A Our external auditors are now working with Marc Panoff,
- 17 | as I say, he's only been on board with us for a while, had
- 18 determined that there was a handling of some items called
- 19 settlement agreements that required us to restate our prior
- 20 results effectively and we needed -- that needed to be
- 21 | captured in an amended reporting document.
- 22 O And who were the external auditors?
- 23 A At this point it was Marcum.
- 24 O And who from Marcum?
- 25 A The lead colleague was Ed Hackert and there was one other

- 1 | colleague, Sunil -- my apologies, I forget his name -- but Ed
- 2 Hackert was the lead.
- 3 Q And what do you recall being discussed during this call?
- 4 A The external auditors were taking the board through the
- 5 language that related to what the revisions were in the 10K.
- 6 Q And do you recall anything else being discussed?
- 7 A Well, during that discussion Martin had interjected quite
- 8 | forcefully when Marcum was talking about the settlement
- 9 agreements. And he had said, you know, I don't understand why
- 10 | we're covering this again. I am MSMB and I'm standing by
- 11 | this. We should just move on.
- 12 Q When you say "standing by this," what are you referring
- 13 to?
- 14 A In the detail of what Marcum was taking us through there
- were promissory notes which referred to MSMB and to Martin.
- 16 | So they were taking us through that language which is what he
- 17 | was responding through to say, yes, I'm standing by this.
- 18 Q What was your understanding as to the need for the
- 19 promissory notes?
- 20 A Promissory notes were required because the way that the
- 21 | settlement agreements were being handled for accounting
- 22 purposes is they had to move through the Retrophin books
- 23 | because it was changing the holdings of Retrophin
- 24 shareholders.
- 25 Q And so what were the promissory notes for?

- 1 A And the promissory notes were from both MSMB Capital and
- 2 from Martin himself that they, in fact, would be making
- 3 Retrophin whole on the amount that the settlement agreements
- 4 represented.
- 5 Q Now, did the board of directors ever approve the
- 6 settlement agreements that caused the restatement of
- 7 Retrophin's SEC filings?
- 8 A No. We've never seen the settlement agreements.
- 9 Q And were you aware of the settlement agreements that
- 10 caused the restatement of the filings prior to the fall of
- 11 2013?
- 12 A No, not aware of the settlement agreements.
- 13 Q After this meeting did you have any communications with
- 14 Mr. Panoff?
- 15 A Yes. A couple of days later I was in the office and I
- 16 | spoke with him because, again, he was still very new to the
- 17 | company. And I congratulated him to say because it was a
- 18 | pretty contentious call at times and I felt it was very
- 19 healthy to have that kind of debate and discussion.
- 20 And I said to him, I know you're fairly new but I
- 21 | want to make sure you're on top of this is a restatement and I
- 22 | want to make sure you're on top of this. And he said to me,
- 23 | well, as long as Martin stands by the promissory note, the
- 24 company is okay.
- 25 Q Now, in the latter half of 2013 and early 2014, what was

- 1 | your understanding as to whether Retrophin used consultants?
- 2 A Martin from time to time would bring contract type people
- 3 onboard so that in some specific roles, like we mentioned Ron
- 4 | Tilles earlier, I believe he was on like a contract basis
- 5 | rather than a full employee basis. So Martin would use him
- 6 from time to time.
- 7 Q So let's go back to Government Exhibit 122-49. If we
- 8 look at the line item number 9.
- 9 A Yes.
- 10 Q It's listed there approve retaining Al Geller, Ken Banta
- 11 as consultants. Do you see that?
- 12 A Yes.
- 13 Q You had stated earlier, was this one of the line items
- 14 | that you did not get to on the September 9, 2013 call?
- 15 A That's correct. We didn't get to them.
- 16 Q And did you recall ever reviewing or discussing the Al
- 17 | Geller consulting agreement?
- 18 A No. It had been sent in the attachments, but we never
- 19 got to the discussion.
- 20 Q And what is your understanding as to whether the board of
- 21 directors ever approved Al Geller's consulting agreement?
- 22 A It was -- to the best of my knowledge, it was never
- 23 | brought back to the board. I certainly never saw it or
- 24 approved it.
- 25 Q What about with respect to Ken Banta?

- 1 A It was never brought back to the board.
- 2 | Q Have you ever heard of an individual named Lee Yaffe?
- 3 A No.
- 4 Q Or Efay?
- 5 A No.
- 6 Q Have you ever heard of an individual named Darren
- 7 Blanton?
- 8 A I didn't know him, but I know I had seen his name as one
- 9 of the investors earlier. So I had seen his name, but I
- 10 didn't know him.
- 11 Q Did the Retrophin board of directors ever approve a
- 12 | consulting agreement for Mr. Blanton?
- 13 A No.
- 14 Q Or a consulting agreement for Mr. Yaffe?
- 15 A No.
- 16 Q Have you ever heard of an individual named Steve
- 17 Rosenfeld?
- 18 A No.
- 19 Q Did the board of directors ever approve a consulting
- 20 | agreement for Mr. Rosenfeld?
- 21 A No.
- 22 Q Now, I'm showing you what's been marked for
- 23 identification as Government Exhibit 122-53. It's tab 57 of
- 24 your binder.
- Do you recognize this document?

- 1 A Yes.
- 2 Q What is it?
- 3 A It is an email from Marc Panoff to the board with the
- 4 board agenda and attachments related to the board agenda.
- 5 MS. KASULIS: And the government moves this exhibit
- 6 into evidence. I'm sorry.
- 7 MR. AGNIFILO: No objection.
- 8 THE COURT: We receive Government's 122-53.
- 9 (Government Exhibit 122-53, was received in
- 10 evidence.)
- 11 Q Is this in relation to a board of directors meeting on
- 12 November 6, 2013?
- 13 A I believe the meeting was actually the 8th.
- 14 Q Thank you.
- 15 A I'm just looking at the agenda.
- 16 Q Thank you.
- And so this is an email that was sent prior to the
- 18 | meeting; is that correct?
- 19 A That's correct.
- 20 Q In the recipient line it's sent from Marc Panoff and
- 21 | received by a number of individuals. Listed there is a Neal,
- 22 N-e-a-l. Do you know who Neal is?
- 23 A This is Neal Golding who has just joined us on the board
- 24 as one of our first new board members.
- 25 Q Who is Neal Golding?

- 1 A As I say, we had interviewed and spoken with him and
- 2 appointed him to the board. He had a very strong background
- 3 in finance and had previously sat on audit committees. So he
- 4 was a great addition to bring to our board and he immediately
- 5 headed up our audit committee as we formed it.
- 6 Q And it appears that yourself, Mr. Aselage and Mr. Shkreli
- 7 | are listed there with a cc to Evan Greebel and then two
- 8 individuals, Ed Hackert and Sunil Jain.
- 9 Who are those two individuals?
- 10 A Those are the two individuals I mentioned earlier from
- 11 | our external auditor firm Marcum.
- 12 Q If we turn the page to the actual agenda.
- 13 A Yes.
- 14 Q If you look at line, just line item number 4 there.
- 15 A Yes.
- 16 Q And it says discuss appointment of Dr. Jeff Paley's
- 17 appointment to the board.
- 18 A Yes.
- 19 Q Who is Jeff Paley?
- 20 A He was the next candidate that we'd been speaking to to
- 21 join the board. He was medical director in his own right and
- 22 | had very good experience in investing in the -- in the
- 23 healthcare space.
- 24 Q And we can put this document aside.
- You had mentioned in the course of your testimony

- 1 today about getting documents related to a board meeting very
- 2 close in time to the meetings themselves; is that right?
- 3 A Yes.
- 4 Q Did you express any concern about that?
- 5 A Yes, I mentioned that a number of times. And
- 6 particularly I was reassuring when Marc Panoff came onboard,
- 7 because he was starting to add some of the rigor we were
- 8 lacking before, and I had asked, especially with these large
- 9 documents, that we need at least a day in advance if we're
- 10 going to credibly review them before we have a discussion.
- 11 Q I'm showing you what's been marked for identification as
- 12 Government Exhibit 122-58. And it's tab 58 of your binder.
- 13 A Good.
- 14 Q Do you recognize this exhibit, Mr. Richardson?
- 15 A Yes.
- 16 Q What is it?
- 17 A It is an email from one of Evan Greebel's associates at
- 18 Katten starting to send -- starting to talk about the board
- 19 call and my response.
- 20 MS. KASULIS: The government moves this exhibit into
- 21 evidence.
- MR. AGNIFILO: No objection.
- 23 THE COURT: We receive Government's Exhibit 122-58.
- 24 (Government Exhibit 122-58, was received in
- evidence.)

- 1 Q And if we look at this, the bottom email of the two
- 2 | emails in this exhibit, you had mentioned -- who is David
- 3 Kravitz?
- 4 A He's an associate at the Katten, the external law firm
- 5 | that Evan Greebel worked at.
- 6 Q And the date on this email is January 6, 2014?
- 7 A Yes.
- 8 Q And he writes, All, attached please find the agenda
- 9 today's board of directors meeting along with copies of the
- 10 documents that we will discuss. Regards, David.
- 11 And in response, what do you write there in response
- 12 to Mr. Kravitz?
- 13 A I'm writing to him and then the rest of the group saying,
- 14 | Guys, I just landed back in New York City 50 minutes ago after
- 15 | an agonizing series of delays. We need to set a standard for
- 16 issuing these materials ahead of board calls so we can conduct
- 17 | an adequate review of all materials. Getting them straight
- 18 | ahead of a call does not allow us to -- does not allow us to
- 19 | fill our oversight role adequately. I suggest 48 hours
- 20 | minimum on most items. As of today's call, can we be clear on
- 21 | the items that are time sensitive for your required submission
- 22 deadlines?
- 23 Q And did the situation improve after this point in time?
- 24 A Slowly it did. Not all the time, but slowly it did.
- 25 Q Now, I want to direct your attention to the 2014 time

- 1 period at Retrophin.
- 2 A Yes.
- 3 Q Were you still on the board of directors at that point in
- 4 time?
- 5 A Yes, I was and Jeff Paley had now joined as well. So
- 6 there were five of us on the board.
- 7 Q So just to be clear, who were the five board members of
- 8 Retrophin at the beginning of 2014?
- 9 A Myself, Martin, Steve Aselage, Neal Golding and now Jeff
- 10 Paley as well.
- 11 Q And so at the beginning of 2014 what was your
- 12 understanding as to the status of Retrophin at this point in
- 13 time?
- 14 A It was now a very exciting time for us. We'd gone
- 15 through 2013, as we said before, building out our
- 16 | capabilities. And at this point it was a very exciting time
- 17 | because Martin had started to secure some very interesting
- 18 drug candidates to bring into our Retrophin company, and he'd
- 19 also started to move forward to move us for NASDAQ listing,
- 20 which really would be a very important big step for our
- 21 | company. But to become NASDAQ listed we also had to have a
- 22 | secure, you know, \$40 million in new funding which is one of
- 23 | the requirements to secure NASDAQ listing. So it was a very
- 24 exciting time.
- 25 Q Now, directing your attention to the February 2014 time

- 1 period. Do you recall a board of directors meeting that
- 2 month?
- 3 A Yes, this, in fact, was an offsite meeting and really the
- 4 | very first time the board was going to meet with the
- 5 | management team in a fully -- in a very intense meeting
- 6 format.
- 7 Q And was this an actual face-to-face meeting of the board?
- 8 A This was a face-to-face meeting.
- 9 Q And where did that meeting occur?
- 10 A That happened here in Manhattan, a venue at -- a venue
- 11 | that has meeting rooms on 14th Street here in Manhattan.
- 12 Q And what is that location called?
- 13 A It's called the Norwood Club.
- 14 Q I'm showing you what's been marked for identification as
- 15 | Government's Exhibit 122-64 and 122-70. It's tabs 59 and 60
- 16 of your binder.
- Do you recognize these documents?
- 18 A Yes, I do.
- 19 Q What are they?
- 20 A These are the agendas with the supporting documents for
- 21 | this offsite meeting. It was going to be a full-day meeting
- 22 and a number of us had worked very hard to put together the
- 23 | agenda and the subjects we needed to discuss. And then the
- 24 | next attachment is a summary of who would be the attendees for
- 25 the various parts of the day.

- 1 MS. KASULIS: Government moves these two exhibits
- 2 into evidence.
- 3 MR. AGNIFILO: No objection.
- 4 THE COURT: We receive 122-64 and 122-70.
- 5 (Government Exhibit 122-6 and 122-70, was received
- 6 in evidence.)
- 7 Q Let's go to 122-70 first.
- 8 A Yes.
- 9 Q And what is this document?
- 10 A This is Martin's assistant -- it's coming from Martin's
- 11 | assistant at the company who's laying out who's attending the
- 12 | respective -- we had some board committee meetings first, and
- 13 then we had the main meeting at 10:30 so confirming who would
- 14 be attending each of those respective meetings.
- 15 Q So if we look at the 8:30 a.m. time slot, the attendees
- 16 | listed there, it's Mr. Aselage, Mr. Golding, Mr. Greebel,
- 17 Mr. Panoff, Mr. Richardson and Mr. Shkreli?
- 18 A Yes.
- 19 Q Do you see that?
- 20 A Yes.
- 21 Q What do you recall about this 8:30 a.m. meeting?
- 22 A This was one of the board committee meetings, but,
- 23 | unfortunately, we had to delay it because Martin had been
- 24 delayed.
- 25 Q Do you have an understanding as to why Martin had been

- 1 delayed?
- 2 A Well, part of the exciting news is that he had secured
- 3 | the previous day, he'd secured the acquisition of two new
- 4 drugs and he was proceeding to get the announcement ready for
- 5 | that to go. So in making that happen, he was delayed in
- 6 coming to this meeting.
- 7 Q And did you have an understanding when you -- did
- 8 everyone arrive at 8:30 a.m., did Martin give you notice that
- 9 he would be late?
- 10 A No, unfortunately not.
- 11 Q What was your reaction to that?
- MR. AGNIFILO: I'm going to object to his reaction
- 13 to Martin being laid.
- 14 THE COURT: Overruled.
- 15 You can answer it, sir.
- 16 A It was, you know, it was rather frustrating because,
- 17 | again, a number of us had put extensive time together in
- 18 | putting this meeting together. And while Martin was clearly
- 19 | working on exciting news, I was disappointed that he hadn't
- 20 taken the time to give us a quick call so that we could redo
- 21 | the agenda meaningfully and didn't waste too much time.
- 22 Q And let's look back -- oh, just before we move on from
- 23 this.
- With respect to the 10:30 a.m. meeting that you had
- 25 | stated here that there would be more individuals who would be

- 1 | added at this point. If we look at this list here, the list
- 2 | includes Horacio Plotkin.
- 3 Who is Horacio Plotkin again?
- 4 A He's the chief medical officer for the company.
- 5 Q And Srinivas Rao, who's he?
- 6 A Srinivas was the leader of a neuroscience group that we
- 7 had acquired in I believe December of the year. It was a new
- 8 arm to our company that Martin was very enthusiastic about,
- 9 and Srini was the head of that entity.
- 10 Q And is Ken Banta listed here as well?
- 11 A Yes. Ken had helped craft the meeting agenda as well.
- 12 Q Now, if we look at Government Exhibit 122-64 and if we
- 13 look at the second page of this document. What is this
- 14 document here?
- 15 A This is now the actual agenda with the subjects that we
- 16 | will be covering for the main meeting of the day which is
- 17 | starting at 10:30 through the afternoon.
- 18 Q And were you involved in preparing this document?
- 19 A Yes, I was.
- 20 Q And if we go to the page of this, the third page of the
- 21 | agenda ending in Bates number 935, can we just look at that
- 22 page.
- 23 A Yes.
- 24 | O This appears to be the agenda for an afternoon session of
- 25 | the board of directors meeting; is that right?

- 1 A Yes, the meeting carried on through the day. So we just
- 2 took a lunch break and carried the meeting on through the
- 3 afternoon.
- 4 Q And then if you see here there's a Corporate Governance
- 5 and Risk Management section?
- 6 A Yes.
- 7 Q Underneath it it states distribute D&O questionnaires and
- 8 then cash management investment policy. And the first bullet
- 9 point being discuss investment policy parameters.
- 10 A Yes.
- 11 Q Exhibit C and D.
- 12 What is your understanding of what that bullet point
- 13 was referring to?
- 14 A Again, part of -- now that we're NASDAQ listed, we needed
- 15 | to put in place rigorous policies and guidelines across many
- 16 of the ways the company was operating. And this is one of the
- 17 | subjects that we needed to discuss as a board to make sure
- 18 | that we were all aligned.
- 19 Q When you're talking about investment policy parameters,
- 20 was there anything in particular that was referring to?
- 21 A Once we got into the discussion I think there are a
- 22 | number of subjects that came to bear.
- 23 Q Such as?
- 24 A Any trading, any trading that we were doing, any trading
- 25 | that the company was doing with shareholder money.

- 1 Q So what are you referring to, trading that the company
- 2 was doing with shareholder money?
- 3 A Well, as part of the discussion when we got into this,
- 4 we, as a board, were hearing for the first time that the
- 5 business development team was actually trading company money,
- 6 shareholder money. Effectively, attempting to make deals if
- 7 | you'd like -- well, no. I'm trying to think how to express
- 8 it.
- 9 Well, no. The fact the business development team
- 10 was trading, you know, doing trades as if they were, you know,
- 11 | a hedge fund in their own right if you like.
- 12 Q And who was leading the business development group?
- 13 A That was -- it was accountable to Martin at the time.
- 14 Q And this was the first time you had been hearing about
- 15 this?
- 16 A Yes.
- 17 Q Was there anything discussed with respect to that
- 18 trading?
- 19 A It was a very healthy discussion in the board that we
- 20 engaged with Martin on and that we had laid out that we need
- 21 | to put a policy in place around this because this is
- 22 | shareholder money. You know, we're no longer a fund. You
- 23 | know, we're a company operating, a publicly-traded company and
- 24 | we had to make sure that anything happening in that area was
- 25 | very, very small and very low risk. So it was a very healthy

- 1 discussion with Martin at the meeting.
- 2 Q If I can direct your attention to another attachment.
- 3 It's ending in Bates number 11939 of this document.
- 4 Do you recognize this attachment?
- 5 A Yes.
- 6 0 What is it?
- 7 A I believe this is, again, this is, again, for -- yeah,
- 8 this is the requirement for NASDAQ listing. Now that we're
- 9 NASDAQ listed, both board of directors and executive officers
- 10 had to complete this questionnaire for submission to NASDAQ.
- 11 Q And did you, in fact, complete this questionnaire?
- 12 A Yes, I did.
- 13 | Q And your understanding is that all the board of directors
- 14 and executive officers had to complete this questionnaire?
- 15 A Yes. It was a NASDAQ requirement.
- 16 Q And directing your attention to Bates number ending in
- 17 | 947, that page. The 7.6.1 question, it states "Have you been
- 18 or are you presently the subject of an investigation by the
- 19 SEC, the Commodities Futures Trading Commission, FINRA or any
- 20 other regulatory or self-regulatory organization that could
- 21 | result in the finding of a violation of any federal or state
- 22 | securities or commodities laws"?
- Do you see that?
- 24 A Yes.
- 25 Q And then you have to indicate either yes or no?

- 1 A Yes.
- 2 Q And did you complete this part of the questionnaire as
- 3 well?
- 4 A Yes, I did.
- 5 Q And your understanding is that everyone -- the board of
- 6 directors and all the executive officers completed this as
- 7 well?
- 8 A Yes.
- 9 Q So putting these documents aside. We had spoken earlier
- 10 | about Horacio Plotkin.
- 11 Do you recall whether he participated in the board
- of directors meeting on that day at the Norwood Club?
- 13 A Yes, he did.
- 14 Q And what do you recall about his participation?
- 15 A He gave an update on one of our important drugs in the
- 16 | pipeline. And during that discussion, because he had to -- he
- 17 | was asked to give us an update on the clinical trials, and
- 18 during that discussion Martin got rather upset because
- 19 Horacio's response was admittedly rather vague and a bit, you
- 20 know, lacks emergency. But Martin was very forceful with him
- 21 | in the meeting and he used some pretty forceful language
- 22 | expressing his disappointment and it did create quite an
- 23 | atmosphere in the room. I was facilitating the meeting and
- 24 stepped in and said we need to followup on this item, but
- 25 let's keep this, let's keep this, you know, at an appropriate

- 1 level.
- 2 Q And did Ken Banta participate in that meeting?
- 3 A Yes, he did. Not in the committee meetings, but he
- 4 participated in the main meeting.
- 5 Q Did you recall any discussions you had with Mr. Banta?
- 6 A Yes. Ken had come up to me during one of I think the
- 7 | lunch break and had asked me, because he knew I was on the
- 8 board, and he had asked me do I know the status of his
- 9 consulting agreement.
- 10 Q And what did you state?
- 11 A I said, no, it had been brought to the board, but we
- 12 | hadn't got to it and he needed to go back to Martin for Martin
- 13 to decide when he was going to bring it back to us.
- 14 Q Do you ever recall approving a consulting agreement for
- 15 Mr. Banta?
- 16 A No. In fact, Ken had even called me I think two weeks
- 17 | after this meeting with the same question.
- 18 Q Now, do you recall Evan Greebel being present at this
- 19 | board of directors meeting at the Norwood Club?
- 20 A Yes, he was.
- 21 Q Do you recall him participating at all?
- 22 A Yes.
- 23 Q What do you recall?
- 24 A Well, I met, you know, I met him the night before because
- 25 | we had a dinner the night before where we all joined together.

RICHARDSON - DIRECT - KASULIS

- I met him there. And then I remember him at the meeting. And now, of course, because he is acting internal counsel and I do see him taking the minutes as he should be.
- Q With respect to the dinner, what do you recall about that dinner?

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

that they were circulated.

- At the dinner because it was the first time now the full board with its new members was meeting with many of the management team who were also new. So it was a very exciting time and very social time. And we sat at a long table, and I happened to sit next to Evan Greebel. And in that discussion I had said to him, because I hadn't had much personal time with him before, you know, reminding him that, you know, again, not only was he external counsel, he was acting internal counsel but he was also acting company secretary. And I wanted to make sure he understood that he had to have an independent line to the board. If there's anything that he felt the board ought to be made aware of, I restated to him there that he needed to make sure that he accessed the board if it was necessary. And I also reminded him that he, as acting company secretary, he had to take minutes and make sure
- MS. KASULIS: Your Honor, this may be a good time to take a midmorning break.
- 24 THE COURT: All right. Let's let the jurors take a 25 break.

- MS. KASULIS: Government moves this exhibit into evidence.
- MR. AGNIFILIO: No objection.

- THE COURT: We receive Government Exhibit 122-71 in
- 2 evidence.
- 3 (Government Exhibit 122-71, was received in
- 4 evidence.)
- 5 Q It appears to be an email from Mr. Shkreli to you,
- 6 marc@sixthmanresearch.com.
- 7 Do you see that?
- 8 A Yes.
- 9 Q And who is that?
- 10 A I didn't know him ahead of this email and Martin was
- 11 | introducing me to him through this email.
- 12 Q Okay. And in the body of the email, Mr. Shkreli writes:
- 13 Our board discussed the Retrophin investment program and the
- 14 | feedback missed. In general, the BOD -- is that in reference
- 15 to the board of directors?
- 16 A Yes.
- 17 Q Was intrigued by engaging in a unique and different
- 18 | approach, parens, the program is up over 3 million, a material
- 19 | amount to Retrophin, but was also concerned about risk. After
- 20 | some sole searching and chatting with you, I think we've
- 21 | arrived at good place. Three way sign-off on all investments
- 22 and a strong focus by everyone but me on the portfolio.
- 23 You're right that I don't have the time to do this. I don't
- 24 | need training, but it is stellar tool for my team to
- 25 | investigate investments. So we have systematically exited

- 1 many of the investments in taking down the risk. I think
- 2 there should be more investment but at less size. This would
- 3 lower the risk even further, and I am committed to the
- 4 portfolio being exactly what I described, a tool to teach, not
- 5 a tool to scratch my inch of needing to make trades.
- 6 What was your understanding as to what Mr. Shkreli
- 7 | was referring to here?
- 8 A And that really catches the spirit of what we discussed a
- 9 at the Norwood Club meeting. This is what the board said, we
- 10 | shouldn't be actively trading with shareholder money, but if
- 11 | you want to use it in a very narrowed and defined way as a
- 12 | trading tool, that's a very useful potential vehicle to use.
- 13 And now he's reaffirming that's the spirit of how he wants to
- 14 | proceed in agreement with what the board had discussed with
- 15 him.
- 16 Q And following this, is that, in fact, the way that
- 17 Mr. Shkreli proceeded?
- 18 A That certainly is our understanding.
- 19 Q And you had mentioned that you actually met with
- 20 Mr. Shkreli following the Norwood Club meeting; is that right?
- 21 A Yes, I think it was about a week later from memory.
- 22 | Q And why did you meet with Mr. Shkreli after the Norwood
- 23 | Club meeting?
- 24 A It was such an involved meeting and I wanted to make sure
- 25 | that I was giving him feedback and how it went and feedback I

- 1 | wanted to share with him. And we also had an executive
- 2 session that he wasn't party to at the Norwood Club meeting,
- 3 and I wanted to give him the headlines that I agreed with the
- 4 board, I would share with him that as well.
- 5 Q And what's an executive session?
- 6 A It's an executive session is where the independent
- 7 directors can chose to meet by themselves without having any
- 8 executives of the company there, including Martin, of course,
- 9 who was an executive CEO. So it's effectively a closed
- 10 session of the independent directors and whoever they chose to
- 11 invite.
- 12 Q And did you share what had been discussed in the
- 13 executive session with Mr. Shkreli?
- 14 A Yes. Yes, I did.
- 15 Q And what do you recall discussing with the defendant at
- 16 | that meeting?
- 17 A Well, I know we went over -- the meeting as a whole at
- 18 | Norwood Club went very well. The overall meeting as whole
- 19 | went well. But I did share feedback with him about the one or
- 20 | two things that became sticky; you know, how he handled the
- 21 | Horacio Plotkin situation and trying to couch him about how to
- 22 | handle that differently. Reaffirming that the investment
- 23 | proposal would be handled. Of course, it would be handled the
- 24 | way that we discussed at board meeting. And there are a
- 25 | couple of other subjects. I don't recall a list at this

- 1 point. But those are the two principal ones that I wanted to
- 2 share with him.
- 3 Q And let me direction your attention to Government
- 4 Exhibit 122-72, if you want to refer to this document to see
- 5 | if it refreshes your recollection.
- 6 A Oh, yes. Yeah, this -- yes.
- 7 Q And do you recall anything else that you discussed with
- 8 the defendant at that meeting after reviewing this document?
- 9 A Yes, this is a list that I compiled all ready for the
- 10 discussion. I don't believe we got to all of it, but we
- 11 | certainly did discuss some of the items under one; you know,
- 12 one and two.
- 13 Q And what did you discuss with the defendant at this point
- 14 | in time regarding any use of social media?
- 15 A This was a time when, you know, some of the board in
- 16 | particular were concerned about Martin's use of Twitter. And
- 17 | my discussion with him was, you know, again, as you can see
- 18 | here, you know, you are a little bit younger profile and he
- 19 | wants to be a modern CEO, but he has to respect that he's a
- 20 | public CEO. And we agreed that he would go away and come back
- 21 | with an approach that we as a board could agree with him
- 22 | what's the appropriate use for him, if he's going to be on
- 23 Twitter attached to Retrophin.
- 24 | Q Did you talk at all about Mr. Shkreli making sure to
- 25 inform the board of any development?

- A Yes, one of the items you see here under point C1, look
 for earlier board engagement.
- 3 Q Excuse me. I'm sorry, this is not in evidence,
- 4 Mr. Richardson, it's just to refresh your recollection.
- 5 So does it refresh your recollection at all about
- 6 discussing anything with Mr. Shkreli during this meeting
- 7 regarding engaging with the board of directors?
- 8 A Yes. We wanted to make sure all press releases and
- 9 any -- any future rejections where he might talk about the
- 10 | company performance in the future, we wanted to make sure that
- 11 | we as a board he consulted with us first before anything was
- 12 released to the media.
- 13 Q And what -- what are you referring to there about
- 14 | releasing information to the media before informing the board?
- 15 A There were one or two press releases and one or two, I
- 16 | think he made a Twitter reference some volumes, things that we
- 17 | as the board hadn't seen ahead of time, and we wanted to make
- 18 | sure he wasn't, you know, putting the company at risk by
- 19 disclosing anything that wasn't public information yet.
- 20 Q And how -- what was your observation of how Mr. Shkreli
- 21 reacted to this meeting?
- 22 A As I say, it's the first time that I think we had the
- 23 | whole management, senior management team and the board
- 24 | together and, you know, Martin likes to operate as an
- 25 | entrepreneur. And I think it's fair to say that while the

- 1 | meeting doing go well, it wasn't his favorite environment. He
- 2 | did find it that while he engaged well on the discussions, you
- 3 know, there was clearly a bit of angst that here was a board
- 4 that's going to be guite actively, you know, working with you
- 5 and overseeing you.
- 6 Q And that was in relation to the board of directors
- 7 | meeting at the Norwood Club, or at your meeting with him on,
- 8 you know, shortly thereafter?
- 9 A No, I'm referring to, you know, the discussion I'm having
- 10 | with him about the Norwood Club meeting.
- 11 Q Okay. Did you inform the board that you had had a
- 12 discussion with Mr. Shkreli after the Norwood Club meeting?
- 13 A Yes.
- 14 Q I'm showing you what's been marked for identification as
- 15 Government Exhibit 122-33 -- I'm sorry, 122-73. It's Tab 63
- 16 of your binder.
- 17 A Yes.
- 18 Q Do you recognize this exhibit?
- 19 A Yes.
- 20 Q And what is this?
- 21 A It's an email from me to my fellow board members, and
- 22 copying Marc Panoff and Evan Greebel.
- 23 Q And that's dated February 20th, 2014?
- 24 A That's right.
- 25 MS. KASULIS: The government moves this exhibit into

what it's referring to. They courageously fought through it

24

25

and made the meeting.

- 1 Q Now right under that you said: Confirming on Monday our
- 2 first call will be an executive session and de facto comp
- 3 | committee followup where, and then you state: I will update
- 4 you on my excellent meeting with Martin following our board
- 5 discussions last week. And then we will discuss CEO
- 6 compensation. I am meeting with the compensation consultant
- 7 this Friday and we have written stuff to share with you.
- 8 And so with respect to an excellent meeting this
- 9 | week with Martin, what meeting are you referring to?
- 10 A I'm referring to the meeting where I met him on the 19th.
- 11 Q Now, with respect to this first CEO compensation, did
- 12 | you, in fact, review Mr. Shkreli's compensation during this
- 13 | time period?
- 14 A Yes, I did, because with the board now fully functioning,
- 15 I was actually the head of the compensation committee. And
- 16 one of my accountabilities was CEO compensation and putting
- 17 | that together.
- 18 Q I'm showing you what's been marked for identification as
- 19 Government Exhibit 122-74. It's Tab 64 of your binder.
- 20 A Yes.
- 21 Q And do you recognize this document?
- 22 A Yes, I do.
- 23 Q And what is it?
- 24 A It's confirmation of the compensation for the performance
- 25 year 2013 for Martin.

- 1 Retrophin on to a dynamic and broad-based track for market
- 2 impact, and for starting to build a world class team that
- 3 | shares our vision. And then the board approved this
- 4 compensation; is that right?
- 5 A Yes, it did.
- 6 Q Okay. You can put that aside.
- Now, did there come a point in time when you spoke
- 8 | with the defendant regarding an SEC investigation?
- 9 A Yes, that was in March of 2014.
- 10 Q And that was after this compensation had been approved;
- 11 is that right?
- 12 A Yes.
- 13 O For Mr. Shkreli?
- 14 What happened? Can you please describe that
- 15 discussion to the jury.
- 16 A I believe the initial discussion Martin had with me is
- 17 | that he had framed that a disgruntled employee had filed a
- 18 | complaint with the SEC, Securities and Exchange Commission,
- 19 and this related to MSMB Capital. And that would I
- 20 | consider -- as an investor in MSMB Capital, would I consider
- 21 | going to be voluntarily interviewed by the SEC to answer any
- 22 questions or -- or that they might have. Because he felt that
- 23 | someone, one or two of the investors, myself included went,
- 24 | that would nip this issue in the bud and it would be closed
- 25 down quickly.

- 1 Q And so the first that you learned of this SEC
- 2 investigation was this conversation with Mr. Shkreli?
- 3 A Yes.
- 4 Q And what was your reaction to your conversation with the
- 5 defendant?
- 6 A Well, again, I was seeking at the time reassurance that
- 7 this indeed was a small issue and, again, one that could be --
- 8 you know, that didn't have bigger ramifications and was
- 9 certainly only MSMB. And he assured me it was and -- and I
- 10 | said I would be willing to be interviewed, you know, on that
- 11 basis.
- 12 Q And what happened next?
- 13 A The next thing that followed is I got a letter from the
- 14 | SEC inviting me to come or call in for an interview.
- 15 Q And did you schedule an interview with the SEC?
- 16 A Yes, I did.
- 17 O And when was that?
- 18 A The end of March, 2014.
- 19 Q Prior to that meeting, did you have any discussions
- 20 regarding the SEC investigation with anyone?
- 21 A Yes, I did. I had a discussion with both Evan Greebel,
- 22 | the counsel, and with Martin the day before I believe I was
- 23 going.
- 24 Q And what do you recall regarding your discussion with
- 25 Mr. Shkreli?

A Again, I checked in with him to make sure I had all the facts I needed. And I said is there anything else I need to be aware of? And he said, No, there were a couple of periods in the fund, this is the MSMB fund, where we weren't doing so well, but I covered it. So just be aware of that. And that's

6 when he said to me going into the interview.

Q And what do you recall about your discussion with

8 Mr. Greebel?

7

9

10

11

12

13

14

15

16

17

20

22

23

24

25

A Again, I was checking with him, my concern at that point was to make sure this was indeed only MSMB and had nothing to do with Retrophin. Because I was right that it might have disclosure requirements if indeed it touched on Retrophin, and he assured me it was only to do with MSMB.

Q And were you, in fact, interviewed by the SEC?

A Yes, I did go in person to be interviewed by them.

Q And what was your reaction to that interview?

A The interview as a whole went pretty well and -- and, you

18 know, there were couple of surprises in there that took me

19 back, as they asked me specifically if I knew about a Merrill

Lynch lawsuit, which I didn't know. I told them I didn't know

21 about that.

And they also talked about, do you know about any monies being shared with MSMB investors to do with Retrophin.

And I also said I wasn't aware of that, you know, other than my own case. You know, I knew there were going to be

22

23

24

SIDEBAR CONFERENCE

MR. AGNIFILIO: My objection is it's based on 1 2 relevance and it's also prejudicial. I don't know what the 3 relevance of what he said to the SEC and what he went back and said to Evan about what he said to the SEC, and what his 4 5 expectations were in talking to the SEC and then going back to 6 Evan and saying that my expectations in talking to the SEC 7 weren't met. It's just unduly prejudicial and I find it's 8 irrelevant. 9 MS. KASULIS: Your Honor, part of this, the rest of 10 this, I expect his testimony to be about the processes of 11 Mr. Shkreli as the CEO of Retrophin; that they opened on this 12 issue, that these individuals stole the company from Martin, 13 and we have to lay the ground work as to the decision that 14 they made to remove Mr. Shkreli. It's also effect on the 15 listener, what he does next with respect to learning that information from the SEC interview. And so we believe that, 16 17 you know, that exceptions to the hearsay rule apply and that 18 it is, in fact, relevant to this period of time with respect 19 to the matter regarding the defendant. 20 THE COURT: All right, and at this point is the 21 government alleging that Mr. Greebel is discussing with --22 MS. KASULIS: Yes. 23 THE COURT: -- Mr. Shkreli --24 MS. KASULIS: Yes. 25 THE COURT: -- with regard to the Retrophin account?

SIDEBAR CONFERENCE

1 MS. KASULIS: Yes.

MR. BRAFMAN: Your Honor, the issue of what he said to Mr. Greebel and what Mr. Greebel says to him is a separate issue than what the SEC says to him. We have someone from the SEC essentially testifying through his discussion with Greebel.

THE COURT: No, it's a discussion between this witness and Mr. Greebel, an alleged coconspirator charged in Count Seven and Eight about information he learned from the SEC and asking the attorney for information about, point one was the Merrill Lynch, and also use of Retrophin money purportedly for MSMB investors.

So I think it's fair ground and it's directly relevant to the charges, and I don't believe it's unduly prejudicial to Mr. Shkreli. So I will overrule the objection.

MR. AGNIFILIO: We know the SEC investigation was only on MSMB, and there's no allegation that Greebel as a coconspirator knew of that investigation.

MS. SMITH: The SEC sent documents to Retrophin as well, and they have — they are familiar with the charges in this case, so while it may have begun as a focus on MSMB, it certainly developed and produced communications between the SEC and Mr. Greebel — I'm sorry, Mr. Greebel's associate or fellow partner, Mr. Rosensaft, that shows that the investigation proceeded from MSMB into what was Retrophin's

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

SIDEBAR CONFERENCE

connection to what had happened with the MSMB investors. So by this point in 2014, the SEC investigation has proceeded, and like I said, they did send document requests to Retrophin directly.

MR. AGNIFILIO: You know, I don't think there's been a showing by preponderance that Evan Greebel is a coconspirator. Basically the evidence in this record that Evan Greebel is a coconspirator for purposes of having these discussions with this witness being the exception to the hearsay rule. I think there's layers of hearsay.

THE COURT: Okay, but what I'm seeing is that Mr. Richardson, as a member of board and has a very close relationship with Mr. Shkreli, consults with him in his capacity as a board member and as a friend; he's meeting with him, he's mentoring him, he's giving him tips on how to conduct himself in a board meeting. He's somebody who is taking the part himself, both as a board member and because of his relationship with Mr. Shkreli, to find out what is going on as a result of Mr. Shkreli's request that he show up and basically meet with the SEC on his behalf. If he learned from him initially -- that he otherwise wouldn't have learned if Mr. Shkreli hadn't asked him to meet, and he's consenting now with Mr. Greebel, who he testified was counsel to Retrophin and he said, look, the SEC is raising issues or concerns about Retrophin money and its use with MSMB investors. So I think

- 1 (In open court; Jury present.)
- 2 BY MS. KASULIS:
- 3 Q So you had stated, Mr. Richardson, that you had called
- 4 Mr. Greebel after you met -- after you met with the SEC; is
- 5 that correct?
- 6 A Yes.
- 7 Q Did you also have any discussions with the defendant?
- 8 A Yes. Yes, I did. A few days later.
- 9 Q And where did you have those discussions?
- 10 A I believe they were in the office again.
- 11 | Q What do you recall about that discussion?
- 12 A I raised it and said generally the interview went, you
- 13 know, as I anticipated as he laid out, but with one big
- 14 exception, that he raised a Merrill Lynch lawsuit and what was
- 15 | that. And why didn't I know about it. And he had said to me,
- 16 | yes, that was -- that was one of the areas where we had some
- 17 | problems I referenced, but I didn't tell you the specifics
- 18 | because I didn't want to come across as a failure to you on
- 19 that.
- 20 Q And what was your reaction to that explanation?
- 21 A You know, we talked it through a little bit and I
- 22 | understood, you know, at the end of the day I asked him, I
- 23 | said, Are you telling me there's nothing inappropriate in here
- 24 | and that everything was covered, and that's how we left it,
- 25 yes. Yes, while it was a problem at the time, I covered it

- 1 and we moved on, and you saw that in your own investment.
- 2 Q And so what did you do after this -- after this SEC
- 3 | interview and your discussion with the defendant?
- 4 A You know, I said, you know, you got to keep me up to date
- 5 and the one thing you got to make sure is totally transparent
- 6 so I'm not blindsided by anything in the future. I am on the
- 7 | board and it's critical you keep my fully informed.
- 8 Q Did you actually notify the other board members about the
- 9 interview?
- 10 A I did a little bit later. I had spoken to Evan to double
- 11 | check that this still didn't impact Retrophin, so I wanted to
- 12 | be careful not to get ahead of ourselves, it was still MSMB
- 13 | specific. And as information, I had just let the board
- 14 | members know I think sometime a few week later when I saw
- 15 | them. I just said be aware of this, that it doesn't touch
- 16 Retrophin.
- 17 Q And then directing your attention to May of 2014, was
- 18 | there a board of directors meeting that month?
- 19 A Yes, there was.
- 20 Q And where was it located?
- 21 A It was located at the Manhattan offices. The outside law
- 22 | firm, because it was -- the board meeting was next to -- was
- 23 | happening next to the annual general meeting, which would
- 24 involve potentially more people.
- 25 Q And what's this general annual meeting?

A Again, it's a legal reporting and processing requirement of any publicly-traded company, where any shareholder is free to come along to meet the management of the company. The auditors, the external auditors are there, and it's a chance, very transparently, for the shareholders to engage with the management of the company, and that needs to happen publicly and in a public forum once a year.

- Q And that's why it was conducted at Katten's offices?
- 9 A Yes, because we weren't sure how many people might come.
- 10 It could be 20, 30, 40 people, and they have the space to
- 11 | handle that type of meeting.

8

17

18

19

20

21

22

23

24

25

look like.

- Q And was there also a board of directors meeting that occurred at that time?
- 14 A Yes. That followed the AGN.
- Q What do you recall about that meeting, the board of directors meeting?
 - A We started it with an executive session and we -- because we were moving from the one room to the other meeting, because at this point in time we were just about to appoint Steve Aselage as president of the company, and the independent directors wanted to talk directly with Steve about what that would look like and what some of these areas of focus would
 - So when we held the meeting, Evan Greebel had come up and come in with us, he wanted to join the meeting and I

- 1 | said to him, No, this is probably going to be the independent
- 2 directors with Steve Aselage and we want to exclude you and
- 3 | Martin at this point.
- 4 Q And what did you observe was there reaction to that?
- 5 A Well, the point was only Evan by himself because Martin
- 6 was still walking over from the other meeting. He said, look,
- 7 it's normal for the company executives to sit in, even in
- 8 executive sessions. I said it's normal, it doesn't have to
- 9 happen, and at this meeting we don't want you to be here.
- 10 Q Why didn't you want Mr. Greebel to be there?
- 11 A Again, certainly after the SEC discussion, I was -- I was
- 12 losing some confidence in Evan's independence.
- 13 Q Independence, what do you mean by that?
- 14 A Independence of was he really -- was he taking his role
- 15 as acting company secretary seriously and really talking with
- 16 | the board and letting us know anything we should be aware of,
- 17 or raising any issues that he feels should be raised.
- 18 So part of what I had already done with Martin is to
- 19 | say we must accelerate getting our own general counsel on
- 20 | board so that we, you know, the board has access to them, so
- 21 our own general counsel.
- 22 So that was part of the reason, again, I wanted to
- 23 | have a more private -- we wanted to have a more private
- 24 discussion with Steve Aselage as he was taking -- as he was
- 25 | assuming his new role.

- 1 Q And what did you observe with respect to Martin Shkreli's
- 2 reaction to not being part of the executive session?
- 3 A Because he was walking behind us, because he was talking
- 4 to other people from the annual general meeting, he started to
- 5 | walk in, and I think I was the one who said to him, hey,
- 6 Martin, we don't want you yet, we're going to have this
- 7 | independent to start with, we'll let you know when we're
- 8 ready.
- 9 Q And what was his response?
- 10 A At that point he did stay out there. But about, you
- 11 know, ten minutes into our discussions, he did sort of bang on
- 12 | the door and said, you know, is it about time I can come in
- 13 now? And we said, No, not quite yet.
- 14 Q And why did you exclude Mr. Shkreli from that meeting?
- 15 A Again, we wanted to really have a chat, a discussion with
- 16 Steve Aselage.
- 17 Q And why didn't do that with Mr. Shkreli present?
- 18 A Again, because we were getting role clarity. We wanted
- 19 to get the role clarity that we felt we needed between Steve
- 20 | coming on board as president and chief operations officer and
- 21 Martin.
- 22 Q And you were saying that you were bringing Mr. Aselage on
- 23 as president of the company at that point?
- 24 A Yes.
- 25 Q And was he solely in the president role?

- 1 A Yes.
- 2 Q Okay. And what was his responsibilities as the
- 3 president?
- 4 A He was going to take the commercial side, you know,
- 5 | really bring together and building out the sales force that we
- 6 | would be building the infrastructure for selling the drugs
- 7 that we would to bring is to market, and also some of the
- 8 interfaces with the research and development department.
- 9 That's where he focused.
- 10 Q Okay. And then during the -- after that meeting, during
- 11 | the summer of 2014, what was happening at Retrophin?
- 12 A It was an incredibly busy time, we were just acquiring
- 13 | another drug, and Martin had been bringing forward, you know,
- 14 | almost like an endless stream of new business development
- 15 opportunities, potential acquisitions.
- 16 And as a board, we were getting concerned about the
- 17 | volume of new deals he was potentially bringing forward,
- 18 | because we already had the success of the ones from January,
- 19 | we had another one in May, and we felt the organization needed
- 20 to consolidate so it can cope with these new drugs and build
- 21 | them into our offering model.
- 22 And also coming into that summer window, you know,
- 23 | there was a strained relationship between Martin and the CEO
- 24 | Marc Panoff, which was becoming quite public to the board.
- 25 You know, Martin's raising issues with us, and Martin is

- 1 | raising issues and concerns about with Marc with us.
- 2 So it was an incredibly busy time but there were
- 3 starting to be some cracks, if you like, starting to emerge.
- 4 Q And I'm going to direct your attention to an exhibit
- 5 marked for identification as Government Exhibit 122-84. It's
- 6 Tab 66 of this binder.
- 7 Do you recognize this document?
- 8 A Yes.
- 9 O And what is it?
- 10 A It is an email from myself to Martin copying Steve
- 11 Aselage.
- 12 Q And what is the date on this email?
- 13 A It's dated June 25th, 2014.
- MS. KASULIS: The government moves this exhibit into
- 15 evidence.
- MR. AGNIFILIO: No objection.
- 17 THE COURT: We receive Government Exhibit 122-84.
- 18 (Government Exhibit 122-84, was received in
- 19 evidence.)
- 20 Q So this is an email from you dated June 25th, 2014 to
- 21 Mr. Shkreli with a carbon copy to Steve Aselage; is that
- 22 right?
- 23 A That's right.
- 24 | Q And it's entitled "Board Input Company Confidential" with
- 25 an attachment?

- 1 A Yes.
- 2 Q Can you please read that first paragraph of your email?
- 3 A Excuse me. Martin, as we discussed, I was able to speak
- 4 with each of our board colleagues before I got on the plane.
- 5 They all share the same frustration you have, that much of the
- 6 hard work and breakthroughs of recent months are getting
- 7 buried under a series of items that are both surprises and
- 8 distractions. As a board we want to make sure we support and
- 9 quide you in a manner where you can focus on the things you do
- 10 so well, growing Retrophin and driving for breakthrough
- 11 | patient solutions. If we work together with the right rigor
- 12 and planning, we know we can keep Retrophin on the growth
- 13 trajectory we all want to see.
- 14 Q And then the next paragraph?
- 15 A The collective input of the board is to set out on the
- 16 | attached page, you and I have already discussed most of these
- 17 | items, in keeping with our oversight -- excuse me, the
- 18 | collective input of the board is set out on the attached page,
- 19 | you and I have already discussed most of these items, in
- 20 keeping with our oversight and government's responsibilities,
- 21 | we want to see each of the attached items put in place as soon
- 22 | as possible.
- Q Okay, so let's go ahead and look at the attachment that
- 24 you refer to there.
- Who put together this attachment?

- 1 A I put this together -- this attachment together after
- 2 discussion with the other board members.
- 3 Q And what is the title of this attachment?
- 4 A "Retrophin Growth and Control Initiatives Company
- 5 Confidential June 2014."
- 6 Q What prompted you putting this together this -- this memo
- 7 and sending it to Mr. Shkreli?
- 8 A Two or three things, as I mentioned, were happening
- 9 particularly in June that concerned us as a board.
- 10 First of all, you know, the fact that, you know, as
- 11 I said, the fact that his relationship with Marc Panoff was
- 12 | obviously strained and the concern that we weren't moving
- 13 | ahead at that point to find our own internal general counsel,
- 14 and that we weren't building out some of the other roles that
- 15 | we needed to recruit. And also we were starting to get
- 16 | feedback that there was some control exposures and that he
- 17 | wasn't following through on some of his commitments on the
- 18 business development trading side as well.
- 19 Q And does this document reflect the different parameters
- 20 | that you had set out to Mr. Shkreli regarding your concerns?
- 21 A Yes. These are the things we wanted addressed as a
- 22 | board, and we wanted him to realize how serious we thought
- 23 | about this, because it was critical in the way the company was
- 24 run.
- 25 Q Under this stakeholder insight section, we talked about

1 | an investor perception survey and employee survey.

What was your purpose in asking for those two surveys?

A The other -- the other directors and myself had had a discussion at this point through the month of June, but we really needed to now accelerate the timeline of -- of Martin moving out of the CEO role in a progressive manner.

Q When you say accelerate the timeline for him moving out of the role, what do you mean by that?

A Well, we had been discussing it for quite a while, all the way back to when we were coming to be NASDAQ listed, he was interviewing a potential president who would potentially become CEO, and the context of this, again, is, you know, we saw Martin, again, as we discussed before, he's excellent at the setup stages, but he didn't have the experience and the leadership to really run, you know, a complex multi-product business. And, again, we were — this wasn't about taking him out of the company in any form, it was — this was to prepare ourselves to say, we want to have the facts at our fingertips to have a discussion with him later in the year so say let's have an orderly move towards you assuming a different role, you, Martin, assuming a different role, and then having a new CEO appointed, who had experience running a multi-product line complex business.

Q And what was your position at Retrophin at this point in

- 1 time?
- 2 A As part of the discussions with the other directors, they
- 3 had asked me to become chairman of the board. We didn't have
- 4 a chairman up to this point, because they wanted me to help
- 5 steer these discussions Martin and to lay it out. So they had
- 6 nominated and voted me in as chairman of the board during the
- 7 month of June of 2014.
- 8 Q And in this email, you reference, before you get on the
- 9 plane.
- 10 What are you referring to there?
- 11 A I'm getting off for my family vacation in Europe to meet
- 12 | my family and friends.
- 13 Q And was that something that you do regularly annually?
- 14 A Yes, it's annual. I meet my family usually in Greece.
- 15 Q So after this point in time, what is the next thing that
- 16 | happened with respect to Mr. Shkreli's employment as CEO of
- 17 Retrophin?
- 18 A Well, specific to, you know, this document we just looked
- 19 at, you know, I copied Steve Aselage on it because Martin was
- 20 | going to be with Steve Aselage in San Diego following this
- 21 | communication and I knew I'd be in Greece, so prompting the
- 22 | two of them to discuss this, because I discussed most of it
- 23 | with Martin before he left. So to make sure that there was a
- 24 | follow through suggestion. So that was the specific next step
- 25 that happened in June.

- 1 Q Who was on the board of directors at this point in time?
- 2 A At this point in time, it was still myself, Martin, Steve
- 3 Aselage, Neal Golding, and Jeff Paley.
- 4 Q And with respect to Jeff Paley, what happened, if
- 5 anything, regarding his position on the board of directors?
- 6 A He ended up resigning in early September. In early
- 7 September of 2014, he had shared with me that he was concerned
- 8 about Martin not following the direction of the board, and
- 9 | ignoring some of our instructions, and also the fact that
- 10 | Martin was being forward very significant potential
- 11 | acquisitions, one of them over \$500 million. And he didn't
- 12 | feel as a company we were ready yet to -- to handle an
- 13 | acquisition of that size, so he decided to resign in early
- 14 September.
- 15 Q And so with his resignation, how many board members did
- 16 have at that point?
- 17 A That left us with four.
- 18 Q And with respect to NASDAQ listing requirements, did that
- 19 impact the listing requirements?
- 20 A Yes, it did. Because of the four, two were executive
- 21 | roles, both Martin and Steve Aselage, the CEO and president
- 22 | were executives, which only left myself and Neal Golding as
- 23 | independent. NASDAQ listing requirements are that you have a
- 24 majority of independent directors.
- 25 Q So now directing your attention to September of 2014.

- 1 A Yes.
- 2 | Q In early September what, if any, discussions did you have
- 3 with Mr. Shkreli regarding his position at Retrophin?
- 4 A I arranged to have a meeting with him and a dinner with
- 5 him to talk about how these discussions had moved towards
- 6 through the summer and also raised with him very specifically
- 7 | that I was telling him sort of this one-on-one meeting that he
- 8 was losing support of the board.
- 9 Q And why is that?
- 10 A Again, he -- he was not heeding the direction of the
- 11 | advice that we set out all the way back in June and -- and
- 12 also, we had just learned, about a two weeks or maybe a week
- 13 | before I was meeting with him, but not only had he ignored our
- 14 | instructions on the trading of the business development group,
- 15 he had actually put in place a commission structure to pay
- 16 | them money as compensation, you know, these are Retrophin
- 17 | employees to actually do trading.
- 18 Q And did you raise that with the defendant at that dinner?
- 19 A I raised it as part of the discussion and asked him
- 20 directly had he put a commission structure in place with the
- 21 | business development group and he said no.
- 22 Q And what was your reaction to that?
- 23 A I was stunned. Absolutely stunned.
- 24 Q And why is that?
- 25 A You know, as a board member and chairman at the time,

RICHARDSON - DIRECT - KASULIS

1 he's lying to my face.

2 MR. AGNIFILIO: Objection.

and felt that was important.

THE COURT: I will overrule the objection, it's a perception of the witness.

Q And after -- was there anything else that Mr. Shkreli said to you during that dinner?

A No, the other thing is he basically said, you know, it's a weak board, I can get rid of you whenever I need to.

Q So what did you do after this dinner with the defendant?

A Well, clearly that -- you know, again, up until that point while I still knew he would go ahead in the following weeks with the board meeting and talk about him coming out of the CEO role, we were going to do it more as a discussion with him. Because we certainly wanted him to stay in the company

A very important criteria to me here as a board member is how the street -- how the market reacts. You know, if they hear bad news or something traumatic about the CEO, that can hurt the company dramatically. So I knew we had to handle this in a very appropriate manner, very appropriate manner to protect the board -- to protect the company -- the company. So I had a followup conversation with -- at that time the only other directors, other than Martin, was Steve Aselage and Neal Golding after I had this meeting with Martin. I think two or three days later I had a call with him where I

RICHARDSON - DIRECT - KASULIS

shared with him. And I said -- I previously set out the criteria that I only would be willing to proceed to remove Martin from the CEO role under three -- you know, if we had an interim CEO ready to announce; if we had -- we were able to talk -- make sure that he, Martin, remained on the board of directors in an advisory role, and that we had a very, very good communication plan to handle the news and handle the transition.

And it was on this call that following week, I think it was around the 23rd of September, with Steve Aselage and Neal Golding that it was the first time that Steve Aselage agreed that he would be willing to be interim CEO. And on that call with him, we agreed now that we would proceed the following week after we got our communication plan ready and we would prove to remove Martin as CEO, ask him to stay on the board of directors and play a strategic advisory role.

Q And what happened after that call?

A After that call, you know, Steve Aselage and I focused on the communication plan, or punch list as we called it. We had to make sure that we had a very good communication plan together to make sure, again, we protected the company, and, again, you know, we were preparing on how we would communicate this with Martin. Because, again, while we knew he couldn't stay in an executive role, because of the fact he lied to me, he could no longer stay in an executive role, even at that

RICHARDSON - DIRECT - KASULIS

point wanted him to stay as a board of director because of his ideas and everything else were very valuable to the company.

So we prepared to meet with him, and Steve Aselage and I set up the meeting with him for, I think, 5:00 on the Monday the 29th of September.

- Q And did you, in fact, have that meeting?
- 7 A We had that meeting with Martin, yes.
- 8 Q And who -- who was part of that meeting?
- 9 A It was just myself, and Martin, and Steve Aselage and at
- 10 Martin's office.

3

4

5

6

- 11 Q And what happened during that meeting?
- A As chairman, I took the lead in the discussion and,
 again, because I wanted to make sure that we kept Martin
 playing a role with the company I -- I framed it in two ways.

One, is to talk about the fact that we had many times talked about once the company got to certain size and complexity, we needed a different type of CEO. And we talked about that previously and said that was one of the framing of that, however, we now as a board had decided that he had to -- we wanted him -- to remove him from the CEO role because of -- of three specific incidents and government breaches, which meant he could longer stay in an executive role.

(Continued following page.)

24

15

16

17

18

19

20

21

22

23

SIDEBAR CONFERENCE

I'm hearing this for the first time, 1 MR. AGNIFILO: 2 and he's not charged with this, that he traded when stock was 3 restricted. He's not charged with it, but he's 4 THE COURT: 5 explaining the reasons for removing him. 6 MR. AGNIFILO: That's a new crime that they didn't 7 put in for 404(b). 8 He traded during the lock-up period and MS. SMITH: 9 there is a short swing lawsuit. These were all the reasons he 10 was given in that meeting for why he was being removed as CEO. 11 MR. AGNIFILO: Before you told that to the jury, you 12 should have made a 404(b). 13 MS. SMITH: We're not alleging the separate crime. 14 MR. AGNIFILO: 404(b) is not a separate crime. 15 MS. SMITH: Tweeting inside information, this led up 16 to why he was removed. 17 THE COURT: Let's give the instruction to the jury 18 that he's not charged with trading company stock. What else 19 do you want to list so we'll make it clear. 20 MR. AGNIFILO: But --21 THE COURT: This explains the reasons for --MR. AGNIFILO: -- it could be he was convicted of 22 23 manslaughter, they can't say it's the reason he was fired.

It's duly prejudicial. It's hardly on 404(b). They want to

bring in another crime as background to the offense as

24

SIDEBAR CONFERENCE

- background to the witness's testimony or trial evidence,
 that's why we have 404(b) evidence.
- I had no idea this was coming.

8

9

10

11

12

13

14

15

16

- MS. SMITH: Your Honor, I think it's clearly not

 404(b), it's direct evidence. I'm surprised Mr. Agnifilo was

 not aware of the lock-up issue. They were aware of the short

 swing, there was a lawsuit. This was discussed.
 - MR. AGNIFILO: I'm aware of what you give me notice of. You didn't give us notice of this, you just didn't.
 - MS. SMITH: There was tweeting of the inside information. There was the short swing lawsuit. There was the berating of employees. There was the use of private investigators. There was a whole series of things that led up to the firing, all of which were perfectly fair. I don't think that we saw the trading during the lock-up as any different than anything else. He hasn't been charged with that civilly.
- MR. AGNIFILO: He said it was illegal.
- THE COURT: He said -- I don't believe he used the word illegal. He had traded in company stock.
- MR. AGNIFILO: He had an adjective.
- THE COURT: We can go back and look.
- MS. KASULIS: I can -- we can move on from this
 discussion. But again, if the cross-examination is going to
 be that this Board removed him unfairly, I think that is a

SIDEBAR CONFERENCE

- fair rebuttal evidence. 1
- 2 MR. AGNIFILO: But this isn't rebuttal.
- 3 MS. KASULIS: But if that's where you go, then I
- think, again, that opens the door to eliciting that kind of
- 5 information. Because again, if that's going to be your
- 6 cross-examination that he was being unfairly removed by the
- 7 Board, we should be able to put in their reasons, principled
- 8 reasons, for removing him as CEO of the company. We believe
- this is squarely within purview of evidence that we should be 9
- 10 allowed to admit.
- 11 I can move on from this conversation.
- 12 MR. AGNIFILO: Are you saying that he tweeted inside
- 13 information?

- 14 MS. KASULIS: They basically said he was tweeting
- 15 information about the finances of the company that could be
- 16 construed that -- they warned him about that, do not do that.
- 17 MR. AGNIFILO: They warned him about tweeting.
- 18 They mentioned, he did mention that it THE COURT:
- 19 was about information that wasn't public, that's why they
- 20 asked the Board to approve any outside media.
- 21 MS. KASULIS: Or Twitter.
- 22 MR. AGNIFILO: I was worried, inside information is
- 23 a very specific definition.
- 24 MS. SMITH: I was using that here. I don't think
- 25 that's how either of the witnesses will describe it. We won't

SIDEBAR CONFERENCE

- 1 use that term.
- 2 Non-public information. THE COURT:
- 3 We need a limited instruction. MR. AGNIFILO:
- 4 THE COURT: Let's talk about that. Mr. Shkreli has 5
- not been charged with --
- 6 MS. KASULIS: Yes.
- 7 THE COURT: -- what would you like me to address?
- 8 MR. AGNIFILO: Anything related to the trading that
- 9 was just described by the witness.
- 10 THE COURT: Okay. What else?
- 11 MR. AGNIFILO: Are you guys, you haven't really --
- 12 the tweeting issue.
- 13 MS. KASULIS: That's all I was planning on eliciting
- 14 on tweeting.
- MR. AGNIFILO: 15 I don't know that that's clear, that
- 16 he was tweeting anything that could be construed as inside --
- 17 I'm not sure about the tweeting.
- 18 The way he described it, it was just a THE COURT:
- 19 general board concerned about unauthorized disclosures about
- 20 company business either through tweeting or they wanted to
- 21 suppress releases or disclosures.
- 22 MR. AGNIFILO: Let's leave the tweeting alone.
- 23 THE COURT: Has not been charged with any offenses
- 24 relating to trading Retrophin stock; is that fair?
- 25 MR. AGNIFILO: That's fine.

2976 SIDEBAR CONFERENCE And the other witness will talk about 1 MS. SMITH: 2 We can do it at that level as well with the tweeting. it. 3 MS. KASULIS: That's Mr. Aselage. 4 THE COURT: This was reason number two. What is the 5 third so we don't have anymore sidebar? 6 MS. SMITH: Short swinging stock trading that led 7 to, there was a lawsuit. 8 MS. KASULIS: Shareholder lawsuit. 9 THE COURT: He said three reasons why he was 10 relieved. One was that he ignored the Board's directive 11 regarding business development. He traded in company stock, 12 lied to --13 MS. KASULIS: He had issued more stock options than 14 should have to the Board. That's just an internal company 15 issue. 16 THE COURT: We'll give the instruction and then you 17 can elicit whatever the second or third items are. 18 All right. So before she elicits the third I'll 19 give the instruction. 20 MR. AGNIFILO: Yes. 21 (End of sidebar conference.) 22 (Continued on the next page.) 23

24

- 1 (In open court.)
- 2 THE COURT: Members of the jury, you are instructed
- 3 | that Mr. Shkreli is not being charged with any offenses
- 4 | relating to trading Retrophin stock.
- 5 BY MS. KASULIS:
- 6 Q So Mr. Richardson, you mentioned three separate things
- 7 that you had discussed. We discussed the first two, what is
- 8 the third one?
- 9 A He had been issuing quite a number of stock grants,
- 10 incentive grants, to new employees but hadn't been keeping
- 11 | track of what the available approved pool was, and
- 12 unfortunately he had exceeded the available pool.
- 13 Q So what was the defendant's reaction during this meeting?
- 14 A He did listen throughout the discussion, at the end of
- 15 | the discussion because I had said to him, now it's best that
- 16 you go home and we can talk to you tonight or tomorrow about
- 17 | the appropriate communication around this. And that at that
- 18 point he said, "I'll beat be guys to build a new company.
- 19 I'll get to a billion dollars before you can."
- 20 | Q What happened after this meeting?
- 21 A After this meeting immediately Mr. Aselage and I met with
- 22 | our internal CFO and head of investor relations to start to
- 23 | action our communication plan and start to draft the press
- 24 | release, which we were planning to share with Martin to agree
- 25 to issue the next day.

- 1 That evening, unfortunately, it appears that Martin
- 2 had chosen to speak to some of the investors in the company.
- 3 And Mr. Aselage started to, and I started to, receive e-mails
- 4 from investors expressing their concern and alarm and wanting
- 5 to understand more about these circumstances.
- 6 Q So who are the individuals that you met with after the
- 7 | meeting with Mr. Shkreli?
- 8 A We met with Tom Fernandez, Marc Panoff the CFO, and for
- 9 part of that meeting I believe Chris Klein, who was our new
- 10 investor relations employee manager, he joined as well because
- 11 | we needed him to set up calls with each of our investors.
- 12 Q Did that in fact happen? Were there in fact calls that
- were set up with investors?
- 14 A Yes, yes. Over the next two days Steve Aselage and I
- 15 | handled a series of calls, some of which I joined, some of
- 16 which Steve Aselage handled separately.
- 17 Q With the investors of Retrophin?
- 18 A With the individual investors.
- 19 Q And was there a Board meeting that happened around this
- 20 | time period?
- 21 A Yes. We had already planned the Board meeting. We had
- 22 to delay the original agenda so we could handle these
- 23 discussions before we got back to the agenda itself, normal
- 24 agenda.
- 25 Q What happened during that Board meeting?

- 1 A During the Board meeting, of course we had to formally
- 2 talk about removing Martin from the CEO role, formally
- 3 appointing Steve Aselage as the interim CEO.
- 4 Q The Government is showing you what is marked for
- 5 identification as exhibit 122-44, tab 67 of your binder.
- 6 A Yes.
- 7 Q Do you recognize this exhibit?
- 8 A Yes, it's the minutes of the Board of Directors meeting.
- 9 Q What is the date on these minutes?
- 10 A September 30, 2014.
- 11 MS. KASULIS: The Government moves this exhibit into
- 12 evidence.
- MR. AGNIFILO: No objection.
- 14 THE COURT: We receive Government 122-44.
- 15 (Government Exhibit 122-44, was received in
- 16 evidence.)
- 17 O So is this document the minutes of the Board of Directors
- 18 | meeting that occurred on September 30, 2014, that you were
- 19 just referencing?
- 20 A Yes.
- 21 Q What is your understanding as to who actually prepared
- 22 these minutes?
- 23 A These were prepared by our new in-house general counsel,
- 24 Margaret Valeur-Jensen.
- 25 Q Do you have an opportunity to review these minutes before

- 1 | they were approved?
- 2 A She brought them to the Board for approval.
- 3 Q Your understanding is these were in fact approved by the
- 4 Board?
- 5 A They were approved by the Board, yes.
- 6 Q So directing your attention to, after the first paragraph
- 7 | there is a sentence that reads, "Mr. Richardson acted as
- 8 Chairman of the meeting. Ms. Valeur-Jensen acted as
- 9 | Secretary." Again, who is Ms. Valeur-Jensen?
- 10 A Our new in-house general counsel, which also carries the
- 11 | company's Secretary title as well.
- 12 Q The next paragraph, if you can look at that paragraph,
- 13 can you read that paragraph, please?
- 14 A "Mr. Richardson reported that he and Mr. Aselage had met
- 15 with Mr. Shkreli to discuss the issues with respect to
- 16 Mr. Shkreli's performance as Chief Executive Officer of the
- 17 | company. Mr. Richardson reported that Mr. Shkreli had been
- 18 asked to transition from Chief Executive Officer to a senior
- 19 strategic advisory position with the company, and that
- 20 Mr. Shkreli had declined. Mr. Richardson summarized issues
- 21 | with Mr. Shkreli trading in common stock of the company and
- 22 | the results of litigation. He also outlined the need for
- 23 | stricter governance and controls. The Directors discussed
- 24 Mr. Shkreli's performance and the terms of his employment
- 25 | agreement with the company. And following discussion,

- 1 determined that it was in the best interest of the company
- 2 that Mr. Shkreli no longer serve as Chief Executive Officer of
- 3 the company."
- 4 Q If you look right below that, if we scroll down, it says
- 5 | "Upon motion made and duly seconded, it was unanimously
- 6 resolved that the removal of Mr. Shkreli from all of his
- 7 duties and authority as Chief Executive Officer of the company
- 8 is hereby approved." Do you see that?
- 9 A Yes.
- 10 Q And that Mr. Shkreli was then put on paid administrative
- 11 leave for the remainder of the term of his employment
- 12 agreement?
- 13 A That's right.
- 14 Q Below that, "It was resolved further that Mr. Aselage was
- 15 | to be the Interim Chief Executive Officer of Retrophin;" is
- 16 | that right?
- 17 A Yes.
- 18 Q You had mentioned that investors had started calling and
- 19 that he had a series of communications with them, what were
- 20 | the investors' response to the news of Mr. Shkreli's removal
- 21 as CEO?
- 22 A We took them through what we could appropriately share,
- 23 knowing that they were trading in company stock. As we're
- 24 | speaking to them we had to have their reassurance they weren't
- 25 | trading until this was publicly disclosed information. And in

- 1 | the discussion with them, we took them through why we had made
- 2 this decision and why we had taken this action and that we
- 3 indeed had hoped and still wanted Martin to remain on the
- 4 Board.
- 5 And they were quite surprised, because they said
- 6 | what we were sharing with them was quite different than the
- 7 story that Martin had shared with them the night before.
- 8 Q What ultimately was the investors' response by the
- 9 decision by the Board?
- 10 A They wanted reassurance about the direction the company
- 11 | was taking. And ultimately, I'm proud to say, we didn't lose
- 12 one investor that I'm aware of, each of them continued to
- 13 invest in the company.
- 14 Q What was Martin's reaction to the Board's removal of him
- 15 as CEO of Retrophin?
- 16 A By the 30th he had reacted, the way explained earlier, by
- 17 | the next day he had started to take the more aggressive stance
- 18 | saying, "you can't terminate me," and he became a lot more
- 19 | volatile and said, "I'm not resigning."
- 20 Q I'm showing you what's been marked for identification as
- 21 | Government's Exhibit 122-92, it's tab 68 of the binder. Do
- 22 you recognize this exhibit?
- 23 A Yes.
- 24 0 What is it?
- 25 A An e-mail from Martin.

- 21 borrow against stock. Also interested in resigning now if
- 22 | that is something you're interested in. MS.
- 23 What was your understanding of Mr. Shkreli's posture
- 24 at this point in time regarding his removal as CEO of
- 25 Retrophin?

- 1 A Again, he was sending us mixed messages during this week.
- 2 And part of it was, I think, he was waiting to see the
- 3 investor reaction because he had spoken to many of them. I
- 4 think he had shared with us that he expected many of the
- 5 investors not to stick with the company. And so he was moving
- 6 his stance with us during this week.
- 7 Q After this e-mail -- and you're saying he was moving his
- 8 stance, what, if anything, did the defendant do next?
- 9 A Later this week, unfortunately, despite agreements with
- 10 us, or we thought agreements with us, he went into the
- 11 Retrophin offices and started to actually go through servers
- 12 and files and started to take files out of the offices.
- 13 Q And what happened after that?
- 14 A At this point, again what we agreed in our action plan
- 15 | between Mr. Aselage and myself and Neal Golding, is that Steve
- 16 | Aselage would take the lead in now discussing with Martin and
- 17 | managing this transition with Martin.
- 18 So Steve Aselage and Martin were in discussions
- 19 through the back end of this week. But we made it clear that
- 20 he was not allowed to come into the offices, was not allowed
- 21 | to take files out. And that at this point we actually worked
- 22 | with our technology people to remove his access to the
- 23 servers.
- 24 | Q Was there a subsequent Board of Directors meeting from
- 25 | the September 30, 2014, meeting we've discussed? A meeting

- 1 | which Mr. Shkreli participated after the Board of Directors
- 2 | meeting in September 30, 2014?
- 3 A Excuse me, yes, yes. Through the various discussions and
- 4 through the rocky period here, Steve Aselage and Martin
- 5 Shkreli were able to put together an agreement, I think by
- 6 October 13, at which point Martin was being forward part of
- 7 | the agreement, his resignation from the company and the Board.
- 8 As part of that, we agreed as a company, that we would sell
- 9 him for his new company that he was setting up for at this
- 10 point, he was telling, two drugs that weren't of core
- 11 | importance to our company. We were going to sell two drugs to
- 12 him, which is one of the drugs he wanted to kickstart his new
- company.
- 14 Q What happened with respect to Mr. Greebel's involvement
- 15 | with Retrophin in the September 2014 time period?
- 16 A At this point we were of pulling back from him totally.
- 17 | We had already been pulling back from involvement with Katten
- 18 | and him ever since we had Valeur-Jensen on Board and she was
- 19 bringing in external advisers.
- 20 Q Are you still on Retrophin's Board of Directors?
- 21 A No, I'm not.
- 22 Q Why not?
- 23 A I made the decision. The decision was made I think March
- 24 of 2015. I decided not to remain on the Board when I came up
- 25 for reelection at that year's annual general meeting.

- 1 Q Did you ultimately leave the Board of Directors?
- 2 A I left the Board of Directors effective March 2015.
- 3 Q Prior to your departure from the Board of Directors do
- 4 you have an understanding as to whether an internal
- 5 investigation was initiated by Retrophin?
- 6 MR. AGNIFILO: I object. He is no longer on the
- 7 Board.
- 8 MS. KASULIS: This is prior to when he left.
- 9 MR. AGNIFILO: I object anything about this.
- 10 THE COURT: What is the ground, one word.
- 11 MR. AGNIFILO: I think it's hearsay and irrelevant.
- 12 THE COURT: Does the Government want to make a
- 13 proffer on relevancy?
- MS. KASULIS: Your Honor, just the purpose was to
- 15 say he was separate and apart from that.
- 16 THE COURT: All right. I'll overrule the objection
- 17 then.
- 18 BY MS. KASULIS:
- 19 | O Did you have any involve in any sort of internal
- 20 investigation undertaken by Retrophin?
- 21 A No. Through the October/November window, we had
- 22 appointed, as I mentioned, a new external general counsel. We
- 23 | had asked them to start to do an investigation so we could
- 24 | find out if indeed there were any other problems that we
- 25 | weren't aware of. As part of that investigation we had

- 1 appointed an oversight committee from the Board, which were
- 2 | the two new directors we appointed. And to make sure that
- 3 | indeed any director, like myself, who was involved through the
- 4 | time while Martin was CEO, wasn't any part of the
- 5 investigation's oversight.
- 6 | Q Were you compensated for serving on Retrophin's Board of
- 7 Directors?
- 8 A Yes, I was, from the end of 2013 through to when I left
- 9 the Board in March 2015.
- 10 Q What was your compensation as a Board member of
- 11 Retrophin?
- 12 A In total for those two periods, again, much of this is in
- 13 | stock that I still hold. So again, it's stock I hold, but the
- 14 | total value of the stock I hold and the cash retainer that I
- 15 received was just over \$400,000.
- 16 Q Separate from your compensation as a Board of Directors
- 17 | member, what about your MSMB Capital investment that you had
- 18 | rolled over into Retrophin. Do you understand what the value
- 19 is of that investment?
- 20 A It's all, again, in Retrophin stock that I still hold.
- 21 | So it's based on whatever the market right is, but I'd
- 22 estimate if the price stayed the same the last couple days
- 23 \$1.9 million.
- 24 | Q Then separate and apart from that, you have your own
- 25 Retrophin shares that you purchased independently of anything

- 1 | with respect to your MSMB Capital investment?
- 2 A Yes.
- 3 Q Or your compensation on the Board of Directors; is that
- 4 right?
- 5 A Yes, yes.
- 6 Q You still hold those shares?
- 7 A I still hold those shares.
- 8 Q When was the last time you had contact with the
- 9 defendant?
- 10 A The last time, he sent me an e-mail I believe when it was
- 11 | publicly announced that I wasn't going to be standing on the
- 12 Board again, that would have been March 2015.
- 13 Q What do you recall from that e-mail?
- 14 A It was an e-mail sort of saying that he was pleased that
- 15 I wasn't going to be staying on the Board and now can we
- 16 rekindle our friendship.
- 17 Q What was your response to that?
- 18 A My response was, I'm still on the Board for the
- 19 | foreseeable future. And I would be willing to meet with him.
- 20 I really wanted to understand at this point why he comprised
- 21 our friendship and why he held so many things back from me as
- 22 a Board member.
- 23 Q Did you have any further discussions with the defendant
- 24 after that e-mail exchange?
- 25 A No.

2990 S. RICHARDSON - CROSS - AGNIFILO 1 (In open court: 1:08 p.m.) 2 (Jury enters the courtroom.) 3 THE COURT: All right. We have all our jurors back. 4 Mr. Agnifilo, if you'd like to cross examine 5 Mr. Richardson we'll bring him back to the witness stand. 6 (Witness takes the stand.) 7 THE COURT: Sir, you're still under oath. 8 THE WITNESS: Yes, Judge. 9 CROSS-EXAMINATION 10 BY MR. AGNIFILO: 11 Good afternoon, Mr. Richardson. 12 Good afternoon. 13 My name is Marc Agnifilo. I'm one of Martin Shkreli's 14 lawyers. I'm going to ask you some questions. If I ask you a 15 question that's not clear to you, please ask me to rephrase 16 it. I'm happy to do that. 17 Okay. 18 Before we broke you gave three reasons, three primary 19 reasons why the board of Retrophin removed Martin as the CEO. 20 Do you remember that testimony? 21 Yes. Α

the business commission, the business group that was doing the

And you said that he was giving essentially incentives to

- 24 trading, correct?

22

25 A The business development group, yes.

- S. RICHARDSON CROSS AGNIFILO
- 1 Q And they were the ones doing trading?
- 2 A Yes.
- 3 Q You said he was trading in the company, correct?
- 4 Trading company stock?
- 5 A When the window was closed.
- 6 Q And you said that he was giving stock grants to new
- 7 employees, correct?
- 8 A In excess of the approval.
- 9 Q Got it. None of the reasons related to unauthorized
- 10 settlement agreements, correct? Yes or no?
- 11 A No.
- 12 Q None of the reasons related to unauthorized consulting
- 13 agreements, yes or no?
- 14 A No.
- 15 Q None of the reasons related to him steeling from the
- 16 | company through such agreements, yes or no?
- 17 A No.
- 18 Q None of them related to him lying to Retrophin through
- 19 | reaching such agreements, correct?
- 20 A Correct.
- 21 Q Now, before we broke you said that you were paid for your
- 22 duties as a board of directors member, correct?
- 23 A From late 2013, yes.
- 24 | Q And you worked very hard in that capacity, fair to say?
- 25 A Yes.

- S. RICHARDSON CROSS AGNIFILO
- 1 Q And you were paid \$400,000 by today's value of Retrophin
- 2 stock?
- 3 A That's correct. Across that period.
- 4 | Q And you also said that the exchange of your MSMB value to
- 5 | your Retrophin stock is what as of today's value?
- 6 A 1.9 million.
- 7 Q So between your pay on the board and your profit, we're
- 8 talking about \$2.3 million, fair to say?
- 9 A Yes.
- 10 Q Now, you were with American Express how long?
- 11 A Thirty-six years.
- 12 Q American Express, one of the leading companies in the
- world by many metrics, correct?
- 14 A Yes.
- 15 Q Founded in 1850, correct?
- 16 A Yes.
- 17 Q I did my research.
- 18 A You did. The Wells Fargo.
- 19 Q Yes. And you were Senior Vice President of HR, correct?
- 20 A Yes. I wasn't the number one person in HR, but I was
- 21 | Senior Vice President of HR.
- 22 Q And how many people did you supervise, if I can ask?
- 23 A At that time about 400.
- 24 | Q And so you had 400 people working under you in your
- 25 | capacity in the HR department of AMEX, right?

- S. RICHARDSON CROSS AGNIFILO
- 1 A Yes. My responsibilities.
- 2 Q And how long a period of time did you have those
- 3 responsibilities where you were supervising 400 people?
- 4 A Really through that 12-year period that I was in the
- 5 human resources area.
- 6 Q And at one point you were something called the Chief
- 7 Talent Officer?
- 8 A That was part. It was an adjunct title. They went
- 9 together.
- 10 Q I see. And tell us about that. What are your duties and
- 11 responsibilities in that capacity?
- 12 A It was -- I was responsible for all the international
- 13 regions, so outside of the United States from the human
- 14 resources point of view. I was responsible for the
- 15 | recruitment of our talent of our employees going forward. I
- 16 was responsible for the development, planning of our existing
- 17 | employees. I was responsible for employee relations, you
- 18 | know, if there were any issues with employees. A whole mix of
- 19 portfolio of account abilities.
- 20 Q So fair to say you had a very significant job at a very
- 21 | significant company?
- 22 A Yes.
- 23 | Q And you left American Express after 36 years in 2008?
- 24 A That's correct.
- 25 Q And then you were with the Boston Consulting Group?

- S. RICHARDSON CROSS AGNIFILO
- 1 A That was as a senior advisor, not as an employee. Yes.
- 2 Q Right. Right. And despite its name, the Boston
- 3 Consulting Group has offices in 80 different locations around
- 4 the world, correct?
- 5 A Yes.
- 6 Q And it's a large very successful management consulting
- 7 firm, correct?
- 8 A Yes.
- 9 Q And in your capacity as senior advisor there, what were
- 10 your duties and responsibilities?
- 11 A It was to join their consultant teams as an outside
- 12 | advisor and external voice, if you'd like, as they work with
- 13 their clients largely around the gain of people and
- 14 organizational issues that I described in my role.
- 15 Q And if there's such a thing, what was a typical client
- 16 | that you would handle with the Boston Consulting Group?
- 17 A They were large multinational organizations mostly.
- 18 Q What type of services would you provide?
- 19 A I joined them for meetings and meet with some of their
- 20 | leadership team. You know, again, perhaps their businesses
- 21 | were having problems with growth. Talk with their leaders
- 22 about how they can improve their growth plans and what they
- 23 | could do to improve the performance of their employees.
- 24 Q And you also had your own consulting business, Diverse
- 25 Outcomes is the name?

- S. RICHARDSON CROSS AGNIFILO
- 1 A Yes.
- 2 Q Tell me about that business.
- 3 A And, again, those two pieces, Diverse Outcomes, I had
- 4 just two or three direct clients that I had, again, in the
- 5 same kind of areas. Working with clients about their
- 6 organizational models, their people strategies, how they got
- 7 | the best performance they could out of their employees.
- 8 Q And you were also involved with the United Way Worldwide,
- 9 correct?
- 10 A Yes, up until 2010.
- 11 Q Tell us what that is exactly.
- 12 A United Way, as you know, is one of the largest, globally
- one of the largest nonprofit organizations in terms of money
- 14 that they are stimulating for local development, and I was
- 15 | involved with the international board which is, again, all the
- 16 | United Way affiliates around the world outside of the United
- 17 States and helping steer them and how they collaborate
- 18 together.
- 19 Q And what were your duties and responsibilities on the
- 20 international board of the United Way?
- 21 A I started as a board -- on the board of directors, again,
- 22 | part of our role is a part from any personal contributions one
- 23 | is making as well, is to really work with their management and
- 24 help them think through how can they accelerate their vision,
- 25 | their charter. How can they accelerate the impact of their

- S. RICHARDSON CROSS AGNIFILO
- 1 programs.
- 2 Q Did you have traditional board responsibilities with the
- 3 United Way?
- 4 A Yes, I ended up being chairman of the international board
- 5 for a while.
- 6 Q And just -- I don't need too much detail. Generally
- 7 speaking, what's the structure of the board that you were the
- 8 | chairman of?
- 9 A It's fairly normal. It would have the secretary and it
- 10 | would have, you know, the management team would be there. And
- 11 | it was probably eight to ten -- no, probably about 12
- 12 external board members and we meet regularly.
- 13 Q And how regularly?
- 14 A Probably quarterly. I think we had face-to-face meetings
- 15 quarterly.
- 16 | Q Did you ever have meetings on the phone?
- 17 A As a full board I don't believe we did. As subsets of
- 18 | the board on specific subjects, I think we had meetings, we
- 19 had calls.
- 20 | Q So that the board would have certain sort of like
- 21 subgroups within the overall board?
- 22 A Yes. That might be working on a particular project or a
- 23 particular geography of support.
- 24 | Q Fair to say that you're a sophisticated investor?
- 25 A Certainly capable, a capable investor, yeah.

Case 1:15 cr 00637 KAM Document 315 Filed 08/15/17 Page 121 of 297 PageID #: 6512

S. RICHARDSON - CROSS - AGNIFILO

- 1 Q Do you remember telling the Securities and Exchange
- 2 | Commission you were a sophisticated investor?
- 3 A I think in response to the question I probably said yes,
- 4 | but -- or I may have said what I just said now which is
- 5 capable may be the better word.
- 6 Q This will only take a second. Let me ask you, do you
- 7 | recall what you said to the SEC about the type of investor you
- 8 are? Do you have any specific recollection?
- 9 A I don't about the particular adjectives used or
- 10 descriptors used, I don't.
- 11 MR. AGNIFILO: Just give me one second.
- 12 Q Bear with me one second, Mr. Richardson. I apologize.
- 13 A Okay.
- 14 Q What I'm going to do, with your permission, it's 3500-SR
- 15 | 1-1. Mr. Richardson, I'm just going to show you something and
- 16 I'm just going to ask if it refreshes your recollection.
- 17 | That's the only question I'm going to ask you, and I'd ask you
- 18 | to look right under where it says investment experience and
- 19 just read that to yourself, if you could.
- 20 A Yeah.
- 21 Q Do you recall if you told the SEC you were a
- 22 | sophisticated but conservative investor?
- 23 A Yes. And I think it's the word "conservative." I knew
- 24 | that I had put a qualifier in there to my earlier response to
- 25 you.

Case 1:15 cr 00637 KAM Document 315 Filed 08/15/17 Page 122 of 297 PageID #: 6513

S. RICHARDSON - CROSS - AGNIFILO

- 1 Q Very good. Very good.
- Now, your investments are broken into real estate
- 3 holdings and other holdings, correct?
- 4 A Yes.
- 5 Q And tell us about your real estate holdings, if you
- 6 could.
- 7 A Yes, again, I've always tried to split my investments
- 8 roughly half and half if I can or at least make sure I
- 9 diversify them well. So I have a property here in New York,
- 10 I have two properties in Mexico and I have a property in
- 11 Greece.
- 12 Q Do you have a property in Australia?
- 13 A No.
- 14 Q And in Canada?
- 15 A No. My partner has a property there.
- 16 Q And your partner is Canadian?
- 17 A Yes.
- 18 Q And how long have you had the property in -- its in
- 19 Mykonos in Greece, correct?
- 20 A Yes.
- 21 Q How long have you had that?
- 22 A About, about over 20 years. Must be about 25 years. I
- 23 | actually had it built.
- 24 | Q During the time period that we've been talking about,
- 25 | this 2009 to 2014 time period, you would frequently go to

- S. RICHARDSON CROSS AGNIFILO
- 1 Mykonos, correct?
- 2 A Yeah, I always spend summer there, always have summer
- 3 there with my family for vacation.
- 4 Q And you would frequently go to Mexico as well?
- 5 A Yeah. Mexico is more recent. Mexico is the last few
- 6 years.
- 7 Q Now, your non-real estate holdings are generally of what
- 8 type?
- 9 A They're a classic retirement fund with conservative
- 10 | profile and a mix of the mutual funds and, you know, basically
- 11 | that's it. It's a fairly conservative portfolio.
- 12 Q And I think you said yesterday that you had never
- 13 invested in a hedge fund before meeting Martin, is that fair
- 14 to say?
- 15 A That's correct.
- 16 Q And you said that you were considering your investment
- 17 options and you decided that there was a certain amount of
- 18 | money that you were willing to put in a riskier investment,
- 19 correct?
- 20 A Yes, which I had spoken to my financial planner about
- 21 that year, yes.
- 22 | Q And so you decided you would take a portion of your
- 23 | overall investment and invest it in some hedge fund, correct?
- 24 A Yes.
- 25 | Q And I think you told us yesterday what that -- you were

- S. RICHARDSON CROSS AGNIFILO
- 1 | willing to go up to 8 percent of your non-real estate
- 2 holdings?
- 3 A Up to like 8-to-10 percent. 8-to-10 percent.
- 4 Q Okay. And so you met Martin at a cocktail party in the
- 5 | East Village, correct?
- 6 A Yes.
- 7 Q It was like on a roof?
- 8 A Yeah. The apartment had a roof level and the apartment
- 9 level. So an indoor level and an outdoor level.
- 10 Q And the apartment was owned by Ken Banta and Tony Powe?
- 11 A Yes.
- 12 Q Now, did you speak with Ken Banta at all that evening?
- 13 A I think in passing, yes. It was Tony who I was more the
- 14 | friend with and Ken was his partner, so I had only met Ken
- 15 | very briefly before, but Tony I knew.
- 16 | Q Did you know if Mr. Banta had invested with Martin
- 17 previously?
- 18 A Not that night, no.
- 19 Q You came to learn that though?
- 20 A I came to learn that later.
- 21 Q And so give us an idea of how large is this cocktail
- 22 party. This is like the fall of 2009, fair to say?
- 23 A Yes. Fall of 2009, late summer. Yes, fall.
- 24 Q Okay.
- 25 A Probably I would have thought 40-to-50 people probably

- S. RICHARDSON CROSS AGNIFILO
- 1 | churned through. Again, it was the nature of cocktail
- 2 parties, people come and go and it was on two floors.
- 3 Q And you met Martin Shkreli for the first time at this
- 4 time; is that correct?
- 5 A Yes.
- 6 Q And you said that you told him you thought he was cocky?
- 7 A Yes, because of the way he'd been interacting and the
- 8 first time, literally the first time I saw him.
- 9 Q Tell me what you remember seeing.
- 10 A It was a group of colleagues standing together and
- 11 | chatting and talking with each other that I had just joined as
- 12 I walked in there with my other friends, and, again, he was
- 13 talking a little bit about his plans and what he was doing.
- 14 And it was just a natural social interaction of people.
- 15 Q And how old was he at the time, do you know?
- 16 | A I assumed, you know, probably late 20s. Mid-to-late 20s,
- 17 I assume.
- 18 Q And was he there with other people his age, could you
- 19 tell?
- 20 A It was a mix, mixed, a mixed group of people. Mixed
- 21 ages. Mixed group of people.
- 22 | Q So you and he got to talking, correct?
- 23 | A Yes. A little bit there, but later on. We talked later
- 24 on.
- 25 Q Later on on a different day?

- S. RICHARDSON CROSS AGNIFILO
- 1 A No. No, later on that day, yes. Because, again, we were
- 2 | floating around talking with different people from the
- 3 | cocktail party.
- 4 Q And so when you and he got to talking, what did you talk
- 5 about?
- 6 A We talked about, you know, as I say, we started and he
- 7 | was interested in my human resources background, and we talked
- 8 about quite a few things. Started to talk about family and
- 9 other dimensions. And, again, because I used that cocky line,
- 10 I think he was, you know, he was intrigued about my
- 11 directness. So it was a very lively, lively conversation,
- 12 meeting someone for the first time.
- 13 Q And you recall it all these years later?
- 14 A Yeah. I don't recall the specifics of what we have
- 15 | covered, but I remember that we, you know, we created, you
- 16 know, an understanding of who each of us was to some extent.
- 17 Q But you remember all these years later you met him in the
- 18 | East Village in an apartment that had a roof access, right?
- 19 A Yes.
- 20 Q And that you spoke to him and you told him he was cocky,
- 21 right?
- 22 A Yes.
- 23 Q And the way you put it yesterday, I think he kind of
- 24 | followed you a little after you said that and engaged you in
- 25 conversation again?

- S. RICHARDSON CROSS AGNIFILO
- 1 A He just found me later. I don't want to give the
- 2 | impression he was following me. He just found me later
- 3 because I had moved down inside -- into the apartment itself.
- 4 Q The second time that you guys spoke, how long do you
- 5 think you spoke about?
- 6 A Probably 45 minutes maybe. Maybe up to an hour.
- 7 Q All right. And then the next thing that happened is you
- 8 and he had dinner, correct?
- 9 A Yes.
- 10 Q And you said that Marek Biestek was there for some period
- 11 of time, but he had car trouble, correct?
- 12 A Yes.
- 13 Q So he wasn't there the whole time?
- 14 A No.
- 15 Q You and Martin were there the whole time?
- 16 A Yes.
- 17 Q And do you remember where you went?
- 18 A Yes, I believe the first dinner was a restaurant in the
- 19 Village.
- 20 Q What was the name?
- 21 A Cafe Loup.
- 22 Q Cafe Loup. Okay.
- Do you recall that you and he went to Cafe Loup on
- 24 September 28, 2009?
- 25 A I don't recall the dates, exact date, but that's

- S. RICHARDSON CROSS AGNIFILO
- 1 certainly the right time period.
- 2 Q That's about right?
- 3 A That's about right.
- 4 Q And you and he had dinner a lot, right?
- 5 A From that point, yes. Once I was interested in the fund
- 6 and we were starting to forge a friendship, yes.
- 7 Q You went to a place called Olives pretty frequently?
- 8 A I don't think we went there frequently.
- 9 Q How many times would you say?
- 10 A Olives I would think only a couple I would think.
- 11 Q You went to a place called Blue Water?
- 12 A Blue Water Grill, yes.
- 13 Q How many times would you say you were there?
- 14 A Probably -- we did brunch and dinner over the two or
- 15 three years because it was one of my favorite restaurants.
- 16 Probably four times, five times.
- 17 Q And he came to your apartment?
- 18 A Yes. Two or three times.
- 19 Q Now, at the time he was living with his parents?
- 20 A I don't remember exactly when he overlapped to his own
- 21 apartment.
- 22 Q Do you think he had his own apartment when you met him in
- 23 2009?
- 24 A I don't recall.
- 25 Q Because you said that often he would sleep in a sleeping

- S. RICHARDSON CROSS AGNIFILO
- 1 | bag in his office, correct?
- 2 A No. He told me. He told me that, you know, he'd do that
- 3 sometimes.
- 4 Q And he would tell you that he did that quite frequently,
- 5 | correct?
- 6 A I don't recall. I don't recall quite frequently, but I
- 7 certainly recall him telling me he had done it a few times.
- 8 Q And you'd bought him gifts, correct?
- 9 A Yes. Through the years, yes, through the years.
- 10 Q What sort of gifts have you gotten him?
- 11 A A shirt, a jacket. I think they were mainly clothes.
- 12 Again, as I said yesterday in terms of helping him with his
- 13 own sharpening his image.
- 14 Q Right. He's not a particularly fashionable person? No
- 15 offense to my client?
- 16 A That's a good way of putting it.
- 17 Q Okay. Thank you.
- 18 There are less diplomatic ways of putting it,
- 19 correct?
- 20 A Yes.
- 21 Q And from your perspective, it seemed clear that he looked
- 22 up to you, correct?
- 23 A Yes. As I say, from very early meeting him particularly
- 24 when he knew I was human resources, I had been in human
- 25 | resources, I think I did quickly assume a mentor role as I

- S. RICHARDSON CROSS AGNIFILO
- 1 | said previously.
- 2 Q Didn't he tell you many times that you made him happy?
- 3 A I don't particularly know the phrase happy, making him
- 4 happy, but certainly he said he enjoyed my company and he
- 5 liked my positive vibes.
- 6 Q Didn't he refer to you in messages he sent you as a
- 7 | blessing in his life? Do you remember him saying that?
- 8 A There were some very, very praiseworthy comments and
- 9 both, I think both of us reciprocated in our messages.
- 10 Q But it wasn't just comments along the lines of I highly
- 11 regard you as a professional. He would say things to you like
- 12 you're a blessing in my life.
- 13 A I don't recall that particular phrase, but, no, there
- 14 | were some very complementary phrases used.
- 15 Q And you could tell he felt very close to you, correct?
- 16 A I think there was, yeah, we developed trust very early
- 17 on. I think, yes, we got to -- we were very caring for each
- 18 other particularly given, as I mentioned, some of the family
- 19 dynamics. There was a lot of caring about the support that we
- 20 were giving each other.
- 21 Q And he told you that his brother has autism, correct?
- 22 A No. I don't recall him ever saying autism.
- 23 Q What did he say about his brother?
- 24 A That he had severe anxiety issues and had problems
- 25 | socializing outside of the house.

Caso 1:15 cr 00637 KAM Document 315 Filed 08/15/17 Page 131 of 297 PageID #: 6522

- S. RICHARDSON CROSS AGNIFILO
- 1 Q And did Martin also tell you that Martin had severe
- 2 anxiety issues?
- 3 A No. Martin, Martin only ever labeled depression.
- 4 Depression that he was given medication for.
- 5 Q So he told you that he suffered from depression?
- 6 A Yes. He told me that later on probably 2013 or '14 is
- 7 when he said the doctor is giving him some medication for it.
- 8 Q Did he tell you that there were times he couldn't bring
- 9 himself to leave his house?
- 10 A No.
- 11 Q He never told you that?
- 12 A No. Not for himself, only for his brother.
- 13 Q Just for the moment I'm just talking about Martin.
- Did you have to give him advice from time to time
- 15 | about hygiene?
- 16 A A little bit, yes.
- 17 Q He wasn't brushing his teeth?
- 18 A He phrased that to me a couple of times. When he slept
- 19 | in the sleeping bag in the office he wouldn't clean his teeth.
- 20 Q And fair to say you noticed that he wasn't always taking
- 21 | good care of himself, correct?
- 22 A Yes. Both from the health point of view and occasionally
- 23 looking disheveled.
- 24 | Q And these were among the ways that you were trying to
- 25 help him, correct?

- S. RICHARDSON CROSS AGNIFILO
- 1 A Yes.
- 2 Q Because you, you have the good fortune to have moved
- 3 through the business world at a fairly high level.
- 4 Let me rephrase the question.
- 5 You had a very responsible job at American Express,
- 6 correct? You have to answer yes or no.
- 7 A Excuse me. Yes.
- 8 Q That's fine. You know how executives behave. You've
- 9 seen them?
- 10 A Yes.
- 11 Q And from your perspective, fair to say, Martin was doing
- 12 things that were not in keeping with being a traditional
- 13 executive, fair to say?
- 14 A Yes, with a qualifier in that, again, part of my job in
- 15 human resources is studying the difference between
- 16 | generations. And I'm an older gentleman. I'm a baby boomer.
- 17 | Martin was at the time a 20 something or young 30 something,
- 18 | so I respected that there were differences in the way a young
- 19 | leader might want to act. So I just want to distinguish, you
- 20 know, I don't expect an executive at one large corporation to
- 21 | necessarily act or look the same as an entrepreneur.
- 22 Q Did he complain to you a lot that he was sick?
- 23 A Quite often in his emails he said I have a headache. I
- 24 have a headache. I have a cold.
- 25 Q And did he complain in his emails that you would invite

- S. RICHARDSON CROSS AGNIFILO
- 1 | him out and he said I just can't do it tonight?
- 2 A Yeah, sometimes he'd say that.
- 3 Q And often you would invite him places and he would say
- 4 he's not well enough to go?
- 5 A It certainly happened. You know, again, I can't put a
- 6 number on that, but it certainly happened.
- 7 Q And I think we talked when you were talking to my
- 8 colleague with the government, you said that there were in
- 9 your emails with each other you would express love for each
- 10 other, correct?
- 11 A We certainly used the label, yeah, the word.
- 12 Q Did you not mean it?
- 13 A Well, again, I just want to clarify, implication in terms
- of loving each other or caring for each other as friends.
- 15 Yes, again, part of, you know, what clearly he was enjoying
- 16 about my company is the fact that, you know, once we could
- 17 | remove any question of anything that wasn't outside of being
- 18 | platonic, you know. He was very comfortable, you know,
- 19 because he didn't share any of these emotions with many
- 20 people.
- 21 | Q And did he say to you on more than one occasion that you
- 22 | are the first person that he feels he can be himself with?
- 23 | A I don't remember if it was the first person, but it was
- 24 | certainly, you know, again, I'm one of the few people.
- 25 Q And you knew that you had that role in his eyes, correct?

- S. RICHARDSON CROSS AGNIFILO
- 1 A Well, as a mentor and someone that he cared about and
- 2 trusted.
- 3 Q But as someone who he viewed as a blessing in his life,
- 4 correct?
- 5 A Again, I don't remember that phrase but.
- 6 Q Someone one of the few people that he expressed that he
- 7 | felt happiness with, correct?
- 8 A Again, using the word "happy" again. You know, I know
- 9 that he enjoyed my company and enjoyed my present in his life,
- 10 yes, that's the way I'll express it.
- 11 | Q I won't stick to words. I want to talk about concepts.
- 12 A Okay.
- 13 Q You were a very special person to him and you knew it?
- 14 A I think it certainly thought over time, yes.
- 15 | Q And he would say things in emails to you that led you to
- 16 | believe that he had feelings for you, fair to say?
- MS. KASULIS: Objection.
- 18 THE COURT: Sustained.
- 19 Q He would tell you that he loved you, correct?
- 20 A He'd used the word in some emails and to my face
- 21 sometimes, yes.
- 22 Q He told you to your face that he loved you?
- 23 A Yeah.
- 24 | Q And he wrote in an email messages that he loved you,
- 25 right?

Caso 1:15 cr 00637 KAM Document 315 Filed 08/15/17 Page 135 of 297 PageID #: 6526

3011

S. RICHARDSON - CROSS - AGNIFILO

- 1 A Yes.
- 2 Q And you wrote in email messages that you loved him?
- 3 A Sometimes.
- 4 Q Did you not mean it?
- 5 A But, again, loving, loving and caring as a friend.
- 6 Q Do you have other business, male or female business
- 7 | associates that you're not involved in a relationship with and
- 8 you tell them that you love them repeatedly?
- 9 A Certainly with friends I use it, yes.
- 10 Q And is that how you were using it with Martin?
- 11 A As a friend.
- 12 Q Only as a friend?
- 13 A Yes.
- 14 Q Now, you talked yesterday about you would get these
- 15 performance reports. Do you remember talking about that?
- 16 A Yes.
- 17 | Q And in addition to performance reports from time to time
- 18 | Martin would send you other reports about companies, correct?
- 19 A No. He'd send his quarterly letter in which he included
- 20 reference to other companies.
- 21 Q Do you remember a company called GenVec?
- 22 A I remember seeing the name, but I don't remember detail.
- 23 Q And do you remember him sending you information about
- 24 GenVec and a drug that it had failed, a phase three clinical
- 25 trial.

- SIDEBAR CONFERENCE MR. AGNIFILO: This man lied to this jury about 1 2 their relationship and I'm going to prove it. I'm going to 3 prove it. 4 THE COURT: By? 5 MR. AGNIFILO: By his own words. 6 MS. KASULIS: You're asking him questions and he's 7 saying he doesn't recall. 8 Do you have something to refresh his recollection? 9 MR. AGNIFILO: Yes. If that's the objection, I'll 10 refresh his recollection, sure. 11 MS. KASULIS: I mean, I'm not certain why you're 12 doing that. 13 MR. AGNIFILO: No. No. No. That's fine. I'm happy to do that. I'll refresh his recollection. We're good. 14 15 MS. KASULIS: If you have something to show him, you can show it to him to refresh his memory and you can ask him 16 17 that. 18 THE COURT: I thought we were talking about GenVec. 19 MR. AGNIFILO: Well, no. There is a context. "Only 20 if I can touch your soft skin." And I'm quoting. 21 MR. BRAFMAN: He's not speaking to the Judge. He's 22 quoting from an email. 23 THE COURT: Understood.
- MR. AGNIFILO: Thank you.
- MS. KASULIS: So the issue is that he's asking him a

- series of questions clearly about an email exchange. If he wants to say he doesn't recall -- if he wants to refresh his recollection, he can.
- 4 MR. AGNIFILO: I will. Absolutely.
- MS. KASULIS: And then he can ask a question. And if it's objectionable, we will object.
 - MR. BRAFMAN: So we maybe don't have to come back here, they opened this door with a crow bar. They suggested the relationship. Martin was infatuated with him. He didn't believe Martin was really gay, sat him down on his bed and confronted him, they started that. The fact is we're not --
- 12 THE COURT: I get it.

7

8

9

10

11

15

16

17

18

19

- MS. SMITH: Your Honor, we need to put something on the record.
 - MS. KASULIS: Your Honor, we actually contacted defense this weekend prior to this witness testifying and asked specifically if they were going to get into this relationship issue and if they were going to imply or insinuate that there was a romantic relationship.
 - MR. BRAFMAN: And we said yes.
- 21 MS. KASULIS: And they said yes. And we asked, we 22 vetted, we talked about --
- MR. BRAFMAN: He --
- 24 THE COURT: Let her finish.
- MS. KASULIS: We asked, we vetted and we talked

about it with him because we don't do these things lightly. 1 2 And so we called them, we asked them. They said they intended 3 to go into this with the witness, and so when we responded 4 accordingly with respect to our direct examination and that 5 was something that we had vetted. So I just want to correct 6

the record that we opened the door and this is a crow bar.

- MR. BRAFMAN: No. No. No. That's not what I She's right about all of that. But what we said was that we intend to go down that path, but we're not barred by what the witness says on direct to suggest that that's the true nature of the relationship.
- THE COURT: All right. But my question is this. know you opened with this whole thing that people thought he was gay. I just think sexual preference is not relevant in this case.
 - MR. BRAFMAN: It is.

7

8

9

10

11

12

13

14

15

16

19

20

21

22

23

24

- 17 MR. AGNIFILO: He doesn't care about the performance 18 They were together.
 - THE COURT: In the opening they are talking --Mr. Brafman went at length about all those perceptions that people had about Mr. Shkreli, that he's odd, that he's autistic. We have no evidence that he's autistic. We have no evidence that he's odd. Numerous witnesses have denied using these terms to describe him. And now I've heard I quess at recent sidebars a few days ago that the autism may have

- 1 interfered with his ability to form an intent to defraud or to 2 understand.
- 3 MR. BRAFMAN: No.
- THE COURT: Well, I can pull that part of the transcript, but I think that sexual preference just isn't relevant.
- 7 MR. AGNIFILO: It doesn't matter. They're having a 8 romantic --
- 9 THE COURT: He's admitted that he's gay.
- 10 MR. AGNIFILO: It's not about sexual preference. It
 11 could be a man or a woman, two women, two men, it doesn't
 12 matter. He invested with him. They were having a

relationship. That's critical. It's central, Judge.

- 14 And no one is objecting. We have had this
- discussion between us for days now.

- MS. KASULIS: Your Honor, he wants to ask him about
 the nature of his relationship and if that influenced his
 decision, he can do that, but to go and try to humiliate this
 witness.
- 20 MR. AGNIFILO: I'm not going to humiliate --
- MS. KASULIS: You can just ask --
- MR. AGNIFILO: The relationship took place when they
 were together. He's going to lie. I don't get to be stuck
 with his answer.
- 25 THE COURT: One moment. The fact that someone has

- made comments of someone's touching soft skin, I mean, I'm not sure what you mean by a relationship. They're obviously very close.
- 4 MR. AGNIFILO: I think they have a romantic relationship.
- 6 THE COURT: A sexual relationship?
- 7 MS. SMITH: Then they can ask him.
- 8 THE COURT: I think, as Mr. Brafman said, it's 2017. 9 Are we going to try to humiliate this witness because he's
- 10 gay?
- MR. AGNIFILO: No. You're missing the whole point.
- 12 No, Judge, I would never do that. I would never do that in a
- 13 | million years. I'm surprised we have to have this discussion.
- The reason I'm doing this is because they're not
- arm's length business people. I think they're having a
- 16 | romantic relationship. I think that's critical to the actual
- 17 charge here. He's not invested. They said yesterday, the
- 18 performance reports meant a lot to you. They're not. I'm
- 19 going to go through --
- 20 THE COURT: But he's testified both on direct and so
- 21 | far in court that they're very close. They expressed
- 22 thoughts. They do love each other.
- MR. AGNIFILO: A romantic relationship is different,
- Judge. It's different. It is. A romantic relationship is
- 25 different. It just -- it's always been different. People who

- love each other and are in a romantic relationship are just 1 2 different with each other. That's the last thing I'm going to do because I would never do that. I am not going to embarrass 3 4 this man, not in a million years. I would never do that. 5 trying to establish I think what is a healthy and loving 6 relationship between two people. 7 THE COURT: All right. That's fine. I do think 8 though to the extent there's a comment about soft skin, it 9 could be arguably evidence that there's more than a platonic 10 relationship. 11 MS. KASULIS: Right. 12 THE COURT: So I think it's fair ground. 13 MR. AGNIFILO: I will. I will. 14 MS. KASULIS: So ask him that. 15 MR. AGNIFILO: I will. 16 THE COURT: I think he can impeach, but I don't want 17 this to evolve into --MS. KASULIS: That's our concern as well, Your 18 19 That's our concern as well. 20 MS. SMITH: We understand the argument of bias. 21 That's fair. 22 MS. KASULIS: Right. We get that. 23 MR. AGNIFILO: Okay.
 - know, I mean, because as Mr. Brafman said, and I totally

THE COURT: So just tread carefully. Don't, you

24

ANGELA GRANT, RPR, CRR

24

S. RICHARDSON - CROSS - AGNIFILO

- 1 BY MR. AGNIFILO:
- 2 Q So what you believe when you said, "only if I can touch
- 3 | your soft skin, " you were referring to a rash on his neck?
- 4 A The fact that he had fixed it, after leaving it alone for
- 5 too long.

- 7 Q Do you recall any other conversation in this e-mail or
- 8 | any other e-mail about a rash?
- 9 A No, just verbally with him and seeing him of course with
- 10 this infection.
- 11 Q And you have a clear recollection as you sit here today
- 12 | that that's what you're talking about?
- 13 A I'm trying -- again, context is important. That's, I
- 14 | certainly have that recollection. Again, if I'm talking about
- 15 | skin, his skin infection was probably that's what I'm
- 16 referring to.
- 17 Q Now, to the extent you received periodic performance
- 18 reports, correct?
- 19 A On the MSMB Capital fund.
- 20 Q Right?
- 21 A Yes.
- 22 Q And when you got the periodic performance report on
- 23 | February 12 at 10:07 a.m., did you ask him how he was feeling
- 24 and whether the bubble bath worked?
- MS. KASULIS: Objection, your Honor.

- S. RICHARDSON CROSS AGNIFILO
- 1 THE COURT: I will overrule that objection. Go
- 2 ahead and answer it.
- 3 Q Only if you recall, if you don't recall I can show you
- 4 something.
- 5 A Again, Counsel, it's context again. Because quite often
- 6 | when he was sick he'd tell me he was sick. I would say things
- 7 that again in isolation may sound a bit weird, but when it's
- 8 | me carrying for him as friend, if it's responding to the fact
- 9 that he just told me he's was sick, I might have said, have a
- 10 bubble bath, make yourself feel better.
- 11 Q DX9029, e-mail from you from February 12, 2010, at
- 12 | 10:07 a.m.
- 13 A I actually did say, "Did the bubble bath work?" which is
- 14 | consistent again with helping him to try fix a health issue or
- 15 feel better about himself.
- 16 Q That e-mail is in response to him sending a daily
- 17 performance report, right?
- 18 A But, again, we possibly had spoken separately during the
- 19 day. Again, Counsel, I don't have the context of the rest of
- 20 | the discussions that might have triggered that. I did say,
- 21 "Did the bubble bath work," again.
- 22 | Q I'll give you the whole e-mail, I want to make sure you
- 23 | have the right context. Here is the whole e-mail. Fair to
- 24 | say he's sending you a performance report, right?
- 25 A Then I'm probably speaking to him on the phone

- S. RICHARDSON CROSS AGNIFILO
- 1 separately.
- 2 | Q In response to you getting the performance report you ask
- 3 him about a bubble bath?
- 4 A Again, it's coming from my personal e-mail just checking
- 5 in with him. I called it "checking in." I changed the title
- 6 to checking in, I changed the subject but I used the same
- 7 e-mail.
- 8 Q He sends you your daily performance report. He tells you
- 9 how your fund is doing. You change the subject, literally and
- 10 | figuratively --
- MS. KASULIS: Objection, your Honor.
- 12 THE COURT: Sustained.
- 13 Q You got an e-mail from Martin with the performance report
- 14 for the fund, correct?
- 15 A Yes.
- 16 Q You changed the subject line of the e-mail, correct?
- 17 A Yes.
- 18 Q To "checking in," correct?
- 19 A Yes.
- 20 Q And you asked him how the bubble bath worked or if the
- 21 bubble bath worked, correct.
- 22 A Yes.
- 23 | Q All right. You didn't ask him anything about what was in
- 24 | the performance report in that e-mail, correct?
- 25 A No.

- S. RICHARDSON CROSS AGNIFILO
- 1 Q Thank you. I'm done with this, thank you.
- 2 This was the performance report sent you to on
- 3 February 12, 2010, correct?
- 4 A The one you just showed me? Yes.
- 5 Q Did you frequently, when you got these performance
- 6 reports, change the subject line then send him a personal
- 7 e-mail in exchange?
- 8 A Occasionally, I think. All of it was coming to my
- 9 personal e-mail address. I just used whatever the last e-mail
- 10 was that I received quite often.
- 11 Q Do you remember if in response to the performance report
- 12 from March 7, 2010, you told him you hoped he was enjoying the
- 13 lovely day and that he was headache free?
- 14 A I quite often checked in with him, particularly if he
- 15 told me he was ill.
- 16 Q But you're getting these performance reports, correct --
- 17 A Yes.
- 18 Q -- on a regular basis?
- 19 A Daily.
- 20 Q Daily. You're using these e-mails that he's sending you
- 21 | to send personal emails back to him, correct?
- 22 A It's all in my personal e-mail account, so.
- 23 | Q My point is you're not asking questions about the fund?
- 24 A Separately, I might be verbally when I update with him.
- 25 Q But you agree with me -- do you recall specifically what

Case 1:15 cr 00637 KAM Document 315 Filed 08/15/17 Page 149 of 297 PageID #: 6540

- S. RICHARDSON CROSS AGNIFILO
- 1 | you might have said on March 7, 2010?
- 2 A No.
- 3 Q I'm going to show you Defense Exhibit 9030. I'm going to
- 4 ask if it refreshes your recollection, an e-mail March 7,
- 5 2010, from you to Martin.
- 6 A Yes.
- 7 Q He sent you a daily performance report?
- 8 A Yes.
- 9 Q You asked him how he was feeling?
- 10 A Yes.
- 11 Q Which is a nice thing.
- 12 A Yes.
- 13 Q Because you cared about him?
- 14 A Yes.
- 15 Q You cared about him, you asked him how he was feeling,
- 16 right?
- 17 A Yes.
- 18 Q Then you're not asking about the performance report or
- 19 about the fund in that e-mail, right?
- 20 A Not in this e-mail. But again, these are daily e-mails.
- 21 On the monthly one I might have questions on the fund, not
- 22 daily.
- 23 Q At some point you went to the MSMB Capital offices,
- 24 correct?
- 25 A Yes.

Caso 1:15 er 00637 KAM Document 315 Filed 08/15/17 Page 150 of 297 PageID #: 6541

- S. RICHARDSON CROSS AGNIFILO
- 1 Q And those were in lower Broadway?
- 2 A Yes, Broadway close to Wall Street.
- 3 Q You said I think you testified yesterday that you went
- 4 there and that Martin was there, correct?
- 5 A Yes.
- 6 Q And Marek was there?
- 7 A Yes.
- 8 Q I think you described the setting as sort of a, I think
- 9 you put it, not a huge office, correct.
- 10 A That's correct.
- 11 Q It was actually quite a small office; fair to say?
- 12 A Five or six work stations, I think two offices.
- 13 Q Sort of a humble, paired down office?
- 14 A Yes.
- 15 Q Obviously a start-up company.
- 16 A Yes.
- 17 Q There is no pretensions about it, right?
- 18 A That's right.
- 19 Q It was two young guys with a start-up hedge fund, right?
- 20 A Yes, back to the office question again? Sorry.
- 21 Q Marek was there, right.
- 22 A Yes.
- 23 Q Martin was there?
- 24 A And one other.
- 25 Q The third guy was even younger than them. You said he

- 1 was junior?
- 2 A His position was junior, I wasn't casting any question on
- 3 his age.
- 4 Q And you knew what you were getting into. You were going
- 5 to invest with these two young guys out of this small office
- 6 in lower Broadway?
- 7 A Yes.
- 8 Q And soon after you decide to invest with them, Martin
- 9 tells you he's dissolving the fund.
- 10 A A few weeks later, yes.
- 11 Q A few weeks later, right, he sends you an e-mail. He
- 12 | says, "Marek and I have irreconcilable differences. I'm
- 13 dissolving the fund."
- 14 A Yes.
- 15 Q You go down to lower Broadway, two young guys in this
- 16 office, and couple weeks later Martin says we're dissolving
- 17 | the fund, and you decide to stick with it, right?
- 18 A After I met with them and help reconcile them.
- 19 Q Right. So you met with -- you met with Martin right soon
- 20 thereafter, you had dinner. Do you recall having dinner with
- 21 him after you were in the office?
- 22 A It was probably a dinner; I met with him about the
- 23 subject.
- 24 Q You and he discussed the business, right.
- 25 A Yes.

- S. RICHARDSON CROSS AGNIFILO
- 1 Q Just the two of you at dinner.
- 2 A Yes.
- 3 Q Do you remember where you went?
- 4 A No.
- 5 Q And then you met with Marek?
- 6 A Yes, who had been on vacation for a few days, when he
- 7 | came back I met with him.
- 8 Q You told Martin to try to stick it out, right?
- 9 A After I had my discussion with Marek, because Martin
- 10 believed it couldn't be redeemed, the relationship couldn't be
- 11 redeemed. And after my meeting with Marek I could see a
- 12 glimmer of hope that it could be.
- 13 Q Then you basically, you tried to put them back together
- 14 | so the business would work?
- 15 A I suggested, I had discussions with both of them, but I
- 16 | left it for the two of them to see if they could figure it
- 17 out.
- 18 Q And they figured out.
- 19 A They figured out, yes.
- 20 Q With your guidance?
- 21 A I think I acted as a catalyst with my discussion, yes.
- 22 Q I think you testified yesterday from time to time Martin
- 23 | would send you these -- you testified even a little while
- 24 | ago -- these periodic letters describing different stocks?
- 25 A Yes, investor commentaries, I think the plan was

- S. RICHARDSON CROSS AGNIFILO
- 1 quarterly.
- 2 Q Fair to say Martin, you knew because you got to know
- 3 Martin fairly well, he worked very hard; fair to say?
- 4 A Oh, yes, he worked very hard.
- 5 Q He worked days and nights?
- 6 A He worked extensively long hours.
- 7 Q Every day?
- 8 A I can't speak to the weekends, but certainly often a
- 9 weekend too.
- 10 Q Did you know him to take a pleasure vacation?
- 11 A Certainly not this early in our friendship.
- 12 Q At any point?
- 13 A He went to Italy. He went to Italy with his girlfriend
- 14 in 2013.
- 15 Q And other than going to Italy with his girlfriend in
- 16 2013, anything else?
- 17 A No. He did -- when he did trips for business he quite
- 18 often took three or four days. If he went to the West Coast
- 19 he would take a weekend for himself afterwards on the back of
- 20 another trip.
- 21 Q Part of what you were counseling him to do was take more
- 22 time for himself?
- 23 A Yes.
- 24 Q You thought he worked too hard?
- 25 A Generally, yes, certainly in the early years.

- S. RICHARDSON CROSS AGNIFILO
- 1 Q You thought he worked so hard to the point he was
- 2 | actually effecting his health?
- 3 A Yes, I did.
- 4 Q You thought he was, working so hard it actually impacted
- 5 on his ability to take care of himself?
- 6 A Certainly some of the physical aspects of looking after
- 7 himself.
- 8 Q Like what?
- 9 A The infection I talked about before, which may or may not
- 10 have come from eating, sleeping bad, that sort of thing. And
- 11 | the headaches the frequent headaches I noticed in the e-mails.
- 12 Q Did you notice that he was often complaining to you that
- 13 he was getting teeth extracted?
- 14 A I don't remember a discussion around teeth extractions.
- 15 I know he had dental issues, I don't remember him sharing the
- 16 | specifics of it.
- 17 | Q Now, at one point you said in 2010, you and he started
- 18 | having discussions around building a company, correct?
- 19 A That was later in 2010 I believe, yes.
- 20 | Q Could it have been the summer of 2010?
- 21 A It could have been summer, the discussion was around this
- 22 | issue of the short sales various the long that I had talked
- 23 about before. And the desire to want to be behind drugs that
- 24 | were succeeding not failing, that was the genesis of my first
- 25 discussion with him.

- S. RICHARDSON CROSS AGNIFILO
- 1 Q It could have been as early as summer 2010?
- 2 A Certainly the issue of long versus short sales.
- 3 Q So the jury understands, short sales are when you think
- 4 | that stock is going to go down, right? And long sales are you
- 5 | think the stock is going to go up, you buy the stocks and
- 6 hold?
- 7 A Yes.
- 8 Q One of the difference is in long sales the idea is you
- 9 think this is a fundamentally good company that is doing
- 10 something worthwhile enough that the stock will increase in
- 11 price?
- 12 A Yes.
- 13 Q With the short sales, at least in the pharmaceutical
- 14 | industry, correct me if I'm wrong, it's very often that a
- 15 | company will have a drug that is not going to pass FDA
- 16 approval and you can predict that?
- 17 A Through the clinical trial process it may not come out
- 18 positively.
- 19 O One of the things you said yesterday was that Martin was
- 20 especially good at predicting which drugs would not pass the
- 21 | FDA clinical process, correct?
- 22 A That's part of what he'd written in one of his letters.
- 23 He'd had more success with short sales versus the long.
- 24 O You preferred to be in long sales with companies that had
- 25 inherent value, correct?

- S. RICHARDSON CROSS AGNIFILO
- 1 A Yes.
- 2 | Q You and Martin were talking about that in the summer/fall
- 3 | 2010; fair to say?
- 4 A Certainly by the fall, yes.
- 5 Q You said I think yesterday that at one point he -- I
- 6 | think the way you phrased it -- "he went off and he did
- 7 research, " correct?
- 8 A Research? Sorry? About starting a company?
- 9 Q Correct.
- 10 A Yes, yes. Late in 2010 he had said to me, "Give me time
- 11 | to go away, do my research. I want to bring some ideas back."
- 12 Q By research, do you know what he was doing?
- 13 A No, he specifically said, "give me time to go away and do
- 14 my research."
- 15 Q Did you understand him to be going away, physically going
- 16 | away? Or, I'm going to go in my Martin Shkreli hubble and
- 17 | think and read?
- MS. KASULIS: Objection.
- 19 THE COURT: Sustained.
- 20 Q Did you think he was physically going away?
- 21 A I didn't think he was physically going away.
- 22 Q What did you think he was doing?
- 23 A He would do his own desk research and figure out what is
- 24 | the market opportunity.
- 25 Q At one point he came to you and he says, "I think I

- S. RICHARDSON CROSS AGNIFILO
- 1 | figured it out," right?
- 2 A Yes, about March of 2011.
- 3 Q Do you recall having discussions with him about Retrophin
- 4 before March of 2011?
- 5 A I recall him updating me a little bit about his progress.
- 6 I don't recall the name appearing much before that.
- 7 Q You know of a company called Lonza?
- 8 A I don't recall that.
- 9 Q A Swiss biochemical company?
- 10 A Lonza, I don't have any recollection at the moment.
- 11 Q Do you recall Martin telling you that he had actually
- 12 | hired a Swiss company to basically try to build molecules?
- MS. KASULIS: Objection.
- 14 THE COURT: Sustained.
- 15 Q Do you remember him telling you anything about the
- 16 building of molecules?
- 17 A He certainly talked about molecules in the sense of can
- 18 | we take one molecule and use it differently for different
- 19 diseases. He talked about it in a broad application with me.
- 20 Q Okay. Do you recall him having conversations with you
- 21 | about this process as early as February of 2011?
- MS. KASULIS: Objection.
- 23 Only if you remember?
- 24 THE COURT: All right, clarify "this process."
- 25 Q The process of using molecules for other purposes in the

- S. RICHARDSON CROSS AGNIFILO
- 1 | creation of a potential drug for disease?
- 2 A I remember him discussing, raising that with me. I don't
- 3 remember the time table.
- 4 Q Do you remember him telling you in February that
- 5 Retrophin was growing like a weed?
- 6 THE COURT: February of what year, sir?
- 7 BY MR. AGNIFILO:
- 8 Q February 2011.
- 9 I can show you something, Defense 4221, an e-mail
- 10 | from Martin to you, February 26, 2011, at 12:22 a.m.
- 11 A Yes, I do recall this, just the time I couldn't remember
- 12 the time.
- 13 Q Very good. Tell us what you recall.
- 14 A That he was starting to put the company into motion,
- 15 | starting to put the company in motion, establish the investors
- 16 | behind it. That's all I remember in this time period.
- 17 Q That's February 2011, correct?
- 18 A This is dated February, the end of February.
- 19 Q Very good, thank you, sir.
- 20 Do you recall you and he having what seemed to be
- 21 excited communications about Retrophin in February 2011?
- 22 A Again, I don't recall the exact times; but yes, the
- 23 excitement he was now bringing to life for me, the idea that
- 24 | we talked some months earlier, yes, I do remember the
- 25 excitement.

- S. RICHARDSON CROSS AGNIFILO
- 1 Q Because this is something you really wanted him to do,
- 2 correct?
- 3 A Yes, something I felt personally very, very passionate
- 4 about in terms of a legacy I could help contribute towards.
- 5 Q You said yesterday you had realized success in the
- 6 business context of your life, correct?
- 7 A Yes.
- 8 Q And where you were in your life at that time, is you
- 9 | wanted a legacy of having done something actually good and
- 10 meaningful in your time here?
- 11 A Specific to the impact of people's lives through
- 12 hopefully bringing drugs to cure or help cure diseases.
- 13 Q The one doing the work at this period of time to try to
- 14 bring that about was Martin, correct?
- 15 A Yes.
- 16 Q At one point in March he sort of unveiled Retrophin,
- 17 | correct?
- 18 A That's right.
- 19 Q We're going to look at what is admitted into evidence as
- 20 Government's Exhibit 122-6, the first page. You talked about
- 21 | this yesterday with the Government. This is the Retrophin
- 22 presentation from March of 2011, correct?
- 23 A Yes.
- 24 Q It says, "Martin Shkreli, Interim CEO," right?
- 25 A Yes.

- S. RICHARDSON CROSS AGNIFILO
- 1 Q You answered questions that the Government was asking you
- 2 | yesterday about why he would be the interim CEO, fair to say
- 3 he has some of the qualities but not all the qualities as
- 4 | someone you would typically hand-pick as a CEO; fair to say?
- 5 A That's fair to say, in terms of a operating company, yes.
- 6 Q So he was going to get the company off the ground, right?
- 7 A Yes.
- 8 Q Because essentially he was providing the scientific
- 9 content to the company, correct?
- 10 A Well, again, until we go through the presentation I'm
- 11 | still learning more. This is exactly what I'm -- he's
- 12 | starting to unveil what it's going to look like. I don't know
- 13 | about roles in context yet, Counsel. I wanted to clarify my
- 14 direct answer your question.
- 15 | Q The next page is the executive summary. The executive
- 16 says, "Retrophin is a bio technology company dedicated to the
- 17 | developing drugs for rare and life-threatening diseases." You
- 18 | see that, right?
- 19 A Yes.
- 20 Q "Specifically, our mission is to become the first company
- 21 to receive FDA approval for the Duchenne Muscular Dystrophy
- 22 | drug." You understand that was the point of Retrophin,
- 23 correct?
- 24 A Yes.
- 25 Q That was the whole reason for Retrophin's existence

- S. RICHARDSON CROSS AGNIFILO
- 1 right?
- MS. KASULIS: Objection.
- 3 THE COURT: Sustained.
- 4 Q At this point in time, this is the executive summary
- 5 about what the company is going to do, correct?
- 6 A Certainly in terms of, he called it a mission, but of
- 7 | course at the end of the day if there are investors and
- 8 shareholders, it has to be a return to them not just the drug
- 9 approval as well.
- 10 Q You thought that trying to be the first company to bring
- 11 | about a cure for Duchenne Muscular Dystrophy was certainly a
- 12 | worthwhile endeavor from your perspective?
- 13 A Yes.
- 14 Q It's a horrible disease; fair to say?
- 15 A Yes.
- 16 Q There is no cure.
- 17 A I down know whether there cure is the right word, but in
- 18 | terms of treatment, extensive treatment. Cure is a lovely
- 19 aspiration.
- 20 Q It's a disease where there is no meaningful way of
- 21 defeating the disease?
- MS. KASULIS: Objection.
- THE COURT: Sustained.
- 24 Q From your perspective, I'm really talking about, because
- 25 | you said you wanted a legacy, correct? You wanted Martin

- S. RICHARDSON CROSS AGNIFILO
- 1 Shkreli to stop shorting stocks, correct? Not stop, but you
- 2 | want him to add something to his --
- 3 THE COURT: Counsel, I'm going to tell you now you
- 4 | need to ask one question at a time; there are two right there.
- 5 MR. AGNIFILO: Very good, Judge.
- 6 Q You were looking for Retrophin to be your legacy; fair to
- 7 say?
- 8 A Again, you position it such a broad way. An important
- 9 part of my legacy. I'm a brother. I'm an uncle. All of
- 10 | those things. Part of my legacy was I want to do this. I
- 11 | don't want to give the impression this is the only part of my
- 12 legacy.
- 13 Q This is part of your legacy; fair to say?
- 14 A I was looking for this kind of direction as part of my
- 15 legacy.
- 16 | Q Something as important as curing this particular disease
- or bringing about a potential cure was certainly something you
- 18 | thought was worthwhile?
- 19 A It was certainly worthwhile.
- 20 Q When Martin gave you this presentation, you thought he
- 21 was on to something; fair to say?
- 22 A Yes, it seemed like a very good starting position.
- 23 Q Let's go to the next page. So we're clear, this
- 24 highlighting is mine.
- It says, "Pipeline, RE-001. Is our main asset in

- S. RICHARDSON CROSS AGNIFILO
- 1 preclinical development for Duchenne Muscular Dystrophy." You
- 2 | see that, right?
- 3 A Yes.
- 4 Q "RE-001 replaces the missing protein that causes Duchenne
- 5 Muscular Dystrophy, dystrophin, by providing a recombinant
- 6 | supply of a very similar protein, " right?
- 7 A Yes.
- 8 Q Now the idea here is that this dystrophin is the type of
- 9 protein that the cell needs to be healthy, correct?
- MS. KASULIS: Objection.
- 11 THE COURT: Sustained.
- 12 Q This is a company that you ended up being on the Board
- of -- let me ask you, do you know how Martin plans for this to
- 14 work?
- 15 A Even for this presentation he's laying out the next
- 16 | steps. I'm clearly not a medical expert. Once we get into
- 17 | the medical analysis, I'm not an expert.
- 18 Q But you knew that he had an idea even in March of 2011
- 19 that could be a significant idea for the future of the
- 20 company; fair to say?
- 21 A Again, just to go back to saying this is the first time
- 22 I'm seeing him layout the business plan. I'm assimilating it
- 23 | as I'm reading it at that point in time. I was certainly
- 24 | excited about it. But I -- this is the first time I'm going
- 25 through it at this time.

SIDEBAR CONFERENCE

1	MR. AGNIFILO: He can't explain the presentation.
2	If he doesn't know the answer, he doesn't know the answer.
3	THE COURT: You're assuming medical facts not in
4	evidence.
5	MR. AGNIFILO: I'm assuming he read the
6	presentation.
7	THE COURT: I think you should ask is this
8	Mr. Shkreli's idea, but you're almost implying that this
9	witness should be able to say, 'this is great idea, I think
10	it's going to work.'
11	MR. AGNIFILO: But he might think it's a great. He
12	thinks it's a great idea. He's putting his time and money
13	into it.
14	THE COURT: Asking specific medical questions about
15	the chemistry of this product and how it works in the cell and
16	the disease process is something he
17	MR. AGNIFILO: I'll stick what is in evidence.
18	That's fine.
19	MS. KASULIS: Thank you, your Honor.
20	(End of sidebar conference.)
21	(Continued on the next page.)
22	
23	
24	
) L	

- 1 (In open court.)
- 2 BY MR. AGNIFILO:
- 3 Q We'll do it this way. Next page, "R0001 mechanism of
- 4 | action, " do you see that on the screen?
- 5 A Yes.
- 6 Q There is a diagram there?
- 7 A Yes.
- 8 Q Do you know if Martin drew that? Do you know?
- 9 A No.
- 10 Q "Dystrophin anchors the cell membrane, known as the
- 11 | sarcolemma in muscle cells to actin filaments. This provides
- 12 | vital cell stability." That's what it says?
- 13 A That's what it says.
- 14 Q "Dystrophin is missing or unusable in Duchenne Muscular
- 15 Dystrophy patients." That's what it says?
- 16 A Yes.
- 17 Q "RE-001 would replace the missing dystrophin actin
- 18 | connection and restore muscle cell stability. The only known
- 19 | problem in Duchenne Muscular Dystrophy, " correct, that's what
- 20 it says?
- 21 A That's what it says.
- 22 Q Fair to say you don't know exactly how the science works,
- 23 correct?
- 24 A No, definitely not qualified on the science side.
- 25 Q But you trusted that Martin did; fair to say?

- 1 A Yes. And that he started a network with some scientific
- 2 groups and individuals as he did his research.
- 3 Q Do you know that he went up to Harvard to talk to a
- 4 doctor at Harvard?
- 5 A I don't remember Harvard specifically.
- 6 Q Do you remember Darren Blanton being around at this time?
- 7 A No, I only heard the name. I thought he was an investor
- 8 in the MSMB fund. I could be wrong. I know the name, but I
- 9 didn't know who he was.
- 10 Q After this presentation, you understood that Martin was
- 11 | working on building Retrophin, correct?
- 12 A Yes.
- 13 Q And you were working on building Retrophin; fair to say?
- 14 A In a small way at that point.
- 15 Q So the one who was building Retrophin in February/March
- 16 April 2011 really was Martin, correct?
- 17 A Yes.
- 18 Q From your perspective, were there any other people that
- 19 played significant roles in helping him?
- 20 A No. He had reaching out, I don't remember when colleague
- 21 Andrew Vaino came on board. At this point, no, Martin was the
- 22 visible end of this work to me.
- 23 Q And so Martin is working on Retrophin and also working on
- 24 MSMB Capital, correct?
- 25 A Correct.

- 1 Q So he's doing both at the same time?
- 2 A Yes, with Marek the portfolio manager on the MSMB Capital
- 3 fund.
- 4 Q In the beginning do you remember they were doing both
- 5 that out of their office in lower Broadway?
- 6 A I don't remember it starting at lower Broadway. I don't
- 7 remember when they moved to the new office. This is a timing
- 8 issue. I know they were sharing an office from a
- 9 cost-effective point of view in terms of two entities.
- 10 Q You remember in April 2011 they went to Madison Avenue?
- 11 A Sounds about right in terms of the office move time.
- 12 Q Then after April 2011 Retrophin and MSMB were both out of
- 13 the office in Madison Avenue, correct?
- 14 A Yes.
- 15 Q I think you testified yesterday that they had common
- 16 employees, correct?
- 17 A Yes.
- 18 Q And they had I think you said common facilities?
- 19 A Yes, the same real estate.
- 20 Q The same physical office?
- 21 A Same physical space.
- 22 Q Do you know if they had the same computers?
- 23 A I'm assuming so, but I can't answer if they were distinct
- 24 terminals for an activity.
- 25 Q And Martin was essentially running MSMB, correct, with

- 1 Marek?
- 2 A With Marek.
- 3 Q And Martin was essentially running Retrophin, correct?
- 4 A Yes.
- 5 Q Now, I think yesterday you said that MSMB and Retrophin
- 6 | were on parallel tracks. Do you remember when you said that?
- 7 A Again, can you give me the context?
- 8 Q I was going to ask you what you meant. Is that true? Do
- 9 you view them as running on parallel tracks?
- 10 A In terms of resources, the resources that we talked about
- 11 | being shared. I think that might be a reference to parallel
- 12 tracks. They were distinct entities but sharing resources,
- 13 | running them, I think that's what I was saying.
- 14 Q That's fine. One of the problems that you were aware
- 15 | that Retrophin was having in these early days is how was it
- 16 going to raise money, correct?
- 17 A In any start-up that's always a critical question.
- 18 Q That's what every start-up faces at one point or another?
- 19 A That's fair.
- 20 Q At one point you said that there was a conversation that
- 21 | you and Martin had about Vivo Ventures. Do you remember that?
- 22 A That was well into 2012.
- 23 | Q Okay, all right. Do you remember having conversations
- 24 | with Martin in 2011 about the best way to try to raise capital
- 25 for Retrophin?

- 1 A I don't remember a distinct dialogue around that. We
- 2 talked about it generally. I don't remember a distinct
- 3 discussion.
- 4 Q You were always very much against the venture capital
- 5 group, correct?
- 6 A The Vivo one, which is late 2012.
- 7 Q Right. But weren't you against venture capital for
- 8 Retrophin as a general concept?
- 9 A What I was against, was giving up control.
- 10 Q Fair to say that's what would happen if you brought a
- 11 | venture capital firm on board?
- 12 A Most likely, most likely.
- 13 Q Tell the jury, if you would, why that would be? Why does
- 14 | bringing a venture capital firm into a business cause the
- 15 | preexisting people who control the business to have less
- 16 | control?
- 17 A Because basically the venture capital's intent is to try
- 18 | to get as much profit or value out of that entity. So they
- 19 | want to bring their own people in, their own people in to run
- 20 | it, and potentially run it quite differently so they can
- 21 leverage the assets that they are putting their money into.
- 22 Q You didn't want that to happen?
- 23 A At the end of 2012, which is the first time I was aware
- 24 of a venture capital proposal.
- Q We'll talk now about 2012, end of 2012. You were against

Case 1:15 or 00637 KAM Document 315 Filed 08/15/17 Page 171 of 297 PageID #: 6562

3047

- 1 | the venture capital company coming into Retrophin?
- 2 A Yes.
- 3 Q And you Martin had that discussion; fair to say?
- 4 A Yes.
- 5 Q And Martin said to you that he had been speaking to this
- 6 | venture capital company, Vivo Ventures, right?
- 7 A Yes.
- 8 Q And he said they could bring a lot of much-needed money
- 9 to the company, right?
- 10 A Yes.
- 11 | Q He says, "But we would be giving up the baby," right?
- 12 A That was his phrase, yes.
- 13 Q From your perspective, did he say that he viewed
- 14 Retrophin as his baby?
- 15 A I don't remember if it was an invert the way he wrote it.
- 16 | He looked -- he expressed, he knew I was part of the genesis
- of Retrophin as well, so I read it in that light, we would be
- 18 giving up the baby.
- 19 Q That's what he said, "we would be giving up the baby,"
- 20 | you and he would be giving up the baby?
- 21 A Collective baby.
- 22 Q The baby is Retrophin?
- 23 A Yes.
- 24 Q And you advised him to not go with the Vivo Venture
- 25 Group, correct?

- 1 A I said I was against it. Again, it wasn't in the spirit
- 2 of what I thought what we talked in 2010. At this point we
- 3 had no drugs. We had nothing to take to market. The idea of
- 4 starting a legacy was evaporating, that was my concern.
- 5 Q Fair to say that you thought that the company was founded
- 6 on a potentially very good idea?
- 7 A Yes.
- 8 Q And the concern is, an idea without any money just
- 9 remains an idea, correct?
- 10 A In many cases, yes.
- 11 | Q And so what you were struggling with is how to get the
- 12 | money to build this into a profitable company?
- 13 A I think not just me, the collective all of us who were
- 14 | involved with Retrophin, yes, come up with a right financing
- 15 strategy where we could maintain control, was the genesis of
- 16 | my question of push back to him.
- 17 | Q You ultimately decided that the best way to raise the
- 18 | company would be a reverse merger, correct?
- 19 A Yes, by the end, now it's end of 2012, yes.
- 20 Q There is nothing wrong with a reverse merger, correct?
- 21 A No, no.
- 22 | Q Just tell the jury very quick what a reverse merger is?
- 23 A Again, it's when one business, in particular a start-up
- 24 | business, buys the shell company that we talked about before.
- 25 A shell company is, again, something that is listed but

- 1 basically has no operations. The owner is comfortable to sell
- 2 that shell company to an existing company, so when they merge
- 3 | the company, in this case Retrophin, can use the operating
- 4 over-the-counter approval that that shell company already
- 5 holds.
- 6 Q Do you recall in about April 2012 a patent for something,
- 7 | for a drug PKAN, the disease PKAN?
- 8 A Yes. I don't remember the exact timing, but PKAN, yes, I
- 9 remember PKAN.
- 10 Q What do you remember about?
- 11 A That PKAN was, is, a particularly nasty disease that
- 12 | impacts young children. And it's a neurological one, where
- 13 | slowly their body stops operating. It's a very, very dramatic
- 14 | and aggressive disease. It didn't have a cure or any really
- 15 | meaningful treatment.
- 16 Q And Duchenne Muscular Dystrophy is a disease that
- 17 | afflicts children as well, right?
- 18 A Yes.
- 19 Q Do you recall there was a drug that Retrophin patented,
- 20 RE-024?
- 21 A Yes.
- 22 Q What do you remember about that?
- 23 \mid A That is actually the one focused on this PKAN disease.
- 24 Q Fair say that was an important step forward, correct?
- 25 A Yes, it was. Again, it hadn't reached drug standards yet

- 1 | in terms of markets. It is still in clinical trial. This was
- 2 | the first, a very exciting first look that this might have a
- 3 possibility to impact those poor children positively.
- 4 Q So Retrophin was going in the direction that you had
- 5 | hoped; fair to say?
- 6 A Yes.
- 7 Q So now it had a patent, correct?
- 8 A Again, I want to separate, the ability to patent is very
- 9 different to having a drug to take to market and commercially
- 10 sell and get to the patients.
- 11 Q It's not a drug that you can buy, but it is a patented
- 12 product.
- 13 A Yes, that we can move forward as a company exclusively to
- 14 build a towards clinical trial to a drug.
- 15 Q And fair to say that Martin was instrumental in securing
- 16 | the patent?
- 17 | A Yes, he was. I believe, going from discussions, were
- 18 | that it was also Marek Biestek and Andrew Vaino, two of the
- 19 key players, working with Martin in shaping how do we come up
- 20 with that particular PKAN piece.
- 21 Q You talked a lot on direct examination about this
- 22 | Capitalization Table from November 19, 2012, 122-32. Do you
- 23 | see it on your screen okay?
- 24 A Yes.
- 25 Q An e-mail from Martin to you and to Steve Aselage?

- 1 A Yes.
- 2 Q "We have a lot going on, but this is I think what the
- 3 founders Cap Table should look like versus what it does."
- 4 A Yes.
- 5 Q So he's talking about sort of something that right now
- 6 doesn't exist, he says what it should look like; fair to say?
- 7 A The left hand side is what it is today, just to clarify,
- 8 | and the right-hand side is what it could look like and should
- 9 look like.
- 10 Q He says, "I will talk to Evan Greebel in a few minutes if
- 11 doing something like this is even possible and/or to what
- 12 degree it can be done." Do you see that?
- 13 A Yes.
- 14 Q So as he's writing this to you, he's not even sure that
- 15 | those columns on the right is something he can do, correct?
- 16 A Yes.
- 17 | Q It's fair to say it's something that you knew he wanted
- 18 | to do, right?
- 19 A Yes, he told me verbally it would happen, for me at least
- 20 it would happen.
- 21 Q What he's actually writing in the e-mail is he has to
- 22 | talk to the lawyer, Evan Greebel, right, that's what he's
- 23 | saying?
- 24 A Yes.
- 25 Q Because he doesn't even know if this is possible to

- 1 accomplish, correct?
- 2 A Yes.
- 3 Q Nothing in this is a promise, correct?
- 4 A No, this is not a promise this page.
- 5 Q And he says, "This is for informational purposes only,"
- 6 you see that there, right?
- 7 A Yes.
- 8 Q "It basically reflects my vision of what folks deserve in
- 9 relation to the founding of the company, " you see that?
- 10 A Yes.
- 11 Q "As opposed to where they are at the moment," correct?
- 12 A Yes.
- 13 Q So he obviously greatly valued your role as one of the
- 14 | founders of the company, correct?
- 15 A Yes, founder may be -- well, in this context, yes,
- 16 | founder is okay.
- 17 0 It's his words.
- 18 A Yes.
- 19 Q "Please keep in mind, I'm happy to move forward with not
- 20 | changing the Cap Table as well. Having said that, I would
- 21 | like to highlight the discrepancy (self-afflicted)." Do you
- 22 | see that there?
- 23 THE COURT: I'm wondering if the jurors might need a
- 24 | break right now. Do you need your afternoon break? Why don't
- 25 | we ask you to retire to the jury room, refresh yourself and

- 1 A Certainly I -- I skimmed it. These are ones that came
- 2 | very late to the meeting, or just before the meeting was
- 3 | called. So I skimmed them, yes.
- 4 Q Okay. So you knew that this was a consulting agreement
- 5 and release, because that's the title of the document, right?
- 6 A I certainly skimmed it, so I would have read -- I would
- 7 have read the heading, I didn't register it, but I read the
- 8 heading.
- 9 Q Okay. And did you have the phone call, the board phone
- 10 call without knowing what this was?
- 11 A Again, we received it almost immediately before the call,
- 12 | so there wasn't the chance to read it in great deal, and we
- 13 didn't discuss it on the call, because they were only brought
- 14 | back to us. So I didn't dwell and them, because I knew it was
- 15 | going to go brought back to the board, at which point I could
- 16 look at it in the detail.
- 17 | Q Would it possible to put the call off until you had the
- 18 chance the read the attachments?
- 19 A I'm sorry, what's the point, Counselor?
- 20 Q Is it possible to put off the call until you have a
- 21 | chance to read the attachments?
- 22 | A Well, that was basically, as you heard on direct, part of
- 23 | what I was asking Marc and others to do, is that we had to, as
- 24 | a board, we should be receiving these documents much earlier
- 25 | so we could do justice to the them before the discussion.

- 1 Q I understand that you're saying you didn't get it in
- 2 | time, but isn't it something that you have the ability to do
- 3 to say I don't want to have the call now, I'm not ready; fair
- 4 to say?
- 5 A No, I believe there were time sensitive items on the
- 6 agenda that we had to proceed with and we couldn't delay the
- 7 | call because of other agenda items.
- 8 Q So this is the first page of the Alan Geller consulting
- 9 agreement and release, correct?
- 10 A Yes.
- 11 | Q Okay. It's a seven page -- I can show it to you just so
- 12 | we can have it. It's part of that same exhibit.
- THE COURT: Can we just, for the record, identify
- 14 the exhibit number?
- MR. AGNIFILIO: Sure. It's the same exhibit, Judge,
- 16 | it's all attached to 122-48.
- 17 THE COURT: Thank you.
- MS. KASULIS: It's Tab 54.
- 19 THE WITNESS: Okay.
- 20 BY MR. AGNIFILIO:
- 21 Q Okay.
- 22 A Thank you. Or maybe 55.
- 23 Q Well, there's two of them. There's Banta and there's
- 24 Geller. This one is Geller.
- 25 A Yes.

- 22 Q And then we'll turn to the other agreement. The
- 23 | agreement -- other agreement -- same exhibit, I think it's
- 24 probably right after that one in your book there, is in regard
- 25 to Ken Banta, correct?

- 1 A Yes.
- 2 Q And Ken Banta also is promised on page 1, certain shares
- 3 of stock in exchange for his role as a consultant, correct?
- 4 A Yes.
- 5 Q All right. Now, through these consulting agreements, the
- 6 company is looking to give these shares of stock to these two
- 7 people for their role in being consultants, correct?
- 8 A That's certainly what the agreement is outlining.
- 9 Q Okay. And when Marc Panoff sent you these agreements at
- 10 4:32 p.m. on September 9th, 2013, he sent them to you so you
- 11 | could read them, correct?
- 12 A Yes. For a 5:30 call.
- 13 Q Okay. And now you knew that these were things that the
- 14 | board was being asked to consider, correct?
- 15 A Yes.
- 16 Q Okay. And you knew that as of September 9th, 2013; fair
- 17 to say?
- 18 A Once I received them, yes.
- 19 O Okay. And fair to say that these agreements were -- you
- 20 | had further discussions with at least Ken Banta about the
- 21 agreement, correct?
- 22 A Certainly not at this time.
- 23 Q Later on?
- 24 A Later. Later, yes, right.
- 25 | Q Right. And because Ken Banta and you were at the same

- 1 meeting, correct?
- 2 A In February '14.
- 3 Q Okay. And when you -- and he discussed the consulting
- 4 agreement with you, correct?
- 5 A Yes. Asking if it's been brought to the board for
- 6 approval and been approved.
- 7 Q And when you met him in February of 2014, what was he
- 8 doing?
- 9 A He was supporting the -- supporting Martin.
- 10 Q Did you think he was doing that for free?
- 11 A I knew he had a previous agreement that predated, because
- 12 Ken had been involved with Martin for many years, so I didn't
- 13 know if there was a, you know, an interim agreement that that
- 14 was party to, and this one was the revised one.
- 15 Q But you knew he was working, he was working on behalf of
- 16 | Martin, right?
- 17 A Yes.
- 18 | Q And Martin was new at the company at the time?
- 19 A A CEO.
- 20 Q Okay. So he was working directly for the benefit of the
- 21 | CEO, correct?
- 22 A Yes.
- 23 | Q And you knew also that some months earlier you had gotten
- 24 | that consulting agreement for that same person, correct?
- 25 A Yes.

- 1 Q Now, at this point, you're saying that you received these
- 2 | two agreements, you just didn't take official board action on
- 3 them, correct?
- 4 A No. And I do recall that I actually, as I said, I took a
- 5 cursory look at them the best I could in the available time,
- 6 and I made a couple of notes on my own agenda, questions
- 7 really to raise about them.
- 8 Q Okay. And looking at the agenda, that is Government
- 9 Exhibit 122-49. It's already in evidence. And you see there
- 10 it's agenda item number 9, correct?
- 11 A Yes.
- 12 Q All right. And it references Exhibits I and J.
- You see that, right?
- 14 A Yes.
- 15 Q Okay. And now switching back to 122-48, which is the
- 16 original email at 4:32 p.m. from Marc Panoff, to you and
- 17 others, you see that Exhibit I is the Geller consulting
- 18 | agreement, right?
- 19 A Yes.
- 20 Q And that Exhibit J is the consulting agreement for Banta,
- 21 correct?
- 22 A Yes.
- 23 Q All right. So they correspond. What's in the agenda is
- 24 exactly the same exhibit numbers what Panoff had sent you,
- 25 correct?

- 1 A Yes.
- 2 Q All right. So Martin wasn't trying to sneak this by you;
- 3 fair to say?
- 4 MS. KASULIS: Objection.
- 5 THE COURT: Sustained.
- 6 Q Did you feel like someone was trying to sneak this past
- 7 you?
- 8 A No. Not at this point because they were going to come
- 9 back to us for discussion.
- 10 Q You were being told flat out that these consulting
- 11 | agreements has to be considered by the board, right?
- 12 A Yes. Asked to be considered, yes.
- 13 Q Right. So it was sent to you, right?
- You have to answer, "yes".
- 15 A Oh, yes. Excuse me.
- 16 Q It was specifically on the agenda item, correct?
- 17 A Yes.
- 18 Q Okay. And you knew later, when you saw Ken Banta, at
- 19 | least, that he was actually working, correct?
- 20 A Yes.
- 21 | Q Now, there was a later email the same day from Marc
- 22 Panoff, correct?
- I'll show it to you. It's in evidence as 122-50.
- 24 122-50 is an email from Marc Panoff to you, to Steve
- 25 | Aselage, to Martin Shkreli with copies to Evan Greebel Ed

23 Q All right. And it says the latest draft of the amended

24 10Q from March 31st, 2013.

Do you see that there?

- 1 A Yes.
- 2 Q Okay. And what's a 10Q?
- 3 A It's just -- it's the quarterly version. It's the need
- 4 to do this quarterly, and then "K," meaning annually.
- 5 Q Okay. And then it mays Marcum, LLP's audit communication
- 6 letter for the quarter ended June 30th, 2013, correct?
- 7 A Yes.
- 8 Q All right. And then there's also a draft 10Q for the
- 9 quarter ending June 30th, 2013.
- Do you see that there, too?
- 11 A Yes.
- 12 Q Okay. Now, as part of that same exhibit -- so I'm not
- 13 | sure where it would be in your book, but it's in that same
- 14 exhibit.
- MS. KASULIS: It's tab 56.
- 16 Q Tab 56. There's a 10Q. There's a 10Q and an amended
- 17 100A.
- 18 A Yes.
- 19 Q Do you see that there?
- 20 A Yes.
- 21 Q I'm going to ask if you could go to page 9 of that
- 22 document. It's already in evidence.
- 23 MS. KASULIS: Is there a Bates number on this?
- MR. AGNIFILIO: The Bates number is 19377.
- MS. KASULIS: Thank you.

- 1 A 377.
- 2 Q Yes. 19377. Tell me when you're there.
- Now, I'm going to ask you to go to page 9, I'll put
- 4 it up, the highlighting is mine, but the document's the
- 5 original.
- 6 Looking at the highlighted part, and I'll read it to
- 7 you, you tell me if I read it correctly. And I'm about one
- 8 third of the way down and it says: In the second quarter of
- 9 2013, the company, its chief executive officer, and related
- 10 party, became party to a series of agreements to settle up to
- 11 2,286,511 of liabilities, which company management believes
- 12 | are the primary obligation of the related party.
- Do you see that there?
- 14 A Yes.
- 15 Q The company and related party have entered into an
- 16 | indemnification agreement, whereby related party has agreed to
- 17 defend and hold the company harmless against all such
- 18 obligations and amounts, whether paid or unpaid, arising from
- 19 these agreements.
- Do you see that?
- 21 A Yes.
- 22 Q Do you know what agreement they're talking about?
- 23 A Not these agreements, no.
- 24 O Do you have an understanding of what is in this document?
- 25 A I have an understanding of what sits behind -- what this

- 1 | is referring to, but I haven't seen specific agreements, is
- 2 the only point I want to clarify.
- 3 Q Okay. And what's your understanding of what it refers
- 4 to?
- 5 A It refers to the monies being paid to MSMB investors who
- 6 move their money over to Retrophin that Martin is talking up,
- 7 if you like, making them whole of what they should have got.
- 8 Q And you understand that there were settlement agreements?
- 9 A No.
- 10 Q You never saw the settlement agreements?
- 11 A We never saw the settlement agreements.
- 12 Q Do you know if the settlement agreements were included in
- 13 the form S1, registration statements for Retrophin?
- 14 A I can't -- I can't recall.
- 15 Q And do you know what a form S1 registration statement is?
- 16 A It is about clarifying someone's stock holding.
- 17 | Q I'm not sure it's in your book, what I'm going to do, if
- 18 | it's okay -- actually, I'm going to move this into evidence,
- 19 Judge, it Defendant's Exhibit 4237.
- MS. KASULIS: No objection.
- THE COURT: We received Defendant's Exhibit 4237.
- 22 (Defendant's Exhibit 4237, was received in
- evidence.)
- 24 | Q And I'm just going to ask, if I could, Judge, I'm just
- 25 | going to approach the witness, I think it will be guicker.

LINDA D. DANELCZYK, RPR, CSR Official Court Reporter

doesn't have a page number on it, but what does -- what does

So now within that document, and I apologize, the page

24

- 1 | that page read?
- You know what I'll do, I'll put it up. I'll make it
- 3 easier, let me take it back and I'll put it up. You can see
- 4 it on the screen.
- 5 Thank you, sir.
- 6 THE COURT: Let's just describe what it is for the
- 7 record, please.
- 8 MR. AGNIFILIO: Yes.
- 9 THE COURT: If they don't -- do you not have a copy?
- MS. KASULIS: We have one but the witness doesn't
- 11 | have a full copy, so we just asked if there was an extra one.
- 12 THE COURT: Does the defense have a full copy?
- 13 Q Do you see the page, okay?
- 14 A Yes.
- 15 Q So on the bottom, just so we're clear, on the bottom it
- 16 says?
- MS. SMITH: Your Honor, just for the record this is
- 18 Exhibit 10.12 is the filing.
- MR. AGNIFILIO: There's a legend on the bottom. I'm
- 20 | trying to pull it up to see. That will be Exhibit 10-12 of
- 21 the S1 filing.
- 22 Q And then the rest of the page it says: Settlement and
- 23 | release agreement. And then it goes on to say, tell me if I
- 24 read this right, the settlement and release agreement, the
- 25 | agreement, is made and entered into as of -- the date is kept

- 1 blank, by and among the releasor, Martin Shkreli, Shkreli,
- 2 MSMB Capital, LP; MSMB Capital, a Delaware limited
- 3 | partnership; MSMB Healthcare -- I'm sorry, MSMB Capital
- 4 Management, LLC; MSMB Capital, LLC, a Delaware limited
- 5 liability company; a number of MSMB entities and Retrophin,
- 6 Inc., a Delaware corporation, releasor, Shkreli --
- 7 THE COURT: Sir, use the microphone, sir. I just
- 8 can't hear you.
- 9 MR. AGNIFILIO: Yes.
- 10 Q All of the releasors, Retrophin and the MSMB entities,
- 11 | referred to as the parties, it says, whereas Shkreli is the
- 12 | managing member of MSMB Capital, LLC, MSMB Investors
- 13 MSMB Management; whereas MSMB Investment is the general
- 14 partner of MSMB Healthcare; whereas MSMB Capital, LLC is the
- 15 | general partner of MSMB Capital LP; whereas Shkreli is the
- 16 | president and chief executive officer of Retrophin; and
- 17 | whereas the parties are entering into this agreement in order
- 18 | to settle and compromise fully and finally, any and all
- 19 presently existing or future disputes and claims, the release
- 20 | they may have against Shkreli, Retrophin, and any of the MSMB
- 21 entities or their respective affiliates.
- Do you see that there?
- 23 A Yes.
- 24 | Q Okay. And fair to say -- and that's part of the first --
- 25 I'm not going to read the whole document, that's part of the

- 1 | first page, correct?
- 2 A Yes.
- 3 Q All right. And then there's a second page, which I'm not
- 4 going to read, but the document continues, correct?
- 5 A Yes.
- 6 Q All right. And there's a third page, which I'm not going
- 7 | to read, but the document continues, correct?
- 8 A Yes.
- 9 Q There's a fourth page, which I'm not going to read. The
- 10 | document continued, right?
- 11 A Yes.
- 12 Q And then there's a fifth page, that I'm not going to read
- 13 but, the document it continues, correct?
- 14 A Yes.
- 15 | Q All right. And then there's a signature page, right?
- 16 A Yes.
- 17 Q Okay. And this is all included in a public filing on
- 18 behalf of Retrophin, correct?
- 19 A I don't recall this section at all, but...
- 20 Q Do you have any doubt that this was included as part of
- 21 the S1 public filing with the SEC?
- 22 A No, it's not a public filing, it must be in there. It's
- 23 | not something that I have recall on.
- 24 | O No, I understand you don't recall it, but -- but this is
- 25 | all part of the S1 Retrophin filing with the SEC?

- 1 A Right.
- 2 Q So the exact settlement agreements, the form of the
- 3 settlement agreements, was publicly file?
- 4 MS. KASULIS: Objection.
- 5 THE COURT: Sustained.
- 6 Q What I just read to you, what we just read, says the
- 7 settlement and release agreement is part of a public filing on
- 8 behalf of Retrophin, correct?
- 9 A But it doesn't change that we, the board, never received
- 10 settlement agreements to review and approve.
- 11 Q No, I'm not -- that's not the question.
- 12 The question is that -- is that this is a public
- 13 | filing, right, for Retrophin, correct?
- 14 A Yes.
- 15 Q And you're on the board of directors, correct?
- 16 A Yes.
- 17 | Q And you're telling me you didn't read this?
- 18 A I'm sure I read through whatever I can of the S1.
- 19 O The S1 is an important public filing, correct?
- 20 A Yes. But, again, I don't recall this specific section.
- 21 | Q So you might have read it and forgot; it is what you're
- 22 saying?
- 23 A I just don't recall it.
- 24 Q But you think you read it?
- 25 A If the draft was sent to us for approval, I would have

- 1 read it.
- 2 Q It's also on the SEC website to read publicly-filed
- 3 documents by the company that you're on the board of, correct?
- 4 A I could do, but obviously being on the board, I'd expect
- 5 to see them before their publicly disclosed.
- 6 Q And you're -- and you don't have a recollection as to
- 7 whether you read this or not?
- 8 A I'm sure I looked at draft S1, but I have no recollection
- 9 of this particular section.
- 10 Q Now, we're going to go to a November 6th, 2013 email from
- 11 Panoff to you and others. It's Government Exhibit 122-53.
- 12 You can see it on the screen, we can do it that way.
- 13 A Okay.
- 14 Q All right. It's from Marc Panoff, it's to Neal Golding;
- 15 is that right?
- 16 A Yes, who is now on the board; yes.
- 17 Q To you?
- 18 A Yes.
- 19 Q To Mr. Aselage, to Martin Shkreli, with copies to
- 20 Mr. Greebel, Mr. Hackert and Sunil Jain, correct?
- 21 A Yes.
- 22 | Q All right. And there is -- there are number of things
- 23 attached here, correct?
- 24 A Yes.
- 25 Q All right. There's a telephone board meeting agenda,

- RICHARDSON CROSS AGNIFILIO
- 1 correct?
- 2 A Yes.
- 3 Q There is a Marcum, LLP audit communication letter for
- 4 September 30th, 2013, correct?
- 5 A Yes.
- 6 Q All right. And there are other things attached here,
- 7 correct?
- 8 A Yes.
- 9 Q Including the Martin Shkreli employment agreement,
- 10 correct?
- 11 A Yes.
- 12 Q Did you have a hand in drafting the Shkreli employment
- 13 agreement?
- 14 A No.
- 15 Q You had no role in drafting it?
- 16 A No.
- 17 Q Do you know that if it called that said he can only be
- 18 discharged if he was convicted of a felony? Do you remember
- 19 | that provision?
- 20 A I missed that when it was circulated here, but I picked
- 21 | it up in February of '14 when I got a second copy of the
- 22 agreement.
- 23 Q Okay. So did you know it at some point?
- 24 A In February of '14.
- 25 Q Okay. Now, in regard to this particular email, it

- 1 attached the letter from Martin, correct?
- 2 A Yes, the external auditors.
- 3 Q And what do external auditors do?
- 4 A They're really reviewing all the books, reviewing all of
- 5 | the financial results to make sure that -- that -- and they
- 6 | can flesh out any concerns I have, any inconsistencies so they
- 7 can report that back to the management.
- 8 Q All right. And this is the first page of the Marcum
- 9 letter, it's a November 8, 2013 letter to Retrophin, correct?
- 10 A Yes.
- 11 Q And we're going to look at the third page.
- 12 MS. KASULIS: This is Tab 57 for the record.
- MR. AGNIFILIO: Tab 57.
- 14 Q And the third page is 8717 on the number.
- 15 A Okay.
- 16 Q Do you see that now okay?
- 17 A Yes.
- 18 Q Okay. So here, on November 8th, the day of the Marcum
- 19 letter, the external auditors have a section there saying,
- 20 accounting for full exposure of settlement agreement.
- Do you see that there?
- 22 A Yes.
- 23 Q Okay. And I'm just going to read it, and you just tell
- 24 me if I read it correctly.
- During the quarter ending June 30th, 2013, the

RICHARDSON - CROSS - AGNIFILIO

- 1 | company, its chief executive officer, and MSMB Capital, MSMB,
- 2 became parties to a series of agreements to settle up to
- 3 \$2,286,511 of liabilities, which company management believes
- 4 | are the primary obligation of MSMB.
- 5 Do you see that there?
- 6 A Yes.
- 7 Q Okay. And then under it there's another small paragraph
- 8 that says: In August 2013, the company entered an additional
- 9 settlement agreement for \$300,000 and made payment on
- 10 August 29th, 2013, to settle such agreement.
- 11 Do you see that?
- 12 A I see that.
- 13 Q Okay. Did you take any action after reading this on or
- 14 about November 8th, 2013?
- 15 A No, the action I had taken was earlier with Marc Panoff
- 16 to be comfortable with the promissory note that Martin and
- 17 | MSMB had signed behind these agreements was being actioned.
- 18 Q But by this point you're being told by the auditor that
- 19 | there's over \$2 million in liability, correct?
- 20 A Yes, but with promissory notes behind them. Holding the
- 21 company whole.
- 22 (Continues on following page.)

23

24

RICHARDSON - CROSS - AGNIFILIO

- 1 | Q And do you know if Steve Aselage told Martin not to worry
- 2 about the promissory note?
- 3 MS. KASULIS: Objection.
- 4 THE COURT: Sustained. Sustained.
- 5 Q Did you ever have a conversation with Steve Aselage about
- 6 | the promissory notes?
- 7 A No.
- 8 O Never?
- 9 A No.
- 10 Q Did you ever have conversation with Martin about the
- 11 promissory notes?
- 12 A No. Only Marc Panoff.
- 13 Q And did you and Steve Aselage ever discuss the settlement
- 14 | agreements at all?
- 15 A Only in the context of the board, any board discussion
- 16 | that we wanted to make sure, obviously, they're fulfilled.
- 17 | Q And you understand that the company is picking these up
- 18 | as liabilities, correct?
- 19 A Initially.
- 20 | Q These are appearing as liabilities in Retrophin's public
- 21 | filings, correct?
- 22 A Yes. But with a promissory note from MSMB and Martin to
- 23 make the company whole.
- 24 Q But you understand that in terms of the auditor here,
- 25 | correct, they are considering this a liability of Retrophin,

- 1 | fair to say?
- 2 A At that point in time.
- 3 Q And so you -- fair to say, you as a board member --
- 4 THE COURT: I'm sorry. Did you say it was a
- 5 | liability of Retrophin or MSMB?
- 6 MR. AGNIFILO: No, a liability of Retrophin. A
- 7 | liability of Retrophin.
- 8 Q You understood that it was on the books of Retrophin as a
- 9 | liability of Retrophin, fair to say, at this point in time?
- 10 A Yes, but with recognition of the promissory note again.
- 11 Q And you were aware at this point in time of the
- 12 settlement agreement, correct?
- 13 A We were aware of the settlement. The subject had been
- 14 | moved. We weren't aware of the specific settlement
- 15 | agreements. None had been brought to us.
- 16 Q Well, two consulting agreements were sent to you,
- 17 | correct?
- 18 A That's a very different, settlement agreements.
- 19 Q No. No. I understand. But you understood that there
- 20 | were settlement agreements that were being reached, correct?
- 21 A Between Martin, MSMB and certain investors.
- 22 | Q And Retrophin. These are on Retrophin books as
- 23 | liabilities, yes or no?
- 24 A At this point in time, yes.
- 25 Q Now, I think you also talked in direct examination about

- 1 | an email that is in evidence as Government's 122-43 that
- 2 Panoff sent to you July 2, 2013. It's Martin Shkreli, Steve
- 3 Aselage, Richardson, Greebel concerning a board call.
- 4 Do you see that?
- 5 A Yes.
- 6 Q And in connection with this email you also had in
- 7 | evidence and I think you looked at a Retrophin incorporated
- 8 summary cash flow for the six months ended June 30, 2013.
- 9 Do you see that there?
- MS. KASULIS: It's tab 53 of your binder.
- 11 A Yes. Thank you.
- 12 Q And I think you said on direct examination, correct me if
- 13 I'm wrong, that toward the bottom there there's an entry that
- 14 | says MSMB's settlements, Spencer Spielberg.
- 15 MS. KASULIS: Your Honor, can I just object to all
- 16 | the -- the version with counsel's writing on it.
- 17 THE COURT: I don't know whose writing that is.
- 18 MR. AGNIFILO: It's mine.
- 19 THE COURT: The government has a clean copy. Do you
- 20 want to put that one up?
- 21 MR. AGNIFILO: I think I got rid of it.
- I'm all about efficiency. Okay.
- 23 Q Toward the bottom there it says MSMB settlement, Spencer
- 24 | Spielberg, Sarah Hassan, Trachtenberg & Rodes. Do you see
- 25 that there?

- 1 THE COURT: You might need to move the document.
- 2 A Yeah, move the -- I have it on my hard copy. Yeah.
- 3 Q Can you see it okay?
- 4 A Yes.
- 5 Q There we go. All right. And the sum is 548,711,
- 6 correct?
- 7 A Yes.
- 8 Q And I think your testimony on direct is you don't recall
- 9 seeing this?
- 10 A No. I think I said I recalled seeing it. I said that
- 11 | there wasn't any discussion about it.
- 12 Q Well, you saw it. What did you think it was?
- 13 A Well, again, I go back to counsel to what I said before
- 14 | is, you know, I was aware that settlements were being
- 15 | processed, but they were being backed up by the promissory
- 16 | note so that the company was being made whole at some point in
- 17 time.
- 18 Q But this is being captured as an expense, correct?
- 19 A Yes.
- 20 Q An expense of Retrophin, right?
- 21 A Yes.
- 22 | Q And it's an expense that's in excess of a half a million
- 23 dollars, correct?
- 24 A Yes.
- 25 Q And it's right there in a financial report that's given

- 1 to you in your capacity as a board member, correct?
- 2 A Yes.
- 3 Q And you're saying you saw it, but you didn't think much
- 4 about it?
- 5 A No. I spoke to the new CFO at this point, Marc Panoff.
- 6 I spoke to him both here and in September, and he said as long
- 7 as Martin and MSMB stand by the promissory note, the company
- 8 | will be made whole. So I was a board of directors. I'm
- 9 comfortable with that coming from my CFO.
- 10 Q Did you speak to Martin about it?
- 11 A I didn't speak to Martin about it, no. Not specifically
- 12 I didn't.
- 13 Q You never raised this with Martin?
- 14 A Not as a specific discussion point.
- 15 Q Is there a reason why you didn't raise it with Martin?
- 16 A No. I had raised it with Marc and I felt that was
- 17 adequate.
- 18 Q I mean, here's a \$548,000 plus liability to Retrophin.
- 19 You're given an explanation from someone other than Martin
- 20 | that Martin is going to pay it, and you don't confront Martin
- 21 about it?
- 22 | A Well, no, but remember, counsel, what I said in my direct
- 23 | is I'd spoken to Martin in March of that year and he'd already
- 24 | told me specifically he was going to take from his personal
- 25 | stock to top me up and the other investors. So the angle I

- 1 | had from Martin was he said to me all the way back in March,
- 2 I, Martin, am making each of you good again from my personal
- 3 stockholding so I didn't need to go back to him because that
- 4 was my frame of reference.
- 5 Q But if Martin was going to use his personal stock, why is
- 6 it on a Retrophin financial document?
- 7 A That was part of what he must have, you know, arranged.
- 8 Because we never saw the agreements, I didn't see the
- 9 agreements, maybe someone wanted cash. I don't know what the
- 10 outcome was. My frame of reference was Martin was making them
- 11 | whole and the promissory note confirmed that to me as a board
- 12 | member and that I took as adequate. And then I'd spoke to the
- 13 | CFO about it who also confirmed the same thing. So I had all
- 14 | the reassurances I felt I needed as a board member.
- 15 Q But you will agree with me that this financial report
- 16 | doesn't say anything along those lines, correct?
- 17 A The --
- 18 Q Go ahead. Yes?
- 19 A But the audit letter says, it refers to the promissory
- 20 | notes. If you pull up some other audit letters, you'll see it
- 21 refers specifically to the promissory notes that make the
- 22 | company good.
- 23 | Q Then at a minimum there are inconsistencies within the
- 24 recordkeeping of Retrophin, is that fair to say?
- MS. KASULIS: Objection.

- 1 THE COURT: Sustained.
- 2 Q Do you see this document as consistent with -- let me ask
- 3 you a different question.
- This document doesn't indicate that anybody other
- 5 than Retrophin is paying this bill, correct?
- 6 A On this one page, yes.
- 7 Q Yes. This one page is a Retrophin liability to the tune
- 8 of \$548,000 plus, correct?
- 9 A Yes.
- 10 Q And you never at any time after receiving this
- 11 | information had a conversation with Mr. Shkreli about this?
- 12 A Not that I remember specifically, no.
- 13 Q But wouldn't that have been important to do to understand
- 14 | what the overall situation was? Wouldn't you want to speak to
- 15 Martin directly about it?
- MS. KASULIS: Objection.
- 17 THE COURT: Mr. Agnifilo, this is the third or
- 18 | fourth time you have asked the question so I'm going to
- 19 | sustain the objection.
- MR. AGNIFILO: No, I know he didn't, but I want to
- 21 | ask him why he didn't.
- 22 A Again, because I had the reassurances from Martin and
- 23 then the promissory note was reconfirming that. And then
- 24 going forward the audit letter again, you know, said there
- 25 were no lingering issues.

- 1 | Q Now, at one point you're saying that Martin never paid
- 2 this debt back, correct?
- MS. KASULIS: Objection as to this debt. I don't
- 4 know.
- 5 Q Did Martin ever pay the \$548,000?
- 6 A I understood he was paying some of it. I don't know at
- 7 | what point and how much was paid.
- 8 Q How was he paying it back?
- 9 MS. KASULIS: Objection.
- 10 THE COURT: All right.
- 11 A I wasn't party to that.
- 12 THE COURT: If you know.
- Do you know?
- 14 THE WITNESS: No, I wasn't party to it.
- 15 Q You don't know?
- 16 A No.
- 17 Q But you'll agree with me that none of this was cited in
- 18 | the reasons that Martin was let go as CEO, correct?
- 19 A That's correct.
- 20 Q Part of the concern that the board had with Martin toward
- 21 | the end of his time as the CEO is that he was tweeting,
- 22 | correct?
- 23 A Yes, his use of Twitter.
- 24 Q And the board had talked to him about using Twitter, and
- 25 he kept using Twitter, right?

- 1 A Yeah. We talked to him. It was me specifically and Jeff
- 2 Paley numerous times.
- 3 Q And despite that it was bad for him, he kept using
- 4 Twitter?
- 5 A No. I agreed with him, as you heard in direct that, you
- 6 know, again, he was a younger profile CEO. There is an
- 7 | appropriate way, but he needed to tell us how he wanted to use
- 8 it.
- 9 Q And what do you think the excuse is for Donald Trump?
- 10 He's not a younger CEO.
- MS. KASULIS: Objection.
- 12 THE COURT: Sustained. Sustained.
- MR. AGNIFILO: Withdrawn.
- 14 THE COURT: Just disregard these gratuitous
- 15 remarks. They are completely irrelevant and inappropriate.
- 16 | All right.
- MR. AGNIFILO: I apologize.
- 18 Q But this was of great concern to the board, the tweeting?
- 19 A Not tweeting as a total, but certain types of tweets that
- 20 he was making that could be, you know, could be suggesting he
- 21 was somehow sharing company information.
- 22 Q Understood. Now, you talked a lot on your direct and
- 23 | cross examination about Evan Greebel, correct?
- 24 A Yes.
- 25 Q Evan Greebel is a partner at Katten Muchin Rosenman,

- 1 correct?
- 2 A Yes, which was -- we had -- he was our external counsel.
- 3 Q And I think you said he's external counsel, but he was
- 4 present for the board meetings, correct?
- 5 A Yes.
- 6 Q And I think you said that you assumed he was taking notes
- 7 during the meetings, correct?
- 8 A Yes, because I was only physically with him once or
- 9 twice. So, yes, I assumed he was taking the minutes.
- 10 Q Right. Because he was the secretary of the board?
- 11 A Yes.
- 12 Q And he was also someone that was on a great amount of the
- 13 | email traffic that would go on within Retrophin?
- 14 A Yes, he was copied on virtually everything.
- 15 Q On virtually everything, right?
- 16 A Yes.
- 17 Q And his job is to provide sound legal advice, fair to
- 18 say?
- 19 A Yes.
- 20 Q And he was involved in the capitalization tables,
- 21 correct?
- 22 A Yes.
- 23 Q He was involved in the information that was given to
- 24 | board members in preparation for the meetings, correct?
- 25 A Yes.

- 1 | Q And he was copied on all of those emails?
- 2 A Yes.
- 3 Q Martin, very often, would, if a legal question came his
- 4 | way, would say he had to speak to Evan, fair to say?
- 5 MS. KASULIS: Objection.
- 6 THE COURT: Sustained.
- 7 Q Did Martin ever refer legal questions to Evan in your
- 8 experience?
- 9 A I certainly saw a few referrals, yes, that either through
- 10 email or.
- 11 Q And in conversations with Martin, would Martin say to you
- 12 | that I need to run this past Evan?
- 13 A I think one or two specific instances he probably did,
- 14 yes.
- 15 Q Do you remember what those were?
- 16 A Well, certainly, again, in terms of my own, my own
- 17 | topping up of my own stock, that was one area that he said I
- 18 have to get back to Evan on.
- 19 Q Because he wanted to be appropriate, correct?
- 20 A Yes.
- 21 | Q And, to your knowledge, did he speak with Evan about it?
- 22 | A Only -- through the email exchange Evan was copied. I
- 23 | don't know if he spoke to him.
- 24 | Q And you've met Evan a number of times, correct?
- 25 A Yes.

RICHARDSON - CROSS - AGNIFILIO

- 1 | Q When Martin introduced you to Evan he said this is going
- 2 to be essentially the company's counsel, correct?

- 4 A Well, he, he didn't say that. I already met him
- 5 electronically, if you would. Like, I already know the role
- 6 | before. I don't believe Martin ever said that, he knew I knew
- 7 what Evan's context was.
- 8 | Q At one point Martin asked you to go down to the
- 9 Securities Exchange Commission, right?
- 10 A Yes.
- 11 | Q Tell us what he told you in preparation for your
- 12 interview there?
- 13 A He had said this complaint has been triggered by a
- 14 disgruntled employee. There is no substance to it. It would
- 15 | really help if there was one of the investors in MSMB Capital
- 16 | could answer go and speak to them because I think that would
- 17 | immediately close down this complaint.
- 18 Q Do you know who Jackson Su is?
- 19 A Yes, he was on the Retrophin team I believe in 2011,
- 20 2012.
- 21 | Q Do you know if he made a complaint with the SEC? Only if
- 22 you know.
- 23 A No.
- 24 Q You did go down to the SEC, correct?
- 25 A Yes.

Case 1:15 cr 00637 KAM Document 315 Filed 08/15/17 Page 213 of 297 PageID #: 6604

- 1 | Q And you told the SEC that you were happy with your
- 2 investment in MSMB; fair to say?
- 3 A Yes.
- 4 Q And you told the SEC that you would invest with Martin
- 5 Shkreli again, if given the opportunity?
- 6 A Yes.
- 7 Q And you meant that at the time, right?
- 8 A At the time, yes.
- 9 Q The \$1.9 million that you hold in Retrophin shares from
- 10 | the stock conversion, how much money did you put into MSMB?
- 11 A Into MSMB I put \$400,000 in.
- 12 Q And your total now is 1.9 million?
- 13 A Yes.
- 14 Q That's a good investment; fair to say?
- 15 A Yes.
- 16 Q Now yesterday you described a situation between you and
- 17 | Martin in your apartment, do you remember telling the jury
- 18 about that?
- 19 A Yes.
- 20 Q Were you being fully accurate?
- 21 A Yes.
- 22 O Yes?
- 23 A Yes.
- 24 Q You and Martin did not have a physical relationship?
- 25 A No.

Caso 1:15 er 00637 KAM Document 315 Filed 08/15/17 Page 214 of 297 PageID #: 6605

- S. RICHARDSON REDIRECT KASULIS
- 1 Q Do you remember telling him at one point, "I'm drunk,
- 2 where are you"?
- 3 A I don't recall that.
- 4 Q I'm going to show you an e-mail, Defendant's Exhibit
- 5 | 4223, an e-mail from you to Martin, March 29, 2010, 9:55 p.m.
- 6 A I don't recall it, but I'm reading it now.
- 7 Q Did you write to him, "Martin, I'm drunk. Where are
- 8 you?"
- 9 MS. KASULIS: Objection.
- 10 THE COURT: Overruled. You can answer the question.
- 11 A It's from my e-mail. It's on here.
- 12 Q Did you send it?
- 13 A I must have, but I don't have any recall of it.
- 14 Q Thank you, Mr. Richardson?
- 15 MR. AGNIFILO: Thank you. No further questions at
- 16 | this point.
- 17 THE COURT: Any redirect of this witness?
- MS. KASULIS: Briefly, your Honor.
- 19 REDIRECT EXAMINATION
- 20 BY MS. KASULIS:
- 21 Q Mr. Richardson, earlier in cross-examination there had
- 22 been some discussion about touching soft skin, do you recall
- 23 that?
- 24 A Yes.
- 25 Q You made some reference to some sort of a neck

(Government Exhibit 122-99, was received in

23

24

25

122-99.

evidence.)

Caso 1:15 cr 00637 KAM Document 315 Filed 08/15/17 Page 216 of 297 PageID #: 6607

- S. RICHARDSON RECROSS AGNIFILO
- 1 Q So the date on this e-mail is April 13, 2010; is that
- 2 right?
- 3 A Yes.
- 4 Q And it's from Mr. Shkreli to yourself; is that right?
- 5 A Yes.
- 6 Q The subject is, "the skin around my neck is all better."
- 7 Do you see that?
- 8 A Yes.
- 9 Q Is that a reference, is that another reference to the
- 10 | neck infection that you were testifying about earlier?
- 11 A Yes.
- MS. KASULIS: No further questions.
- 13 RECROSS-EXAMINATION
- 14 BY MR. AGNIFILO:
- 15 | O You remember clearly there is reference to a neck
- 16 infection, that this e-mail, you're saying you remember this
- 17 | e-mail? Is that what you're saying?
- 18 A It says, "the skin around my neck is all better."
- 19 Q Do you know what he's talking about?
- 20 A Yes, the infection that I referred to earlier.
- 21 | Q And had you ever touched his soft skin?
- MS. KASULIS: Objection.
- THE COURT: Overruled. You can answer it.
- 24 A Well, in terms of a hug or something like that, yes, I
- 25 touched him in a hug or whatever.

Where do you live?

Case 1:15 or 00637 KAM Document 315 Filed 08/15/17 Page 218 of 297 PageID #: 6609

- 1 A New York City.
- 2 Q Which borough?
- 3 A Manhattan.
- 4 Q How long have you lived there?
- 5 A Probably about 20 years.
- 6 Q Are you married?
- 7 A I am.
- 8 Q Do you have any children?
- 9 A I do, I have a 12-and-a-half year old boy.
- 10 Q Could you please describe your educational background?
- 11 A I had a BS in finance from Syracuse University.
- 12 Q About when did you graduate?
- 13 A 1984.
- 14 | Q Could you please describe your professional background
- 15 after college?
- 16 A After college I was, I had a couple of odd jobs, amongst
- 17 | a salesman for six months. Then I became an assistant trader
- 18 at Shearson Lehman Brothers.
- 19 0 What is Shearson Lehman Brothers?
- 20 A A large brokerage firm that doesn't exist any longer.
- 21 | Q How long were you at Shearson Lehman?
- 22 A Five years.
- 23 Q What did you do after that?
- 24 A After that I continued in the industry. I had a few
- 25 different jobs, same industry. I assisted some law traders

Case 1:15 or 00637 KAM Document 315 Filed 08/15/17 Page 219 of 297 PageID #: 6610

- D. GELLER DIRECT SRINIVASAN
- 1 and then I traded on my own.
- 2 Q When you say trading, what do you mean?
- 3 A Just pretty much speculating buying and selling, buying
- 4 low, selling high.
- 5 Q Any particular kinds of things that you were trading?
- 6 A Just basic equities, nothing in particular.
- 7 Q Since about 2011 or so, what have you done?
- 8 A In 2011 I was still trading. I think I maybe took a
- 9 break in 2012 for a couple of years. Market has been getting
- 10 a lot harder with the computer derivatives and black boxes,
- 11 | all that kind of stuff. And in the last year-and-a-half I
- 12 took on trading part-time again.
- 13 Q Do you know an individual named Martin Shkreli?
- 14 A I do.
- 15 Q Have you met him in person?
- 16 A I have.
- 17 Q How do you know him?
- 18 A I was introduced to him a while ago and I became an
- 19 investor in his fund.
- 20 Q Who were you introduced by?
- 21 A My brother, Alan.
- 22 | Q About when was your first contact with Martin Shkreli?
- 23 A In the beginning of 2011.
- Q Do you see Martin Shkreli in the courtroom today?
- 25 A I do.

Caso 1:15 cr 00637 KAM Document 315 Filed 08/15/17 Page 220 of 297 PageID #: 6611

- D. GELLER DIRECT SRINIVASAN
- 1 Q Can you point him out and pick out --
- 2 A Sitting over there, to the right.
- 3 MR. BRAFMAN: We'll stipulate to the identification.
- 4 A He's wearing a collared shirt, pink or white.
- 5 THE COURT: We will note that Mr. Geller has
- 6 identified Mr. Shkreli.
- 7 MR. SRINIVASAN: Thank you, your Honor.
- 8 Q How did you first contact him, by phone in person?
- 9 A By phone.
- 10 Q Why did you speak to him?
- 11 A I spoke to him because I just wanted to feel him out a
- 12 little.
- 13 O Feel him out in terms of what?
- 14 A See a little about his background. I wanted to hear him
- 15 | talk about his investing style. And I just wanted to see what
- 16 | type of strategy he used. And I guess lastly, to try to get a
- 17 | feel of what type of guy he was.
- 18 Q Was he running any kind of company at that time or fund?
- 19 A Repeat it?
- 20 Q Was he running any company or fund at the time?
- 21 A Yes, he was.
- 22 0 What was that?
- 23 A MSMB Healthcare.
- 24 Q Did you discuss MSMB Healthcare with him?
- 25 A We did.

Caso 1:15 cr 00637 KAM Document 315 Filed 08/15/17 Page 221 of 297 PageID #: 6612

- D. GELLER DIRECT SRINIVASAN
- 1 Q What did he tell you about MSMB Healthcare?
- 2 A He said it was a long/short balanced fund that invested
- 3 primarily in health care securities.
- 4 Q When you say long/short, what did that mean?
- 5 A That meant at any one time he, in his position, balances
- 6 he had to have a certain amount of shorts or longs or setting
- 7 the shorts or longs.
- 8 THE COURT: Can I ask you to push the mic a little I
- 9 away. You're a little too close. Push the base away. Thank
- 10 you.
- 11 Q Did he say anything about the liquidity in the fund?
- 12 A He did. He said it was a very liquid fund.
- 13 Q What did that mean to you?
- 14 A That meant that if an investor wanted to cash out or take
- 15 part of his cash out, it would be simple.
- 16 Q Did this information make any impression on you with
- 17 | respect to MSMB Healthcare?
- 18 A It did.
- 19 0 What was that?
- 20 A It fit my objectives at the time. Because I was looking
- 21 | for a fund such as that. I just wanted a liquid fund. Low
- 22 volatility, balance.
- 23 | Q Had you invested in any hedge funds before this?
- 24 A I did.
- 25 Q What was your prior experience with investing in hedge

- 1 funds?
- 2 A My prior experience unfortunately was not too good.
- 3 Because I invested a big portion of my money in 2006, 2007 and
- 4 that, as you know, was right before the stock market crashed.
- 5 So a lot of the investments I had were illiquid and they were
- 6 they were hedge funds that required 120 days written notice.
- 7 And one of them was, I invested with a friend, and
- 8 | they invested in pipes which are similar to like a secondary
- 9 investments, and that fund lost 90 percent. The big hedge
- 10 funds, I had didn't do too well.
- 11 | Q Mr. Geller, just so the record is clear, you say that
- 12 | your investments were liquid or illiquid?
- 13 A Illiquid, a lot of them. Some were liquid but a decent
- 14 portion that was illiquid.
- 15 Q Did that experience have any effect on how you evaluated
- 16 hedge fund investments going forward?
- 17 A Absolutely.
- 18 Q How so?
- 19 A The next, if I invested again, the next investment I
- 20 | wanted to make was going to be a fund that I could recoup any
- 21 | cash, if I wanted to cash out, on my terms not anyone else's
- 22 terms.
- 23 Q You mentioned a second ago you were trying to get a sense
- 24 of the defendant, did he describe his background to you?
- 25 A He told me that, what impressed me was he worked for Jim

1	MR. BRAFMAN: Your Honor, we have a witness that
2	testified to what the defendant told him. He said, "I was
3	working at Jim Cramer." The fact that he had previously
4	worked for Elea Capital is not spoken about either in a good
5	way or a bad way. If he said, "I worked at Elea Capital and I
6	did great there," that would be an affirmative
7	misrepresentation. I don't think every time you pitch
8	yourself to a prospective investor you need to tell them
9	everything in your career that may be good or bad. It's what
10	did you say, what did you rely on.
11	He was referred to this man by his brother, who is
12	in the fund and made millions. He's referred to by Kevin
13	Mulleady.
14	If the next question is, if he had told you that he
15	was in Elea and Elea didn't work out, would you have wanted to
16	know that. Those are inappropriate questions.
17	THE COURT: Were you going to move on?
18	MR. SRINIVASAN: The next question is, "If the
19	defendant had performed well or poorly at a previous hedge
20	fund, would that have been important to your investing," which
21	the form of the question I think Ms. Kasulis asked yesterday.
22	So it's not eliciting anything more than a hypothetical.
23	THE COURT: Why don't we do this. We can strike the
24	whole Elea reference.

MS. SMITH: It's a fact question, not a

1 hypothetical.

12

13

14

15

16

17

18

19

20

21

22

23

24

- 2 THE COURT: When he told him --
- MS. SMITH: You can of argue later that it's not
- 4 material, but we have a right to ask.
- 5 MR. BRAFMAN: The next question is, if you know of
- 6 | that Elea didn't work out.
- 7 MR. SRINIVASAN: That's not what I said, "would 8 information about whether the defendant performed well or 9 poorly as a hedge fund manager been important to your 10 investment," it could be anything.
- 11 THE COURT: It's a neutral question.
 - MR. BRAFMAN: It's not a neutral question, because this jury has heard throughout the trial, over our objection, about Elea Capital and that Elea was something that didn't perform well, because they have asked everybody about it over our objection. And now with someone who could careless, who had no clue about Elea, good or bad, made his investment on what of his brother Alan Geller told him.
 - MS. SMITH: The defense withdrew the objection to Elea Capital.
 - MR. BRAFMAN: We withdrew our objection as a -- when we were talking about motions in limine there was a question as to whether or not you could reference Elea or RBC. That doesn't mean you can do it in the way that you are using it.
 - MS. SMITH: In what way would we use it?

MR. BRAFMAN: This man has had no conversation with 1 2 him about anything. He says he was impressed with Jim Cramer. 3 THE COURT: We established that Elea never came up. 4 The next question is not going to Elea. If we can move 5 forward with the question, whether or not prior performance as 6 a hedge fund manager positive or negative would have been 7 important to him, I think that's neutral enough. 8 If the objection was withdrawn, then the motions I 9 think --10 MR. BRAFMAN: Judge, we're talking about apples and 11 oranges. 12 What we said first, if Mr. Shkreli -- if the 13 witnesses are coming here from Elea they can testify to it. 14 If Elea was properly mentioned because it's in many of the 15 PPMs Elea is noted. So we withdrew our objection because Elea comes up in several of the PPMs. 16 17 That doesn't mean we withdraw our objection to what 18 you ask about Elea. We've been pressing this objection since 19 the trial started. In particular with this person we don't believe you have -- I want to make the record clear. I do not 20 21 believe that someone who is pitching you to invest has an 22 affirmative obligation to go through their entire track record 23 every time they suggest that you should invest with them. 24 MR. SRINIVASAN: This is argument. He's entitled to 25 argue it. In our motion initially we clearly had the grounds

why Elea matters in terms of its knowledge, in terms of direct evidence in this case. They withdrew their objection. The next question is neutral, not about if you learned about Elea, or if Elea bust would that have mattered to you. That's not the question.

MR. BRAFMAN: The next question following reference to Elea is only being asked to imply that Elea was a bad hedge fund.

MS. SMITH: In fact, there is other examples which may or may not come in, where the defendant performed poorly in trading. So it is a completely fair question, "if you had known if he performed poorly as a hedge fund or trader, would that have effected your decision to invest." The defendant chose not to disclose that the information. We can argue that material. We have a right to ask the questions. We have a right to ask the hypothetical questions. We have neutralized them, but we have have a right to ask those as well.

THE COURT: You can ask the question in the form that you're proposing the next question.

MR. BRAFMAN: We're not waiving our objection.

THE COURT: We're not striking anything.

(End of sidebar conference.)

(Continued on the next page.)

- D. GELLER DIRECT SRINIVASAN
- 1 (In open court.)
- THE COURT: Please proceed.
- 3 BY MR. SRINIVASAN:
- 4 Q Mr. Geller, would information about whether the defendant
- 5 had performed well or poorly as a hedge fund manager had been
- 6 important to your investing decision?
- 7 A Yes.
- 8 Q Why is that?
- 9 A Because I think everyone basically needs some type of a
- 10 | track record just to base your decision on.
- 11 | Q While you were considering an investment, did you receive
- 12 documents about MSMB Healthcare?
- 13 A Yes.
- 14 Q What were they?
- 15 A They were the basic documents you get before an
- 16 | investment. There is a Private Placement Memorandum, there is
- 17 | a subscription agreement, and there is an investor
- 18 questionnaire.
- 19 Q Did you review those documents?
- 20 A I went over them, I briefed them.
- 21 Q What do you mean by brief them?
- 22 A I looked them. I didn't sit and read every word for word
- 23 for five hours. I did look them over. I'd seen documents
- 24 like that before, a lot of it is just the same language.
- Q When you do that, do you have a sense of what you're

- D. GELLER DIRECT SRINIVASAN
- 1 | looking for in the document?
- 2 A There is a couple of key words, yes, absolutely.
- 3 Q Did you rely on the information contained in the
- 4 documents we were just talking about?
- 5 A Yes.
- 6 Q I'm showing you what is marked for identification as
- 7 Government's Exhibit 109-3.
- 8 Mr. Geller, you have a big binder and a little
- 9 binder. In the big binder, it's tab three. On the front page
- 10 what kind of document is this?
- 11 A Investment letter with all the attachments of the
- 12 documents.
- MR. SRINIVASAN: Your Honor, we move Government's
- 14 Exhibit 109-3 into evidence.
- MR. BRAFMAN: No objection.
- THE COURT: We will receive 109-3.
- 17 (Government Exhibit 109-3, was received in
- 18 | evidence.)
- 19 Q Focusing on the top for a minute, who sent these
- 20 documents to you?
- 21 A Kevin Mulleady.
- 22 Q Who is Kevin Mulleady?
- 23 A Kevin was the, he was the salesman of the hedge fund and
- 24 he performed other tasks as well.
- Q When you say the hedge fund, we're talking about MSMB

- D. GELLER DIRECT SRINIVASAN
- 1 Healthcare?
- 2 A MSMB Healthcare.
- 3 Q When did he send this e-mail to you?
- 4 A June 22, 2011.
- 5 Q You mentioned attachments a second ago, what are the
- 6 attachments that are listed here?
- 7 A Private Placement Memorandum, a subscription agreement,
- 8 and a individual questionnaire.
- 9 Q Let's go to the third page of this exhibit, which is
- 10 Bates number R036371, what is this document?
- 11 A This is the cover letter to the Private Placement
- 12 Memorandum.
- 13 O For which fund?
- 14 A MSMB Healthcare.
- 15 Q Who is listed as the managing partner?
- 16 A Martin Shkreli.
- 17 0 What is the date on this document?
- 18 A January 1st, 2011.
- 19 O Mr. Geller, I'm showing you what is marked for
- 20 identification as Government's Exhibit 11A, if you keep a
- 21 | finger on the page that you have now, tab three, then go to
- 22 tab 30.
- 23 A Okay.
- 24 0 What is the document that's behind tab 30?
- 25 A Private Placement Memorandum.

mean?

- 1 A It meant that it was pretty much in line with what I was
- 2 looking for to invest in. But it meant to me that superior
- 3 | absolute returns means, that if the general market has a big
- 4 move on the upside or the down side, the investment will be
- 5 | shielded because it has long and shorts. It also meant that
- 6 there will be low volatility, which means not wild swings.
- 7 And long and short investment in health care companies will be
- 8 long investment and short investments in health care companies
- 9 in the U.S. and the world.
- 10 Q Mr. Geller, was this information important to your
- 11 investing decision?
- 12 A Very important.
- 13 Q Why was that?
- 14 A Because it fit my objective. I was looking for only an
- 15 investment that was liquid.
- 16 Q Let's go to Bates R036381, the 11th page of this exhibit,
- 17 | the paragraph capital withdrawals?
- 18 A Yes.
- 19 Q The first sentences say, "Limited partners may withdraw
- 20 any or all of their capital accounts subject to certain
- 21 | reserves which may be established by the general partner to
- 22 | cover contingent liabilities of the partnership monthly at the
- 23 | last calendar day, of each month commencing one full month
- 24 | after the date of their initial investment in the partnership
- of upon not less than 30 days prior written notice to the

- D. GELLER DIRECT SRINIVASAN
- general partner." Do you see that?
- 2 A Yes.
- 3 Q What did you understand this to mean?
- 4 A This means that an investor in the fund can cash out on a
- 5 monthly basis, giving 30 days' written notice.
- 6 Q Was this information important to your investing
- 7 decision?
- 8 A Yes.
- 9 Q Why is that?
- 10 A It was part of the whole liquidity. If you needed your
- 11 | money back you can get it without any road blocks or other
- 12 obstacles.
- 13 Q Let's go to the next page, which is Bates R036382, do you
- 14 | see the paragraph that starts, "Partnership reports"?
- 15 A Yes.
- 16 | Q The first sentence says, "Following the end of each
- 17 | fiscal year, the partnership's certified public accountants
- 18 | will audit for delivery by the general partner to each limited
- 19 partner financial statements of the partnership for such year,
- 20 | as well as a statement of such limited partner's capital
- 21 | account and certain tax information for the preparation of
- 22 | such limited partner's income tax returns." Do you see that?
- 23 A Yes.
- 24 O There is a reference there to certified public
- 25 | accountants will audit, what, if anything, did that mean to

- 1 you?
- 2 A That's pretty much what, from what I understand, all
- 3 hedge funds have. They have a certified public accountant who
- 4 does the audits at the end of the year.
- 5 Q When you invested in hedge funds in the past, have those
- 6 hedge funds had auditors?
- 7 A Yes.
- 8 O And administrators?
- 9 A Yes.
- 10 Q Was the presence of an auditor important to your
- 11 investing decision?
- 12 A Yes.
- 13 Q Why is that?
- 14 A Because this way everything was checks and balances,
- 15 everything was done right.
- 16 Q When you say everything was done right, what do you mean?
- 17 A Well, the brokerage firm or hedge fund has certain
- 18 responsibilities to the investors as a due diligence type of
- 19 thing to make sure the booking of the positions are, the
- 20 positions are looked at, positions are right, there will be
- 21 | monthly statements sent out, accurate monthly statements and
- 22 so on.
- 23 | Q Now how would having or not having an auditor affect your
- 24 investing decision?
- 25 A I would not invest in any investment if there wasn't an

- D. GELLER DIRECT SRINIVASAN
- 1 auditor or a certified public accountant.
- 2 Q I'm showing you what is marked for identification as
- 3 Government's Exhibit 109-4, which is tab four of your binder,
- 4 do you recognize this document?
- 5 A Yes.
- 6 0 What kind of document is it?
- 7 A It's an investor letter.
- 8 | Q Did you receive it?
- 9 A I did.
- MR. SRINIVASAN: Your Honor we move to admit 109-4.
- MR. BRAFMAN: No objection.
- 12 THE COURT: We receive 109-4.
- 13 (Government Exhibit 109-4, was received in
- 14 evidence.)
- 15 Q Looking at the top, Mr. Geller, who sent this to you?
- 16 A Kevin Mulleady.
- 17 Q When did he send it to you?
- 18 A June 23, 2011.
- 19 | O Let's look at the first two paragraphs, if we could zoom
- 20 | in on those, please. The first paragraph says, "MSMB Capital
- 21 | management, a fund specializing in long-term strategic
- 22 investments in healthcare and biotechnology businesses, today
- 23 | announced that it had made a proposal to the Board of
- 24 Directors of SeraCare" --
- MR. BRAFMAN: Objection, your Honor.

Case	1:15 cr 00637 KAM Document 315 Filed 08/15/17 Page 236 of 297 PageID #: 6627
	D. GELLER - DIRECT - SRINIVASAN
1	THE COURT: What is the objection, sir?
2	MR. BRAFMAN: It's not relevant.
3	MR. SRINIVASAN: I can make a proffer, your Honor.
4	THE COURT: I'll hear from the parties.
5	(Continued on the next page.)
6	(Sidebar conference.)
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	

MR. SRINIVASAN: Your Honor, this is a notification 1 2 that was sent out to investors of a press release. We've done 3 this before with other investors and shown this document and 4 talked to them about it, Dr. Rosenfeld for example. 5 Two, the relevance for this witness is that it 6 impressed him about the financial wherewith all of MSMB 7 entities. For example, you'll see \$82 million cash offer to 8 SeraCare, that offer is not subject to any financing 9 condition. This is just days before he invests, which is what 10 we're going to get to in just a few minutes. So what it 11 impresses him about is about the assets and the finances that 12 the defendant has. It gives him confidence in the investment. 13 If the concern is that we are somehow getting into details --14 MR. BRAFMAN: Are you putting this into evidence? 15 THE COURT: You did. You didn't object. 16 MR. SRINIVASAN: We're not getting into the details 17 of the deal, that there is false information, just the 18 impression to the witness. 19 THE COURT: The effect on him. 20 MS. SMITH: We did the same document in for 21 Rosenfeld, the same discussion. 22 THE COURT: Okay. 23 (End of sidebar conference.) 24 (Continued on the next page.) 25

- 1 (In open court.)
- 2 BY MR. SRINIVASAN:
- Q Mr. Geller, why don't I start by starting the reading this paragraph again.
- 5 So the first paragraph there says, "MSMB Capital
- 6 Management, a fund specializing in long-term strategic
- 7 investments in healthcare and biotechnology businesses today
- 8 announced that it has made a proposal to the Board of
- 9 Directors of SeraCare Sciences Inc. to acquire all the
- 10 outstanding common stock of SeraCare for \$4.25 per share or an
- 11 | aggregate of \$82 million. This proposal represents an
- 12 | approximate 22 percent premium of the closing price of
- 13 | SeraCare stock 3.49 on June 22, 2011. MSMB's offer is
- 14 | conditioned upon completion of cursory due diligence and other
- 15 | customary provisions. MSMB's offer is not subject to any
- 16 | financing condition."
- In the second paragraph it says, "MSMB's offer is
- 18 | not subject to any financing conditions, " do you see that?
- 19 A Yes.
- 20 Q What did that language mean to you?
- 21 A That they don't, they can do it themselves, they don't
- 22 | really, they don't need help with loans or bridge financing or
- 23 any of those other financial things.
- 24 | O What, if any, impression did this e-mail make on you
- about MSMB Healthcare and the defendant?

- D. GELLER DIRECT SRINIVASAN
- 1 A Actually it made a very good impression.
- 2 Q Why is that?
- 3 A Well, after reading it, it led me to believe that MSMB
- 4 | Healthcare was very-well capitalized, if they were going to
- 5 purchase a public company for this amount of money.
- 6 Q Did you in fact invest in MSMB Healthcare?
- 7 A I did.
- 8 Q How much did you invest?
- 9 A 200,000.
- 10 Q I'm showing you what is marked for identification as
- 11 Government's Exhibit 28, tab 32 in your binder. What is this
- 12 document?
- 13 A It's a subscription agreement.
- 14 Q Is this a document that you signed?
- 15 A It is.
- 16 Q For what fund?
- 17 A MSMB Healthcare.
- 18 MR. SRINIVASAN: Your Honor we move to admit
- 19 Government's Exhibit 28.
- 20 MR. BRAFMAN: No objection.
- 21 THE COURT: We will receive Government's Exhibit 28.
- 22 (Government Exhibit 28, was received in evidence.)
- 23 Q Mr. Geller, let's go to the 12th page, Bates R011939.
- 24 Did you sign this document?
- 25 A I did.

- D. GELLER DIRECT SRINIVASAN
- 1 Q When did you sign it?
- 2 A June 29, 2011.
- 3 Q At the time you invested, did the defendant ever mention
- 4 | a company called Orexigen or Orex?
- 5 MR. BRAFMAN: Objection, no testimony that he spoke
- 6 to Mr. Shkreli before he invested.
- 7 MR. SRINIVASAN: He had a phone call, your Honor.
- 8 THE COURT: Let's not argue in front of the jury.
- 9 Lay a foundation about conversations.
- 10 BY MR. SRINIVASAN:
- 11 Q Mr. Geller --
- 12 THE COURT: Before the investment.
- 13 Q Mr. Geller, before you invested in MSMB Healthcare, did
- 14 you ever speak to the defendant?
- 15 A I did.
- 16 Q And in that conversation and before the time you
- 17 | invested, did the defendant ever mention a company called
- 18 Orexigen sometimes abbreviated as Orex?
- 19 A He did not.
- 20 Q Over the course of your investment, did you receive
- 21 | information about the performance of your investment?
- 22 A Yes.
- 23 Q How did you receive that information?
- 24 A I got investor statements.
- 25 Q You have a binder that's labeled 91 series, it has ten

- D. GELLER DIRECT SRINIVASAN
- 1 tabs in it. These exhibits are marked for identification as
- 2 Government's Exhibits 91-1 through 91-10, do you recognize
- 3 these documents?
- 4 A Yes.
- 5 Q What are they?
- 6 A These are the investor statements.
- 7 MR. SRINIVASAN: Your Honor we move to admit
- 8 Government's Exhibit 91-1 through 9-10.
- 9 MR. BRAFMAN: No objection.
- 10 THE COURT: We will receive 91-1 through 91-10.
- 11 (Government Exhibit 91-1 through 91-10, was received
- 12 in evidence.)
- 13 Q Tab one, 91-1, if you look at the middle e-mail, it
- 14 | should be on your screen, who sent the e-mail to you?
- 15 A NAVConsulting.net.
- 16 Q What, if anything, did you understand NAV Consulting to
- 17 be?
- 18 | A I believed it was their consulting and administrative
- 19 type firm.
- 20 Q What is the date on the e-mail?
- 21 A August 9, 2011.
- 22 O For what month is this statement?
- 23 A July 2011.
- 24 | Q Let's go to page two of this exhibit, Bates R013294, what
- 25 | was your ending balance according to this statement?

- 1 A They had some. Just pretty much, you know, you see to
- 2 | how the game is going, to see what the score is.
- 3 DIRECT EXAMINATION (CONTINUED)
- 4 BY MR. SRINIVASAN:
- 5 Q Okay. Let's go to the next tab, which is Government
- 6 Exhibit 91-2.
- 7 And focusing on the middle email, Mr. Geller, what's
- 8 the date on this email?
- 9 A October 27th, 2017.
- 10 Q For what month is this statement?
- 11 A September 2011.
- 12 Q Let's go to page 2. What was your ending balance for
- 13 this month?
- 14 A \$210,354.
- 15 Q Mr. Geller, do you see some fine print at the bottom of
- 16 | that page?
- 17 A Yes.
- 18 Q And is there a reference to Retrophin in this fine print?
- 19 A Yes.
- 20 Q Did this fine print make any impression on you at this
- 21 time?
- 22 A To tell you truth, I didn't -- I didn't notice -- I mean,
- 23 | there was something there but I never -- I never -- I never
- 24 bothered to really read it.
- 25 Q Let's go to Government Exhibit 91-3, which is the next

- 1 tab in your binder.
- 2 Mr. Geller, what's the date on the email?
- 3 A November 30th, 2011.
- 4 Q And for what month is the statement?
- 5 A October 2011.
- 6 Q Let's go to the second page. What was your ending
- 7 balance for this month?
- 8 A \$199,938.
- 9 Q And if we could zoom in on that paragraph at the bottom.
- Mr. Geller, do you see a reference to Retrophin in
- 11 | this time frame?
- 12 A Yes.
- 13 Q Did this fine print make any impression on you at this
- 14 time?
- 15 A Yes, it did. It absolutely did. I mean, I did notice
- 16 | the footnote at this time.
- 17 Q At this point what, if anything, was your understanding
- 18 of Retrophin?
- 19 A I really had no idea what it was.
- 20 Q And in the first sentence of the fine print, it says:
- 21 MSMB Healthcare, LP has accepted the transfer of 30,000
- 22 | investment units consisting of Class A common units of
- 23 | Retrophin, LLC, a Delaware limited liability company focused
- 24 on developing biopharmaceutical products for Martin Shkreli at
- 25 no consideration as a gift.

- 1 What, if anything, was your understanding of the
- 2 language "at no consideration as a gift"?
- 3 A My understanding was that it was -- it was a gift that
- 4 was gifted to all -- whoever he gifted it to.
- 5 Q To MSMB Healthcare?
- 6 A Well, in looking at this footnote, yes, MSMB Healthcare.
- 7 Q At this point, did you believe that MSMB Healthcare had
- 8 paid money to invest in Retrophin?
- 9 A I'm sorry, say it again?
- 10 Q Of course. At this point, did you believe that MSMB
- 11 | Healthcare had paid money to invest in Retrophin?
- 12 A No.
- 13 Q Did you have any understanding of the size of MSMB
- 14 | Healthcare's position in Retrophin?
- 15 A I did not.
- 16 Q So let's go back to the big binder. And I'm showing you
- 17 | what's been marked for identification as Government
- 18 | Exhibit 109-6. It's Tab 6 in your -- in the big binder.
- 19 A Okay.
- 20 Q Now, what kind of document is this?
- 21 A An investor letter.
- 22 Q Did you receive it?
- 23 A I did.
- MR. SRINIVASAN: Your Honor, we move to admit
- 25 Government's Exhibit 109-6.

- 1 A That's my email.
- 2 Q Okay. So let's go to the fourth page of this exhibit,
- 3 which is Bates number DG00010.
- 4 What is this document?
- 5 A A private placement memorandum.
- 6 Q For what month?
- 7 A MSMB Healthcare.
- 8 0 What's the date of this document?
- 9 A October 28th, 2011.
- 10 Q Now, if you could just keep this page open for a second.
- 11 I'm showing you what's been marked for identification as
- 12 Government Exhibit 11B, which is Tab 31 in your binder.
- What is this document?
- 14 A Private placement memorandum.
- 15 Q What's the date on this document?
- 16 A October 28th, 2011.
- 17 Q Mr. Geller, is this the same document that we saw just a
- 18 | minute ago?
- 19 A Yes.
- MR. SRINIVASAN: Your Honor, we move Government's
- 21 Exhibit 11B into evidence.
- MR. AGNIFILIO: No objection.
- 23 THE COURT: We received Government's Exhibit 11B.
- 24 (Government Exhibit 11B, was received in evidence.)
- 25 Q Mr. Geller, let's go back to the Tab 6 in the binder and

GELLER - DIRECT - SRINIVASAN

stick to the documents there. And that's Government Exhibit 109-6 in evidence.

If you can go back two pages from where you were, it's Bates-numbered DG0008.

So this is a letter to investors from the defendant. And if we can zoom in on the first three paragraphs of this letter?

MR. BRAFMAN: Is that a separate exhibit number?

MR. SRINIVASAN: No, this is all part of 109-6, the attachments to the email.

Q Mr. Geller, this part of the letter reads: MSMB
Healthcare, LP has updated it's private placement memorandum
to reflect new disclosures regarding the fund. Specifically,
MSMB Healthcare, LP has expanded its disclosure regarding its
ability and intent to invest in illiquid securities including
venture capital, private equity limited partnerships and other
hedge funds. If you disagree with these changes, we will
facilitate your redemption within our standard parameters.
MSMB Healthcare, LP has and will continue to invest in
MSMB-affiliated entities, which are controlled by the
MSMB Capital umbrella. These entities may or may not be
administered and audited, and the fund will rely heavily on
our impressions of value of these assets. These investments
are expected to be a material portion of the funding assets.

MSMB Healthcare, LP may invest in private equity, directly or

- 1 indirectly. MSMB-affiliated partnerships are most likely to
- 2 | carry out these private equity investments. There's no
- 3 assurance that these investments will be profitable, and any
- 4 | equity invested may not be able to be returned for a
- 5 redemption.
- 6 What, if anything, was your reaction to receiving
- 7 | this information?
- 8 A Very negative reaction.
- 9 Q Why is that?
- 10 A Because they were changing the objective of the fund,
- 11 | which is not what I originally planned for. Originally
- 12 wanted.
- 13 Q Was it consistent or inconsistent with your objectives?
- 14 A Inconsistent.
- 15 Q In what way?
- 16 A It looked like they were trying to turn the fund into an
- 17 | illiquid fund that invested in -- in private type -- private
- 18 | type of investments, as it says, in the first paragraph.
- 19 Q At some point after you received this information, did
- 20 you try to redeem your investment?
- 21 A Yes.
- 22 | Q I'm showing you what's marked for identification as
- 23 Government's Exhibit 109-7, which is Tab 7 in your binder.
- Now, what kind of document is this?
- 25 A It's a email.

was -- sorry, a liquid balanced fund. And now it looks like,

- 1 | you know, after they sent this letter, they wanted to change
- 2 the make up of the fund.
- 3 Q What happened after you sent this email? Did you redeem?
- 4 A I never fully, no, I never redeemed.
- 5 Q Why not?
- 6 A Because I had some conversations with Kevin and Martin
- 7 and they convinced me to stay in the fund.
- 8 Q And what did Kevin Mulleady and the defendant say?
- 9 A I think the main thing they said was this private
- 10 | investment letter that they sent to me, they -- it was just
- 11 going to be -- when they did invest in the liquid private --
- 12 | private other hedge fund things, that it was going to be a
- 13 very small portion of the fund.
- 14 Q And was this a conversation by phone or in person?
- 15 A Conversation by phone.
- 16 Q And did it take place after you sent the email or before?
- 17 A It took place after I sent the email.
- 18 Q And at this point, was your understanding of the size of
- 19 | the MSMB Healthcare's investment in illiquid securities
- 20 important for your investing decision?
- 21 A Yes.
- 22 Q Let's go back to the binder that's labeled 91 series.
- 23 | The smaller binder that you have. And if you can go to
- 24 Government's Exhibit 91-8, which is Tab 8 in that binder.
- 25 What is the date on this email?

- 1 A September 9th, 2012.
- 2 Q What month does this statement cover?
- 3 A May of 2012.
- 4 Q Going to the second page. What was your ending balance
- 5 here?
- 6 A \$251,228.
- 7 THE COURT: I'm sorry, did you say it was in
- 8 evidence.
- 9 MR. SRINIVASAN: It is part of Government's
- 10 Exhibit 91-1 through 10. They're admitted.
- 11 THE COURT: Right.
- 12 Q Mr. Geller, some of the statements we saw earlier were
- 13 sent to you by NAV Consulting.
- Do you recall that?
- 15 A Yes.
- 16 Q And if we go back to the first page of this exhibit, who
- 17 | sent this one to you?
- 18 A Martin Shkreli.
- 19 Q Did there come a point when your statements no longer
- 20 came from NAV Consulting?
- 21 A This statement did not -- did not come from NAV
- 22 Consulting.
- 23 Q And did you have any understanding of how that change
- 24 | came about or why?
- 25 A No.

3129

GELLER - DIRECT - SRINIVASAN

- 1 | Q At this point, in September 2012, did you believe that
- 2 MSMB Healthcare had an administrator?
- 3 A Yes.
- 4 Q And at this point, was having or not having an
- 5 administrator important to your decision to keep investing in
- 6 MSMB Healthcare?
- 7 A Yes.
- 8 Q Why is that?
- 9 A Because if they didn't have an administrator, then
- 10 | something would be wrong.
- 11 Q What do you mean by "wrong"?
- 12 A Well, what we talked about before, like the administrator
- 13 has -- I mean, the fund has to run with an administrator.
- 14 Q Go to the next tab, Government's Exhibit 91-9.
- What's the date of this email?
- 16 A June 2012.
- 17 | Q If you look closer to the top, what's the date on the
- 18 email?
- 19 A Oh, I'm sorry. September 9th, 2012.
- 20 Q And for what month is it, the statement?
- 21 A June 2012.
- 22 | Q And if we go to page 2 of the document. What's your
- 23 | ending balance here?
- 24 A \$272,760.
- 25 Q And let's go to the next tab, which is Government's

3130

GELLER - DIRECT - SRINIVASAN

- 1 Exhibit 91-10 in evidence.
- 2 What's the date on this email?
- 3 A September 10, 2012.
- 4 Q For what month is this statement?
- 5 A July 2012.
- 6 Q And going to the second page, what was the value of your
- 7 investment here?
- 8 A \$299,343.
- 9 MR. SRINIVASAN: Ms. Zellan, if we can put the first
- 10 pages of 91-9 and 91-10 side by side. And if we can zoom in,
- 11 please, on the email at the top of this page.
- 12 Q Mr. Geller, it's on your screen.
- Taking these exhibits together, in your experience,
- 14 | was there anything unusual about the timing of these investor
- 15 statements?
- 16 A Yes.
- 17 0 What was that?
- 18 A There was a four- or five-month lag from when the
- 19 | statements were sent out from the actual -- from the actual
- 20 date.
- 21 Q Did you have any reaction to the timing of the
- 22 statements?
- 23 A It wasn't -- it wasn't kosher with me because I mean a
- 24 | five-month lag, I didn't understand why there was a five-month
- 25 lag.

3131

GELLER -	DIRECT -	SRINIVASAN
----------	----------	------------

- 1 I was -- I was a little bit worried.
- 2 Q Mr. Geller, now taking all of these performance
- 3 statements together, did you rely on them?
- 4 A Yes.
- 5 Q Do you believe them to be accurate?
- 6 A I did.
- 7 Q To what extent were inaccurate or accurate performance
- 8 statements important to your investment decision?
- 9 A Repeat that again, I'm sorry.
- 10 Q I'm sorry, I said that quickly.
- 11 To what extent were accurate or inaccurate
- 12 performance statements important to your continued investment
- 13 decisions?
- 14 A It's -- I think I said it before, it's just like a -- an
- 15 ongoing line score just to see how the fund is doing, how --
- 16 | how the month -- how the performance changes month to month.
- 17 Q Now, during the course of your MSMB Healthcare
- 18 | investment, did you approve any personal loans by MSMB
- 19 Healthcare to the defendant?
- 20 A No.
- 21 MR. BRAFMAN: Objection, Your Honor, it assumes a
- 22 requirement.
- 23 THE COURT: I think this was the subject of a prior
- 24 discussion.
- A sidebar, I'm going to sustain the objection.

Case	1:15 cr 00637 KAM Document 315 Filed 08/15/17 Page 256 of 297 PageID #: 6647
	3132 GELLER - DIRECT - SRINIVASAN
1	MR. SRINIVASAN: Your Honor, could we just explain
2	very briefly on this one question.
3	THE COURT: All right.
4	(Continued on the next page.)
5	(Sidebar conference.)
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	

MR. SRINIVASAN: This exact question I think Your Honor overruled the objection to. There was a follow-on question that related to the notification of personal loans and so on. This is in connection when you checked the statements.

THE COURT: Oh, okay. Okay.

MR. SRINIVASAN: This factual question was okay, but I'm not going to follow-up questions.

MR. BRAFMAN: Objection, Judge. It's hard for me to remember, you know, everything. But this presumes a duty by the general partner to disclose this to a limited partner, because otherwise why ask the question. And there is no such duty anywhere in the private placement memorandum. And just asking him, would you have liked to know, or did you know is just not fair. It suggests to the jury that there's an obligation by the general partner to inform every limited partner every time they do something. And the private placement memorandum gives the general partner substantial discretion in what to do and how to do it. There's no obligation for them to notify him that they're going to borrow money or loan money. None.

THE COURT: Well, I think there's a distinction between borrowing and lending money for fund purposes versus borrowing money for personal general partner purposes.

Are you saying that he has the authority under the

SIDEBAR CONFERENCE 1 private placement memo or any other arrangement to take 2 personal loans from the fund? 3 MR. BRAFMAN: It's not addressed anywhere, which 4 means there's no legal obligation. 5 THE COURT: All right. MR. SRINIVASAN: We're almost done. 6 7 THE COURT: Ladies and gentlemen of the jury, I 8 think rather than give you a break, I will dismiss you for the 9 day and ask you to come back at 9:00 in the morning. 10 Please don't talk about the case. Please leave your 11 notebooks on the chair and, you know, conscientiously avoid 12 any media, please. 13 (Jury exits the courtroom.) 14 MR. BRAFMAN: Your Honor, I can conceive a hundred 15 different things that a limited partner would like to know, 16 which might peak their interest every time the general partner 17 makes a decision. But the fact remains that there is nothing 18 in the partnership agreement, or in the private placement 19 memorandum that addresses these matters. 20 THE COURT: One moment, I just want to excuse the 21 witness, too. Sorry. Bear with me. 22 Sir, Mr. Geller, you're excused for the remainder of 23 the day. 24 (Whereupon, the witness was excused.)

All right, so let's hear from the

THE COURT:

25

1 government on this issue, please.

MR. SRINIVASAN: Your Honor, there's nothing in the PPM that authorizes the defendant to take personal loans from the partnership. And these are the partners' assets, that he's managing.

There are provisions, for example, for a 1 percent management fee for operating expenses; there's a 20 percent performance fee that he gets. Those are the kinds of things that he's allowed to take from the fund.

One of the reasons this issue comes up is, I think as we addressed this last time, the 775,000-dollar payment comes back to MSMB Healthcare, the defendant has claimed that this was a payment that will be distributed back to the limited partners. It was money that belongs to the limited partners, it never happened.

THE COURT: This is a loan?

MR. SRINIVASAN: He classifies it as loan, but this is part of, I think, the process of moving money between entities to pay off Merrill Lynch and various other obligations.

So I think it's part of our proof and part of the misappropriation scheme. This is relevant. This is money that he's using and he's described it in a certain way and nobody knew about it.

MR. BRAFMAN: I'm not quarreling with you that it's

1 relevant for you to be able to show it through your 2 accountants, which you've already to show the movement of 3 It's not relevant to confront the witness because he has no opinion to offer. We have a lot of discretion under 4 5 the terms of the agreement. 6 MR. SRINIVASAN: We also have to establish that the 7 witness does not know and then argue the other elements, that 8 that's irrelevant for the jury's consideration. I think we 9 have a duty to find out what the witness knows and or does not 10 know, which is something that Mr. Brafman and his colleagues 11 have been doing repeatedly in his cross-examination of 12 witnesses. 13 MR. BRAFMAN: Would it be relevant if you knew that 14 the general partner was sleeping on the floor of his office 15 Would that be relevant? It would affect your like a vagrant? 16 ability -- your willingness to participate if you knew that 17 the person in charge had these issues? Why is that different?

MR. SRINIVASAN: That's what the witness knows.

think that's relevant.

18

19

20

21

22

23

24

25

MR. BRAFMAN: That's relevant to who Martin Shkreli is, not what he knows. You want to put in the loan, you have it in your records.

MR. SRINIVASAN: I'm establishing he doesn't know.

MR. BRAFMAN: But why does he have to know?

MS. SMITH: There's an argument in the testimony,

- and we're not putting it into evidence, but Mr. Shkreli's claim has been that he got permission from the limited partners to take out this personal loan.
 - MR. BRAFMAN: From the limited partners?

4

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

- 5 MS. SMITH: At least some of the limited partners.
- 6 MR. BRAFMAN: I don't think there's any discussion with him about this.
 - MS. SMITH: There may be with other witnesses, and we would like to establish that this is not, in fact, certain of the investors whether he took it as a personal loan.
 - THE COURT: Is there going to be evidence about the SEC testimony regarding whether or not certain of the limited partners were aware of the loan?
 - MS. SMITH: Not from the SEC testimony. But I think we will establish through our witnesses that they did not know, and then the SEC testimony from the defendant will establish that he classified it as a personal loan and that he did not make a written disclosure.
 - MR. BRAFMAN: I'm not arguing that there is going to be evidence that Mr. Shkreli took it as a loan. What I'm suggesting, obviously not compellingly enough, is that just because he does something, doesn't impose an obligation to notify a limited partner who is bound by the partnership agreement.
 - If you and I run a store together, we have a

- 1 partnership agreement. It doesn't mean I have to tell you if
- 2 I borrow money from somebody to put my money into your
- 3 business. It doesn't say that. That's the legal operative
- 4 document.
- 5 MS. SMITH: It's a misuse of corporation funds.
- 6 You're allowed to take out 1 percent of the management fees.
- 7 The operating fees are very clear. There's nothing else in
- 8 | there that let's him take it out.
- 9 We can argue it, but we have a right to establish
- 10 | that there was no extra agreement outside of that PPM between
- 11 | the partner and Mr. Shkreli that would have permitted him to
- 12 do that.
- MR. BRAFMAN: Your Honor, I made the record. I
- 14 | don't want to delay. Everyone's going home.
- I've questioned this argument. I've objected. You
- 16 have a ruling, and I stand by my objection.
- 17 THE COURT: All right. So just to be clear, I was
- 18 | confused about the prior sidebar where Ms. Smith was going to
- 19 go back for emails about the personal loan. And I thought it
- 20 | was going to be put to rest.
- 21 But to the extent it is directly relevant to the
- 22 | charge that's misappropriated the funds, I think that this
- 23 | should be permitted, and I understand and I overrule your
- 24 objection.
- MR. BRAFMAN: Thank you.

```
3140
 1
                                INDEX
 2
                                               PAGE
     WITNESS
 3
     STEVEN RICHARDSON
                                               2879
     DIRECT EXAMINATION
                          BY KASULIS
     CROSS-EXAMINATION BY AGNIFILO
 4
                                               2990
     REDIRECT EXAMINATION BY KASULIS
                                               3090
 5
     RECROSS-EXAMINATION BY AGNIFILO
                                               3092
 6
     DAVID GELLER
     DIRECT EXAMINATION
                          BY SRINIVASAN
                                               3093
                                * * *
 7
                                INDEX
 8
                                EXHIBITS
 9
     GOVERNMENT
                                PAGE
     122-39
                                2880
10
     122-97
                                2882
     122-42
                                2893
11
     122-43
                               2910
     122-48, 122-49, 122-50
                               2915
12
     122-53
                                2921
     122-58
                                2923
     122-6 and 122-70
13
                               2927
     122-71
                                2938
14
     122-73
                               2944
     122-74
                                2946
15
     122-84
                               2961
     122-44
                                2979
16
     122-92
                               2983
     122-99
                                3091
17
                                3105
     109 - 3
     11A
                                3107
18
     109 - 4
                               3111
     28
                               3115
19
     91-1 through 91-10
                               3117
                               3122
     109-6
20
     11B
                               3123
     109 - 7
                               3126
21
     DEFENDANT
                             PAGE
22
     4237
                               3066
23
24
25
```

```
$2,621,2891,773075,19
$2,631,1000,730,750,750 #: 6656
Case 1:15-cr-00637-KAM Doci
                                      3068/93071/33074/113076/23078/99
COURTROOM DEPUTY: [2] 2877/24
                                       3078/14 3081/24 3082/15 3083/2
                                                                             $2,286,511 [1] 3075/3
3093/16
                                       3083/8 3084/10 3086/4 3090/8 3090/17
                                                                            $2.3 [1] 2992/8
MR. AGNIFILIO: [23] 2937/24 2944/1
                                       3091/18 3092/11 3092/21 3093/4
                                                                             $2.3 million [1] 2992/8
2946/4 2950/13 2950/20 2952/15
                                       MS. SMITH: [28] 2885/8 2886/20
                                                                             $20 [1] 2895/16
2953/4 2954/6 2961/15 2968/1 3054/5
                                       2952/18 2972/7 2972/12 2972/14
                                                                             $210,354 [1] 3119/14
3057/14 3058/2 3058/9 3064/23 3067/2
                                       2973/3 2973/9 2974/23 2975/25 2976/5
                                                                             $25 [1] 2895/16
3067/11 3068/7 3068/18 3069/8
                                       3014/12 3017/6 3018/19 3068/16
                                                                             $251,228 [1] 3128/6
3074/12 3121/25 3123/21
                                       3093/13 3100/24 3101/2 3101/18
                                                                             $272,760 [1] 3129/24
MR. AGNIFILO: [82] 2880/6 2881/8
                                       3101/24 3103/8 3113/19 3136/24
                                                                             $299,343 [1] 3130/8
2882/1 2884/16 2885/1 2886/2 2886/17
                                       3137/4 3137/7 3137/13 3138/4 3138/25
                                                                             $300,000 [1] 3075/9
2886/22 2887/6 2887/9 2888/1 2893/9
                                       THE COURT: [178] 2878/1 2878/4
                                                                             $303,247 [2] 2913/13 2914/3
2903/23 2910/1 2915/12 2921/6
                                       2878/7 2878/13 2878/19 2878/23
                                                                             $4.25 [1] 3114/10
2923/21 2927/2 2928/11 2971/9
                                       2880/7 2881/10 2882/3 2884/17
                                                                             $4.90 [1] 2889/14
2971/12 2971/15 2972/5 2972/10
                                       2884/20 2885/24 2886/12 2887/8
                                                                             $40 [2] 2898/6 2925/22
2972/13 2972/19 2972/21 2973/7
                                       2888/4 2893/10 2903/24 2910/2
                                                                             $40 million [1] 2898/6
2973/17 2973/20 2974/1 2974/11
                                       2915/13 2921/7 2923/22 2927/3
                                                                             $400,000 [4] 2894/8 2987/15 2992/1
2974/16 2974/21 2975/2 2975/7
                                       2928/13 2935/23 2937/1 2937/25
                                                                             3089/11
2975/10 2975/14 2975/21 2975/24
                                       2944/2 2946/5 2950/16 2951/19
                                                                             $500 [1] 2966/11
2976/19 2979/12 2983/6 2986/5 2986/8
                                       2951/22 2951/24 2952/6 2953/10
                                                                             $500 million [1] 2966/11
2986/10 2989/3 2997/10 3012/14
                                       2954/8 2961/16 2968/2 2971/11 2972/3
                                                                             $548,000 [3] 3080/18 3082/8 3083/5
3012/16 3012/20 3013/4 3013/8
                                       2972/16 2972/20 2973/18 2973/21
                                                                             $548,711 [1] 2913/19
3013/12 3013/18 3013/23 3014/3
                                       2974/17 2975/1 2975/3 2975/6 2975/9
                                                                             $550,000 [1] 2946/20
3015/16 3016/6 3016/9 3016/19
                                       2975/17 2975/22 2976/3 2976/8
                                                                             $583,482 [1] 2894/14
3016/21 3017/3 3017/10 3017/22
                                       2976/15 2977/1 2979/13 2983/7 2986/9
                                                                             $602,288.40 [1] 2889/15
3018/12 3018/14 3018/22 3019/5
                                       2986/11 2986/15 2989/2 2989/7 2990/2
                                                                             $80 [1] 2895/16
3038/4 3040/5 3040/9 3041/4 3041/10
                                       2990/6 3010/17 3012/10 3012/13
                                                                             $82 [2] 3113/7 3114/11
3041/16 3078/17 3078/20 3084/12
                                       3012/15 3012/17 3013/3 3013/17
                                                                             $82 million [2] 3113/7 3114/11
3084/16 3090/14 3091/20 3093/2
                                       3013/22 3014/11 3014/23 3015/11
                                                                             $86,967 [1] 2895/6
MR. BRAFMAN: [47] 2878/3 2952/1
                                       3015/18 3016/3 3016/8 3016/24 3017/5
                                                                             $88 [1] 2897/15
3013/20 3014/6 3014/19 3014/22
                                       3017/7 3017/19 3018/6 3018/11
                                                                             $88 million [1] 2897/15
3015/6 3015/15 3016/2 3019/1 3096/2
                                       3018/15 3018/23 3019/3 3021/25
                                                                             $9,954,451 [1] 2911/17
3099/5 3099/7 3099/10 3099/15 3101/4
                                       3023/11 3032/18 3033/13 3033/23
3101/11 3101/20 3101/25 3102/9
                                       3034/5 3037/2 3037/22 3038/2 3039/10
3103/5 3103/19 3105/14 3107/9
                                       3040/4 3040/6 3041/2 3041/6 3041/13
                                                                             '14 [5] 2909/11 3007/6 3060/2 3073/21
3111/10 3111/24 3112/1 3113/13
                                                                             3073/24
                                       3052/22 3053/5 3054/3 3054/6 3057/12
3115/19 3116/4 3117/8 3124/7 3126/6
                                       3057/16 3058/7 3062/4 3066/20
                                                                             'this [1] 3041/9
3131/20 3133/8 3134/2 3134/13
                                       3066/25 3067/3 3067/9 3068/5 3068/8
3135/24 3136/12 3136/19 3136/23
                                       3068/11 3069/6 3071/4 3076/3 3077/3
3137/3 3137/5 3137/18 3138/12
                                                                                             -----x [2] 2877/2
                                       3078/16 3078/25 3081/25 3082/16
3138/24 3139/5
                                                                             2877/8
                                       3083/9 3083/11 3084/11 3084/13
MR. KAPLAN: [1] 2887/1
                                                                             -against [1] 2877/5
                                       3086/5 3090/9 3090/16 3091/21
MR. SRINIVASAN: [31] 3093/8
                                       3092/22 3093/3 3093/5 3093/15
3093/18 3096/6 3100/17 3101/6
                                       3093/19 3096/4 3097/7 3099/8 3099/12
3102/23 3105/12 3107/7 3111/9 3112/2
                                                                             001 [3] 3038/25 3039/4 3042/17
                                       3100/16 3100/22 3101/1 3101/10
3112/6 3113/15 3115/17 3116/6 3117/6
                                                                             00637 [1] 2877/2
                                       3102/2 3103/17 3103/20 3104/1
3121/23 3123/19 3124/8 3126/4 3128/8
                                                                             024 [1] 3049/20
                                       3105/15 3107/10 3111/11 3111/25
3130/8 3131/25 3132/5 3133/6 3134/5
                                       3112/3 3113/14 3113/18 3113/21
3135/1 3135/16 3136/5 3136/17
                                       3115/20 3116/7 3116/11 3117/9 3122/1
3136/22 3139/6
                                                                             1 percent [2] 3135/6 3138/6
                                       3123/22 3126/7 3128/6 3128/10
MS. KASULIS: [89] 2878/11 2878/22
                                                                             1,000 [2] 2882/18 2883/7
                                       3131/22 3132/2 3133/5 3133/21 3134/4
2880/4 2881/24 2884/14 2886/1
                                                                             1-1 [1] 2997/15
                                       3134/6 3134/19 3134/24 3135/15
2886/24 2887/3 2893/7 2909/24
                                                                             1.5 [1] 2896/7
                                       3137/10 3138/16 3139/4
2915/10 2921/4 2923/19 2926/25
                                                                             1.5 million [1] 2896/15
                                       THE WITNESS: [6] 2878/14 2878/21
2935/21 2937/3 2937/22 2943/24
                                                                             1.9 million [2] 2992/6 3089/12
                                       2990/7 3057/18 3083/13 3093/17
2946/2 2951/8 2951/21 2951/23
                                                                             10 [11] 2898/7 3000/3 3000/3 3117/2
2951/25 2954/7 2961/13 2973/22
                                                                             3117/8 3117/10 3117/11 3128/10
2974/2 2974/13 2974/20 2975/5
                                                                             3130/1 3130/3 3130/10
                                      $1,053,000 [1] 2912/5
2975/12 2976/2 2976/7 2976/12
                                                                             10 million [1] 2898/10
                                      $1.9 [2] 2987/23 3089/9
2979/10 2983/4 2986/7 2986/13
                                                                             10-K [2] 3063/7 3063/10
                                      $1.9 million [2] 2987/23 3089/9
2988/25 2989/4 3010/16 3012/9
                                                                             10.12 [1] 3068/18
                                      $10 [1] 2911/21
3012/12 3013/10 3013/14 3014/4
                                                                             10017 [1] 2877/19
                                      $10 million [1] 2911/21
3014/14 3014/20 3014/24 3016/15
                                                                             109-3 [4] 3105/7 3105/14 3105/16
                                      $100,000 [1] 2895/6
3016/20 3018/10 3018/13 3018/17
                                                                             3105/17
                                      $11,388 [1] 2911/11
3021/24 3023/10 3032/17 3033/12
                                                                             109-4 [4] 3111/3 3111/10 3111/12
                                      $13,033 [1] 2895/7
3033/21 3037/1 3037/21 3039/9 3040/3
                                                                             3111/13
                                      $199,938 [1] 3120/8
3041/18 3057/17 3058/1 3062/3
```

3064/14 3064/22 3064/24 3066/19

Case 1:15-cr-00637-KAM Docu	19377 [3] 3064/24 3065/2 1 1984 [17 3694] 19ed 08/15/17 Page	205 000 [1] 31 18/1 205 [2] 300 / 16 300 PH #: 6657
109-6 [3] 3122/2 3122/3 3124/9	14984 [17] 3094 713 EU 00/13/17 Pagi	726s [2] 3607/16 300 F/16 #. 0057
109-7 [2] 3126/8 3126/9	19th [1] 2945/10	20th [2] 2943/23 2944/14
10:07 a.m [2] 3021/23 3022/12	1:05 [1] 2989/11	22 [2] 3106/4 3114/13
10:30 [2] 2927/13 2929/17	1:08 [1] 2990/1	22 percent [1] 3114/12
	1st [4] 2983/2 2983/14 3106/18 3107/4	2268 [1] 2877/22
10:30 a.m [1] 2928/24		23 [1] 3111/18
10K [2] 2916/12 2917/5	2	23rd [1] 2969/10
10Q [6] 2916/12 3063/24 3064/2 3064/8	2,286,511 [1] 3065/11	24 [2] 2880/4 2880/14
3064/16 3064/16	2.50 [1] 2891/7	24 million [1] 2898/8
10QA [1] 3064/17	20 [4] 2898/6 2957/10 3008/17 3094/5	24th [1] 3126/12
11201 [1] 2877/14	20 percent [1] 3135/7	25 years [1] 2998/22
11939 [1] 2932/3	20 years [1] 2998/22	25,000 [1] 2889/18
11A [5] 3106/20 3107/9 3107/11	200,000 [1] 3115/9	25th [2] 2961/13 2961/20
3107/12 3107/13	2006 [1] 3098/3	26 [1] 3034/10
11B [4] 3123/12 3123/21 3123/23	2007 [1] 3098/3	264,361 [1] 2895/24
3123/24	2008 [1] 2993/23	271 [1] 2877/14
11th [1] 3108/16	2009 [5] 2998/25 3000/22 3000/23	27th [1] 3119/9
12 [6] 2877/5 2996/11 3021/23 3022/11	3003/24 3004/23	28 [5] 3003/24 3115/11 3115/19
3024/3 3068/20	2010 [19] 2995/10 3020/8 3022/11	3115/21 3115/22
12 million [5] 2883/13 2883/21 2883/24	3024/3 3024/12 3025/1 3025/5 3030/17	28th [3] 3122/9 3123/9 3123/16
2883/25 2896/6	3030/19 3030/20 3031/1 3032/3	29 [4] 3020/8 3090/5 3091/9 3116/2
12-and-a-half [1] 3094/9	3032/10 3048/2 3090/5 3091/9 3091/9	29th [2] 2970/5 3075/10
12-year [1] 2993/4	3091/18 3092/1	
120 [1] 3098/6	2011 [31] 3033/2 3033/4 3033/21	3
122,916 [1] 2889/14	3034/8 3034/10 3034/17 3034/21	3 million [2] 2896/7 2938/18
122-32 [1] 3050/22	3035/22 3039/18 3043/16 3044/10	3.49 [1] 3114/13
122-38 [1] 2879/18	3044/12 3045/24 3088/19 3095/7	30 [15] 2913/8 2913/12 2914/3 2957/10
122-39 [3] 2879/19 2880/8 2880/9	3095/8 3095/23 3106/4 3106/18 3107/4	2979/10 2979/18 2984/25 2985/2
122-41 [3] 2884/7 2888/6 2893/19	3111/18 3114/13 3116/2 3117/21	3008/17 3078/8 3106/22 3106/24
122-42 [4] 2893/1 2893/12 2893/13	3117/23 3119/11 3120/3 3120/5 3122/9	3107/13 3108/25 3109/5
2904/23	3123/9 3123/16	30,000 [1] 3120/21
122-43 [4] 2909/17 2910/4 2910/5	2012 [29] 2879/5 2879/7 2892/5	300,000 [3] 2897/17 2897/25 2902/10
3078/1	2894/14 2905/10 2905/21 2907/5	30th [6] 2982/16 3064/6 3064/9 3073/4
122-44 [3] 2979/5 2979/14 2979/15	2911/11 2916/12 3045/22 3046/6	3074/25 3120/3
122-48 [6] 2915/3 2915/14 2915/16	3046/23 3046/25 3046/25 3048/19	31 [3] 2911/11 2916/13 3123/12
2915/18 3057/16 3061/15	3049/6 3050/22 3087/2 3088/20 3095/9	31st [1] 3063/24
122-49 [4] 2915/3 2915/14 2915/16	3126/12 3128/1 3128/3 3129/1 3129/16	32 [2] 3050/22 3115/11
2915/18	3129/19 3129/21 3130/3 3130/5	33 [1] 2943/15
122-50 [5] 2915/3 2915/15 2915/16	2013 [59] 2879/6 2879/7 2880/4	3500-SR [1] 2997/14
3062/23 3062/24	2880/14 2881/24 2882/10 2884/14	36 years [1] 2993/23
122-53 [2] 2921/8 2921/9	2888/14 2888/25 2897/9 2905/7	377 [1] 3065/1
122-58 [1] 2923/24	2905/20 2906/19 2907/2 2907/7	38 [1] 2879/18
122-6 [2] 2927/5 3035/20	2907/11 2907/23 2909/12 2911/6	39 [3] 2879/19 2880/8 2880/9
122-64 [1] 2927/4	2913/8 2913/12 2914/3 2914/18	
122-70 [4] 2926/15 2927/4 2927/5	2914/23 2916/13 2918/11 2918/25	4
2927/7	2919/14 2921/12 2925/15 2937/8	4.90 [1] 2891/7
122-71 [2] 2937/15 2938/3	2945/25 2946/9 2987/8 2991/23 3007/6	40 [1] 2957/10
122-73 [3] 2943/15 2944/3 2944/4	3029/14 3029/16 3054/11 3055/23	40-to-50 [1] 3000/25
122-74 [2] 2946/6 2946/7	3059/10 3059/16 3063/24 3064/6	400 [3] 2992/23 2992/24 2993/3
122-84 [1] 2961/18	3064/9 3065/9 3067/19 3067/20	400,000 [3] 2894/12 2894/13 2897/13
122-92 [3] 2982/21 2983/8 2983/9	3072/10 3073/4 3074/9 3074/25 3075/8	
122-97 [3] 2881/17 2882/5 2882/6	3075/10 3075/14 3078/2 3078/8 3087/3	2972/24 2973/2 2973/5
122-99 [4] 3091/6 3091/12 3091/23	3087/4	41 [3] 2884/7 2888/6 2893/19
3091/24	2014 [37] 2905/8 2908/22 2908/25	42 [4] 2893/1 2893/12 2893/13 2904/23
12:10 [1] 2989/14	2909/2 2909/4 2909/9 2909/10 2918/25	4218 [1] 3020/7
12:22 a.m [1] 3034/10	2924/6 2924/25 2925/8 2925/11	4221 [1] 3034/9
12th [1] 3115/23	2925/25 2937/22 2943/23 2944/14	4223 [1] 3090/5
13 [7] 2884/14 2888/13 2888/25 2985/6	2944/22 2947/9 2948/18 2953/2	4237 [3] 3066/19 3066/21 3066/22
3091/18 3092/1 3139/10	2956/17 2960/11 2961/13 2961/20	43 [4] 2909/17 2910/4 2910/5 3078/1
13,033 [1] 2895/8	2963/5 2965/7 2966/7 2966/25 2979/10	44 [3] 2979/5 2979/14 2979/15
14 [1] 2897/9	2979/18 2983/4 2983/14 2984/25	45 minutes [1] 3003/6
14,361 [1] 2895/24	2985/2 2985/15 2998/25 3060/7	460,000 [1] 2889/12
14th [3] 2926/11 2937/7 2937/22	2015 [4] 2985/24 2986/2 2987/9	48 [7] 2915/3 2915/3 2915/14 2915/16
15-CR-00637 [1] 2877/2	2988/12	2915/18 3057/16 3061/15
15th [1] 3067/20	2017 [5] 2877/5 3017/8 3019/1 3119/9	48 hours [1] 2924/19
1850 [1] 2992/15	3139/10	49 [8] 2879/18 2879/21 2915/3 2915/14
19 [1] 3050/22		

Case 1:15-cr-00637-KAM Doci	9030 [1] 3025/3 ment 315Filed 08/15/17 Page	acquiring 1172960/12 #: 6658
49 [4] 2915/16 2915/18 2919/7 3061/9	5.[_] 56/_5 5/	
4:32 p.m [2] 3059/10 3061/16	91-1 [5] 3117/2 3117/8 3117/10 3117/11	acquisitions [2] 2900/13 2900/11
4:50 [1] 3139/9	3117/13	act [3] 2902/21 3008/19 3008/21
4.00 [1] 0.100/0	91-10 [4] 3117/2 3117/10 3117/11	acted [3] 2980/7 2980/8 3028/21
5	3130/10	actin [2] 3042/11 3042/17
5 percent [6] 2883/11 2883/15 2883/18	91-9 [1] 3130/10	acting [10] 2877/13 2899/10 2907/12
2890/15 2896/6 2897/14	910 million [1] 2898/23	2908/15 2908/16 2935/2 2935/13
50 [7] 2881/17 2915/3 2915/15 2915/16	92 [3] 2982/21 2983/8 2983/9	2935/14 2935/20 2958/15
	935 [1] 2929/21	action [9] 2896/21 2977/23 2982/2
3000/25 3062/23 3062/24	947 [1] 2932/17	2984/14 3042/4 3061/2 3075/13
50 minutes [1] 2924/14	97 [3] 2881/17 2882/5 2882/6	3075/15 3122/10
503 [1] 2897/8		actioned [1] 3075/17
505 [1] 2893/17	99,000 [1] 2882/24	actions [3] 2885/24 2896/17 2896/18
51 [1] 2884/7	99,055 [1] 2882/17	actively [2] 2939/10 2943/4
52 [1] 2893/1	9:00 [3] 2877/5 3134/9 3139/10	activity [1] 3044/24
53 [6] 2909/17 2920/23 2921/8 2921/9	9:21 p.m [1] 3020/8	actual [7] 2890/25 2922/12 2926/7
3072/11 3078/10		2929/15 3017/16 3130/19 3130/19
54 [2] 2915/4 3057/18	9:55 p.m [1] 3090/5	
548,711 [1] 3079/5	9th [6] 3054/11 3055/23 3059/10	add [2] 2923/7 3038/2
55 [1] 3057/22	3059/16 3128/1 3129/19	added [3] 2895/20 2899/2 2929/1
56 [3] 2915/4 3064/15 3064/16	A	adding [1] 2882/16
57 [3] 2920/23 3074/12 3074/13		addition [2] 2922/4 3011/17
58 [4] 2923/12 2923/12 2923/23		additional [4] 2894/18 2894/19 2894/22
2923/24	2928/24 3021/23 3022/12 3034/10	3075/8
583,482 [1] 2894/16	3139/10	additionally [1] 2883/7
59 [1] 2926/15	abbreviated [1] 3116/18	address [9] 2885/11 2885/15 2885/19
5:00 [1] 2970/4	abilities [1] 2993/19	2910/9 2910/11 2910/13 2975/7
5:30 call [1] 3059/12	ability [6] 3016/1 3030/5 3050/8 3057/2	2983/13 3024/9
	3124/15 3136/16	addressed [4] 2910/9 2963/21 3134/3
6	able [11] 2881/3 2885/2 2885/16	3135/11
60 [1] 2926/15	2892/14 2962/3 2969/4 2974/7 2985/5	addresses [1] 3134/19
61 [1] 2937/15	3041/9 3125/4 3136/1	adequate [3] 2924/17 3080/17 3081/12
63 [1] 2943/15	absolute [2] 3107/19 3108/3	adequately [1] 2924/19
64 [4] 2926/15 2927/4 2929/12 2945/19	absolutely [5] 2967/23 3014/4 3098/17	adjective [1] 2973/21
66 [1] 2961/6	3105/2 3120/15	adjectives [1] 2997/9
67 [1] 2979/5	abusing [1] 2903/1	adjourned [1] 3139/9
	accelerate [5] 2958/19 2964/6 2964/8	adjunct [1] 2993/8
671,515 [1] 2895/14	2995/24 2995/25	adjustments [1] 2950/1
68 [1] 2982/21 6th [1] 3072/10	accept [1] 2890/24	administered [1] 3124/22
011 [1] 3072/10	accepted [1] 3120/21	administrative [3] 2916/9 2981/10
7	access [6] 2879/10 2894/15 2905/16	3117/18
7.6.1 [1] 2932/17	2958/20 2984/22 3002/18	administrator [5] 3129/2 3129/5 3129/9
70 [4] 2926/15 2927/4 2927/5 2927/7	accessed [2] 2907/15 2935/18	3129/12 3129/13
71 [3] 2937/15 2938/1 2938/3	accommodate [1] 2897/18	administrators [1] 3110/8
	accomplish [2] 2899/6 3052/1	admit [8] 2888/5 2974/10 3107/8
718-613-2268 [1] 2877/22	according [2] 2889/17 3117/25	3111/10 3115/18 3117/7 3121/24
72 [1] 2941/4	accordingly [2] 3015/4 3019/5	3126/5
73 [3] 2943/15 2944/3 2944/4	account [5] 2887/3 2951/25 2993/19	admitted [4] 2887/9 3016/9 3035/19
74 [3] 2945/19 2946/6 2946/7	3024/22 3109/21	3128/10
75,000 [1] 2894/22	accountabilities [1] 2945/16	admittedly [1] 2933/19
767 [1] 2877/18	accountable [2] 2902/25 2931/13	advance [1] 2923/9
775,000-dollar [1] 3135/11	accountant [2] 3110/3 3111/1	advice [1] 2923/9 advice [3] 2967/11 3007/14 3085/17
7th [1] 2881/24	accountants [3] 3109/17 3109/25	advised [1] 3047/24
8	3136/2	advisers [1] 2985/19
8 million [4] 2883/12 2883/22 2883/23	2896/19 2896/24 2897/18 2900/20	advisory [3] 2969/6 2969/16 2980/19
2884/1	2917/21 3074/20	affect [2] 3110/23 3136/15
8-to-10 [2] 3000/3 3000/3		affiliated [2] 3124/20 3125/1
80 [1] 2994/3	accumulated [1] 2891/8	affiliates [2] 2995/16 3069/21
84 [3] 2961/5 2961/17 2961/18	accumulating [1] 2900/15	affirmed [2] 2878/18 3093/13
8717 [1] 3074/14	accurate [18] 2882/25 2890/20 2891/8	afflicted [1] 3052/21
8:30 a.m [3] 2927/15 2927/21 2928/8	2891/15 2891/16 2891/25 2892/4	afflicts [1] 3049/17
8th [3] 2921/13 3074/18 3075/14	2897/19 2899/14 2900/20 2901/14	afternoon [7] 2929/17 2929/24 2930/3
9	2902/9 3089/20 3110/21 3118/3 3131/5	2990/11 2990/12 3052/24 3093/23
	3131/7 3131/11	afterwards [1] 3029/19
9-10 [1] 3117/8	acquire [1] 3114/9	age [2] 3001/18 3027/3
9.275 million [1] 2911/24 90 percent [1] 3098/9	acquired [3] 2912/10 2912/12 2929/7	agenda [28] 2915/20 2915/25 2921/4
ao heireiif il anana	2042or [e] _0, 10 _0, 12 _0, 1	agonau [20] 2010/20 2010/20 2021/4
	1	

allowed [6] 2971/8,2974/10 2984/20 12984/20 3735/5 3138/6/15/17 Pag 2920/11,2920/19 2974/20,3071/10 3199/pg 297 Pagel D #. 6659 ase 1:15-cr-00637-KAM Docu agenda... [25] 2921/4 2921/15 2922/12 almost [4] 2960/14 3041/8 3056/11 approved [10] 2919/21 2919/24 2947/3 2924/8 2926/23 2928/21 2929/11 3134/6 2947/10 2977/11 2980/1 2980/3 2980/5 2929/15 2929/21 2929/24 2944/18 alone [3] 2905/25 2975/22 3021/4 2981/8 3060/6 2978/22 2978/23 2978/24 3054/14 amazingly [1] 2900/13 approving [1] 2934/14 3054/14 3054/23 3057/6 3057/7 3061/6 amended [5] 2916/15 2916/21 3063/7 approximate [1] 3114/12 3061/8 3061/10 3061/23 3062/16 3063/23 3064/16 April [6] 3043/16 3044/10 3044/12 3072/25 amendments [1] 2916/12 3049/6 3091/18 3092/1 agendas [1] 2926/20 April 13 [2] 3091/18 3092/1 **AMERICA [1]** 2877/3 agent [2] 2880/19 2891/14 April 2011 [3] 3043/16 3044/10 3044/12 American [4] 2992/10 2992/12 2993/23 ages [1] 3001/21 3008/5 April 2012 [1] 3049/6 aggregate [1] 3114/11 area [3] 2931/24 2993/5 3086/17 **AMEX** [1] 2992/25 aggressive [2] 2982/17 3049/14 amount [6] 2918/3 2938/19 2999/17 areas [3] 2955/16 2957/22 2995/5 **AGN [1]** 2957/14 3085/12 3097/6 3115/5 arguably [1] 3018/9 AGNIFILO [11] 2877/20 2973/5 2990/4 amounts [2] 2911/16 3065/18 argue [6] 3101/3 3102/25 3103/14 2990/10 2990/13 3077/6 3082/17 analysis [1] 3039/17 3116/8 3136/7 3138/9 3082/20 3091/8 3140/4 3140/5 anchors [1] 3042/10 arguing [1] 3137/19 ago [7] 2924/14 3015/25 3028/24 **ANDREA [1]** 2877/20 argument [4] 3018/20 3102/24 3136/25 3095/18 3098/23 3106/5 3123/18 Andrew [2] 3043/21 3050/18 3138/15 agonizing [1] 2924/15 angle [1] 3080/25 arising [1] 3065/18 agree [9] 2897/13 2900/20 2902/1 angst [1] 2943/3 arm [1] 2929/8 2941/21 2977/24 3019/1 3024/25 announce [1] 2969/4 arm's [1] 3017/15 3081/15 3083/17 announced [3] 2988/11 3111/23 3114/8 arranged [2] 2967/4 3081/7 agreed [11] 2891/6 2904/17 2940/3 announcement [1] 2928/4 arrangement [1] 3134/1 2941/20 2969/12 2969/13 2984/14 annual [5] 2956/23 2956/25 2959/4 arrive [2] 2901/17 2928/8 2985/8 3065/16 3084/5 3139/3 2965/14 2985/25 arrived [1] 2938/21 agreement [53] 2919/17 2919/21 annually [2] 2965/13 3064/4 **ASAP [1]** 2889/23 2920/12 2920/14 2920/20 2934/9 answer [14] 2928/15 2947/21 2950/15 Aselage [46] 2895/24 2907/1 2907/6 2934/14 2939/14 2980/25 2981/12 3008/6 3016/24 3022/2 3036/14 3041/2 2908/2 2922/6 2925/9 2927/16 2944/21 2985/5 2985/7 3055/4 3055/7 3055/16 3041/2 3044/23 3062/14 3088/16 2957/20 2958/2 2958/24 2959/16 3055/19 3056/4 3057/9 3058/9 3058/11 3090/10 3092/23 2959/22 2961/11 2961/21 2965/19 3058/22 3058/23 3058/23 3059/8 answered [1] 3036/1 2965/20 2966/3 2966/21 2968/24 3059/21 3060/4 3060/11 3060/13 anticipated [1] 2955/13 2969/10 2969/11 2969/18 2970/3 3060/24 3061/18 3061/20 3065/16 anxiety [2] 3006/24 3007/2 2970/9 2976/3 2977/21 2978/3 2978/14 3065/22 3068/23 3068/24 3068/25 2978/16 2979/3 2980/14 2981/14 anyway [1] 2954/6 3069/17 3071/7 3073/9 3073/13 **AOL [1]** 2887/2 2983/12 2984/15 2984/16 2984/18 3073/22 3074/20 3075/9 3075/10 aol.com [1] 3122/25 2985/4 3050/25 3054/18 3062/25 3077/12 3104/17 3106/7 3115/13 apart [3] 2900/18 2986/15 2987/24 3072/19 3076/1 3076/5 3076/13 3078/3 3134/18 3136/5 3137/24 3138/1 apartment [9] 3000/8 3000/8 3000/10 Aselage's [2] 2910/9 2910/11 3138/10 3002/18 3003/3 3004/17 3004/21 aside [4] 2914/19 2922/24 2933/9 agreements [39] 2916/19 2917/9 3004/22 3089/17 2947/6 2917/21 2918/3 2918/6 2918/8 2918/9 apologetic [1] 2899/17 aspects [2] 2890/16 3030/6 2918/12 2984/9 2984/10 2991/10 aspiration [1] 3037/19 apologies [1] 2917/1 2991/13 2991/16 2991/19 3059/5 apologize [4] 2902/21 2997/12 3067/24 assessed [1] 2891/6 3059/9 3059/19 3061/2 3062/11 3084/17 assessment [2] 2893/6 2901/13 3065/10 3065/19 3065/23 3066/1 appear [3] 2893/18 2893/25 2913/5 asset [1] 3038/25 3066/8 3066/10 3066/11 3066/12 **APPEARANCES [1]** 2877/11 assets [5] 3046/21 3113/11 3124/23 3071/2 3071/3 3071/10 3075/2 3075/17 appearing [2] 3033/6 3076/20 3124/24 3135/4 3076/14 3077/15 3077/16 3077/18 assimilating [1] 3039/22 apples [1] 3102/10 3077/20 3081/8 3081/9 assistant [4] 2877/16 2927/10 2927/11 application [1] 3033/19 ahead [10] 2924/16 2924/18 2938/10 apply [1] 2951/17 3094/17 2942/17 2956/12 2962/23 2963/13 appoint [1] 2957/19 assisted [1] 3094/25 2968/11 3022/2 3081/18 appointed [7] 2909/1 2909/23 2922/2 associate [2] 2924/4 2952/23 aided [1] 2877/24 associates [3] 2877/18 2923/17 3011/7 2964/23 2986/22 2987/1 2987/2 air [1] 2902/22 assume [2] 3001/17 3005/25 appointing [1] 2979/3 Al [3] 2919/10 2919/16 2919/21 appointment [2] 2922/16 2922/17 assumed [6] 2897/21 2907/4 2907/21 Alan [4] 3057/8 3058/14 3095/21 appreciate [1] 2900/10 3001/16 3085/6 3085/9 3101/18 approach [6] 2884/17 2938/18 2941/21 assumes [1] 3131/21 alarm [1] 2978/4 2971/11 3040/6 3066/25 assuming [6] 2958/25 2964/21 2964/22 aligned [1] 2930/18 appropriate [9] 2933/25 2941/22 3041/3 3041/5 3044/23 **ALIXANDRA [1]** 2877/15 2954/1 2968/20 2968/20 2977/17 assurance [1] 3125/3 allegation [1] 2952/17 3084/7 3086/19 3139/3 assured [2] 2948/9 2949/13 alleged [1] 2952/8 appropriately [1] 2981/22 atmosphere [1] 2933/23 alleging [2] 2951/21 2972/13 approval [8] 2980/2 2991/8 3031/16 attached [11] 2915/9 2924/8 2941/23 allocution [1] 2896/1 3036/21 3037/9 3049/4 3060/6 3071/25 2962/16 2962/18 2962/21 3057/16 allow [2] 2924/18 2924/18 approve [8] 2916/11 2918/5 2919/10 3072/23 3073/6 3074/1 3122/7 allowable [1] 2971/8

balances [2] 3097/5 3110/14 bang [1] 2959/14 0 08/15/17 ase 1:15-cr-00637-KAM Docu attachment [10] 2926/24 2932/2 2932/4 bank [2] 2879/10 2905/16 2961/25 2962/23 2962/25 2963/1 Banta [18] 2919/10 2919/25 2929/10 2963/3 3107/6 3122/16 2934/2 2934/5 2934/15 3000/10 attachments [16] 2910/23 2919/18 3000/12 3000/16 3055/7 3055/15 2921/4 3054/25 3055/1 3055/3 3055/13 3057/23 3058/25 3059/2 3059/20 3056/18 3056/21 3063/4 3105/11 3059/25 3061/20 3062/18 3106/5 3106/6 3122/17 3122/19 bar [2] 3014/8 3015/6 3124/10 barred [1] 3015/9 attempting [2] 2931/6 3107/19 base [2] 3097/9 3104/10 attend [1] 2944/21 based [3] 2947/1 2951/1 2987/21 attendees [2] 2926/24 2927/15 basic [2] 3095/6 3104/15 attending [2] 2927/11 2927/14 basis [6] 2904/24 2919/4 2919/5 attention [14] 2909/12 2914/18 2924/25 2948/11 3024/18 3109/5 2925/25 2932/2 2932/16 2936/3 2941/3 batch [1] 2909/8 2944/6 2956/17 2961/4 2966/25 2980/6 Bates [14] 2929/21 2932/3 2932/16 3064/23 3064/24 3067/14 3106/10 attorney [2] 2877/13 2952/10 3107/14 3108/16 3109/13 3115/23 Attorneys [1] 2877/16 3117/24 3123/3 3124/4 attract [2] 2898/18 2898/21 Bates-numbered [1] 3124/4 attracting [1] 2907/16 bath [7] 3021/24 3022/10 3022/13 attractive [1] 2898/21 3022/21 3023/3 3023/20 3023/21 audit [9] 2922/3 2922/5 3064/5 3073/3 bear [4] 2879/20 2930/22 2997/12 3081/19 3081/20 3082/24 3109/18 3134/21 3109/25 beat [1] 2977/18 audited [1] 3124/22 became [7] 2905/18 2940/20 2982/18 auditor [6] 2922/11 3075/18 3076/24 3065/10 3075/2 3094/17 3095/18 3110/10 3110/23 3111/1 become [4] 2925/21 2964/13 2965/3 auditors [9] 2916/16 2916/22 2917/4 3036/20 2957/4 2957/4 3074/2 3074/3 3074/19 becomes [1] 2898/20 3110/6 becoming [2] 2905/9 2960/24 audits [1] 3110/4 bed [1] 3014/10 August [3] 3075/8 3075/10 3117/21 begin [1] 2901/11 August 2013 [1] 3075/8 beginning [4] 2925/8 2925/11 3044/4 August 29th [1] 3075/10 3095/23 August 9 [1] 3117/21 begun [1] 2952/21 Australia [1] 2998/12 behalf [5] 2895/9 2953/20 3060/15 authentic [2] 2885/17 2886/14 3070/18 3071/8 authority [2] 2981/7 3133/25 behave [1] 3008/8 authorizes [1] 3135/3 behind [9] 2900/17 2959/3 3030/23 autism [3] 3006/21 3006/22 3015/25 3034/16 3063/13 3065/25 3075/17 autistic [2] 3015/22 3015/22 3075/20 3106/24 available [6] 2880/2 2905/15 2916/7 believes [2] 3065/11 3075/3 2977/11 2977/12 3061/5 belongs [1] 3135/14 Avenue [3] 2877/18 3044/10 3044/13 below [10] 2890/21 2890/24 2895/10 avoid [2] 2902/24 3134/11 2895/18 2895/22 2896/4 2912/1 2912/8 aware [20] 2918/9 2918/12 2935/17 2981/4 2981/14 2949/3 2949/5 2949/24 2956/15 benefit [1] 3060/20 2958/16 2973/6 2973/6 2973/8 2982/12 **BENJAMIN** [1] 2877/19 2986/25 3045/14 3046/23 3077/11 berating [1] 2973/12 3077/13 3077/14 3079/14 3137/13 best [8] 2898/3 2919/22 2977/15 2981/1 2995/7 3045/24 3048/17 3061/5 better [5] 2997/5 3022/10 3022/15

baby [8] 3008/16 3047/11 3047/14 3047/18 3047/19 3047/20 3047/21 3047/22

backed [1] 3079/15

background [10] 2903/9 2906/10 2922/2 2972/25 2973/1 3002/7 3094/10 3094/14 3096/14 3098/24

bad [7] 2968/18 3030/10 3084/3 3100/5 3100/9 3101/17 3103/7

bag [2] 3005/1 3007/19

balance [10] 2911/11 2913/8 2913/12 2914/3 3097/22 3117/25 3119/12 3120/7 3128/4 3129/23

balanced [2] 3097/2 3126/25

biggest [1] 22898/4 bill[1] 3082/5 PageID #: 6660

billion [1] 2977/19 binder [33] 2879/18 2879/21 2881/17

2884/7 2893/1 2909/17 2915/4 2920/24 2923/12 2926/16 2937/15 2943/16 2945/19 2961/6 2979/5 2982/21 2989/6 3078/10 3105/8 3105/9 3105/9 3111/3 3115/11 3116/25 3120/1 3121/16 3121/18 3123/12 3123/25 3125/23 3127/22 3127/23 3127/24

binders [1] 3093/15 bio [1] 3036/16 biochemical [1] 3033/9

biopharmaceutical [1] 3120/24 biotechnology [2] 3111/22 3114/7 bit [11] 2933/19 2941/18 2943/3 2955/21 2956/10 3001/13 3001/23 3007/16 3022/7 3033/5 3131/1

black [1] 3095/10 blank [1] 3069/1

Blanton [3] 2920/7 2920/12 3043/6

blatantly [1] 2971/3

blessing [3] 3006/7 3006/12 3010/3 blind [3] 2891/13 2891/18 2892/1

blindly [1] 2891/24 blindsided [1] 2956/6 blocks [1] 3109/11

Blue [2] 3004/11 3004/12 board [227] 2889/25 2890/2 2895/21 2899/4 2905/11 2906/2 2906/4 2907/6

2907/22 2907/25 2908/4 2908/18 2908/20 2909/3 2909/6 2909/13 2909/24 2910/17 2910/18 2911/9

2914/13 2914/20 2915/10 2915/22 2916/10 2916/17 2917/4 2918/5 2919/20 2919/23 2920/1 2920/11

2920/19 2921/3 2921/4 2921/4 2921/11 2921/23 2921/24 2922/2 2922/4

2922/17 2922/21 2923/1 2923/18 2924/9 2924/16 2925/3 2925/6 2925/7 2926/1 2926/4 2926/7 2927/12 2927/22 2929/25 2930/17 2931/4 2931/19

2932/9 2932/13 2933/5 2933/11 2934/8 2934/11 2934/19 2935/7 2935/16 2935/17 2935/18 2937/8 2938/13

2938/15 2939/9 2939/14 2940/4 2940/24 2941/15 2941/21 2941/25

2942/2 2942/7 2942/11 2942/14

2942/17 2942/23 2943/3 2943/6 2943/11 2943/21 2944/11 2944/17

2944/21 2945/4 2945/14 2946/16

2947/3 2953/12 2953/14 2953/16 2953/17 2956/7 2956/8 2956/13

2956/18 2956/22 2957/12 2957/15 2958/16 2958/20 2958/20 2959/20

2960/16 2960/24 2961/24 2962/4 2962/8 2962/15 2962/18 2963/2 2963/9

2963/22 2965/3 2965/6 2966/1 2966/5 2966/8 2966/15 2967/8 2967/25 2968/8

2968/12 2968/16 2968/21 2969/5 2969/16 2970/1 2970/19 2971/3

2973/25 2974/7 2974/20 2975/19 2976/14 2978/19 2978/21 2978/25

2979/1 2979/8 2979/17 2980/2 2980/4 2980/5 2982/4 2982/9 2983/16 2983/20 2984/24 2985/1 2985/7 2985/18

bigger [1] 2948/8

between [18] 2881/22 2884/12 2888/10

2896/7 2952/7 2952/22 2959/19

2960/23 2984/15 2992/7 3008/15

3016/15 3018/6 3077/21 3089/16

Biestek [3] 2937/20 3003/10 3050/18

3098/3 3098/9 3105/8 3105/9 3108/3

big [10] 2899/15 2925/20 2955/13

3133/23 3135/18 3138/10

beyond [1] 3087/7

bias [1] 3018/20

3121/16 3121/18

3092/6 3092/18

3100/5 3101/14 3101/20 3108/17 3108/20 3109/20 39 17/20 31 14/5 1 Base 1:15-cr-00637-KAM Doc 3110/17 Brooklyn [2] 581974 08/1/5417 board... [66] 2985/20 2985/24 2986/1 brother [7] 3006/21 3006/23 3007/12 3124/16 3124/21 2986/2 2986/3 2986/7 2987/1 2987/6 3038/9 3095/21 3100/11 3101/18 capital's [1] 3046/17 2987/9 2987/10 2987/16 2988/3 Brothers [2] 3094/18 3094/19 capitalization [9] 2883/18 2890/17 2988/12 2988/15 2988/18 2988/22 2891/21 2892/5 2895/23 2896/22 brought [9] 2919/23 2920/1 2934/11 2990/19 2991/22 2992/7 2995/15 2980/2 3046/10 3056/13 3056/15 2904/19 3050/22 3085/20 2995/20 2995/21 2995/21 2996/2 3060/5 3077/15 capitalized [1] 3115/4 2996/4 2996/7 2996/12 2996/17 brunch [1] 3004/14 captured [2] 2916/21 3079/18 2996/18 2996/20 2996/21 3039/12 brushing [1] 3007/17 car [1] 3003/11 3043/21 3046/11 3054/23 3056/9 BS [1] 3094/11 carbon [1] 2961/21 3056/15 3056/24 3059/14 3060/5 **bubble [7]** 3021/24 3022/10 3022/13 care [7] 3007/21 3015/17 3030/5 3097/3 3061/2 3062/11 3071/9 3071/15 3072/3 3022/21 3023/3 3023/20 3023/21 3108/7 3108/8 3122/13 3072/4 3072/16 3072/25 3076/15 cared [3] 3010/1 3025/13 3025/15 bud [1] 2947/24 3076/15 3077/3 3078/3 3080/1 3080/8 build [9] 2906/1 2906/5 2906/8 2947/2 career [1] 3100/9 3081/11 3081/14 3083/20 3083/24 2960/20 2977/18 3033/12 3048/12 careful [2] 2956/12 3126/14 3084/18 3085/4 3085/10 3085/24 3050/14 carefully [2] 3018/24 3122/12 3087/8 3087/10 3111/23 3114/8 building [13] 2906/2 2906/3 2906/7 careless [1] 3101/16 Board's [2] 2976/10 2982/14 2907/16 2925/15 2960/5 2960/6 caring [4] 3006/17 3006/19 3009/14 BOD [3] 2938/14 2983/14 2983/16 2963/14 3030/18 3033/16 3043/11 3011/5 body [2] 2938/12 3049/13 3043/13 3043/15 carried [2] 2930/1 2930/2 **bold [1]** 2889/13 built [1] 2998/23 carries [1] 2980/10 book [3] 3058/24 3064/13 3066/17 carry [1] 3125/2 bullet [3] 2930/8 2930/12 3040/3 booking [1] 3110/19 buried [1] 2962/7 carrying [1] 3022/8 books [4] 2917/22 3074/4 3077/8 burning [1] 2914/11 case [9] 2898/5 2936/2 2949/25 3077/22 business [33] 2931/5 2931/9 2931/12 2952/21 2989/12 3015/15 3049/3 boomer [1] 3008/16 2937/10 2960/14 2963/18 2964/17 3103/2 3134/10 borough [1] 3094/2 2964/24 2967/14 2967/21 2971/4 cases [1] 3048/10 borrow [3] 2983/21 3133/20 3138/2 2975/20 2976/11 2983/13 2990/23 cash [18] 2889/12 2905/14 2911/5 borrowing [2] 3133/23 3133/24 2990/23 2990/25 2994/24 2995/2 2911/11 2913/8 2913/12 2914/3 2930/8 Boston [3] 2993/25 2994/2 2994/16 3008/3 3011/6 3011/6 3017/15 3027/24 2946/19 2987/14 3078/8 3081/9 bothered [1] 3119/24 3028/14 3029/17 3035/6 3039/22 3097/14 3097/15 3098/21 3098/21 bottom [13] 2889/2 2893/17 2897/7 3046/14 3046/15 3048/23 3048/24 3109/4 3113/7 2913/11 2924/1 2946/1 3068/15 casting [1] 3027/2 3138/3 3068/15 3068/19 3078/13 3078/23 catalyst [1] 3028/21 businesses [3] 2994/20 3111/22 3119/15 3120/9 3114/7 catches [1] 2939/8 bought [1] 3005/8 bust [1] 3103/4 caused [2] 2918/6 2918/10 bound [1] 3137/23 busy [2] 2960/12 2961/2 causes [1] 3039/4 boxes [1] 3095/10 buy [2] 3031/5 3050/11 cc [1] 2922/7 boy [1] 3094/9 buying [2] 3095/3 3095/3 cell [6] 3039/9 3040/2 3041/15 3042/10 BRAFMAN [6] 2877/18 2877/19 buys [1] 3048/24 3042/12 3042/18 3015/20 3017/8 3018/25 3136/10 cells [1] 3042/11 breaches [1] 2970/21 center [1] 2900/12 break [9] 2930/2 2934/7 2935/23 C1 [1] 2942/1 central [1] 3016/13 2935/25 3052/24 3052/24 3058/18 Cadman [1] 2877/14 CEO [45] 2904/6 2907/4 2907/6 2907/8 3095/9 3134/8 Cafe [3] 3003/21 3003/22 3003/23 2940/9 2941/19 2941/20 2945/5 breakthrough [1] 2962/10 calculation [2] 2891/5 2896/11 2945/11 2945/16 2946/9 2946/24 breakthroughs [1] 2962/6 calendar [1] 3108/23 2951/11 2960/23 2964/7 2964/13 bridge [1] 3114/22 Canada [1] 2998/14 2964/23 2965/16 2966/21 2968/13 **BRIDGET [1]** 2877/12 Canadian [1] 2998/16 2968/18 2969/3 2969/4 2969/12 brief [2] 2989/7 3104/21 candidate [3] 2888/14 2906/22 2922/20 2969/15 2970/17 2970/20 2972/10 briefed [1] 3104/20 candidates [3] 2888/20 2906/11 2974/8 2979/2 2979/3 2981/21 2982/15 briefly [3] 3000/15 3090/18 3132/2 2925/18 2983/24 2987/4 2990/19 3035/24 bring [17] 2878/3 2916/10 2919/2 Cap [2] 3051/3 3052/20 3036/2 3036/4 3060/19 3060/21 2922/4 2925/18 2934/13 2960/5 2960/7 capabilities [2] 2906/6 2925/16 3083/18 3083/21 3084/6 3084/10 2972/25 2990/5 3007/8 3032/11 capability [1] 2906/1 certain [15] 2970/16 2971/8 2996/20 3035/14 3037/10 3046/19 3047/8 capable [3] 2996/25 2996/25 2997/5 2999/17 3013/11 3059/2 3077/21 3053/1 capacity [6] 2953/14 2991/24 2992/25 3084/19 3097/6 3108/20 3109/21 bringing [11] 2898/19 2906/1 2906/2 2993/11 2994/9 3080/1 3110/17 3135/23 3137/9 3137/12 2959/22 2960/13 2960/17 2985/19 capital [45] 2882/14 2885/11 2889/3 certainly [41] 2879/9 2892/19 2899/12 3034/23 3035/12 3038/17 3046/14 2889/9 2894/9 2903/22 2905/22 2918/1 2904/1 2919/23 2939/18 2941/11 broad [3] 2947/1 3033/19 3038/8 2947/19 2947/20 2987/17 2988/1 2948/9 2952/22 2954/1 2958/11 broad-based [1] 2947/1 3021/19 3025/23 3043/24 3044/2 2968/14 2996/25 3004/1 3005/7 3006/4 Broadway [6] 3026/1 3026/2 3027/6 3045/24 3046/4 3046/7 3046/11 3009/5 3009/6 3009/11 3009/24 3027/15 3044/5 3044/6 3046/14 3046/24 3047/1 3047/6 3069/2 3010/14 3011/9 3021/14 3029/8 broke [2] 2990/18 2991/21 3069/2 3069/3 3069/4 3069/12 3069/14 3029/11 3029/25 3030/6 3031/2 3032/4 broken [2] 2913/6 2998/2 3069/15 3075/1 3088/15 3099/4 3100/4 3033/17 3037/6 3037/11 3038/17 brokerage [4] 2880/22 3094/20 3099/2

ease 1:15-cr-00637-KAM Doc certainly... [8] 3038/19 3039/23 3056/1 3056/6 3059/8 3059/22 3086/9 3086/16 certificates [4] 2880/2 2880/16 2880/21 2880/21 certified [4] 3109/17 3109/24 3110/3 3111/1 CFO [6] 2914/14 2977/22 2978/8 3080/5 3080/9 3081/13 chain [8] 2882/10 2888/10 2888/10 2893/17 2897/6 2902/16 2904/23 2944/9 chair [2] 2936/1 3134/11 chairman [8] 2965/3 2965/4 2965/6 2967/25 2970/12 2980/8 2996/4 2996/8 **chance [5]** 2957/4 3056/12 3056/18 3056/21 3067/8 change [7] 2886/1 2890/12 3023/9 3024/6 3071/9 3127/1 3128/23 changed [6] 2890/11 2904/25 2907/3 3023/5 3023/6 3023/16 changes [5] 2902/4 2902/19 3122/11 3124/17 3131/16 changing [3] 2917/23 3052/20 3125/10 charge [3] 3017/17 3136/17 3138/22 charged [8] 2952/8 2972/2 2972/4 2972/18 2973/16 2975/5 2975/23 2977/3 charges [2] 2952/14 2952/20 charter [1] 2995/25 chat [2] 2959/15 3126/20 chatting [2] 2938/20 3001/11 check [3] 2887/4 2895/8 2956/11 checked [4] 2949/1 2950/9 3024/14 3133/4 checking [5] 2949/9 3023/4 3023/5 3023/6 3023/18 checks [1] 3110/14 **chemistry [1]** 3041/15 chief [17] 2888/20 2906/14 2906/15 2906/20 2906/23 2909/23 2929/4 2959/20 2980/16 2980/18 2981/2 2981/7 2981/15 2993/6 3065/9 3069/16 3075/1 children [4] 3049/12 3049/17 3050/3 3094/8 choice [1] 2880/22 **chose [5]** 2903/14 2903/17 2940/7 2940/10 3103/14 chosen [2] 2903/21 2978/2 Chris [1] 2978/9 chronologically [1] 2882/10 **churned [1]** 3001/1 circle [1] 3139/2 circulated [3] 2908/23 2935/21 3073/20 circumstances [1] 2978/5 cited [1] 3083/17 City [2] 2924/14 3094/1 civilly [1] 2973/17 claim [1] 3137/2 claimed [1] 3135/12 **claims [1]** 3069/19 clarified [1] 2904/24 clarify [7] 2882/11 2896/21 3009/13 3033/24 3036/13 3051/7 3066/2 clarifying [1] 3066/16

clarity [2] 2959/18 2959/19

committed [2] 2895/7 2939/3 class [2] 12947/2 3120/27 classic [1] 2999/9 0 08/15/17 Pag committee [7] 2922/5 2927/12 2927/22 classified [1] 3137/17 2934/3 2945/3 2945/15 2987/1 classifies [1] 3135/17 **committees** [1] 2922/3 clean [2] 3007/19 3078/19 commodities [2] 2932/19 2932/22 clear [21] 2885/9 2891/22 2895/25 common [7] 2882/18 2980/21 3044/15 2897/20 2897/22 2924/20 2925/7 3044/18 3058/18 3114/10 3120/22 2972/19 2975/15 2984/19 2990/15 communicate [1] 2969/22 3005/21 3021/11 3038/23 3067/15 communication [10] 2902/8 2965/21 3068/15 3098/11 3102/20 3138/7 2969/7 2969/14 2969/19 2969/20 3138/17 3139/1 2977/17 2977/23 3064/5 3073/3 clearest [2] 2886/25 2887/5 communications [5] 2918/13 2937/9 clearly [10] 2882/23 2928/18 2943/3 2952/22 2981/19 3034/21 2968/10 2973/4 3009/15 3014/1 comp [1] 2945/2 3039/16 3092/15 3102/25 companies [7] 2992/12 3011/18 client [2] 2994/15 3005/15 3011/20 3031/24 3107/21 3108/7 clients [3] 2994/13 2995/4 2995/5 3108/8 clinical [6] 2933/17 3011/24 3031/17 company [152] 2879/9 2880/19 3031/21 3050/1 3050/14 2883/19 2889/21 2889/24 2890/16 close [9] 2911/22 2923/2 2953/12 2897/14 2897/15 2898/21 2900/1 2900/4 2905/9 2905/25 2907/5 2909/2 3006/15 3017/3 3017/21 3026/2 3088/17 3097/9 2911/5 2911/13 2912/10 2914/4 closed [3] 2940/9 2947/24 2991/5 2918/17 2918/24 2925/18 2925/21 closer [1] 3129/17 2927/11 2929/4 2929/8 2930/16 2930/25 2931/1 2931/5 2931/23 closing [1] 3114/12 clothes [1] 3005/11 2931/23 2935/14 2935/20 2940/8 2942/10 2942/18 2951/12 2957/2 Club [12] 2926/13 2933/12 2934/19 2939/9 2939/20 2939/23 2940/2 2957/3 2957/6 2957/20 2958/7 2958/15 2940/18 2943/7 2943/10 2943/12 2959/23 2961/24 2963/4 2963/23 2944/21 2964/18 2966/12 2968/14 2968/19 clue [1] 3101/17 2968/21 2968/22 2969/21 2970/2 2970/14 2970/16 2971/7 2972/18 CNBC [1] 3099/2 2973/20 2974/8 2974/15 2975/20 Coast [1] 3029/18 cocktail [4] 3000/4 3000/21 3001/1 2976/11 2976/14 2977/18 2978/2 3002/3 2980/17 2980/19 2980/21 2980/25 2981/1 2981/3 2981/7 2981/23 2982/10 cocky [3] 3001/6 3002/9 3002/20 2982/13 2984/5 2985/7 2985/8 2985/9 coconspirator [4] 2952/8 2952/18 2953/7 2953/8 2985/11 2985/13 2991/3 2991/4 cold [1] 3008/24 2991/16 2993/21 3006/4 3009/16 collaborate [1] 2995/17 3010/9 3011/21 3026/15 3030/18 collared [1] 3096/4 3031/9 3031/15 3032/8 3033/7 3033/9 colleague [5] 2908/25 2916/25 2917/1 3033/12 3034/14 3034/15 3036/5 3009/8 3043/20 3036/6 3036/9 3036/16 3036/20 3037/5 colleagues [3] 2962/4 3001/10 3136/10 3037/10 3039/12 3039/20 3047/1 collective [4] 2962/15 2962/18 3047/21 3047/6 3047/9 3048/5 3048/12 3048/18 3048/13 3048/24 3048/25 3049/2 3049/2 3049/3 college [2] 3094/15 3094/16 3049/4 3050/13 3052/9 3052/14 3059/6 columns [1] 3051/15 3060/18 3063/12 3063/21 3065/9 3065/11 3065/15 3065/17 3069/5 comfortable [4] 3009/18 3049/1 3072/3 3075/1 3075/3 3075/8 3075/21 3075/16 3080/9 3076/17 3076/23 3079/16 3080/7 coming [14] 2891/21 2892/3 2927/10 2928/6 2959/20 2960/22 2964/11 3081/22 3084/21 3096/18 3096/20 2968/12 2973/3 3023/4 3024/8 3047/1 3115/5 3116/4 3116/17 3120/23 3080/9 3102/13 company's [3] 2910/19 2980/11 3088/2 comma [1] 2946/24 **compellingly** [1] 3137/21 commencing [1] 3108/23 compensate [1] 2946/16 **comment** [1] 3018/8 compensated [1] 2987/6 compensation [16] 2945/6 2945/6 commentaries [1] 3028/25 comments [3] 3006/8 3006/10 3017/1 2945/11 2945/12 2945/15 2945/16 commercial [1] 2960/4 2945/24 2946/9 2946/19 2947/4 2947/10 2967/16 2987/10 2987/16 commercially [1] 3050/9 2988/3 3058/14 commission [7] 2932/19 2947/18 2967/15 2967/20 2990/23 2997/2 compiled [1] 2941/9 3088/9 complain [2] 3008/22 3008/25 commit [1] 2900/17 complaining [1] 3030/12 commitments [3] 2883/17 2890/23 complaint [4] 2947/18 3088/13 3088/17 2963/17 3088/21

Case 1:15-cr-00637-KAM complementary [1] 3006/14 complete [4] 2932/10 2932/11 2932/14 2933/2 completed [1] 2933/6 completely [2] 3084/15 3103/11 completion [1] 3114/14 complex [2] 2964/16 2964/24 complexity [1] 2970/17 compliance [1] 2983/19 components [1] 3126/19 compounded [1] 2891/1 comprised [1] 2988/20 **compromise** [1] 3069/18 computer [2] 2877/24 3095/10 computer-aided [1] 2877/24 computers [1] 3044/22 conceive [1] 3134/14 concept [1] 3046/8 concepts [1] 3010/11 concern [15] 2890/8 2890/12 2899/25 2923/4 2949/9 2950/4 2963/12 2978/4 3018/18 3018/19 3048/4 3048/8 3083/20 3084/18 3113/13 concerned [6] 2938/19 2941/16 2960/16 2963/9 2966/7 2975/19 **concerning** [1] 3078/3 concerns [5] 2953/24 2954/2 2961/1 2963/20 3074/6 condition [2] 3113/9 3114/16 conditioned [1] 3114/14 conditions [1] 3114/18 conduct [2] 2924/16 2953/16 conducted [1] 2957/8 conference [15] 2884/20 2887/11 2950/20 2954/10 2971/15 2976/21 3012/20 3019/7 3040/9 3041/20 3099/15 3103/22 3112/6 3113/23 3132/5 confidence [2] 2958/12 3113/12 Confidential [2] 2961/24 2963/5 confirmation [2] 2883/14 2945/24 confirmed [2] 3081/11 3081/13 confirming [2] 2927/13 2945/1 conflict [1] 3040/3 confront [2] 3080/20 3136/3 confronted [1] 3014/11 confused [1] 3138/18 congratulated [1] 2918/17 connection [4] 2953/1 3042/18 3078/6 3133/4 conscientiously [1] 3134/11 consent [1] 2908/12 consenting [1] 2953/22 conservative [4] 2997/22 2997/23 2999/9 2999/11 consider [3] 2947/20 2947/20 3059/14 consideration [3] 3120/25 3121/2 3136/8 **considered [2]** 3062/11 3062/12 considering [3] 2999/16 3076/25 3104/11 consistent [3] 3022/14 3082/2 3125/13 consisting [1] 3120/22 consolidate [1] 2960/20 **construed [2]** 2974/16 2975/16 2961/10 consultant [5] 2945/6 2994/11 3058/15

3058/20 3059/3 **CORSUITANTS [3]** 129 98235947 36539 consulted [1] 2942/11 consulting [34] 2919/17 2919/21 2920/12 2920/14 2920/19 2934/9 2934/14 2991/12 2993/25 2994/3 2994/6 2994/16 2994/24 3055/3 3055/7 3055/15 3055/19 3056/4 3057/8 3058/8 3058/11 3059/5 3060/3 3060/24 3061/17 3061/20 3062/10 3077/16 3117/16 3117/18 3122/6 3128/13 3128/20 3128/22 consults [1] 2953/13 consumer [1] 2895/2 contact [3] 2988/8 3095/22 3096/8 contacted [1] 3014/15 contained [1] 3105/3 content [1] 3036/9 contentious [1] 2918/18 context [14] 2964/13 3013/19 3020/6 3020/18 3021/13 3022/5 3022/19 3022/23 3035/6 3036/13 3045/7 3052/15 3076/15 3088/7 contingent [1] 3108/22 continue [6] 2878/10 2878/21 2884/2 2899/1 2937/3 3124/19 continued [32] 2878/25 2884/19 2887/12 2905/11 2907/6 2912/13 2936/8 2937/5 2950/19 2954/11 2970/23 2971/14 2976/22 2982/12 2989/15 3012/19 3019/8 3020/20 3040/8 3041/21 3054/8 3070/10 3087/11 3094/24 3099/14 3103/23 3112/5 3113/24 3118/11 3119/3 3131/12 3132/4 continues [4] 3070/4 3070/7 3070/13 3075/22 Continuing [1] 2907/12 contract [2] 2919/2 2919/4 contribute [1] 3035/4 contributing [1] 2902/10 contributions [2] 2901/7 2995/22 control [6] 2963/4 2963/16 3046/9 3046/15 3046/16 3048/15 controlled [1] 3124/20 controlling [1] 2879/8 controls [1] 2980/23 **convenience** [1] 2880/23 conversation [17] 2903/7 2948/2 2948/4 2968/22 2974/11 3002/11 3002/25 3012/6 3021/7 3045/20 3076/5 3076/10 3082/11 3102/1 3116/16 3127/14 3127/15 conversations [7] 2895/19 3033/20 3045/23 3086/11 3099/4 3116/9 3127/6 **conversion [2]** 2889/14 3089/10 convicted [2] 2972/22 3073/18 convinced [1] 3127/7 cope [1] 2960/20 copied [5] 2965/19 3054/20 3085/14 3086/1 3086/22 copies [4] 2924/9 3062/25 3072/19 3091/6 copy [7] 2961/21 3068/9 3068/11 3068/12 3073/21 3078/19 3079/2 copying [4] 2885/10 2937/20 2943/22

core [2], 2900/14 2985/10 Corporate [1] 2939/41D#: 6663 corporation [3] 3008/20 3069/6 3138/5 correct [185] 2886/16 2890/4 2894/6 2894/24 2895/11 2895/12 2896/7 2901/19 2919/15 2921/18 2921/19 2955/5 2990/24 2991/3 2991/7 2991/10 2991/19 2991/20 2991/22 2992/3 2992/13 2992/15 2992/19 2993/24 2994/4 2994/7 2995/9 2998/3 2998/19 2999/1 2999/15 2999/19 2999/23 3000/5 3001/4 3001/22 3003/8 3003/11 3005/1 3005/5 3005/8 3005/19 3005/22 3006/15 3006/21 3007/21 3007/25 3008/6 3009/10 3009/25 3010/4 3010/7 3010/19 3011/18 3015/5 3021/18 3023/14 3023/16 3023/18 3023/21 3023/24 3024/3 3024/16 3024/21 3025/24 3026/4 3026/9 3026/10 3030/18 3031/14 3031/21 3031/25 3032/7 3032/9 3034/17 3035/2 3035/6 3035/14 3035/17 3035/22 3036/9 3036/23 3037/5 3037/25 3038/1 3039/9 3042/19 3042/23 3043/11 3043/16 3043/24 3043/25 3044/13 3044/16 3044/25 3045/3 3045/16 3046/5 3047/25 3048/9 3048/18 3048/20 3049/24 3050/7 3051/15 3052/1 3052/3 3052/11 3052/14 3054/18 3054/21 3055/11 3055/16 3055/23 3055/24 3057/9 3058/15 3058/20 3058/25 3059/3 3059/7 3059/11 3059/14 3059/21 3060/1 3060/4 3060/21 3060/24 3061/3 3061/10 3061/21 3061/25 3062/16 3062/19 3062/22 3063/5 3064/6 3067/19 3070/1 3070/4 3070/7 3070/13 3070/18 3071/8 3071/13 3071/15 3071/19 3072/3 3072/20 3072/23 3073/1 3073/4 3073/7 3073/10 3074/1 3074/9 3075/19 3076/18 3076/21 3076/25 3077/12 3077/17 3077/20 3078/12 3079/6 3079/18 3079/23 3080/1 3081/16 3082/5 3082/8 3083/2 3083/18 3083/19 3083/22 3084/23 3085/1 3085/4 3085/7 3085/21 3085/24 3086/19 3086/24 3088/2 3088/24 correctly [3] 2883/1 3065/7 3074/24 correspond [1] 3061/23 cost [1] 3044/9 cost-effective [1] 3044/9 couch [1] 2940/21 counsel [29] 2878/2 2899/9 2899/10 2907/12 2907/13 2908/15 2908/15 2908/16 2909/2 2935/2 2935/13 2935/14 2948/22 2953/23 2958/19 2958/21 2963/13 2979/23 2980/10 2986/22 3022/5 3022/19 3036/13 3038/3 3079/13 3080/22 3085/2 3085/3 3088/2 counsel's [1] 3078/16 counseling [1] 3029/21 Counselor [1] 3056/19 count [2] 2902/20 2952/9 counter [2] 2905/24 3049/4 counts [1] 2954/5 couple [13] 2892/11 2918/15 2940/25

dated [10] 2880/4 2888/25 2937/22 Pag delays [1], 2924/15 €ase 1:15-cr-00637-KAM_Docu couple... [10] 2949/3 2949/18 2987/22 2983/14 3034/18 3122/9 3004/10 3007/18 3027/16 3061/6 dates [3] 2894/8 2894/20 3003/25 delivery [1] 3109/18 3094/16 3095/9 3105/2 David [6] 2924/2 2924/10 3093/9 deltas [1] 2898/4 courageously [1] 2944/24 3093/12 3093/18 3126/20 denied [1] 3015/23 course [11] 2881/4 2922/25 2935/2 days [16] 2890/15 2903/4 2918/15 dental [1] 3030/15 2940/8 2940/23 2979/1 3021/9 3037/7 2955/8 2968/25 2978/14 2987/22 3116/20 3121/10 3131/17 3015/25 3016/15 3028/6 3029/5 Courthouse [1] 2877/3 3029/18 3045/15 3098/6 3108/25 deposit [1] 2880/22 courtroom [9] 2878/7 2936/4 2937/1 3113/9 2989/13 2990/2 3053/4 3054/3 3095/24 days' [1] 3109/5 **de [1]** 2945/2 cover [5] 2895/7 2915/21 3106/11 deadline [1] 2899/25 3108/22 3128/2 deadlines [2] 2900/2 2924/22 covered [8] 2909/24 2916/5 2916/6 deal [3] 2896/5 3056/12 3113/17 2937/13 2949/5 2955/24 2955/25 deals [2] 2931/6 2960/17 Dear [1] 3122/7 covering [2] 2917/10 2929/16 debate [1] 2918/19 CR [1] 2877/2 debrief [2] 2888/17 2937/12 deserve [1] 3052/8 cracks [1] 2961/3 debt [2] 3083/2 3083/3 desire [1] 3030/23 craft [1] 2929/11 **December [3]** 2905/10 2911/11 2929/7 desk [1] 3032/23 Cramer [4] 3099/1 3099/1 3100/3 **December 2012 [1]** 2905/10 3102/2 **December 31 [1]** 2911/11 crashed [1] 3098/4 decent [1] 3098/13 3056/16 crazy [1] 2944/19 decide [3] 2934/13 3027/8 3027/17 create [1] 2933/22 decided [8] 2946/16 2966/13 2970/19 3113/16 created [1] 3002/15 2985/24 2999/17 2999/22 3048/17 creation [1] 3034/1 3126/15 2981/1 **credibly [1]** 2923/10 decision [21] 2896/21 2905/21 2951/13 crime [4] 2972/6 2972/13 2972/14 2982/2 2982/9 2985/23 2985/23 2972/25 3016/18 3103/13 3104/6 3104/10 **CRIMINAL** [1] 2877/9 3108/11 3109/7 3110/11 3110/24 criteria [2] 2968/16 2969/2 3122/13 3126/16 3127/20 3129/5 critical [8] 2896/11 2956/7 2963/23 3131/8 3134/17 3016/13 3017/16 3045/17 3063/20 decisions [3] 2891/11 2896/20 3131/13 2995/14 3039/1 3122/9 declined [1] 2980/20 DG00010 [1] 3123/3 cross [9] 2973/24 2974/6 2989/3 dedicated [1] 3036/16 **DG0008** [1] 3124/4 2990/4 2990/9 3054/8 3084/23 3090/21 deduction [2] 2911/23 2913/18 deeply [2] 2894/17 2898/5 diagram [1] 3042/6 cross-examination [6] 2973/24 2974/6 defeating [1] 3037/21 dialogue [1] 3046/1 2990/9 3054/8 3090/21 3136/11 defend [1] 3065/17 **Diego [1]** 2965/20 cross-examine [1] 2989/3 defendant [45] 2877/7 2877/18 2879/14 **crow [2]** 3014/8 3015/6 2881/7 2881/14 2884/3 2885/24 **CSR [1]** 2877/22 2892/23 2903/2 2905/2 2937/10 cure [8] 3035/12 3035/12 3037/11 2940/15 2941/8 2941/13 2947/8 2948/5 3037/16 3037/17 3037/18 3038/17 2951/19 2955/7 2956/3 2967/18 2968/9 3049/14 2984/8 2988/9 2988/23 3091/3 3098/24 curing [1] 3038/16 3099/5 3100/2 3100/19 3101/8 3103/10 current [2] 2900/23 2910/19 3103/13 3104/4 3113/12 3114/25 cursory [2] 3061/5 3114/14 3116/3 3116/14 3116/17 3124/5 3127/8 **customary [1]** 3114/15 3131/19 3135/3 3135/12 3137/16 3136/17 3140/21 defendant's [5] 2977/13 3066/19 3046/20 **D-A-V-I-D** [1] 3093/18 3066/21 3066/22 3090/4 difficult [1] 2886/15

daily [7] 3022/16 3023/8 3024/19 3024/20 3025/7 3025/20 3025/22 damages [1] 2901/11 Darren [2] 2920/6 3043/6 data [1] 2900/23 date [29] 2880/3 2880/14 2881/23 2884/13 2924/6 2937/21 2956/4 2961/12 2979/9 2983/1 3003/25 3067/17 3067/18 3068/25 3091/17 3092/1 3106/17 3107/3 3108/24 3117/20 3119/8 3120/2 3123/8 3123/15 3127/25 3129/15 3129/17 3130/2 3130/20

defense [7] 2989/6 3014/16 3020/7 3025/3 3034/9 3068/12 3101/19

defined [1] 2939/11

definitely [2] 2950/11 3042/24

definition [1] 2974/23

defraud [1] 3016/1

degree [1] 3051/12

Delaware [4] 3069/2 3069/4 3069/6 3120/23

delay [4] 2927/23 2978/22 3057/6 3138/14

delayed [3] 2927/24 2928/1 2928/5

deleted [2] 92885 AGE 186# 6664 delivered [1] 2946/25 department [2] 2960/8 2992/25 departure [1] 2986/3 depression [3] 3007/3 3007/4 3007/5 derivatives [1] 3095/10 describe [7] 2947/14 2974/25 3015/24 3068/6 3094/10 3094/14 3098/24 described [7] 2939/4 2975/9 2975/18 2994/14 3026/8 3089/16 3135/23 describing [1] 3028/24 descriptors [1] 2997/10 Desert [2] 2897/14 2905/23 despite [3] 2984/9 2994/2 3084/3

detail [4] 2917/14 2996/6 3011/22

details [4] 2900/19 3063/12 3113/13

determined [3] 2905/23 2916/18

developed [2] 2952/22 3006/16 developing [2] 3036/17 3120/24 development [16] 2931/5 2931/9 2931/12 2937/10 2941/25 2960/8 2960/14 2963/18 2967/14 2967/21 2971/4 2976/11 2990/25 2993/16

DGTE [3] 2897/14 2897/15 2899/15

difference [2] 3008/15 3031/8 differences [2] 3008/18 3027/12 different [28] 2885/3 2890/9 2890/14 2892/20 2938/17 2963/19 2964/21 2964/22 2970/17 2973/16 2982/6 2994/3 3001/25 3002/2 3017/23 3017/24 3017/25 3017/25 3018/2 3028/24 3033/18 3050/9 3058/18 3077/18 3082/3 3094/25 3134/15

differently [4] 2899/16 2940/22 3033/18

diligence [2] 3110/18 3114/14 diluted [3] 2883/12 2883/25 2903/16

dimensions [1] 3002/9

dinner [18] 2891/9 2934/25 2935/4 2935/5 2935/6 2967/4 2967/18 2968/6 2968/9 3003/8 3003/18 3004/4 3004/14 3027/20 3027/20 3027/22 3028/1 3087/7

dinners [2] 3087/8 3087/10 diplomatic [1] 3005/18 direct [27] 2879/1 2885/6 2886/6

2897/22 2924/25 2932/2 2937/5 2944/6

Pase 1:15-cr-00637-KAM Docu 2924/10,2926/17,2926/20,2933/9 2914/12 2917/7:2918/19,2919/19 2952/19 2989/6 3096/24 3072/305 2923/10 2930/21 2931/3 2931/19 direct... [19] 2961/4 2973/5 2995/4 2932/1 2933/16 2933/18 2935/10 3104/12 3104/15 3104/19 3104/23 3015/4 3015/10 3017/20 3036/14 2941/10 2941/17 2943/9 2943/12 3105/4 3105/12 3105/20 3117/3 3050/21 3054/10 3056/22 3077/25 2947/15 2947/16 2948/21 2948/24 3122/13 3124/1 3078/12 3079/8 3080/22 3084/5 2949/7 2950/5 2950/6 2952/5 2952/7 dollar [1] 3135/11 3084/22 3093/21 3103/1 3119/3 2955/11 2956/3 2958/11 2958/24 dollars [3] 2898/21 2977/19 3079/23 directing [8] 2909/12 2914/18 2925/25 2959/15 2963/2 2964/5 2964/20 **Donald [1]** 3084/9 2932/16 2956/17 2966/25 2980/6 done [15] 2897/21 2899/3 2905/23 2967/19 2968/13 2970/12 2973/24 2977/14 2977/15 2980/25 2982/1 2958/18 2971/7 3005/7 3019/4 3024/1 direction [9] 2892/19 2892/20 2941/3 3016/15 3017/13 3028/9 3028/21 3035/9 3051/12 3095/7 3110/15 2966/8 2967/10 2971/3 2982/10 3030/14 3030/21 3030/25 3046/3 3110/16 3113/2 3134/6 3038/14 3050/4 3047/3 3056/25 3062/9 3076/15 door [4] 2959/12 2974/4 3014/8 3015/6 directive [1] 2976/10 double [2] 2950/9 2956/10 3079/11 3080/14 3090/22 3113/21 directly [9] 2907/19 2952/13 2953/4 3131/24 3137/6 doubt [1] 3070/20 2957/21 2967/20 3060/20 3082/15 discussions [28] 2879/14 2881/13 down [21] 2903/12 2904/7 2911/15 3124/25 3138/21 2884/3 2901/16 2903/2 2908/8 2934/5 2939/1 2947/25 2981/4 3003/3 3014/10 directness [1] 3002/11 2943/2 2945/5 2948/19 2953/9 2955/7 3015/9 3026/13 3027/15 3031/4 director [3] 2922/21 2970/1 2987/3 2955/9 2959/11 2965/2 2965/5 2967/2 3037/17 3053/2 3053/5 3058/18 3065/8 directors [62] 2905/11 2906/4 2907/6 3088/8 3088/17 3088/24 3108/4 2967/5 2978/23 2984/18 2985/3 2907/22 2907/25 2908/20 2909/13 2988/23 3022/20 3028/15 3030/18 **Dr [1]** 3113/4 2914/20 2915/22 2918/5 2919/21 3033/3 3050/17 3059/20 Dr. [1] 2922/16 2920/11 2920/19 2921/11 2924/9 disease [11] 3034/1 3037/14 3037/20 **Dr. Jeff [1]** 2922/16 2925/3 2926/1 2929/25 2932/9 2932/13 draft [6] 2977/23 3063/7 3063/23 3037/21 3038/16 3041/16 3049/7 2933/6 2933/12 2934/19 2937/8 3064/8 3071/25 3072/8 3049/11 3049/14 3049/16 3049/23 2938/15 2940/7 2940/10 2942/7 2943/6 diseases [3] 3033/19 3035/12 3036/17 drafted [1] 2909/6 2956/18 2957/12 2957/16 2957/21 disgruntled [2] 2947/17 3088/14 drafting [2] 3073/12 3073/15 2958/2 2964/4 2965/2 2966/1 2966/5 disheveled [1] 3007/23 dramatic [2] 2904/11 3049/13 2966/24 2968/23 2969/6 2969/16 dramatically [2] 2904/7 2968/19 dismiss [1] 3134/8 2979/8 2979/17 2980/23 2983/16 dispute [1] 3055/22 dread [1] 2902/25 2984/24 2985/1 2985/20 2986/1 2986/2 disputes [1] 3069/19 drew [1] 3042/8 2986/3 2987/2 2987/7 2987/16 2988/3 drive [3] 2891/13 2891/18 2892/1 disregard [1] 3084/14 2991/22 2995/21 3071/15 3080/8 dissolving [3] 3027/9 3027/13 3027/16 driving [1] 2962/10 3111/24 3114/9 distinct [4] 3044/23 3045/12 3046/1 drug [15] 2912/11 2925/18 2960/13 disagree [1] 3124/17 3011/24 3012/8 3031/15 3034/1 3046/2 disappointed [3] 2897/1 2897/2 3036/22 3037/8 3049/7 3049/19 distinction [1] 3133/22 2928/19 3049/25 3050/9 3050/11 3050/14 distinguish [1] 3008/19 disappointment [3] 2891/12 2891/17 distractions [1] 2962/8 drugs [13] 2906/2 2928/4 2933/15 2933/22 2960/6 2960/20 2985/10 2985/11 distribute [1] 2930/7 discharged [1] 3073/18 distributed [1] 3135/13 2985/12 3030/23 3031/20 3035/12 disclose [2] 3103/14 3133/11 **DISTRICT [4]** 2877/1 2877/1 2877/10 3036/17 3048/3 disclosed [2] 2981/25 3072/5 2877/13 drunk [2] 3090/1 3090/7 disclosing [1] 2942/19 Diverse [2] 2994/24 2995/3 Duchenne [7] 3036/21 3037/11 3039/1 disclosure [3] 2949/12 3124/14 diversify [1] 2998/9 3039/4 3042/14 3042/19 3049/16 3137/18 doctor [2] 3007/7 3043/4 due [3] 3110/18 3114/14 3122/13 disclosures [3] 2975/19 2975/21 duly [4] 2878/18 2972/24 2981/5 document [77] 2879/23 2881/19 2884/9 3124/13 2885/18 2885/19 2888/4 2888/23 3093/12 discounted [4] 2894/17 2895/15 2898/5 during [28] 2879/7 2879/10 2881/13 2909/19 2911/2 2911/8 2911/10 2898/20 2915/19 2916/21 2920/25 2922/24 2884/2 2917/3 2917/7 2933/16 2933/18 discrepancies [1] 2900/21 2927/9 2929/13 2929/14 2929/18 2934/6 2942/6 2945/12 2960/10 discrepancy [1] 3052/21 2932/3 2937/16 2941/4 2941/8 2945/21 2960/10 2965/6 2968/6 2970/11 2972/8 discretion [2] 3133/19 3136/4 2946/14 2953/3 2961/7 2963/19 2973/15 2977/13 2978/25 2979/1 discuss [18] 2889/23 2899/18 2903/15 2965/18 2979/17 3055/10 3056/5 2984/1 2984/6 2998/24 3022/18 2905/7 2922/16 2924/10 2926/23 3058/4 3058/6 3063/20 3063/21 3074/25 3085/7 3131/17 2930/9 2930/17 2936/2 2941/11 3064/22 3065/24 3067/9 3067/16 duties [5] 2981/7 2991/22 2993/10 2941/13 2945/5 2965/22 2980/15 3067/17 3067/24 3069/25 3070/4 2994/10 2995/19 3056/13 3076/13 3096/24 3070/7 3070/10 3070/13 3079/1 3081/6 duty [3] 3133/10 3133/13 3136/9 discussed [28] 2885/11 2888/3 2890/2 3082/2 3082/4 3105/1 3105/10 3106/10 dwell [1] 3056/14 2901/2 2904/23 2911/9 2917/3 2917/6 3106/17 3106/24 3107/3 3107/5 **DX9029 [1]** 3022/11 2931/17 2937/11 2938/13 2939/8 3107/13 3107/15 3111/4 3111/6 3113/3 dynamic [1] 2947/1 2939/14 2940/12 2940/24 2941/7 3113/20 3115/12 3115/14 3115/24 dynamics [1] 3006/19 2962/3 2962/16 2962/19 2964/14 3121/20 3122/20 3123/4 3123/8 dystrophin [6] 3039/5 3039/8 3040/2 2965/22 2973/7 2977/7 2977/7 2980/23 3123/13 3123/15 3123/17 3125/24 3042/10 3042/14 3042/17 2984/25 3027/24 3060/3 3129/22 3138/4 Dystrophy [7] 3036/21 3037/11 3039/1 discussing [10] 2883/6 2903/7 2916/1 3039/5 3042/15 3042/19 3049/16 document's [1] 3065/4 2919/16 2940/15 2942/6 2951/21 documents [25] 2885/14 2885/14

2915/8 2915/9 2916/4 2923/1 2923/9

2964/10 2984/16 3034/2

discussion [62] 2897/3 2913/24 2914/8

Ease 1:15-cr-00637-KAM_Doc e-mails [10] 2885/10 2886/10 2886/16 2893/18 2895/16 2903/16 2978/3 3024/20 3025/20 3030/11 ear [2] 3020/13 3020/17 earliest [2] 2888/9 2893/17 early [15] 2885/11 2900/15 2900/16 2918/25 2966/6 2966/6 2966/13 2967/2 3005/23 3006/16 3029/11 3029/25 3031/1 3033/21 3045/15 easier [1] 3068/3 East [3] 2877/14 3000/5 3002/18 **EASTERN [2]** 2877/1 2877/13 eating [1] 3030/10 Ed [4] 2916/25 2917/1 2922/8 3062/25 3129/23 **educational** [1] 3094/10 Efay [1] 2920/4 effect [4] 2896/22 2951/14 3098/15 3113/19 effected [1] 3103/13 effecting [1] 3030/2 effective [3] 2896/1 2986/2 3044/9 effectively [3] 2916/20 2931/6 2940/9 efficiency [1] 3078/22 eight [2] 2952/9 2996/11 either [6] 2908/8 2932/25 2974/25 2975/20 3086/9 3100/4 Elea [24] 3099/4 3100/4 3100/5 3100/15 3100/15 3100/24 3101/6 3101/14 3101/14 3101/17 3101/20 3101/23 3102/3 3102/4 3102/13 3102/14 3102/15 3102/15 3102/18 3103/1 3103/3 3103/4 3103/7 3103/7 electronically [1] 3088/5 **ELEIS [1]** 2877/15 elements [1] 3136/7 3102/24 elicit [1] 2976/17 eliciting [3] 2974/4 2975/13 3100/22 elicits [2] 2950/16 2976/18 email [62] 2877/23 2882/9 2921/3 2921/17 2923/17 2924/1 2924/6 2937/19 2937/21 2938/5 2938/10 2938/11 2938/12 2943/21 2944/7 2944/11 2961/10 2961/12 2961/20 2962/2 2965/8 3010/24 3011/2 3012/6 3013/22 3014/1 3020/4 3020/10 3054/10 3054/17 3055/11 3061/16 3062/21 3062/24 3063/5 3072/10 3073/25 3078/1 3078/6 3085/13 2877/21 3086/10 3086/22 3119/7 3119/8 3120/2 3122/5 3122/7 3122/17 3123/1 3124/10 3125/25 3126/1 3126/3 3126/11 3127/3 3127/16 3127/17 3127/25 3129/15 3129/18 3130/2 3130/11 emails [12] 2885/4 2894/2 2924/2 3108/21 3008/23 3008/25 3009/9 3010/15 3010/20 3020/8 3024/21 3086/1 3138/19 3044/19 **embarrass** [1] 3018/3 **emerge [1]** 2961/3 emergency [1] 2933/20 **emotions [1]** 3009/19 employee [7] 2919/5 2947/17 2964/1 2978/10 2993/17 2994/1 3088/14 employees [10] 2967/17 2973/12 2977/10 2991/7 2993/15 2993/17

2993/18 2994/23 2995/7 3044/16

employment [5] 2965/16 2980/24 Page end [25] 2887/11 2905/9 2905/21 2948/18 2954/10 2955/22 2976/21 2977/14 2984/19 2987/8 3019/7 3034/18 3037/7 3041/20 3043/22 3046/23 3046/25 3048/19 3048/19 3083/21 3091/9 3103/22 3109/16 3110/4 3113/23 endeavor [1] 3037/12 ended [6] 2916/12 2966/6 2996/4 3039/12 3064/6 3078/8 ending [12] 2893/16 2897/8 2929/21 2932/3 2932/16 3064/9 3074/25 3117/25 3119/12 3120/6 3128/4 endless [1] 2960/14 endorsing [1] 2900/14 ends [1] 2892/15 engage [1] 2957/5 engaged [3] 2931/20 2943/2 3002/24 engagement [1] 2942/2 engaging [2] 2938/17 2942/7 enjoyed [3] 3006/4 3010/9 3010/9 enjoying [2] 3009/15 3024/12 entered [3] 3065/15 3068/25 3075/8 entering [2] 2896/15 3069/17 enters [5] 2878/7 2878/13 2937/1 2990/2 3054/3 enthusiastic [1] 2929/8 entire [2] 2950/14 3102/22 entities [10] 2907/20 3044/9 3045/12 3069/5 3069/10 3069/21 3113/7 3124/20 3124/21 3135/19 entitled [8] 2894/5 2895/2 2895/18 2896/11 2896/17 2912/1 2961/24 entity [2] 2929/9 3046/18 entrepreneur [2] 2942/25 3008/21 entry [1] 3078/13 environment [1] 2943/1 **equals [1]** 2889/15 equities [1] 3095/6 equity [7] 2898/15 3107/20 3124/16 3124/25 3125/2 3125/4 3126/19 errors [1] 2901/5 especially [2] 2923/8 3031/20 **ESQ [8]** 2877/12 2877/15 2877/15 2877/16 2877/19 2877/20 2877/20 essentially [6] 2952/5 2990/22 3036/8 3044/25 3045/3 3088/2 establish [8] 3018/5 3034/15 3058/4 3136/6 3137/9 3137/15 3137/17 3138/9 established [3] 2905/24 3102/3 establishing [1] 3136/23 estate [5] 2998/2 2998/5 2999/7 3000/1 estimate [1] 2987/22 Europe [1] 2965/11 evaluated [1] 3098/15 Evan [43] 2898/3 2899/4 2899/7 2899/7 2899/9 2899/19 2900/24 2901/2 2902/3 2907/10 2908/15 2910/15 2922/7 2923/17 2924/5 2934/18 2935/10 2943/22 2948/21 2950/4 2950/10

2951/4 2951/6 2953/6 2953/8 2956/10 2957/24 2958/5 3091/10 3051/22 3054/20 3062/25 3084/23 3084/25 3086/4 3086/7 3086/12 3086/18 3086/21 3086/22 3086/24 3087/6 3088/1 Evan's [3] 2882/16 2958/12 3088/7 evaporating [1] 3048/4 evening [2] 2978/1 3000/12 evidence [74] 2880/6 2880/10 2882/1 2882/7 2884/16 2893/9 2893/14 2910/1 2910/6 2915/12 2915/17 2921/6 2921/10 2923/21 2923/25 2927/2 2927/6 2937/24 2938/2 2938/4 2942/3 2944/1 2944/5 2946/4 2946/8 2953/7 2961/15 2961/19 2973/1 2973/2 2973/5 2974/1 2974/9 2979/12 2979/16 2983/6 2983/8 2983/10 3015/22 3015/23 3018/9 3035/19 3041/4 3041/17 3054/13 3055/18 3061/9 3062/23 3064/22 3066/18 3066/23 3078/1 3078/7 3091/20 3091/25 3103/2 3105/14 3105/18 3107/12 3107/14 3111/14 3113/14 3115/22 3117/12 3122/4 3123/21 3123/24 3124/2 3126/10 3128/8 3130/1 3137/1 3137/11 3137/20 evolution [1] 2896/16 **evolve [1]** 3018/17 exact [5] 3003/25 3034/22 3049/8 3071/2 3133/1 exactly [8] 2890/20 2903/10 2939/4 2995/11 3004/20 3036/11 3042/22 3061/24 examination [20] 2878/11 2878/21 2879/1 2937/5 2973/24 2974/6 2990/9 3015/4 3050/21 3054/8 3054/10 3077/25 3078/12 3084/23 3090/19 3090/21 3092/13 3093/21 3119/3 3136/11 examine [2] 2989/3 2990/4 examined [2] 2878/18 3093/13 example [4] 2887/5 3113/4 3113/7 3135/6 examples [1] 3103/9 **exceeded [1]** 2977/12 excellent [3] 2945/4 2945/8 2964/14 exception [2] 2953/9 2955/14 **exceptional** [1] 2946/25 **exceptions** [1] 2951/17 excess [2] 2991/8 3079/22 exchange [18] 2881/22 2881/23 2883/3 2884/12 2884/13 2893/7 2893/20 2947/18 2988/24 2992/4 2997/1 3014/1 3024/7 3058/14 3058/19 3059/3 3086/22 3088/9 exchanges [1] 2903/8 excited [2] 3034/21 3039/24 excitement [2] 3034/23 3034/25 exciting [7] 2925/14 2925/16 2925/24 2928/2 2928/19 2935/8 3050/2 exclude [2] 2958/2 2959/14 exclusively [1] 3050/13 excuse [10] 2891/3 2913/10 2942/3 2962/3 2962/17 2985/3 3008/7 3062/15 3084/9 3134/20 excused [4] 3093/6 3093/8 3134/22

exhibits [10] 2882/2 2915/3 2915/5 3190/25-3193/9-3115/6-3134/17-3137/9 facto [1] 2945/2 age D #: 6667 Ease 1:15-cr-00637-KAM Documents 2927 Filed 1923 177 (31479 excused... [1] 3134/24 3130/13 3140/8 factors [1] 2895/19 executive [29] 2932/9 2932/14 2933/6 exist [2] 3051/6 3094/20 facts [7] 2891/10 2893/6 2894/3 2894/4 2940/1 2940/5 2940/6 2940/9 2940/13 existence [1] 3036/25 2949/2 2964/19 3041/3 2945/2 2957/17 2958/8 2959/2 2966/20 factual [3] 2890/22 2901/5 3133/7 existing [3] 2993/16 3049/2 3069/19 2969/24 2969/25 2970/22 2980/16 failed [1] 3011/24 exited [1] 2938/25 2980/18 2981/2 2981/7 2981/15 exits [4] 2936/4 2989/13 3053/4 failing [1] 3030/24 3008/13 3008/20 3036/15 3036/15 failure [1] 2955/18 3134/13 3037/4 3065/9 3069/16 3075/1 fair [57] 2942/25 2952/13 2973/14 expanded [1] 3124/14 executives [4] 2940/8 2958/7 2966/22 expect [3] 2951/10 3008/20 3072/4 2974/1 2975/24 2991/24 2992/8 3008/8 2993/20 2996/24 2999/13 3000/22 expectations [2] 2951/5 2951/6 **exercise** [1] 3122/13 3007/20 3008/11 3008/13 3010/16 expected [2] 2984/4 3124/24 exhibit [126] 2879/18 2880/5 2880/9 expecting [3] 2890/1 2891/25 2896/14 3018/12 3018/21 3022/23 3026/11 2881/17 2881/25 2882/4 2882/6 2884/7 **expense [3]** 3079/18 3079/20 3079/22 3029/2 3029/3 3032/3 3036/2 3036/4 2884/15 2888/6 2893/1 2893/2 2893/8 expenses [5] 2913/2 2913/5 2914/11 3036/5 3037/14 3038/6 3038/13 2893/11 2893/13 2893/16 2893/19 3038/21 3039/20 3042/22 3042/25 2914/12 3135/7 2897/8 2909/17 2909/25 2910/3 2910/5 experience [9] 2922/22 2964/15 3043/13 3045/19 3046/10 3047/3 2911/1 2915/16 2919/7 2920/23 2921/5 2964/23 2997/18 3086/8 3097/25 3048/5 3049/24 3050/5 3050/15 3051/6 2921/9 2923/12 2923/14 2923/20 3051/17 3057/3 3059/16 3059/19 3098/2 3098/15 3130/13 2923/23 2923/24 2924/2 2926/15 3062/3 3069/24 3077/1 3077/3 3077/9 expert [2] 3039/16 3039/17 2927/5 2929/12 2930/11 2937/15 3081/24 3085/17 3086/4 3089/2 **expertise** [1] 2906/3 2937/23 2938/1 2938/3 2941/4 2943/15 explain [3] 2946/14 3041/1 3132/1 3089/14 3103/11 3133/15 2943/18 2943/25 2944/4 2945/19 explained [2] 2971/2 2982/16 fairly [6] 2893/22 2918/20 2996/9 2946/3 2946/7 2961/4 2961/5 2961/14 **explaining [1]** 2972/5 2999/11 3008/3 3029/3 2961/17 2961/18 2979/5 2979/7 faith [5] 2891/13 2891/18 2892/1 explains [1] 2972/21 2979/11 2979/15 2982/21 2982/22 **explanation [2]** 2955/20 3080/19 2901/1 2901/17 2983/5 2983/9 3020/7 3025/3 3035/20 fall [6] 2918/10 3000/22 3000/23 **exposure [1]** 3074/20 3055/18 3057/12 3057/14 3057/15 3000/23 3032/2 3032/4 exposures [1] 2963/16 3058/23 3061/9 3061/17 3061/20 express [8] 2923/4 2931/7 2992/10 false [1] 3113/17 3061/24 3064/12 3064/14 3066/19 2992/12 2993/23 3008/5 3009/9 familiar [1] 2952/20 3066/21 3066/22 3068/18 3068/20 family [6] 2965/11 2965/12 2965/14 3010/10 3072/11 3090/4 3091/6 3091/12 expressed [4] 2904/1 3010/6 3017/21 2999/3 3002/8 3006/18 3091/19 3091/22 3091/24 3105/7 3047/16 far [2] 2900/18 3017/21 3105/14 3105/17 3106/9 3106/20 expressing [2] 2933/22 2978/4 Fargo [1] 2992/18 3107/9 3107/12 3108/16 3111/3 extensive [2] 2928/17 3037/18 fashionable [1] 3005/14 3111/13 3115/11 3115/19 3115/21 extensively [1] 3029/6 fault [1] 2897/20 3115/22 3117/8 3117/11 3117/24 extent [6] 3002/16 3018/8 3021/17 favor [1] 2901/11 3119/6 3119/25 3121/18 3121/25 3131/7 3131/11 3138/21 favorite [2] 2943/1 3004/15 3122/3 3123/2 3123/12 3123/21 external [19] 2907/12 2911/18 2916/16 FDA [3] 3031/15 3031/21 3036/21 3123/23 3123/24 3124/2 3124/8 2916/22 2917/4 2922/11 2924/4 fearing [1] 2891/16 3125/23 3126/6 3126/9 3127/24 February [24] 2894/14 2925/25 2937/7 2935/13 2937/19 2957/4 2985/19 3128/10 3128/16 3129/14 3130/1 2986/22 2994/12 2996/12 3074/2 2937/22 2943/23 2944/14 2944/22 Exhibit 10-12 [1] 3068/20 3074/3 3074/19 3085/2 3085/3 3021/23 3022/11 3024/3 3033/21 Exhibit 107-9 [1] 3126/6 extra [3] 2882/23 3068/11 3138/10 3034/4 3034/6 3034/8 3034/10 3034/17 Exhibit 109-6 [3] 3121/18 3121/25 extracted [1] 3030/13 3034/18 3034/18 3034/21 3043/15 3124/2 extractions [1] 3030/14 3060/2 3060/7 3073/21 3073/24 Exhibit 109-7 [1] 3125/23 eyes [1] 3009/25 February 12 [3] 3021/23 3022/11 Exhibit 11B [2] 3123/21 3123/23 3024/3 Exhibit 122-33 [1] 2943/15 February 14th [1] 2937/7 Exhibit 122-49 [2] 2919/7 3061/9 face [11] 2908/4 2908/4 2926/7 2926/7 February 2011 [3] 3034/8 3034/17 Exhibit 122-53 [2] 2920/23 3072/11 2926/8 2926/8 2968/1 2996/14 2996/14 3034/21 Exhibit 122-58 [2] 2923/12 2923/23 3010/20 3010/22 February 2012 [1] 2894/14 Exhibit 122-64 [2] 2926/15 2929/12 face-to-face [4] 2908/4 2926/7 2926/8 February 2014 [1] 2925/25 Exhibit 122-71 [1] 2938/1 2996/14 February 20th [1] 2944/14 Exhibit 122-72 [1] 2941/4 faces [1] 3045/18 February 26 [1] 3034/10 Exhibit 122-74 [1] 2945/19 facilitate [1] 3124/18 February/March [1] 3043/15 Exhibit 122-84 [2] 2961/5 2961/17 facilitating [1] 2933/23 federal [1] 2932/21 Exhibit 4218 [1] 3020/7 facilities [1] 3044/18 **FedEx [1]** 2880/20 Exhibit 4237 [2] 3066/19 3066/21 fact [38] 2886/15 2892/6 2892/22 fee [4] 2912/3 2912/11 3135/7 3135/8 **Exhibit 91-1 [1]** 3128/10 2902/23 2906/13 2907/3 2915/22 feedback [5] 2938/14 2939/25 2939/25 Exhibit 91-10 [1] 3130/1 2918/2 2926/3 2931/9 2932/11 2934/16 2940/19 2963/16 **Exhibit 91-2 [1]** 3119/6 2939/16 2945/12 2949/14 2951/18 feelings [1] 3010/16 Exhibit 91-3 [1] 3119/25 2963/10 2963/11 2966/9 2969/24 fees [3] 2911/23 3138/6 3138/7 Exhibit 91-8 [1] 3127/24 2970/6 2970/15 2971/4 2978/12 fellow [2] 2943/21 2952/24 Exhibit 91-9 [1] 3129/14 2978/12 2980/3 3009/16 3014/11 felony [1] 3073/18 Exhibit I [1] 3061/17 3016/25 3020/15 3021/4 3022/8 3100/3 felt [12] 2890/13 2918/18 2935/17 Exhibit J [1] 3061/20

Case 1:15-cr-00637-KAM_Docu fortune [1] 3908/2 2950/4-2950/7-2950/13-2962/2-2963/10 լ ար ար 295 դրդանան արագրագրեր հայանակում 1295 դրդանան արագրագրան անագրագրան անագրագրան անագրագրան անագրագրա 2969/17 2972/1 2977/7 2980/6 3001/39 felt... [9] 2947/22 2959/19 2960/19 3001/8 3001/8 3002/12 3003/18 forward [17] 2883/13 2898/4 2900/25 2968/15 3006/15 3010/7 3035/3 3009/22 3009/23 3030/24 3035/20 2901/24 2925/19 2946/18 2960/13 3080/16 3081/14 3036/20 3037/10 3039/21 3039/24 2960/17 2966/10 2985/6 2993/15 female [1] 3011/6 3046/23 3050/2 3050/2 3057/8 3058/13 3049/24 3050/13 3052/19 3082/24 Fernandez [1] 2978/8 3069/24 3070/1 3074/8 3087/3 3087/4 3098/16 3102/5 few [19] 2890/15 2902/2 2903/4 2936/5 3093/12 3095/22 3096/8 3102/12 fought [1] 2944/24 2955/8 2956/14 2999/5 3002/8 3005/7 3108/19 3109/16 3111/19 3111/20 foundation [1] 3116/9 3009/24 3010/6 3015/25 3027/10 founded [2] 2992/15 3048/5 3114/5 3120/20 3122/19 3124/6 3027/11 3028/6 3051/10 3086/9 3125/18 3128/16 3130/9 founder [3] 2946/24 3052/15 3052/16 3094/24 3113/10 fiscal [1] 3109/17 founders [2] 3051/3 3052/14 fifth [3] 2896/11 2983/18 3070/12 fit [2] 3097/20 3108/14 founding [2] 2891/7 3052/9 Fifty [1] 3093/24 five [9] 2925/6 2925/7 3004/16 3026/12 | founds [1] 2903/17 Fifty-four [1] 3093/24 3094/22 3104/23 3130/18 3130/24 four [8] 2895/18 2966/17 2966/20 figuratively [1] 3023/10 3130/24 3004/16 3029/18 3093/24 3111/3 figure [3] 3012/6 3028/16 3032/23 five-month [3] 3130/18 3130/24 3130/18 figured [3] 3028/18 3028/19 3033/1 fourth [3] 3070/9 3082/18 3123/2 3130/24 filaments [1] 3042/11 fix [1] 3022/14 frame [3] 3081/4 3081/10 3120/11 file [3] 2894/5 2905/5 3071/3 fixable [1] 2899/12 framed [2] 2947/17 2970/14 filed [7] 2880/24 2901/10 2947/17 fixed [4] 2900/17 3020/16 3020/19 framing [1] 2970/18 3063/14 3063/15 3067/20 3072/2 3021/4 frankly [1] 2899/3 files [4] 2894/2 2984/12 2984/12 flat [1] 3062/10 free [3] 2957/2 3024/13 3060/10 2984/21 frequent [1] 3030/11 flesh [1] 3074/6 filing [12] 2900/23 2902/3 3063/20 frequently [7] 2998/25 2999/4 3004/7 floating [1] 3002/2 3068/18 3068/21 3070/17 3070/21 floor [1] 3136/14 3004/8 3005/4 3005/6 3024/5 3070/22 3070/25 3071/7 3071/13 floors [1] 3001/2 Friday [1] 2945/7 3071/19 friend [7] 2953/14 3000/14 3011/5 flow [4] 2886/6 2911/5 2913/22 3078/8 filings [4] 2916/15 2918/7 2918/10 focus [7] 2893/22 2914/15 2914/17 3011/11 3011/12 3022/8 3098/7 3076/21 2938/22 2952/21 2957/22 2962/9 friends [5] 2891/9 2965/12 3001/12 fill [1] 2924/19 focused [4] 2960/9 2969/18 3049/23 3009/14 3011/9 filled [2] 2906/16 2906/24 friendship [8] 2891/13 2891/18 2892/1 3120/23 final [2] 2896/4 2906/22 focusing [2] 3105/19 3119/7 2903/1 2988/16 2988/21 3004/6 finalized [1] 2904/19 folks [1] 3052/8 3029/11 finally [1] 3069/18 follow [4] 2903/4 2965/24 3133/2 front [3] 3067/5 3105/9 3116/8 finance [2] 2922/3 3094/11 3133/8 frustrating [1] 2928/16 finances [2] 2974/15 3113/11 follow-on [1] 3133/2 frustration [1] 2962/5 financial [17] 2888/21 2905/13 2906/15 follow-up [1] 3133/8 fueled [1] 2900/11 2906/20 2909/23 2910/20 2913/22 followed [6] 2901/3 2910/23 2948/13 fulfilled [2] 2901/25 3076/16 2914/4 2999/20 3063/12 3074/5 full [9] 2919/5 2926/21 2935/6 2996/17 2957/14 3002/24 3139/2 3079/25 3081/6 3081/15 3109/19 following [24] 2879/13 2905/9 2912/13 3068/11 3068/12 3074/20 3107/16 3113/6 3114/23 2936/8 2939/16 2939/20 2945/4 2950/2 3108/23 financing [15] 2883/13 2883/20 2896/5 2963/17 2965/20 2966/8 2968/11 full-day [1] 2926/21 2898/11 2898/12 2907/17 2910/19 2969/9 2969/14 2970/23 2980/25 fully [6] 2926/5 2945/14 2956/7 2911/15 2911/18 2911/23 3048/14 2989/15 3003/2 3020/20 3075/22 3069/18 3089/20 3127/4 3113/8 3114/16 3114/18 3114/22 3087/11 3103/6 3109/16 3118/11 functioning [1] 2945/14 fine [12] 2901/24 2975/25 3008/8 follows [2] 2878/19 3093/13 fund [68] 2882/21 2903/22 2931/11 3013/13 3018/7 3041/18 3045/14 followup [3] 2933/24 2945/3 2968/22 2931/22 2949/4 2949/4 2999/9 2999/13 3119/15 3119/18 3119/20 3120/13 footnote [3] 2900/24 3120/16 3121/6 2999/23 3004/5 3021/19 3023/9 3120/20 3023/14 3024/23 3025/19 3025/21 force [1] 2960/5 finger [1] 3106/21 3026/19 3027/9 3027/13 3027/17 forceful [2] 2933/20 2933/21 fingertips [1] 2964/19 3043/8 3044/3 3095/19 3096/18 forcefully [1] 2917/8 finish [1] 3014/24 forensic [2] 2896/19 2896/24 3096/20 3097/2 3097/11 3097/12 **FINRA [1]** 2932/19 foreseeable [1] 2988/19 3097/21 3097/21 3098/9 3098/16 fired [1] 2972/23 3098/20 3100/12 3100/20 3101/9 forge [1] 3004/6 firing [1] 2973/14 forget [1] 2917/1 3102/6 3103/8 3103/12 3104/5 3105/23 firm [10] 2922/11 2924/4 2956/22 3105/25 3106/13 3107/1 3109/4 forgot [1] 3071/21 2994/7 3046/11 3046/14 3054/21 form [21] 2881/9 2882/15 2882/17 3110/17 3111/21 3114/6 3115/16 3094/20 3110/17 3117/19 2882/20 2882/24 2883/1 2883/2 3122/8 3124/13 3124/22 3125/10 first [86] 2878/18 2880/18 2882/9 2899/24 2900/3 2901/4 2904/22 3125/16 3125/17 3126/16 3126/22 2888/23 2889/2 2891/21 2892/11 2904/25 2964/18 2983/20 3016/1 3126/24 3126/25 3127/2 3127/7 2893/23 2894/5 2897/2 2897/7 2897/11 3066/13 3066/15 3067/17 3071/2 3127/12 3127/13 3129/13 3131/15 2905/20 2907/1 2907/7 2907/11 3100/21 3103/18 3133/23 3134/2 3135/9 2907/22 2908/24 2909/3 2910/8 2911/7 formally [2] 2979/1 2979/2 fundamentally [1] 3031/9 2911/10 2912/3 2912/4 2914/14 funding [3] 2914/10 2925/22 3124/24 format [2] 2885/3 2926/6 2921/24 2926/4 2927/7 2927/12 2930/8 formed [1] 2922/5 funds [14] 2898/18 2903/11 2914/8 2931/4 2931/14 2935/6 2942/11 forth [1] 2946/19 2999/10 3097/23 3098/1 3098/6 2942/22 2944/9 2945/2 2945/11 2948/1

Ease 1:15-cr-00637-KAM_Docu funds... [7] 3098/10 3110/3 3110/5 3110/6 3124/17 3138/5 3138/22 future [9] 2897/23 2901/18 2907/16 2942/9 2942/10 2956/6 2988/19 3039/19 3069/19 Futures [1] 2932/19 **G-E-L-L-E-R [1]** 3093/18 gain [1] 2994/13 game [1] 3119/2 Gateway [2] 2897/15 2905/24 gay [4] 3014/10 3015/14 3016/9 3017/10 Geller [43] 2919/10 2919/17 3055/3 3055/15 3055/19 3057/8 3057/24 3057/24 3058/8 3058/10 3058/14 3061/17 3093/9 3093/12 3093/18 3093/23 3096/5 3098/11 3101/18 3104/4 3105/8 3106/19 3107/5 3108/10 3111/15 3114/3 3115/23 3116/11 3116/13 3119/7 3119/15 3120/2 3120/10 3122/5 3123/17 3123/25 3124/11 3126/11 3126/20 3128/12 3130/12 3131/2 3134/22 Geller's [1] 2919/21 general [26] 2909/1 2938/14 2956/23 2956/25 2958/19 2958/21 2959/4 2963/13 2975/19 2979/23 2980/10 2985/25 2986/22 3046/8 3069/13 3069/15 3108/3 3108/21 3109/1 3109/18 3133/11 3133/16 3133/18 3133/24 3134/16 3136/14 generally [8] 2905/14 2908/7 2946/14 2955/12 2996/6 2999/7 3029/25 3046/2 generations [1] 3008/16 genesis [3] 3030/24 3047/16 3048/15 gentleman [3] 2906/25 2937/19 3008/16 **gentlemen [1]** 3134/7 GenVec [4] 3011/21 3011/24 3012/8 3013/18 geography [1] 2996/23 gift [3] 3120/25 3121/2 3121/3 gifted [2] 3121/4 3121/4 gifts [2] 3005/8 3005/10 girlfriend [2] 3029/13 3029/15 given [15] 2883/17 2889/1 2889/21 2889/24 2890/13 2892/19 2899/5 2907/3 2972/10 3006/18 3007/4 3079/25 3080/19 3085/23 3089/5 glimmer [1] 3028/12 globally [1] 2995/12 gmail.com [1] 2877/23 goal [1] 3126/23 Golding [11] 2921/23 2921/25 2925/9 2927/16 2944/20 2966/3 2966/22 2968/24 2969/11 2984/15 3072/14 governance [2] 2930/4 2980/23 government [75] 2877/12 2878/10 2878/21 2880/5 2880/9 2881/25 2882/6 2884/15 2886/14 2893/8 2893/13 2909/25 2910/5 2915/11 2915/16 2919/7 2920/23 2921/5 2921/9 2923/12 2923/20 2923/24 2927/1 2927/5 2929/12 2937/15 2937/23 2938/1

2945/19 2946/3 2946/6 2946/7 2951/24 2961/5 2961/14 2961/17 2961/18 2970/21 2971/1 2979/4 2979/11 2979/14 2979/15 2983/5 2983/9 2986/12 3009/8 3035/21 3036/1 3061/8 3072/11 3078/19 3091/19 3091/24 3105/17 3107/12 3111/13 3115/22 3117/11 3119/5 3119/25 3121/17 3122/3 3123/12 3123/24 3124/1 3126/6 3126/9 3135/1 3140/9 government's [39] 2879/18 2881/17

2882/4 2884/7 2888/5 2893/1 2893/11 2893/19 2909/17 2910/3 2915/3 2921/8 2923/23 2926/15 2962/20 2982/21 3035/20 3078/1 3091/6 3091/12 3091/22 3105/7 3105/13 3106/20 3107/8 3111/3 3115/11 3115/19 3115/21 3117/2 3117/8 3121/25 3123/20 3123/23 3125/23 3127/24 3128/9 3129/14 3129/25

graduate [1] 3094/12 grant [3] 2897/21 2899/5 2902/2 grants [3] 2977/9 2977/10 2991/6 gratuitous [1] 3084/14 great [11] 2886/23 2887/7 2897/20 2922/4 3041/9 3041/11 3041/12 3056/12 3084/18 3085/12 3100/6

Greebel [37] 2899/9 2907/10 2908/15 2908/16 2909/7 2910/15 2922/7 2924/5 2927/16 2934/18 2935/10 2943/22 2944/12 2948/21 2949/8 2950/4 2951/21 2952/3 2952/3 2952/6 2952/8 2952/17 2952/23 2953/6 2953/8 2953/23 2955/4 2957/24 2958/10 3051/10 3051/22 3054/20 3062/25 3072/20 3078/3 3084/23 3084/25

Greebel's [3] 2923/17 2952/23 2985/14 Greece [4] 2965/14 2965/21 2998/11 2998/19

grew [1] 2882/21 Grill [1] 3004/12 gross [1] 2911/16

greatly [1] 3052/13

ground [5] 2951/13 2952/13 2986/10 3018/12 3036/6

grounds [1] 3102/25

group [17] 2924/13 2929/6 2931/12 2937/10 2967/14 2967/21 2971/4 2990/23 2990/25 2993/25 2994/3 2994/16 3001/10 3001/20 3001/21 3046/5 3047/25

groups [1] 3043/2

growing [2] 2962/10 3034/5 growth [4] 2962/12 2963/4 2994/21 2994/22

guess [2] 3015/24 3096/16 guidance [1] 3028/20 quide [2] 2962/9 3019/5 guidelines [1] 2930/15 guy [2] 3026/25 3096/17 guys [7] 2924/14 2975/11 2977/18

3003/4 3026/19 3027/5 3027/15

Hackert [5] 2916/25 2917/2 2922/8 3063/1 3072/20

2938/3-2941/3-2943/15-2943/25, 2944/4 half [12], 2893/23, 2905/20, 2907/2 2907/7/2907/11 2987/22 2918/25⁹

> hand [4] 3036/4 3051/7 3051/8 3073/12 hand-pick [1] 3036/4 handed [1] 2989/5 handle [8] 2940/22 2957/11 2966/12 2968/20 2969/7 2969/7 2978/22

2998/8 2998/8 3079/22 3094/9 3095/11

2994/16

handled [8] 2899/16 2899/17 2917/21 2940/20 2940/23 2940/23 2978/15 2978/16

handling [1] 2916/18 happiness [1] 3010/7

happy [11] 2886/3 2886/7 2983/18 2990/16 3006/2 3006/3 3006/4 3010/8 3013/14 3052/19 3089/1

hard [11] 2926/22 2962/6 2991/24 3029/3 3029/4 3029/24 3030/1 3030/4 3067/13 3079/2 3133/9

harder [1] 3095/10 hardly [1] 2972/24

harmless [2] 2885/6 3065/17 Harvard [3] 3043/3 3043/4 3043/5 Hassan [3] 2913/16 2913/25 3078/24

hate [1] 2900/10

head [3] 2929/9 2945/15 2977/22 headache [3] 3008/23 3008/24 3024/13

headaches [2] 3030/11 3030/11

headed [1] 2922/5

heading [2] 3056/7 3056/8

headline [1] 2882/11 headlines [1] 2940/3

health [6] 3007/22 3022/14 3030/2

3097/3 3108/7 3108/8 healthcare [36] 2922/23 3069/3

3069/14 3096/23 3096/24 3097/1 3097/17 3104/12 3106/1 3106/2 3106/14 3107/2 3107/21 3111/22 3114/7 3114/25 3115/4 3115/6 3115/17 3116/13 3118/9 3120/21 3121/5 3121/6 3121/7 3121/11 3123/7 3124/12 3124/14 3124/19 3124/25 3129/2 3129/6 3131/17 3131/19 3135/12

Healthcare's [2] 3121/14 3127/19 healthy [5] 2918/19 2931/19 2931/25 3018/5 3039/9

hear [5] 2968/18 3069/8 3096/14 3112/4 3134/25

heard [8] 2920/2 2920/6 2920/16 3015/24 3043/7 3056/22 3084/5 3101/13

hearing [4] 2931/4 2931/14 2950/12 2972/1

hearsay [4] 2951/17 2953/10 2953/10 2986/11

heavily [2] 2898/7 3124/22

hedge [23] 2931/11 2999/13 2999/23 3026/19 3097/23 3097/25 3098/6 3098/9 3098/16 3100/19 3101/9 3102/6 3103/7 3103/12 3104/5 3105/23 3105/25 3110/3 3110/5 3110/6 3110/17 3124/17 3127/12

heeding [1] 2967/10

held [3] 2900/1 2957/24 2988/21 help [8] 2965/4 2995/24 3007/25 3027/18 3035/4 3035/12 3088/15

inconsistencies [2], 3074/6 3081/23 Case 1:15-cr-00637-KAM Document 315 Filed 08/15/17 inconsistent [2] 3925/13731259 (4) help... [1] 3114/22 INDEX[1] 3140/7 incorporated [1] 3078/7 i.e [1] 2902/9 helped [1] 2929/11 increase [1] 3031/10 helping [5] 2906/8 2995/17 3005/12 idea [16] 2973/3 3000/21 3031/8 incredibly [2] 2960/12 2961/2 3022/14 3043/19 3034/23 3039/8 3039/18 3039/19 indeed [8] 2903/18 2903/19 2948/7 3040/1 3041/8 3041/9 3041/12 3048/3 hereby [1] 2981/8 2949/10 2949/12 2982/3 2986/24 Hi [3] 2882/13 2888/15 2944/16 3048/6 3048/8 3048/9 3120/19 2987/3 high [2] 3008/3 3095/4 ideas [2] 2970/2 3032/11 indemnification [1] 3065/16 highlight [1] 3052/21 identification [25] 2879/17 2881/16 independence [3] 2958/12 2958/13 highlighted [2] 2900/21 3065/6 2884/6 2892/25 2909/16 2915/2 2958/14 highlighting [2] 3038/24 3065/4 2920/23 2923/11 2926/14 2937/14 independent [8] 2935/16 2940/6 highly [1] 3006/10 2943/14 2945/18 2961/5 2979/5 2940/10 2957/20 2958/1 2959/7 himself [15] 2885/21 2885/24 2918/2 2982/20 3091/5 3096/3 3105/6 3106/20 2966/23 2966/24 3111/2 3115/10 3117/1 3121/17 2953/16 2953/17 2958/5 3007/9 independently [1] 2987/25 3007/12 3007/21 3009/22 3022/15 3123/11 3125/22 indicate [3] 2902/19 2932/25 3082/4 3029/19 3029/22 3030/5 3030/7 identified [2] 2906/12 3096/6 indicated [1] 3063/5 identify [1] 3057/13 hired [1] 3033/12 indicates [1] 3058/13 hold [12] 2881/3 2882/17 2896/16 ignored [3] 2967/13 2971/3 2976/10 indirectly [1] 3125/1 2987/13 2987/13 2987/14 2987/20 ignoring [1] 2966/9 individual [7] 2908/8 2920/2 2920/6 2988/6 2988/7 3031/6 3065/17 3089/9 **ill [1]** 3024/15 2920/16 2978/18 3095/13 3106/8 holding [6] 2882/19 2882/22 2892/5 illegal [2] 2973/18 2973/20 individuals [8] 2921/21 2922/8 2922/9 2902/25 3066/16 3075/20 illiquid [8] 3098/5 3098/12 3098/13 2922/10 2928/25 2951/12 2978/6 holdings [11] 2884/3 2892/23 2894/1 3098/14 3124/15 3125/17 3126/19 3043/2 2904/3 2905/3 2917/23 2998/3 2998/3 indoor [1] 3000/9 2998/5 2999/7 3000/2 image [1] 3005/13 industry [4] 3031/14 3094/24 3094/25 holds [1] 3049/5 immediately [7] 2905/8 2922/4 2950/3 3099/2 home [2] 2977/16 3138/14 2950/10 2977/21 3056/11 3088/17 infatuated [1] 3014/9 Honor [49] 2878/12 2878/23 2935/22 impact [7] 2904/11 2947/2 2956/11 infection [9] 3020/12 3020/17 3021/10 2937/4 2951/9 2952/2 2954/8 2973/4 2966/19 2995/25 3035/11 3050/3 3021/15 3030/9 3091/1 3092/10 2986/14 2989/1 2989/5 3012/10 impacted [1] 3030/4 3092/16 3092/20 3012/13 3012/15 3014/13 3014/15 impacts [1] 3049/12 influence [1] 3118/8 3016/16 3018/19 3021/25 3023/11 impeach [1] 3018/16 influenced [1] 3016/17 3041/19 3068/17 3078/15 3090/18 **implication [1]** 3009/13 inform [3] 2941/25 2943/11 3133/16 3093/9 3093/14 3093/19 3096/7 3099/6 imply [2] 3014/18 3103/7 information [34] 2942/14 2942/19 3099/8 3099/11 3100/1 3105/13 implying [1] 3041/8 2951/16 2952/9 2952/10 2956/13 3111/10 3111/25 3112/3 3113/1 importance [1] 2985/11 2972/15 2973/11 2974/5 2974/13 3115/18 3116/7 3117/7 3121/24 important [23] 2925/20 2933/15 2974/15 2974/19 2974/22 2975/2 3123/20 3126/5 3131/21 3132/1 3133/2 2968/15 2968/16 3021/13 3038/8 2981/25 3011/23 3012/2 3082/11 3134/14 3135/2 3138/13 3038/16 3049/24 3071/19 3082/13 3084/21 3085/23 3097/16 3101/8 HONORABLE [1] 2877/9 3100/20 3101/9 3102/7 3104/6 3108/10 3103/14 3104/4 3105/3 3108/10 3109/6 3108/12 3109/6 3110/10 3122/8 hope [6] 2888/15 2899/19 2899/21 3109/21 3113/17 3116/21 3116/23 2902/22 2944/16 3028/12 3127/20 3129/5 3131/8 3131/12 3122/10 3125/7 3125/19 hoped [3] 2982/3 3024/12 3050/5 impose [1] 3137/22 informational [1] 3052/5 impressed [4] 3098/25 3099/3 3102/2 hopefully [1] 3035/12 informed [1] 2956/7 Horacio [5] 2906/25 2929/2 2929/3 informing [1] 2942/14 2933/10 2940/21 impresses [1] 3113/11 infrastructure [1] 2960/6 Horacio's [1] 2933/19 impression [10] 2895/25 2904/18 inherent [1] 3031/25 3003/2 3038/11 3097/16 3113/18 horrible [1] 3037/14 initial [4] 2891/6 2901/6 2947/16 hour [2] 2989/10 3003/6 3114/24 3115/1 3119/20 3120/13 3108/24 hours [3] 2924/19 3029/6 3104/23 impressions [1] 3124/23 initiated [1] 2986/5 house [4] 2979/23 2980/10 3006/25 improve [3] 2924/23 2994/22 2994/23 Initiatives [1] 2963/4 in-house [2] 2979/23 2980/10 3007/9 input [3] 2961/24 2962/15 2962/18 HR [5] 2906/10 2992/19 2992/20 inability [1] 2983/20 inside [6] 2972/15 2973/10 2974/12 2992/21 2992/25 inaccurate [2] 3131/7 3131/11 2974/22 2975/16 3003/3 hubble [1] 3032/16 inappropriate [3] 2955/23 3084/15 insight [1] 2963/25 hug [2] 3092/24 3092/25 3100/16 insinuate [1] 3014/19 huge [3] 2891/12 2891/17 3026/9 Inc [3] 3067/17 3069/6 3114/9 instances [1] 3086/13 human [6] 2993/5 2993/13 3002/7 incentive [2] 2946/17 2977/10 instead [1] 2883/25 3005/24 3005/24 3008/15 incentives [1] 2990/22 instructed [1] 2977/2 **humble [1]** 3026/13 inch [1] 2939/5 instruction [4] 2972/17 2975/3 2976/16 incidents [1] 2970/21 humiliate [3] 3016/18 3016/20 3017/9 2976/19 included [6] 2896/23 2947/23 3011/19 hundred [1] 3134/14 instructions [2] 2966/9 2967/14 hurt [1] 2968/19 3066/12 3070/17 3070/20 instrumental [1] 3050/15 includes [2] 2929/2 2946/17 **hygiene [1]** 3007/15 intend [2] 2902/20 3015/9 including [5] 2880/12 2912/4 2940/8 hypothetical [5] 3100/22 3101/1 intended [2] 2915/21 3015/2 3103/16 3139/2 3139/3 3073/9 3124/15 intense [1] 2926/5 income [1] 3109/22

JACQUELYN [1] 2877/15#: 6671 Jain [3] 2922/8 3083/13072/2671 3116/21 3118/6:3120/22 3122/13 Case 1:15-cr-00637-KAM Docu 13129/2013726/169728/2/13727/10 Pag intent [3] 3016/1 3046/17 3124/15 3127/19 3130/7 3131/8 3131/12 January [7] 2880/4 2880/14 2924/6 interacting [1] 3001/7 3131/18 2960/18 3106/18 3107/4 3126/12 interaction [1] 3001/14 investments [30] 2889/9 2891/5 2891/9 **January 1st [2]** 3106/18 3107/4 interest [3] 2912/5 2981/1 3134/16 2894/5 2894/9 2894/18 2894/19 **January 24 [2]** 2880/4 2880/14 interested [4] 2983/21 2983/22 3002/7 2894/20 2895/2 2896/20 2896/25 January 24th [1] 3126/12 3004/5 2897/3 2898/13 2938/21 2938/25 January 6 [1] 2924/6 interesting [1] 2925/17 2939/1 2998/2 2998/7 3098/5 3098/9 Jeff [7] 2922/16 2922/19 2925/5 2925/9 interfaces [1] 2960/8 2966/3 2966/4 3084/1 3098/12 3098/16 3107/21 3108/8 interfered [1] 3016/1 3111/22 3114/7 3124/23 3125/2 3125/3 Jensen [6] 2909/1 2909/4 2979/24 interim [7] 2969/4 2969/12 2979/3 3125/18 2980/8 2980/9 2985/18 2981/15 3035/24 3036/2 3060/13 Jim [4] 3098/25 3099/1 3100/3 3102/2 investor [26] 2891/8 2947/20 2964/1 interjected [1] 2917/7 2977/22 2978/10 2982/12 2984/3 job [4] 2993/20 3008/5 3008/14 3085/17 internal [12] 2899/10 2907/13 2908/15 2996/24 2996/25 2997/2 2997/7 jobs [2] 3094/16 3094/25 2908/16 2909/1 2935/2 2935/14 2997/22 3028/25 3043/7 3095/19 join [3] 2922/21 2957/25 2994/11 2963/13 2976/14 2977/22 2986/4 3097/14 3100/8 3104/17 3109/4 3111/7 joined [7] 2921/23 2925/5 2934/25 3116/24 3117/6 3118/2 3121/21 3122/7 2978/10 2978/15 2994/19 3001/11 international [4] 2993/12 2995/15 3130/14 journey [1] 2900/19 2995/20 2996/4 JUDGE [19] 2877/10 2903/24 2971/10 investors [36] 2881/2 2898/19 2901/12 interrelated [1] 2954/2 2903/13 2903/17 2903/20 2904/6 2990/8 3013/21 3016/13 3017/12 interrupt [3] 2885/6 2886/6 2886/11 2907/16 2920/9 2947/23 2949/23 3017/24 3038/5 3054/6 3057/15 interview [13] 2906/11 2948/14 2952/12 2953/1 2953/25 2978/2 2978/4 3066/19 3066/24 3067/3 3093/3 2948/15 2949/6 2949/16 2949/17 2978/11 2978/13 2978/17 2978/18 3102/10 3133/9 3139/6 3139/7 2950/2 2950/3 2951/16 2955/12 2956/3 2981/18 2984/5 3034/15 3037/7 3066/5 July [8] 2877/5 2908/24 2909/4 2909/12 2956/9 3088/12 3069/12 3077/21 3080/25 3088/15 3078/2 3117/23 3130/5 3139/10 interviewed [5] 2922/1 2947/21 3110/18 3113/2 3113/3 3122/22 July 13 [1] 3139/10 2948/10 2949/14 2949/15 3122/23 3124/5 3137/10 **July 2 [1]** 3078/2 interviewing [2] 2888/20 2964/12 investors' [2] 2981/20 2982/8 July 2011 [1] 3117/23 interviews [1] 2906/13 invests [1] 3113/9 July 2012 [1] 3130/5 intrigued [2] 2938/17 3002/10 invite [3] 2940/11 3008/25 3009/3 July 2013 [1] 2909/12 introduced [4] 3087/1 3088/1 3095/18 inviting [1] 2948/14 jumping [1] 2900/16 3095/20 June [22] 2911/6 2913/8 2913/12 involve [2] 2956/24 2986/19 introducing [1] 2938/11 involved [10] 2929/18 2939/24 2987/3 2914/3 2961/13 2961/20 2963/5 2963/9 invert [1] 3047/15 2995/8 2995/15 3011/7 3048/14 2964/5 2965/7 2965/25 2967/11 3064/6 invest [21] 2895/8 2900/16 2982/13 3064/9 3074/25 3078/8 3106/4 3111/18 3060/12 3085/20 3085/23 2999/23 3027/5 3027/8 3089/4 3102/21 involvement [2] 2985/14 2985/17 3114/13 3116/2 3129/16 3129/21 3102/23 3103/13 3108/2 3110/25 irreconcilable [1] 3027/12 June 2012 [2] 3129/16 3129/21 3115/6 3115/8 3121/8 3121/11 3124/15 irrelevant [5] 2901/13 2951/8 2986/11 June 2013 [1] 2911/6 3124/19 3124/25 3126/24 3127/11 3084/15 3136/8 June 2014 [1] 2963/5 invested [23] 2889/12 2894/16 2894/22 isolation [1] 3022/7 June 22 [2] 3106/4 3114/13 2895/6 2895/14 2901/12 2999/13 issue [22] 2891/20 2900/25 2901/9 June 23 [1] 3111/18 3000/16 3016/12 3017/17 3097/2 2916/3 2947/24 2948/7 2951/12 2952/2 June 25th [2] 2961/13 2961/20 3097/23 3098/3 3098/7 3098/8 3098/19 2952/4 2954/3 2973/6 2975/12 2976/15 June 29 [1] 3116/2 3110/5 3116/3 3116/6 3116/13 3116/17 2977/25 3013/25 3014/18 3022/14 June 30 [4] 2913/8 2913/12 2914/3 3125/4 3125/17 3030/22 3031/2 3044/8 3135/1 3135/10 3078/8 investigate [1] 2938/25 issued [2] 2902/2 2976/13 June 30th [2] 3064/6 3064/9 investigation [12] 2932/18 2947/8 issues [15] 2878/3 2953/24 2958/17 junior [2] 3027/1 3027/2 2948/2 2948/20 2952/16 2952/18 jurors [6] 2935/24 2937/2 2989/8 2960/25 2961/1 2971/1 2980/15 2952/25 2953/2 2986/5 2986/20 2980/20 2993/18 2994/14 3006/24 2990/3 3052/23 3054/4 2986/23 2986/25 jury [30] 2877/10 2878/7 2878/8 3007/2 3030/15 3082/25 3136/17 investigation's [1] 2987/5 issuing [2] 2924/16 2977/9 2882/12 2897/12 2900/9 2936/4 2937/1 investigators [1] 2973/13 Italy [3] 3029/13 3029/13 3029/15 2947/15 2954/1 2955/1 2972/11 investing [11] 2922/22 3096/15 item [8] 2912/7 2913/21 2916/11 2972/17 2977/2 2989/13 2990/2 3013/1 3097/25 3100/20 3104/6 3108/11 2919/8 2922/14 2933/24 3061/10 3031/3 3046/13 3048/22 3052/25 3109/6 3110/11 3110/24 3127/20 3062/16 3053/4 3054/3 3058/17 3089/17 3129/5 items [20] 2913/14 2915/25 2916/1 3101/13 3116/8 3133/15 3134/7 investment [57] 2879/15 2889/3 2916/1 2916/5 2916/8 2916/9 2916/18 3134/13 2890/25 2892/12 2892/17 2898/13 2919/13 2924/20 2924/21 2941/11 jury's [1] 3136/8 2898/15 2900/14 2900/19 2903/22 2942/1 2962/7 2962/17 2962/19 justice [1] 3056/25 2904/8 2930/8 2930/9 2930/19 2938/13 2962/21 2976/17 3057/5 3057/7 2939/2 2940/22 2956/1 2987/17 itself [2] 2978/23 3003/3 2987/19 2988/1 2997/18 2999/16 KAM [1] 2877/2 2999/18 2999/23 3069/13 3089/2 **KAPLAN [1]** 2877/21 3089/14 3098/19 3101/10 3101/17

jacket [1] 3005/11

JACOB [1] 2877/21

Jackson [3] 2885/4 2895/17 3088/18

3104/11 3104/16 3105/11 3107/18

3110/25 3113/12 3116/12 3116/20

3108/4 3108/7 3108/8 3108/15 3108/24

KARTHIK [1] 2877/16

KASULIS [8] 2877/15 2881/11 3013/6

3013/25 3018/22 3100/21 3140/3

latest [2] 3063/7,3063/23 latter [1] 2918/25 0 08/15/17 Kase 1:15-cr-00637-KAM Tie [1] 36 6/23 PageID #: 6672 Page Doc **KASULIS...** [1] 3140/4 law [4] 2924/4 2956/21 3054/20 lied [4] 2969/24 2971/5 2976/12 3013/1 Katten [5] 2923/18 2924/4 2985/17 3094/25 life [8] 3006/7 3006/12 3010/3 3010/9 3054/20 3084/25 3034/23 3035/6 3035/8 3036/17 laws [1] 2932/22 Katten's [1] 2957/8 life-threatening [1] 3036/17 lawsuit [8] 2949/20 2950/13 2955/14 keep [12] 2897/16 2933/25 2933/25 Ligand [3] 2912/8 2912/9 2912/10 2972/9 2973/7 2973/11 2976/7 2976/8 2956/4 2956/7 2962/12 3019/3 3052/19 lawyer [1] 3051/22 light [1] 3047/17 3106/20 3118/5 3123/10 3129/5 lawyers [1] 2990/14 lightly [1] 3015/1 keeping [5] 2962/17 2962/20 2977/10 likely [3] 3046/12 3046/12 3125/1 lay [3] 2951/13 2965/5 3116/9 3008/12 3118/9 layers [1] 2953/10 limine [1] 3101/22 Ken [17] 2919/10 2919/25 2929/10 laying [3] 2927/11 3039/15 3063/12 limited [19] 2975/3 3069/2 3069/4 2929/11 2934/2 2934/6 2934/16 3108/19 3109/18 3109/20 3109/22 layout [2] 2893/5 3039/22 3000/10 3000/12 3000/14 3000/14 lead [4] 2916/25 2917/2 2970/12 3120/23 3124/16 3133/11 3133/16 3058/25 3059/2 3059/20 3059/25 2984/16 3134/15 3135/14 3135/14 3137/2 3060/12 3062/18 leader [2] 2929/6 3008/19 3137/4 3137/5 3137/12 3137/23 kept [4] 2970/13 3068/25 3083/25 line [24] 2890/7 2890/9 2894/11 2911/7 leaders [1] 2994/21 3084/3 leadership [2] 2964/16 2994/20 2911/10 2911/17 2912/4 2913/12 Kevin [9] 3100/12 3105/21 3105/22 leading [4] 2879/9 2903/24 2931/12 2913/14 2913/21 2919/8 2919/13 3105/23 3111/16 3126/4 3126/14 2921/20 2922/14 2922/14 2935/16 2992/12 3127/6 3127/8 learn [2] 3000/19 3000/20 2950/15 2964/23 3002/9 3023/16 key [5] 2896/17 2896/18 2906/11 3024/6 3108/1 3122/16 3131/15 learned [6] 2948/1 2952/9 2953/20 3050/19 3105/2 2953/21 2967/12 3103/3 lines [2] 3006/10 3081/16 kick [2] 2899/20 2899/22 learning [2] 2951/15 3036/11 lingering [1] 3082/25 kickstart [1] 2985/12 least [7] 2923/9 2998/8 3031/13 liquid [7] 3097/12 3097/21 3098/12 kind [12] 2918/19 2974/4 2995/5 3051/19 3059/20 3062/19 3137/5 3098/13 3108/15 3126/25 3127/11 3002/23 3038/14 3040/2 3095/11 leave [6] 2936/1 2975/22 2981/11 liquidity [2] 3097/11 3109/10 3096/18 3105/10 3111/6 3121/20 2986/1 3007/9 3134/10 list [13] 2889/8 2891/10 2894/8 2894/19 3125/24 2896/18 2901/6 2916/5 2929/1 2929/1 leaving [1] 3021/4 kindly [1] 2882/22 led [5] 2972/15 2973/13 2976/6 3010/15 2940/25 2941/9 2969/19 2972/19 kinds [2] 3095/5 3135/8 3115/3 listed [15] 2913/9 2915/25 2919/10 KIYO [1] 2877/9 2921/21 2922/7 2925/21 2927/16 Lee [1] 2920/2 Klein [1] 2978/9 left [12] 2895/25 2955/24 2965/23 2929/10 2930/14 2932/9 2964/11 knowing [4] 2882/21 2900/18 2981/23 2966/17 2966/22 2986/2 2986/8 2987/8 3048/25 3055/1 3106/6 3106/15 3056/10 2993/23 3020/13 3028/16 3051/7 listen [1] 2977/14 knowledge [3] 2919/22 3086/21 3103/1 legacy [10] 3035/4 3035/9 3037/25 listener [1] 2951/15 known [3] 3042/10 3042/18 3103/12 3038/6 3038/9 3038/10 3038/12 listing [7] 2913/18 2925/19 2925/23 knows [3] 3136/9 3136/18 3136/21 3038/13 3038/15 3048/4 2932/8 2966/18 2966/19 2966/23 kosher [1] 3130/23 legal [10] 2886/4 2907/12 2911/23 lists [1] 2889/2 Kravitz [2] 2924/3 2924/12 2957/1 3063/11 3085/17 3086/3 3086/7 literally [2] 3001/8 3023/9 3134/4 3138/3 litigation [1] 2980/22 legend [1] 3068/19 live [1] 3093/25 label [1] 3009/11 Lehman [3] 3094/18 3094/19 3094/21 lived [1] 3094/4 labeled [3] 3007/3 3116/25 3127/22 lively [2] 3002/11 3002/11 lending [1] 3133/23 lacking [1] 2923/8 length [2] 3015/20 3017/15 lives [1] 3035/11 lacks [1] 2933/20 lengthy [1] 2893/22 living [1] 3004/19 Ladies [1] 3134/7 less [5] 2939/2 2954/6 3005/18 3046/15 LLC [6] 2889/9 3069/4 3069/4 3069/12 lag [3] 3130/18 3130/24 3130/25 3108/25 3069/14 3120/23 laid [4] 2900/20 2928/13 2931/20 **LLP[1]** 3073/3 lesson [2] 2891/13 2891/18 2955/13 **letter [21]** 2948/13 3011/19 3064/6 **LLP's [1]** 3064/5 landed [1] 2924/14 loan [10] 3133/21 3135/16 3135/17 3073/3 3074/1 3074/9 3074/9 3074/19 language [8] 2917/5 2917/16 2933/21 3081/19 3082/24 3105/11 3106/11 3136/21 3137/3 3137/10 3137/13 3104/24 3107/17 3107/24 3114/20 3111/7 3121/21 3122/22 3122/23 3137/17 3137/20 3138/19 3124/5 3124/7 3124/11 3127/1 3127/10 loans [5] 3114/22 3131/18 3133/3 large [7] 2902/19 2923/8 2994/6 letters [3] 3028/24 3031/22 3081/20 3134/2 3135/3 2994/17 3000/21 3008/20 3094/20 letting [6] 2885/7 2886/5 2891/13 local [1] 2995/14 largely [2] 2901/13 2994/13 located [3] 2956/20 2956/21 3107/21 2891/18 2892/1 2958/16 largest [2] 2995/12 2995/13 level [8] 2890/22 2934/1 2976/2 3000/8 location [1] 2926/12 last [23] 2892/12 2892/17 2893/16 3000/9 3000/9 3000/9 3008/3 locations [1] 2994/3 2894/11 2894/11 2894/14 2896/12 lock [3] 2972/8 2973/6 2973/15 leverage [1] 3046/21 2899/11 2902/15 2913/11 2944/7 lock-up [3] 2972/8 2973/6 2973/15 liabilities [6] 3065/11 3075/3 3076/18 2944/9 2944/17 2945/5 2987/22 2988/8 3076/20 3077/23 3108/22 locked [1] 2901/1 2988/10 2999/5 3018/2 3024/9 3095/11 liability [10] 3069/5 3075/19 3076/25 log [1] 2883/3 3108/23 3135/11 3077/5 3077/6 3077/7 3077/9 3080/18 long-term [2] 3111/21 3114/6 lastly [1] 3096/16 long/short [2] 3097/2 3097/4 3082/7 3120/23 late [11] 2892/5 2907/5 2916/4 2928/9 liable [1] 2900/1 longs [2] 3097/6 3097/7 2991/23 3000/23 3001/16 3001/16 license [4] 2912/3 2912/8 2912/10 Lonza [2] 3033/7 3033/10 3032/10 3046/6 3056/2

Case 1:15-cr-00637-KAM Docu look [54] 2881/4 2883/13 2886/2 2892/6 2892/9 2896/10 2896/14 2897/6 2900/8 2901/8 2901/22 2904/7 2906/1 2910/8 2911/1 2911/7 2911/15 2913/1 2915/5 2919/8 2922/14 2924/1 2927/15 2928/22 2929/1 2929/12 2929/13 2929/21 2942/1 2953/24 2957/22 2957/23 2958/6 2962/23 2973/22 2980/12 2981/4 2997/18 3008/21 3020/4 3035/19 3036/12 3050/2 3051/3 3051/6 3051/8 3051/9 3056/16 3061/5 3074/11 3104/23 3111/19 3117/13 3129/17

looked [9] 2898/6 2965/18 3005/21 3047/16 3072/8 3078/7 3104/22 3110/20 3125/16

looking [19] 2898/18 2898/22 2907/16 2921/15 3007/23 3020/16 3030/6 3038/6 3038/14 3059/6 3061/8 3065/6 3097/20 3105/1 3108/2 3108/14 3111/15 3121/6 3122/16

looks [1] 3126/25

lose [2] 2900/13 2982/11

losing [2] 2958/12 2967/8

loss [2] 2890/25 2895/7

losses [1] 2895/7 lost [1] 3098/9

Loup [3] 3003/21 3003/22 3003/23

love [5] 2902/24 3009/9 3011/8 3017/22 3018/1

loved [4] 3010/19 3010/22 3010/24 3011/2

lovely [2] 3024/13 3037/18

loving [4] 3009/14 3011/5 3011/5 3018/5

low [4] 2931/25 3095/4 3097/21 3108/6 lower [6] 2939/3 3026/1 3027/6 3027/15 3044/5 3044/6

LP [7] 3069/2 3069/15 3120/21 3124/12 3124/14 3124/19 3124/25

lunch [4] 2930/2 2934/7 2989/8 2989/14

lying [2] 2968/1 2991/18

Lynch [5] 2949/20 2950/12 2952/11 2955/14 3135/19

Madison [2] 3044/10 3044/13 magic [1] 3040/2 mail [85] 2880/1 2880/3 2880/11 2881/22 2882/12 2883/6 2883/10 2884/12 2884/13 2885/11 2885/14 2885/19 2885/21 2886/1 2886/14 2888/9 2888/10 2888/13 2889/6 2890/4 2890/7 2890/10 2890/18 2890/19 2892/7 2893/6 2893/17 2893/20 2893/22 2893/23 2897/1 2897/4 2898/22 2899/25 2900/6 2902/15 2903/8 2904/23 2909/22 2910/8 2910/9 2910/11 2910/13 2982/25 2983/13 2984/7 2988/10 2988/13 2988/14 2988/24 3021/7 3021/8 3022/11 3022/16 3022/22 3022/23 3023/4 3023/7 3023/13 3023/16 3023/24 3024/7 3024/9 3024/9 3024/22 3025/4 3025/19 3025/20 3027/11 3034/9

3050/25 3051/21 3090/4 3090/5 3090/173991/T33991/P63092/1 3092/16 3092/17 3106/3 3114/24

3117/13 3117/14 3117/20

mails [10] 2885/10 2886/10 2886/16 2893/18 2895/16 2903/16 2978/3 3024/20 3025/20 3030/11

main [5] 2927/13 2929/16 2934/4 3038/25 3127/9

maintain [1] 3048/15

major [4] 2890/8 2890/12 2944/23 2944/23

majority [1] 2966/24 male [1] 3011/6

man [5] 3013/1 3016/11 3018/4 3100/11 3102/1

management [24] 2889/3 2906/2 2906/7 2906/9 2926/5 2930/5 2930/8 2935/8 2942/23 2942/23 2957/3 2957/6 2994/6 2995/23 2996/10 3065/11 3069/4 3069/13 3074/7 3075/3 3111/21 3114/6 3135/7 3138/6

manager [5] 2978/10 3044/2 3101/9 3102/6 3104/5

managing [4] 2984/17 3069/12 3106/15 3135/5

Manhattan [4] 2926/10 2926/11 2956/21 3094/3

manner [4] 2962/9 2964/7 2968/20 2968/21

manslaughter [1] 2972/23 marc [32] 2877/20 2888/16 2888/19 2909/22 2914/13 2916/16 2921/3 2921/20 2923/6 2937/20 2938/6 2943/22 2960/24 2961/1 2963/11 2978/8 2990/13 3054/11 3054/17 3054/17 3055/16 3055/23 3056/23 3059/9 3061/16 3062/21 3062/24 3072/14 3075/15 3076/12 3080/5 3080/16

March [30] 2881/24 2882/10 2884/14 2888/13 2888/25 2891/24 2897/9 2916/13 2947/9 2948/18 2985/23 2986/2 2987/9 2988/12 3020/8 3024/12 3025/1 3025/4 3033/2 3033/4 3035/16 3035/22 3039/18 3043/15 3063/24 3080/23 3081/1 3090/5 3091/9 3091/9

March 13 [2] 2884/14 2888/13

March 14 [1] 2897/9

March 2010 [1] 3091/9

March 2015 [3] 2986/2 2987/9 2988/12 March 29 [3] 3020/8 3090/5 3091/9

March 31 [1] 2916/13

March 7 [4] 2882/10 3024/12 3025/1 3025/4

Marcum [9] 2916/23 2916/24 2917/8 2917/14 2922/11 3064/5 3073/3 3074/8 3074/18

Marek [17] 2892/15 2902/1 2902/6 2902/10 2902/12 2937/20 3003/10 3026/6 3026/21 3027/12 3028/5 3028/9 3028/11 3044/2 3045/1 3045/2 3050/18

Margaret [2] 2908/25 2979/24 mark [2] 2890/22 2906/22 marked [24] 2879/17 2881/16 2884/6 2892/25 2909/16 2915/2 2920/22 2923/11 2926/14 2937/14 2943/14

2945/18-2961/5-2979/4-2982/20-3091/5 3105/63106/193147/23115/103717/1

3121/17 3123/11 3125/22

Page

market [15] 2891/11 2896/16 2898/18 2904/8 2904/12 2947/1 2960/7 2968/17 2987/21 3032/24 3048/3 3050/9 3095/9 3098/4 3108/3

markets [2] 2905/24 3050/1

married [1] 3094/6 MARTIN [215] 2877/6 2879/9 2879/12 2880/1 2881/22 2883/17 2884/12 2891/22 2893/7 2894/4 2901/6 2906/10 2907/5 2907/15 2907/19 2908/2 2908/9 2910/17 2916/10 2917/7 2917/15 2918/2 2918/23 2919/2 2919/5 2925/9 2925/17 2927/23 2927/25 2928/8 2928/13 2928/18 2929/8 2931/13 2931/20 2932/1 2933/18 2933/20 2934/12 2934/12 2937/12 2937/19 2938/10 2940/8 2942/24 2945/4 2945/9 2945/25 2946/17 2946/23 2946/25 2947/16 2948/22 2951/12 2958/3 2958/5 2958/18 2959/1 2959/6 2959/21 2960/13 2960/23 2960/25 2961/10 2962/3 2964/6 2964/14 2964/22 2965/5 2965/19 2965/23 2966/2 2966/8 2966/10 2966/21 2968/23 2968/24 2969/3 2969/5 2969/15 2969/23 2970/7 2970/9 2970/13 2977/24 2978/1 2979/2 2982/3 2982/7 2982/25 2984/16 2984/17 2984/18 2985/4 2985/6 2987/4 2990/13 2990/19 2999/13 3000/4 3000/16 3001/3 3003/15 3007/1 3007/1 3007/3 3007/3 3007/13 3008/11 3008/17 3011/10 3011/18 3014/9 3014/10 3020/2 3020/10 3023/13 3025/5 3026/4 3026/23 3027/8 3027/16 3027/19 3028/8 3028/9 3028/22 3029/2 3029/3 3031/19 3032/2 3032/16 3033/11 3034/10 3035/14 3035/24 3037/25 3038/20 3039/13 3042/8 3042/25 3043/10 3043/16 3043/21 3043/23 3044/25 3045/3 3045/21 3045/24 3047/3 3047/5 3050/15 3050/19 3050/25 3054/18 3060/9 3060/12 3060/16 3060/18 3062/2 3062/25 3066/6 3069/1 3072/19 3073/9 3074/1 3075/16 3076/1 3076/10 3076/22 3077/21 3078/2 3080/7 3080/10 3080/11 3080/13 3080/15 3080/19 3080/20 3080/20 3080/23 3081/1 3081/2 3081/5 3081/10 3082/15 3082/22 3083/1 3083/5 3083/18 3083/20 3086/3 3086/7 3086/11 3086/11 3087/1 3087/6 3088/1 3088/6 3088/8 3089/4 3089/17 3089/24 3090/5 3090/7 3091/16 3095/13 3095/22 3095/24 3106/16 3120/24 3126/4 3126/14 3127/6 3128/18 3136/20 Martin's [8] 2897/2 2902/12 2927/10 2927/10 2941/16 2960/25 2970/10

2982/14

matches [2] 3126/17 3126/22 material [4] 2938/18 3101/4 3103/15 3124/24

materially [1] 3122/8 materials [2] 2924/16 2924/17 Mase 1:15-cr-00637-KAM Doci math [1] 2889/17 **MATSUMOTO** [1] 2877/9 matter [4] 2904/18 2951/19 3016/7 3016/12 3085/24 mattered [1] 3103/4 matters [2] 3103/1 3134/19 mays [1] 3064/5 mean [33] 2880/25 2891/19 2892/2 2898/12 2898/16 2902/7 2958/13 2964/9 3009/12 3011/4 3013/11 3017/1 3017/2 3018/25 3080/18 3095/2 3097/4 3097/13 3101/24 3102/17 3104/21 3107/25 3109/3 3109/25 3110/16 3114/20 3119/22 3120/15 3126/21 3129/11 3129/13 3130/23 3138/1 meaning [2] 2903/21 3064/4 meaningful [3] 3035/10 3037/20 3049/15 meaningfully [1] 2928/21 3134/19 means [4] 3108/3 3108/6 3109/4 3134/4 meant [12] 2905/22 2970/22 3015/8 3017/18 3045/8 3089/7 3097/5 3097/14 3108/1 3108/2 3108/5 3126/23 meantime [1] 2899/18 mechanical [1] 2877/24 mechanism [1] 3042/3 media [5] 2941/14 2942/12 2942/14 2974/20 3134/12 medical [8] 2906/14 2906/23 2922/21 2929/4 3039/16 3039/17 3041/3 3041/14 medically [2] 3020/14 3020/14 medication [2] 3007/4 3007/7 meet [12] 2926/4 2939/22 2940/7 2953/20 2953/22 2957/3 2965/11 2965/14 2970/3 2988/19 2994/19 2996/12 meeting [127] 2900/1 2903/15 2908/18 2908/20 2909/13 2910/24 2914/20 2914/25 2918/13 2921/11 2921/13 2921/18 2923/1 2924/9 2926/1 2926/3 2926/5 2926/7 2926/8 2926/9 2926/11 2926/21 2926/21 2927/13 2927/21 2928/6 2928/18 2928/24 2929/11 2929/16 2929/25 2930/1 2930/2 2932/1 2933/12 2933/21 2933/23 2934/2 2999/5 2934/4 2934/17 2934/19 2935/1 2935/7 2937/8 2937/12 2939/9 2939/20 2939/23 2939/24 2940/2 2940/16 2940/17 2940/18 2940/24 2941/8 2942/6 2942/21 2943/1 2943/7 2943/7 2943/10 2943/12 2944/22 2944/25 2945/4 2945/6 2945/8 2945/9 2945/10 2948/19 2953/14 2953/16 2956/18 2956/22 2956/23 2956/25 2957/11 2957/12 2957/15 2957/16 2957/18 2957/24 2957/25 2958/6 2958/9 2959/4 2959/14 2960/10 2967/4 2967/7

2967/13 2968/12 2968/24 2970/4

2977/13 2977/20 2977/21 2978/7

2978/9 2978/19 2978/21 2978/25

2984/25 2984/25 2985/2 2985/25

2999/13 3002/12 3005/23 3028/11

2970/6 2970/7 2970/8 2970/11 2972/10

2979/1 2979/8 2979/18 2980/8 2984/24

3054/14 3056/2 3056/2 3060/1 3072/25

3017/13,3018/4,3075/19 3079/22 3089/93089/12 3193/73 114/1674 3087/3-3087/5 meetings [16] -2908/42908/72908/189 millions [1] 3100/12 2908/11 2923/2 2927/12 2927/14 2927/22 2934/3 2994/19 2996/14 mind [3] 2904/9 3052/19 3054/2 2996/16 2996/18 3085/4 3085/7 mine [3] 3038/24 3065/4 3078/18 minimize [1] 3107/19 member [17] 2890/1 2890/2 2895/21 minimum [2] 2924/20 3081/23 2953/12 2953/14 2953/17 2967/25 minute [3] 2915/5 3105/19 3123/18 2968/17 2987/10 2987/17 2988/22 minutes [24] 2908/11 2908/14 2908/17 2991/22 3069/12 3077/3 3080/1 2908/17 2908/20 2908/23 2908/24 3081/12 3081/14 2909/3 2909/6 2924/14 2935/3 2935/20 members [14] 2878/8 2910/17 2921/24 2936/5 2959/11 2979/8 2979/9 2979/17 2925/7 2935/7 2943/21 2944/11 2956/8 2979/22 2979/25 3003/6 3051/10 2956/14 2963/2 2966/15 2977/2 3053/2 3085/9 3113/10 2996/12 3085/24 misappropriated [1] 3138/22 membrane [1] 3042/10 misappropriation [1] 3135/22 memo [2] 2963/6 3134/1 miscommunication [1] 2897/19 memorandum [11] 3104/16 3106/7 misrepresentation [1] 3100/7 3106/12 3106/25 3122/21 3123/5 missed [3] 2901/7 2938/14 3073/20 3123/14 3124/12 3133/13 3133/18 missing [5] 2889/18 3017/11 3039/4 3042/14 3042/17 memory [2] 2939/21 3013/16 mission [2] 3036/20 3037/6 men [1] 3016/11 misunderstanding [1] 2899/2 mention [3] 2974/18 3116/3 3116/17 misuse [1] 3138/5 mentioned [16] 2914/6 2919/3 2922/10 mix [3] 2993/18 2999/10 3001/20 2922/25 2923/5 2924/2 2939/19 2963/8 mixed [5] 2984/1 3001/20 3001/20 2974/18 2977/6 2981/18 2986/22 3001/20 3001/21 3006/18 3098/23 3102/14 3106/5 model [1] 2960/21 mentor [2] 3005/25 3010/1 models [1] 2995/6 mentoring [1] 2953/15 modern [1] 2941/19 merge [1] 3049/2 molecule [1] 3033/18 merger [7] 2879/13 2905/8 2905/22 molecules [4] 3033/12 3033/16 2905/23 3048/18 3048/20 3048/22 3033/17 3033/25 moment [8] 2890/23 2989/1 2989/7 merging [1] 2906/5 Merrill [5] 2949/19 2950/12 2952/11 3007/13 3016/25 3033/10 3052/11 2955/14 3135/19 3134/20 Monday [2] 2945/1 2970/5 messages [5] 2984/1 3006/6 3006/9 3010/24 3011/2 money [37] 2900/12 2914/9 2930/25 met [30] 2903/5 2934/24 2934/24 2931/2 2931/5 2931/6 2931/22 2939/10 2935/1 2937/12 2939/19 2945/10 2952/11 2953/25 2967/16 2995/13 2951/7 2955/4 2955/4 2977/21 2978/6 2999/18 3041/12 3045/16 3046/21 2978/8 2980/14 3000/4 3000/14 3001/3 3047/8 3048/8 3048/12 3066/6 3089/10 3002/17 3004/22 3027/18 3027/19 3098/3 3109/11 3115/5 3118/9 3121/8 3121/11 3133/21 3133/21 3133/23 3027/19 3027/22 3028/5 3028/7 3060/7 3086/24 3087/4 3088/4 3095/15 3133/24 3135/14 3135/18 3135/22 metrics [1] 2992/13 3136/3 3138/2 3138/2 monies [4] 2882/14 2903/13 2949/23 Mexico [4] 2998/10 2999/4 2999/5 3066/5 mic [1] 3097/8 month [24] 2909/14 2914/21 2914/22 2926/2 2956/18 2964/5 2965/7 3108/23 microphone [1] 3069/7 mid [3] 2906/17 2906/18 3001/16 3108/23 3117/22 3119/10 3119/13 Mid-to-late [1] 3001/16 3120/4 3120/7 3123/6 3128/2 3129/20 mid-year [2] 2906/17 2906/18 3130/4 3130/18 3130/24 3130/24 middle [5] 2909/2 2911/6 2946/20 3131/16 3131/16 3131/16 3117/13 3119/7 monthly [5] 3025/21 3108/22 3109/5 midmorning [1] 2935/23 3110/21 3110/21 might [19] 2885/2 2942/9 2947/22 months [9] 2890/21 2892/13 2892/17 2949/11 2957/9 2996/22 3008/19 2904/18 2962/6 3034/24 3060/23 3022/9 3022/20 3024/24 3025/1 3078/8 3094/17 3025/21 3041/11 3045/11 3050/2 morning [8] 2878/2 2878/8 2878/14 3052/23 3071/21 3079/1 3134/16 2878/15 2879/3 2879/4 2891/10 3134/9 most [7] 2924/20 2962/16 2962/19 million [33] 2883/12 2883/13 2883/21

2965/22 3046/12 3046/12 3125/1

motions [2] 3101/22 3102/8

motion [4] 2981/5 3034/14 3034/15

mostly [1] 2994/17

3102/25

2883/22 2883/23 2883/24 2883/25

2911/21 2911/24 2925/22 2938/18

2966/11 2987/23 2992/6 2992/8

2884/1 2896/6 2896/7 2896/15 2897/15

2898/6 2898/8 2898/8 2898/10 2898/23

3111/10 3115/18 3117/7 3121/24 3123/20 3126/5 moved [8] 2894/15 2903/13 2956/1 2967/5 3003/3 3008/2 3044/7 3077/14 movement [1] 3136/2 moves [16] 2880/5 2881/25 2884/15 2893/8 2909/25 2915/11 2921/5 2923/20 2927/1 2937/23 2943/25 2946/3 2961/14 2979/11 2983/5 3091/19 moving [8] 2895/23 2957/18 2963/12 2964/7 2964/8 2984/5 2984/7 3135/18 Mr. [189] 2879/3 2880/11 2880/12 2882/9 2882/11 2883/8 2885/9 2885/12 2885/18 2885/20 2885/20 2885/25 2886/16 2888/9 2888/11 2888/14 2888/22 2889/8 2890/5 2890/10 2890/19 2892/6 2893/2 2893/22 2893/25 2897/4 2897/8 2897/8 2898/22 2900/6 2901/8 2901/19 2901/20 2902/15 2907/7 2908/16 2909/7 2910/8 2910/9 2910/10 2910/10 2910/11 2913/21 2915/19 2918/14 2920/12 2920/14 2920/20 2922/6 2922/6 2923/14 2924/12 2927/16 2927/16 2927/17 2927/17 2927/17 2934/5 2934/15 2937/7 2938/5 2938/12 2939/6 2939/17 2939/20 2939/22 2940/13 2941/24 2942/4 2942/6 2942/20 2943/12 2944/12 2944/12 2945/12 2946/12 2947/13 2948/2 2948/25 2949/8 2951/11 2951/14 2951/21 2951/23 2952/3 2952/3 2952/8 2952/15 2952/23 2952/23 2952/24 2953/12 2953/13 2953/18 2953/19 2953/22 2953/23 2955/3 2955/4 2958/10 2959/14 2959/17 2959/22 2961/21 2963/7 2963/20 2965/16 2967/3 2968/5 2976/3 2977/6 2977/21 2978/3 2978/7 2980/7 2980/14 2980/15 2980/16 2980/17 2980/17 2980/20 2980/20 2980/21 2980/24 2981/2 2981/6 2981/10 2981/20 2983/11 2983/15 2983/23 2984/15 2985/1 2985/14 2990/4 2990/5 2990/11 2997/12 2997/15 3000/16 3015/20 3015/21 3017/8 3018/25 3020/2 3041/8 3072/19 3072/20 3072/20 3082/11 3082/17 3090/21 3091/8 3091/10 3092/4 3093/6 3093/23 3096/5 3096/6 3098/11 3102/12 3104/4 3105/8 3106/19 3107/5 3108/10 3111/15 3114/3 3115/23 3116/6 3116/11 3116/13 3119/7 3119/15 3120/2 3120/10 3122/5 3123/17 3123/25 3124/11 3126/11 3128/12 3130/12 3131/2 3134/22 3136/10 3137/1 3137/20 3138/11 Mr. Agnifilo [3] 2990/4 3082/17 3091/8 Mr. Aselage [8] 2922/6 2927/16 2959/22 2976/3 2977/21 2978/3

move [31] 2892/20 2896/6 2900/25

2903/17 2917/11 2917/22 2925/19

2925/19 2928/22 2964/21 2973/23

2974/11 3044/11 3050/13 3052/19

Mase 1:15-cr-00637-KAM_Doc 2894/14,2895/2-2903/11, 2903/22 <u> 2984/15</u> 3<u>0</u>72/19 Mr. Aselage s [2] ed 186125/10711 Page 2912/42912/6 5919/15-2917/10/5 Mr. Banta [3] 2934/5 2934/15 3000/16 2917/15 2918/1 2947/19 2947/20 2948/9 2949/4 2949/10 2949/13 Mr. Blanton [1] 2920/12 Mr. Brafman [4] 3015/20 3017/8 3018/25 3136/10 3066/6 3066/18 3079/1 3079/2 3099/8 Mr. Geller [26] 3093/23 3096/5 3098/11 3100/17 3102/4 3105/13 3107/8 3108/4 3104/4 3105/8 3106/19 3107/5 3108/10 3111/15 3114/3 3115/23 3116/11 3116/13 3119/7 3119/15 3120/2 3120/10 3122/5 3123/17 3123/25 3124/11 3126/11 3128/12 3130/12 3131/2 3134/22 Mr. Golding [1] 2927/16 Mr. Greebel [13] 2908/16 2909/7 2944/12 2949/8 2951/21 2952/3 2952/3 2952/8 2952/23 2953/23 2955/4 2958/10 3072/20 Mr. Greebel's [2] 2952/23 2985/14 Mr. Hackert [1] 3072/20 Mr. Kravitz [1] 2924/12 Mr. Panoff [4] 2910/10 2918/14 2927/17 2944/12 Mr. Panoff's [1] 2910/8 Mr. Richardson [32] 2879/3 2880/12 3135/12 2882/9 2885/18 2885/25 2888/9 2890/5 2893/2 2897/8 2900/6 2901/20 2913/21 2915/19 2923/14 2927/17 2937/7 2942/4 2953/12 2955/3 2977/6 2980/7 2980/14 2980/17 2980/20 2990/5 2990/11 2997/12 2997/15 3020/2 3114/17 3090/21 3091/10 3093/6 Mr. Rosenfeld [1] 2920/20 Muchin [1] 3084/25 Mr. Rosensaft [1] 2952/24 Mr. Shkreli [69] 2880/11 2882/11 3111/16 3126/4 3127/8 2885/12 2886/16 2888/11 2888/14 2889/8 2890/10 2890/19 2892/6 2893/22 2893/25 2897/4 2897/8

2898/22 2901/8 2901/19 2907/7 2910/10 2922/6 2927/17 2938/5 2938/12 2939/6 2939/17 2939/20 2939/22 2940/13 2941/24 2942/6 2942/20 2943/12 2946/12 2947/13 2948/2 2948/25 2951/11 2951/14 2951/23 2952/15 2953/13 2953/18 2953/22 2959/14 2959/17 2961/21 2963/7 2963/20 2967/3 2968/5 2978/7 2980/15 2980/17 2980/20 2980/21 2981/2 2981/6 2981/10 2983/11 2983/15 2985/1 3015/21 3082/11 3092/4 3096/6 3102/12 3116/6 3137/20 3138/11

Mr. Shkreli's [12] 2883/8 2888/22 2902/15 2945/12 2953/19 2965/16 2980/16 2980/24 2981/20 2983/23 3041/8 3137/1

Mr. Su [3] 2885/9 2885/20 2885/20 Mr. Yaffe [1] 2920/14

Ms. [8] 2881/11 2909/4 2944/10 2980/8 2980/9 3100/21 3130/9 3138/18

Ms. Kasulis [2] 2881/11 3100/21

Ms. Smith [1] 3138/18

Ms. Valeur-Jensen [3] 2909/4 2980/8 2980/9

Ms. Zellan [2] 2944/10 3130/9 **MSMB** [110] 2882/14 2882/21 2885/10 2889/3 2889/9 2890/25 2894/6 2894/9

2949/23 2952/12 2952/17 2952/21 2952/25 2953/1 2953/25 2956/12 2987/17 2988/1 2992/4 3021/19 3025/23 3043/8 3043/24 3044/2 3044/12 3044/25 3045/5 3066/5 3069/2 3069/2 3069/3 3069/3 3069/4 3069/5 3069/10 3069/12 3069/12 3069/13 3069/13 3069/14 3069/14 3069/15 3069/20 3075/1 3075/1 3075/4 3075/17 3076/22 3077/5 3077/21 3078/23 3080/7 3088/15 3089/2 3089/10 3089/11 3096/23 3096/24 3097/1 3097/17 3104/12 3105/25 3106/2 3106/14 3107/2 3111/20 3113/6 3114/5 3114/25 3115/3 3115/6 3115/17 3116/13 3118/9 3120/21 3121/5 3121/6 3121/7 3121/10 3121/13 3123/7 3124/11 3124/14 3124/19 3124/20 3124/21 3124/25 3125/1 3127/19 3129/2 3129/6 3131/17 3131/18 MSMB Capital [10] 2947/19 2947/20 3069/2 3069/2 3069/3 3069/4 3069/12 3069/15 3075/1 3124/21 MSMB Management [1] 3069/13 **MSMB's [4]** 3078/14 3114/13 3114/15 MSMB-affiliated [2] 3124/20 3125/1

much-needed [1] 3047/8

Mulleady [6] 3100/13 3105/21 3105/22

multi [2] 2964/16 2964/23

multi-product [2] 2964/16 2964/23

multinational [1] 2994/17 multiplier [1] 2895/18

muscle [2] 3042/11 3042/18

Muscular [7] 3036/21 3037/11 3039/1 3039/5 3042/14 3042/19 3049/16

must [5] 2958/19 2998/22 3070/22 3081/7 3090/13

mutual [1] 2999/10

Mykonos [2] 2998/19 2999/1

N-e-a-l [1] 2921/22 name [13] 2917/1 2920/8 2920/9 2990/13 2994/2 2994/25 3003/20 3011/22 3033/6 3043/7 3043/8 3093/17 3099/4

named [4] 2920/2 2920/6 2920/16 3095/13

narrowed [1] 2939/11 NASDAQ [12] 2925/19 2925/21 2925/23 2930/14 2932/8 2932/9 2932/10 2932/15 2964/11 2966/18 2966/23 2983/18

nasty [2] 3020/16 3049/11 **natural** [1] 3001/14 nature [3] 3001/1 3015/11 3016/17 **NAV [5]** 3117/16 3122/6 3128/13 3128/20 3128/21

NAVConsulting.net [1] 3117/15

3042/3,3098/19:3098/19,3099/14 ase 1:15-cr-00637-KAM Doci 3100/143700/183101/8/3102/4 3103/9 Neal [13] 2921/21 2921/22 2921/23 2921/25 2925/9 2944/18 2944/20 2966/3 2966/22 2968/24 2969/11 2984/15 3072/14 near [1] 2901/17 necessarily [1] 3008/21 necessary [1] 2935/19 nights [1] 3029/5 neck [9] 3020/13 3020/17 3020/19 nip [1] 2947/24 3021/3 3090/25 3092/6 3092/10 **nobody [1]** 3135/24 3092/15 3092/18 need [27] 2882/15 2891/6 2891/10 2896/21 2900/17 2900/25 2917/18 2923/9 2924/15 2931/20 2933/24 2938/24 2949/2 2968/8 2975/3 2980/22 2996/6 3014/13 3038/4 3052/23 3052/24 3064/3 3079/1 3081/3 3086/12 3100/8 3114/22 needed [21] 2905/25 2906/3 2916/15 2996/9 2916/20 2916/20 2926/23 2930/14 normally [1] 2898/19 2930/17 2934/12 2935/18 2949/2 2959/19 2960/19 2963/15 2964/6 2970/17 2978/11 3047/8 3081/14 3084/7 3109/10 needing [1] 2939/5 2943/12 2944/21 needs [5] 2896/19 2901/10 2957/6 3039/9 3104/9 negative [3] 2904/9 3102/6 3125/8 negatively [1] 2904/12 3082/23 3096/5 net [1] 2911/23 network [1] 3043/1 noted [1] 3102/15 neurological [1] 3049/12 neuroscience [1] 2929/6 neutral [4] 3101/11 3101/12 3102/7 3103/3 3085/6 neutralized [1] 3103/16 never [32] 2889/1 2889/21 2889/24 2899/3 2900/11 2900/18 2918/8 2919/18 2919/22 2919/23 2920/1 2999/12 3007/11 3017/12 3017/12 3018/3 3018/4 3066/10 3066/11 3071/9 3076/8 3080/13 3081/8 3082/10 3083/1 3102/3 3119/23 3119/23 3119/23 notices [1] 3122/10 3127/4 3127/4 3135/15 new [46] 2877/1 2877/4 2877/13 2877/14 2877/19 2877/19 2882/2 2895/25 2896/22 2898/18 2898/21 2908/25 2914/7 2914/13 2918/16 2918/20 2921/24 2924/14 2925/22 2928/3 2929/7 2935/7 2935/8 2958/25 2960/14 2960/17 2960/20 2964/22 2972/6 2977/10 2977/18 2978/9 2979/23 2980/10 2983/13 2985/9 2985/12 2986/22 2987/2 2991/6 2998/9 3044/7 3060/18 3080/5 3094/1 3124/13 news [9] 2891/1 2892/14 2896/4 2899/12 2928/2 2928/19 2968/18 2969/7 2981/20 next [57] 2881/4 2884/19 2887/12 2889/5 2896/10 2897/11 2898/2 2905/7 2911/1 2922/20 2926/24 2935/10 2948/12 2948/13 2950/19 2951/15 2954/11 2956/22 2956/23 2962/14

2965/15 2965/24 2971/14 2976/22

2977/25 2978/14 2980/12 2982/17

3038/23 3039/15 3040/8 3041/21

2984/8 3003/7 3012/19 3019/8 3036/15

3103/6 3103/19 3103/23 3109/13 3112/5 3113/24 3119/5 3119/25 3129/14 3129/25 3132/4 nice [3] 2878/20 3025/11 3093/7 night [6] 2901/10 2934/24 2934/25 2982/7 3000/18 3139/6 nominated [1] 2965/6 non [3] 2975/2 2999/7 3000/1 Non-public [1] 2975/2 non-real [2] 2999/7 3000/1 none [7] 2991/9 2991/12 2991/15 2991/18 3077/15 3083/17 3133/21 nonprofit [1] 2995/13 normal [4] 2958/7 2958/8 2978/23 north [3] 2883/11 2883/15 2896/15 Norwood [12] 2926/13 2933/12 2934/19 2939/9 2939/20 2939/22 2940/2 2940/18 2943/7 2943/10 note [13] 2912/3 2912/4 2912/6 2918/23 3075/16 3076/2 3076/22 3077/10 3079/16 3080/7 3081/11 notebooks [1] 3134/11 notes [13] 2917/15 2917/19 2917/20 2917/25 2918/1 2936/1 3061/6 3075/20 3076/6 3076/11 3081/20 3081/21 nothing [11] 2949/10 2950/5 2955/23 3048/3 3048/20 3052/3 3093/3 3095/6 3134/17 3135/2 3138/7 notice [10] 2928/8 2973/8 2973/9 3030/12 3098/6 3108/25 3109/5 3119/22 3120/15 3122/8 noticed [2] 3007/20 3030/11 notification [2] 3113/1 3133/3 notify [3] 2956/8 3133/20 3137/23 November [10] 2891/24 2921/12 2986/21 3050/22 3067/20 3072/10 3074/9 3074/18 3075/14 3120/3 November 30th [1] 3120/3 November 6 [1] 2921/12 November 8 [1] 3074/9 November 8th [2] 3074/18 3075/14 3123/16 number [46] 2880/11 2880/20 2890/3 2895/20 2899/13 2900/21 2901/13 2902/9 2903/17 2904/5 2913/9 2915/25 2916/5 2916/11 2919/8 2921/21 2922/14 2923/5 2926/22 2928/17 3123/16 2929/21 2930/22 2932/3 2932/16 2976/4 2977/9 2992/20 3009/6 3054/25 3055/1 3057/14 3061/10 3063/4 3064/23 3064/24 3067/13 3067/14 3067/25 3069/5 3072/22 3074/14 3086/24 3106/10 3107/14 3123/3 3124/8 numbered [1] 3124/4 numbers [4] 2882/11 2890/24 3058/18

3061/24 numerous [2] 3019/233084/2676 NYC [2] 2888/16 2888/17

oath [2] 2878/20 2990/7 object [11] 2886/19 2903/24 2928/12 2950/14 2971/10 2971/10 2986/6 2986/9 3014/6 3078/15 3113/15 objected [1] 3138/15 objecting [2] 2886/4 3016/14 objection [87] 2880/7 2881/9 2882/3 2885/3 2885/7 2885/20 2886/4 2886/10 2886/17 2886/20 2886/24 2888/3 2893/10 2910/2 2915/13 2921/7 2923/22 2927/3 2937/25 2944/2 2946/5 2951/1 2952/15 2961/16 2968/2 2968/3 2979/13 2983/7 2986/16 3010/17 3012/10 3012/13 3013/9 3021/25 3022/1 3023/11 3032/18 3033/13 3033/22 3037/2 3037/22 3039/10 3040/4 3062/4 3066/20 3071/4 3076/3 3081/25 3082/16 3082/19 3083/3 3083/9 3084/11 3086/5 3090/9 3091/21 3092/22 3099/6 3099/10 3101/13 3101/16 3101/19 3101/21 3102/8 3102/15 3102/17 3102/18 3103/2 3103/20 3105/15 3107/10 3111/11 3111/25 3112/1 3115/20 3116/5 3117/9 3122/1 3122/11 3123/22 3126/7 3131/21 3131/25 3133/2 3133/9 3138/16 3138/24

objectionable [1] 3014/6 objective [7] 3107/18 3108/14 3125/10 3126/16 3126/17 3126/22 3126/22 objectives [2] 3097/20 3125/13 obligation [7] 3065/12 3075/4 3102/22 3133/16 3133/20 3134/4 3137/22 obligations [2] 3065/18 3135/20 observation [1] 2942/20 observe [2] 2958/4 2959/1 obstacles [1] 3109/12 obtained [1] 2906/21 obviously [10] 2885/10 2886/11 2899/14 2963/12 3017/2 3026/15 3052/13 3072/4 3076/16 3137/21 occasion [1] 3009/21 occasionally [2] 3007/22 3024/8 occur [1] 2926/9

occurred [3] 2898/24 2957/13 2979/18 October [9] 2983/2 2983/14 2985/6 2986/21 3119/9 3120/5 3122/9 3123/9

October 13 [1] 2985/6 October 1st [2] 2983/2 2983/14 October 2011 [1] 3120/5 October 27th [1] 3119/9 October 28th [3] 3122/9 3123/9

October/November [1] 2986/21 odd [3] 3015/21 3015/23 3094/16 offense [2] 2972/25 3005/15 offenses [2] 2975/23 2977/3 offer [6] 3113/7 3113/8 3114/13 3114/15 3114/17 3136/4 offering [1] 2960/21

office [21] 2903/5 2918/15 2955/10

ease 1:15-cr-00637-KAM_Doc 3015/13 owner [1] 3049/1 ment 315 3Filed 08/15/17 Pag office... [18] 2970/10 3005/1 3007/19 opens [1] 2974/4 3026/9 3026/11 3026/13 3026/20 operate [1] 2942/24 **P.C** [1] 2877/18 3027/5 3027/16 3027/21 3044/5 3044/7 operating [11] 2883/22 2910/20 2913/1 p.m [7] 2989/14 2990/1 3020/8 3059/10 3044/8 3044/11 3044/13 3044/20 2913/5 2930/16 2931/23 3036/5 3049/3 3061/16 3090/5 3139/9 3087/4 3136/14 page [97] 2884/19 2887/12 2888/23 3049/13 3135/7 3138/7 officer [17] 2888/21 2906/14 2906/15 2888/23 2889/5 2889/10 2893/16 operations [2] 2959/20 3049/1 2906/20 2906/23 2909/23 2929/4 2893/21 2896/10 2897/7 2897/11 operative [1] 3138/3 2959/20 2980/16 2980/18 2981/2 2911/1 2912/13 2913/23 2922/12 opinion [1] 3136/4 2981/7 2981/15 2993/7 3065/9 3069/16 2929/13 2929/20 2929/20 2929/22 opportunities [1] 2960/15 3075/1 2932/17 2936/8 2944/9 2950/19 opportunity [3] 2979/25 3032/24 officers [4] 2932/9 2932/14 2933/6 2954/11 2962/16 2962/18 2970/23 3089/5 2971/8 2971/14 2976/22 2989/15 3012/19 opposed [1] 3052/11 offices [8] 2956/21 2957/8 2984/11 3019/8 3020/20 3035/20 3036/15 optimistic [1] 2898/7 2984/12 2984/20 2994/3 3025/23 3038/23 3040/8 3041/21 3042/3 3052/4 option [1] 2902/2 3026/12 options [6] 2889/1 2897/21 2900/22 3057/8 3057/11 3058/6 3058/13 3059/2 official [1] 3061/2 2907/17 2976/13 2999/17 3064/21 3065/3 3067/11 3067/12 offsite [2] 2926/3 2926/21 oranges [1] 3102/11 3067/13 3067/24 3067/25 3068/1 often [11] 3004/25 3008/23 3009/3 3068/13 3068/22 3070/1 3070/3 3070/6 order [1] 3069/17 3022/5 3024/10 3024/14 3029/8 3070/9 3070/12 3070/15 3074/8 orderly [1] 2964/21 3029/18 3030/12 3031/14 3086/3 3074/11 3074/14 3075/22 3082/6 Orex [2] 3116/4 3116/18 old [3] 3001/15 3093/23 3094/9 3082/7 3087/11 3099/14 3103/23 Orexigen [2] 3116/4 3116/18 older [1] 3008/16 3105/9 3106/9 3106/21 3107/14 organization [2] 2932/20 2960/19 Olives [2] 3004/7 3004/10 3107/15 3108/16 3109/13 3112/5 organizational [2] 2994/14 2995/6 onboard [3] 2914/14 2919/3 2923/6 organizations [2] 2994/17 2995/13 3113/24 3115/23 3117/24 3118/11 once [9] 2880/21 2930/21 2957/7 3119/12 3119/16 3120/6 3122/19 original [4] 2978/22 3061/16 3065/5 2970/16 3004/5 3009/16 3039/16 3123/2 3123/10 3128/4 3128/16 3126/23 3059/18 3085/8 originally [3] 3125/11 3125/11 3139/2 3129/22 3130/6 3130/11 3132/4 3140/2 one [124] 2882/2 2885/3 2885/3 2885/8 3140/9 3140/21 otherwise [4] 2886/17 2900/1 2953/21 2885/11 2888/3 2888/20 2890/13 page 1 [1] 3059/2 3133/12 2891/2 2895/11 2898/11 2898/13 page 2 [2] 3119/12 3129/22 ought [1] 2935/17 2898/16 2901/7 2903/19 2912/5 page 9 [2] 3064/21 3065/3 ourselves [3] 2906/6 2956/12 2964/19 2913/14 2914/14 2916/25 2919/13 pages [3] 3058/4 3124/3 3130/10 outcome [1] 3081/10 2920/8 2921/24 2923/17 2925/22 Outcomes [2] 2994/25 2995/3 paid [9] 2981/10 2991/21 2992/1 2927/22 2930/16 2933/15 2934/6 3065/18 3066/5 3083/1 3083/7 3121/8 outdoor [1] 3000/9 2937/13 2940/19 2941/11 2941/12 outline [1] 2901/24 3121/11 2942/1 2942/15 2942/15 2945/16 pained [1] 2902/20 outlined [1] 2980/22 2947/23 2948/7 2950/6 2952/10 outlining [2] 2894/1 3059/8 painlessly [1] 2897/18 2955/13 2955/16 2956/5 2957/18 outside [9] 2899/9 2956/21 2974/20 pains [1] 2901/25 2959/5 2960/19 2966/11 2967/7 2967/7 2993/13 2994/11 2995/16 3006/25 paired [1] 3026/13 2970/15 2970/18 2971/2 2971/9 Paley [6] 2922/19 2925/5 2925/10 3009/17 3138/10 2976/10 2977/8 2982/12 2985/12 2966/3 2966/4 3084/2 outstanding [1] 3114/10 2986/10 2989/1 2990/13 2992/12 Paley's [1] 2922/16 outweighs [1] 2954/5 2992/20 2993/6 2995/12 2995/13 Panoff [34] 2888/16 2888/19 2906/22 over-the-counter [2] 2905/24 3049/4 2995/22 2997/11 2997/12 3004/15 2909/22 2910/10 2914/13 2916/16 overall [7] 2882/25 2886/10 2886/24 3008/20 3009/21 3009/24 3010/6 2940/18 2996/21 2999/23 3082/14 2918/14 2921/3 2921/20 2923/6 3016/14 3016/25 3024/4 3025/21 2927/17 2937/20 2943/22 2944/12 overdue [2] 2889/2 2889/22 3026/24 3030/17 3031/8 3031/19 2960/24 2963/11 2978/8 3054/11 overlapped [1] 3004/20 3031/22 3032/5 3032/25 3033/18 3054/17 3054/17 3055/16 3055/23 overlooked [1] 2902/23 3035/13 3035/16 3038/4 3043/15 3059/9 3061/16 3061/24 3062/22 overrule [6] 2952/15 2968/3 2986/16 3045/14 3045/18 3045/20 3046/6 3062/24 3072/11 3072/14 3075/15 3022/1 3099/9 3138/23 3048/23 3049/12 3049/23 3052/13 overruled [5] 2903/25 2928/14 3090/10 3076/12 3078/2 3080/5 3055/3 3055/7 3057/24 3058/24 Panoff's [1] 2910/8 3092/23 3133/2 3060/14 3060/14 3065/7 3068/10 papers [1] 2891/2 **overseeing** [1] 2943/5 3068/11 3078/20 3082/6 3082/7 3083/1 paragraph [21] 2881/4 2897/12 oversight [5] 2924/19 2962/17 2962/20 3086/13 3086/17 3087/1 3088/8 2897/24 2898/2 2899/11 2962/2 2987/1 2987/5 3088/15 3090/1 3097/5 3098/7 3108/23 2962/14 2980/6 2980/12 2980/12 owe [1] 2897/17 3117/13 3128/17 3132/2 3134/20 2980/13 3075/7 3107/16 3108/17 owed [3] 2889/22 2897/25 2902/11 3135/10 3109/14 3111/20 3114/4 3114/5 own [25] 2892/22 2893/5 2904/3 one-on-one [1] 2967/7 3114/17 3120/9 3125/18 2922/21 2931/11 2949/25 2956/1 ones [7] 2904/10 2905/3 2916/10 2958/19 2958/21 2963/13 2987/24 paragraphs [2] 3111/19 3124/6 2941/1 2960/18 2991/1 3056/1 2994/24 3004/20 3004/22 3005/13 parallel [3] 3045/6 3045/9 3045/11 ongoing [2] 2989/11 3131/15 parameters [4] 2930/9 2930/19 2963/19 3013/5 3032/23 3046/19 3046/19 open [10] 2888/1 2900/25 2955/1 3061/6 3086/16 3086/16 3086/17 3124/18 2977/1 2990/1 3020/1 3042/1 3104/1 parens [1] 2938/18 3095/1 3126/15 3114/1 3123/10 parents [1] 3004/19 owned [2] 2889/13 3000/10 opened [4] 2951/11 3014/8 3015/6

Case 1:15-cr-00637-KAM 3047/12 3083/8 payment [3] 3575/9 3135/15/13735/139 phrased [2] 3007, \$2032/6 6678 part [64] 2883/6 2885/20 2897/19 peak [1] 3134/16 phrases [1] 3006/14 2897/20 2899/15 2900/3 2902/9 2906/8 penalties [2] 2899/20 2899/22 physical [4] 3030/6 3044/20 3044/21 2908/10 2916/3 2928/2 2930/14 2931/3 people [33] 2899/15 2914/1 2919/2 3089/24 2933/2 2951/9 2953/17 2958/18 2956/24 2957/9 2957/10 2959/4 physically [4] 3032/15 3032/20 3032/21 2958/22 2959/2 2965/2 2967/19 2970/8 2984/22 2992/22 2992/24 2993/3 3085/8 2978/9 2984/2 2985/6 2985/8 2986/25 2994/13 2995/6 3000/25 3001/2 pick [2] 3036/4 3096/1 2987/4 2993/8 2995/22 2995/22 3001/14 3001/18 3001/20 3001/21 picked [1] 3073/20 3008/14 3009/15 3016/4 3029/21 3002/2 3009/20 3009/24 3010/6 picking [1] 3076/17 3031/22 3038/9 3038/10 3038/11 picture [3] 2882/25 2882/25 2891/22 3015/13 3015/21 3017/15 3017/25 3038/13 3038/14 3047/16 3055/18 piece [4] 2883/25 2884/1 3012/8 3018/6 3043/18 3046/15 3046/19 3056/22 3057/12 3064/12 3065/6 3046/19 3059/7 3050/20 3069/24 3069/25 3070/20 3070/25 people's [1] 3035/11 pieces [1] 2995/3 3071/7 3081/7 3083/20 3095/12 per [4] 2892/5 2895/16 2897/1 3114/10 Pierotti [1] 2896/3 3097/15 3109/10 3122/11 3124/9 pink [1] 3096/4 percent [15] 2883/11 2883/15 2883/18 3124/11 3128/9 3135/18 3135/21 pipe [6] 2898/14 2898/15 2898/19 2883/24 2890/15 2896/6 2897/14 3000/1 3000/3 3000/3 3098/9 3114/12 2898/23 2911/20 2911/21 part-time [1] 3095/12 3135/6 3135/7 3138/6 pipeline [2] 2933/16 3038/25 participate [4] 2906/13 2915/22 2934/2 perception [3] 2898/4 2964/1 2968/4 pipes [3] 2898/13 2898/17 3098/8 3136/16 perceptions [1] 3015/20 pitch [1] 3100/7 participated [3] 2933/11 2934/4 2985/1 Perfect [1] 2913/4 pitching [1] 3102/21 participating [1] 2934/21 perfectly [1] 2973/14 **PKAN [7]** 3049/7 3049/8 3049/9 participation [2] 2912/8 2933/14 3049/11 3049/23 3050/20 **perform [1]** 3101/15 particular [15] 2930/20 2941/16 performance [35] 2894/13 2894/14 place [11] 2930/15 2931/21 2938/21 2944/18 2996/22 2996/23 2997/9 2942/10 2945/24 2946/9 2946/25 2962/21 2967/15 2967/20 3004/7 3006/13 3038/16 3048/23 3050/20 2980/16 2980/24 2994/23 2995/7 3004/11 3016/22 3127/16 3127/17 3072/9 3073/25 3095/5 3095/6 3102/19 3011/15 3011/17 3015/17 3017/18 placement [12] 3104/16 3106/7 particularly [9] 2914/13 2923/6 2963/9 3021/17 3021/22 3022/17 3022/24 3106/11 3106/25 3122/21 3123/5 3005/14 3005/23 3006/3 3006/18 3023/2 3023/8 3023/13 3023/24 3024/2 3123/14 3124/12 3133/13 3133/18 3024/14 3049/11 3024/5 3024/11 3024/16 3025/7 3134/1 3134/18 parties [5] 3001/2 3069/11 3069/17 3025/18 3102/5 3116/21 3131/2 3131/7 places [1] 3009/3 3075/2 3112/4 3131/12 3131/16 3135/8 **Plaintiff [1]** 2877/4 partner [23] 2952/24 2998/15 2998/16 performed [6] 3100/19 3101/8 3103/10 plan [11] 2905/19 2910/20 2946/17 3000/14 3069/14 3069/15 3084/25 3103/12 3104/5 3105/24 2969/7 2969/14 2969/19 2969/20 3106/15 3108/21 3109/1 3109/18 perhaps [3] 2889/22 2900/24 2994/20 2977/23 2984/14 3028/25 3039/22 3109/19 3133/11 3133/11 3133/16 period [32] 2879/6 2879/7 2879/7 plane [2] 2962/4 2965/9 3133/17 3133/18 3133/24 3134/15 2879/11 2881/2 2881/13 2884/2 2890/1 planned [2] 2978/21 3125/11 3134/16 3136/14 3137/23 3138/11 2903/11 2903/12 2905/8 2909/13 planner [1] 2999/20 partner's [2] 3109/20 3109/22 2914/19 2914/23 2925/1 2926/1 planning [4] 2962/12 2975/13 2977/24 partners [7] 3108/19 3135/14 3135/15 2945/13 2951/18 2972/8 2978/20 2993/16 3137/3 3137/4 3137/5 3137/13 2985/4 2985/15 2992/3 2993/2 2993/4 plans [3] 2994/22 3001/13 3039/13 partners' [1] 3135/4 2998/24 2998/25 3003/10 3004/1 platonic [2] 3009/18 3018/9 partnership [9] 3069/3 3108/22 3034/16 3035/13 3091/10 play [2] 2907/1 2969/16 3108/24 3109/14 3109/19 3134/18 periodic [3] 3021/17 3021/22 3028/24 played [1] 3043/19 3135/4 3137/23 3138/1 periods [2] 2949/3 2987/12 players [1] 3050/19 partnership's [2] 3107/18 3109/17 permission [2] 2997/14 3137/2 playing [1] 2970/14 partnerships [2] 3124/16 3125/1 permitted [2] 3138/11 3138/23 Plaza [1] 2877/14 parts [1] 2926/25 person [14] 2899/18 2903/6 2949/15 pleased [1] 2988/14 party [12] 2940/2 3000/4 3000/22 2992/20 3005/14 3009/22 3009/23 pleasure [1] 3029/10 3002/3 3060/14 3065/10 3065/10 3010/13 3060/24 3095/15 3096/8 Plotkin [5] 2906/25 2929/2 2929/3 3065/12 3065/15 3065/16 3083/11 3102/19 3127/14 3136/17 2933/10 2940/21 3083/14 personal [23] 2904/11 2935/11 2995/22 plus [2] 3080/18 3082/8 pass [2] 3031/15 3031/20 3023/4 3024/6 3024/9 3024/21 3024/22 point [109] 2890/3 2891/20 2891/25 passing [2] 2904/5 3000/13 3080/24 3081/2 3081/5 3126/15 2892/4 2894/5 2894/18 2895/1 2896/11 passionate [1] 3035/3 3126/17 3126/22 3131/18 3133/3 2896/21 2897/24 2905/1 2905/13 past [4] 3062/6 3086/12 3110/5 3133/24 3134/2 3135/3 3137/3 3137/10 2905/15 2907/3 2907/21 2908/1 2908/5 3126/18 2914/5 2916/23 2924/23 2925/3 3137/17 3138/19 patent [4] 3049/6 3050/7 3050/8 2925/12 2925/16 2929/1 2930/9 personally [2] 2901/12 3035/3 3050/16 perspective [6] 3005/21 3008/11 2930/12 2941/1 2941/13 2942/1 2947/7 patented [2] 3049/19 3050/11 3037/12 3037/24 3043/18 3047/13 2949/9 2951/20 2952/10 2953/2 path [2] 2898/3 3015/9 2957/19 2958/3 2958/5 2959/10 pharmaceutical [1] 3031/13 patient [1] 2962/11 phase [2] 2896/15 3011/24 2959/23 2963/13 2964/5 2964/25 patients [2] 3042/15 3050/10 phone [11] 2877/22 2880/20 2996/16 2965/4 2965/15 2966/1 2966/2 2966/16 pay [5] 2967/15 2992/7 3080/20 3083/5 3022/25 3056/9 3056/9 3096/8 3096/9 2968/11 2970/1 2977/18 2983/24 3135/19 3116/7 3127/14 3127/15 2984/14 2984/21 2985/6 2985/10 payable [2] 2912/4 2912/6 phrase [4] 3006/3 3006/13 3010/5 2985/16 2988/20 2993/6 2993/14 paying [4] 2912/11 3082/5 3083/6

se 1:15-cr-00637-KAM Doc point... [50] 3004/5 3007/22 3017/11 3024/23 3025/23 3029/12 3030/1 3030/17 3032/5 3032/25 3035/16 3036/22 3037/4 3039/23 3043/14 3043/21 3044/9 3045/18 3045/20 3048/2 3056/15 3056/19 3061/1 3062/8 3085/4 3066/2 3073/23 3075/18 3077/2 3077/9 3077/11 3077/24 3079/16 3080/5 3080/14 3083/1 3083/7 3087/1 3087/1 3088/8 3090/1 3090/16 3096/1 3120/17 3121/7 3121/10 3125/19 3127/18 3128/19 3129/1 3129/4 points [3] 2895/11 2896/12 2950/6 **policies [1]** 2930/15 policy [4] 2930/8 2930/9 2930/19 3113/2 2931/21 pool [2] 2977/11 2977/12 poor [1] 3050/3 poorly [5] 3100/19 3101/9 3103/10 3103/12 3104/5 pop [1] 2885/22 portfolio [8] 2895/20 2938/22 2939/4 2993/19 2999/11 3044/2 3107/19 portion [6] 2889/10 2999/22 3098/3 3098/14 3124/24 3127/13 position [20] 2885/4 2885/17 2886/15 2888/21 2905/10 2906/14 2906/15 2906/20 2906/21 2906/23 2910/20 2964/25 2966/5 2967/3 2980/19 3027/2 3038/8 3038/22 3097/5 3121/14 positions [5] 2906/11 2906/16 3110/19 3110/20 3110/20 positive [2] 3006/5 3102/6 positively [2] 3031/18 3050/3 possibility [1] 3050/3 possible [5] 2962/22 3051/11 3051/25 3056/17 3056/20 possibly [1] 3022/18 post [3] 2889/14 2897/14 2897/15 posture [1] 2983/23 potential [7] 2891/2 2939/12 2960/15 2964/12 2966/10 3034/1 3038/17 potentially [5] 2956/24 2960/17 2964/12 3046/20 3048/6 Powe [1] 3000/10 **PPM [4]** 3122/9 3122/12 3135/3 3138/10 PPMs [2] 3102/15 3102/16 praiseworthy [1] 3006/8 precise [1] 2904/17 preclinical [1] 3039/1 predated [1] 3060/11 3104/2 predict [1] 3031/16 predicting [1] 3031/20 **preexisting [1]** 3046/15 **preference [3]** 3015/14 3016/5 3016/10 preferential [1] 2891/4 preferred [5] 2882/19 2894/17 2894/23 2895/15 3031/24 prejudice [2] 2954/3 2954/5 prejudicial [6] 2951/2 2951/7 2952/15 2954/6 2954/6 2972/24 premium [1] 3114/12 processing [1] 2957/1 preparation [3] 3085/24 3088/11 produced [2] 2877/24 2952/22 3109/21

prepare [1] 2964/18 brepared [3] 29/6/3 29/4/2/12379/239 preparing [2] 2929/18 2969/22 preponderance [1] 2953/6 presence [1] 3110/10 present [9] 2878/9 2882/15 2934/18 2937/2 2955/1 2959/17 3010/9 3054/4 presentation [8] 2888/15 3035/22 3036/10 3038/20 3039/15 3041/1 3041/6 3043/10 presently [2] 2932/18 3069/19 president [10] 2957/20 2959/20 2959/23 2959/25 2960/3 2964/12 2966/21 2992/19 2992/21 3069/16 press [4] 2942/8 2942/15 2977/23 pressing [1] 3102/18 pressure [1] 2881/7 **Presumably [1]** 2887/2 presumes [1] 3133/10 pretensions [1] 3026/17 pretty [10] 2903/9 2918/18 2933/21 3082/23 2949/17 3004/7 3095/3 3099/3 3108/1 3110/2 3119/1 previous [3] 2928/3 3060/11 3100/19 previously [7] 2878/17 2922/3 2969/1 2970/18 3000/17 3006/1 3100/3 price [7] 2889/15 2891/6 2896/16 2898/20 2987/22 3031/11 3114/12 pricing [4] 2891/3 2891/4 2891/11 2896/20 primarily [2] 3097/3 3107/20 primary [3] 2990/18 3065/12 3075/4 principal [1] 2941/1 principled [1] 2974/7 print [5] 3119/15 3119/18 3119/20 3120/13 3120/20 printed [1] 2885/22 printing [1] 2885/10 priorities [1] 2914/14 private [27] 2882/22 2895/15 2898/15 2958/23 2958/23 2973/12 3104/16 3106/7 3106/11 3106/25 3122/21 3123/5 3123/14 3124/12 3124/16 3124/25 3125/2 3125/17 3125/17 3126/19 3127/9 3127/11 3127/12 3133/13 3133/17 3134/1 3134/18 probative [1] 2954/4 problem [3] 2903/11 2955/25 3042/19 problems [5] 2955/17 2986/24 2994/21 3006/24 3045/14 proceed [9] 2878/23 2899/11 2939/14 2969/2 2969/13 3054/6 3057/6 3093/19 proceeded [4] 2900/13 2939/17 2952/25 2953/2 proceeding [1] 2928/4 **Proceedings [2]** 2877/24 3139/9 proceeds [2] 2911/16 2912/1 process [9] 2906/8 2910/19 3031/17 3031/21 3033/21 3033/24 3033/25 3041/16 3135/18 processed [1] 3079/15 processes [1] 2951/10

product [4] 2964/16 2964/23 3041/15 3056/12 297 PageID #: 6679 productive [1] 2944/17 products [1] 3120/24 professional [2] 3006/11 3094/14 **proffer [3]** 2950/17 2986/13 3112/3 profile [3] 2941/18 2999/10 3084/6 profit [2] 2992/7 3046/18 profitable [2] 3048/12 3125/3 program [2] 2938/13 2938/18 programs [1] 2996/1 progress [1] 3033/5 progressed [1] 2906/3 progressive [1] 2964/7 project [1] 2996/22 promise [2] 3052/3 3052/4 promised [1] 3059/2 promissory [19] 2917/15 2917/19 2917/20 2917/25 2918/1 2918/23 3075/16 3075/20 3076/2 3076/6 3076/11 3076/22 3077/10 3079/15 3080/7 3081/11 3081/19 3081/21 prompted [1] 2963/6 prompting [1] 2965/21 **proof [1]** 3135/21 properly [1] 3102/14 properties [1] 2998/10 property [5] 2998/9 2998/10 2998/12 2998/15 2998/18 proposal [5] 2940/23 3046/24 3111/23 3114/8 3114/11 propose [1] 2886/14 proposing [1] 3103/19 proprietary [1] 2886/10 prospective [1] 3100/8 protect [2] 2968/21 2968/21 protected [1] 2969/21 protein [3] 3039/4 3039/6 3039/9 proud [1] 2982/11 prove [3] 2969/15 3013/2 3013/3 proved [1] 2898/7 provide [2] 2994/18 3085/17 **provides [1]** 3042/11 providing [2] 3036/8 3039/5 provision [1] 3073/19 provisions [2] 3114/15 3135/6 public [25] 2891/3 2891/4 2891/5 2898/15 2905/9 2905/18 2941/20 2942/19 2957/7 2960/24 2974/19 2975/2 3063/20 3070/17 3070/21 3070/22 3071/7 3071/12 3071/19 3076/20 3109/17 3109/24 3110/3 3111/1 3115/5 publicly [10] 2931/23 2957/2 2957/6 2981/25 2988/11 3063/14 3063/15 3071/3 3072/2 3072/5 publicly-filed [1] 3072/2 publicly-traded [2] 2931/23 2957/2 pull [4] 2894/2 3016/4 3068/20 3081/20 pulling [2] 2985/16 2985/17 punch [1] 2969/19 punitive [1] 2901/11 purchase [2] 2883/5 3115/5 purchased [3] 2882/18 2883/7 2987/25 purchases [1] 2882/16 purportedly [1] 2952/12

2955/14 2958/17 2967/6/2967/19 13680/13 3680/16 ed 08/15/17 recalled [1] 3079/10 receipts [1] 2880/12 ID #: 6680 Case 1:15-cr-00637-KAM purpose [2] 2964/2 2986/14 raising [5] 2953/24 2958/17 2960/25 receive [32] 2880/8 2880/21 2882/4 purposes [6] 2917/22 2953/8 3033/25 2885/21 2893/11 2908/17 2908/20 2961/1 3034/2 3052/5 3133/23 3133/24 2909/6 2910/3 2915/14 2921/8 2923/23 ramifications [1] 2948/8 purview [1] 2974/9 2927/4 2938/1 2961/17 2978/3 2979/14 Rao [1] 2929/5 push [3] 3048/16 3097/8 3097/9 rapidly [2] 2914/9 2914/12 2983/8 3036/21 3091/22 3104/11 pushing [2] 2890/22 2899/4 rare [1] 3036/17 3105/16 3107/11 3111/8 3111/12 put [41] 2885/7 2914/19 2922/24 rash [3] 3020/16 3021/3 3021/8 3115/21 3116/20 3116/23 3117/10 2926/22 2928/17 2930/15 2931/21 rate [5] 2894/17 2894/23 2895/15 3121/22 3122/2 3126/8 2947/6 2962/21 2962/25 2963/1 2898/5 2898/20 received [42] 2880/9 2882/6 2885/19 2967/15 2967/20 2972/7 2974/7 rather [7] 2895/8 2916/4 2919/5 2893/13 2895/25 2908/24 2909/3 2981/10 2985/5 2997/24 2999/18 2928/16 2933/18 2933/19 3134/8 2909/4 2910/5 2915/17 2921/9 2921/21 3002/23 3009/5 3014/13 3026/9 2923/24 2927/5 2938/3 2944/3 2944/4 **RBC [1]** 3101/23 3028/13 3034/14 3034/15 3054/13 **RE [4]** 3038/25 3039/4 3042/17 3049/20 2946/6 2946/7 2961/18 2979/15 2983/9 3056/17 3056/20 3065/3 3067/5 3068/2 **RE-001 [3]** 3038/25 3039/4 3042/17 2987/15 3021/17 3024/10 3056/11 3068/3 3078/20 3089/10 3089/11 3059/18 3061/1 3066/21 3066/22 **RE-024 [1]** 3049/20 3126/15 3130/9 3136/21 3138/2 reached [2] 3049/25 3077/20 3071/9 3091/24 3105/17 3107/12 3138/20 reaching [2] 2991/19 3043/20 3111/13 3115/22 3117/11 3122/3 putting [12] 2886/19 2928/18 2933/9 reacted [2] 2942/21 2982/16 3123/23 3123/24 3125/19 3126/9 2942/18 2945/16 2963/6 3005/16 reaction [15] 2889/23 2928/11 2928/12 receiving [4] 2895/8 3056/24 3082/10 3005/18 3041/12 3046/21 3113/14 2948/4 2949/16 2955/20 2958/4 2959/2 3125/6 3137/1 2967/22 2977/13 2982/14 2984/3 recent [4] 2882/16 2962/6 2999/5 3125/6 3125/8 3130/21 3015/25 reacts [1] 2968/17 recently [2] 2898/24 2909/22 Q1 [1] 2911/16 read [50] 2882/12 2890/18 2892/10 recess [2] 2936/7 2989/14 qualified [1] 3042/24 2892/11 2896/13 2896/17 2897/11 recipient [1] 2921/20 qualifier [2] 2997/24 3008/14 2898/2 2900/8 2901/23 2913/23 2962/2 reciprocated [1] 3006/9 qualities [2] 3036/3 3036/3 2980/13 2997/19 3020/8 3032/17 recognition [5] 2890/1 2895/21 2899/3 quarreling [1] 3135/25 3041/5 3047/17 3055/25 3056/6 3056/7 2946/24 3077/10 quarter [15] 2912/5 2913/2 2913/2 3056/7 3056/12 3056/18 3056/21 recognize [20] 2879/23 2881/19 2884/9 2913/6 2913/6 2913/6 2913/8 2913/14 3059/11 3065/6 3065/7 3067/6 3067/8 2893/2 2909/19 2911/2 2915/6 2920/25 2913/18 2916/12 2936/6 3064/6 3064/9 3068/1 3068/24 3069/25 3070/4 3070/7 2923/14 2926/17 2932/4 2937/16 3065/8 3074/25 3070/9 3070/12 3071/6 3071/6 3071/17 2943/18 2945/21 2961/7 2979/7 quarterly [6] 2996/14 2996/15 3011/19 2982/22 3091/12 3111/4 3117/2 3071/18 3071/21 3071/24 3072/1 3029/1 3064/3 3064/4 3072/2 3072/7 3074/23 3074/24 recognized [2] 2900/16 2913/24 questioned [1] 3138/15 3104/22 3119/24 recognizing [1] 2914/9 questionnaire [6] 2932/10 2932/11 reading [5] 3039/23 3075/13 3090/6 recollection [20] 2914/15 2914/17 2932/14 2933/2 3104/18 3106/8 3114/3 3115/3 2941/5 2942/4 2942/5 2997/8 2997/16 questionnaires [1] 2930/7 reads [3] 2880/18 2980/7 3124/11 3013/8 3013/10 3013/14 3014/3 questions [17] 2947/22 2989/2 2990/14 ready [8] 2928/4 2941/9 2959/8 3020/12 3021/11 3021/14 3025/4 3013/6 3014/1 3024/23 3025/21 3036/1 2966/12 2969/4 2969/14 2989/3 3057/3 3033/10 3072/6 3072/8 3087/5 3087/6 3041/14 3061/6 3086/7 3090/15 reaffirmed [1] 2896/5 recombinant [1] 3039/5 3092/12 3100/16 3103/15 3103/16 reaffirming [2] 2939/13 2940/22 recommendation [1] 2901/2 3133/8 real [5] 2998/2 2998/5 2999/7 3000/1 reconcile [1] 3027/18 quick [3] 2928/20 3048/22 3099/11 3044/19 reconciliation [3] 2882/14 2891/15 quicker [1] 3066/25 realize [1] 2963/22 2893/5 quickly [4] 2904/8 2947/25 3005/25 reconciling [1] 2897/3 realized [1] 3035/5 3131/10 reconfirming [1] 3082/23 really [27] 2891/22 2906/1 2925/20 quite [20] 2917/7 2933/22 2943/4 2926/3 2939/8 2958/14 2958/15 record [16] 2882/19 2891/8 2891/16 2944/17 2959/13 2960/24 2964/10 2959/15 2960/5 2964/6 2964/16 2953/7 3014/14 3015/6 3057/13 3068/7 2977/9 2982/5 2982/6 3002/8 3005/4 2975/11 2988/20 2993/4 2995/23 3068/17 3074/12 3098/11 3102/20 3005/6 3008/23 3022/5 3024/10 3014/10 3035/1 3037/24 3043/16 3102/22 3104/10 3138/13 3139/1 3024/14 3026/11 3029/17 3046/20 3049/14 3061/7 3074/4 3088/15 recorded [2] 2877/24 2908/12 quoting [2] 3013/20 3013/22 3114/22 3119/24 3120/19 3126/24 recordkeeping [1] 3081/24 reason [9] 2886/4 2901/16 2958/22 records [1] 3136/22 2972/23 2976/4 3017/14 3036/25 recoup [1] 3098/20 R0001 [1] 3042/3 3080/15 3122/12 **RECROSS [1]** 3092/13 **R011939 [1]** 3115/23 reasons [14] 2972/5 2972/9 2972/21 RECROSS-EXAMINATION [1] 3092/13 **R013294 [1]** 3117/24 2974/7 2974/8 2976/9 2983/19 2990/18 recruit [1] 2963/15 **R036371 [1]** 3106/10 2990/19 2991/9 2991/12 2991/15 recruitment [1] 2993/15 **R036372 [1]** 3107/15 3083/18 3135/10 redeem [2] 3125/20 3127/3 **R036381 [1]** 3108/16 reassurance [3] 2948/6 2981/24 redeemed [3] 3028/10 3028/11 3127/4 **R036382 [1]** 3109/13 2982/10 redemption [3] 3124/18 3125/5 raise [7] 2914/8 2967/18 3045/16 reassurances [2] 3081/14 3082/22 3126/15

reassuring [1] 2923/6

rebuttal [2] 2974/1 2974/2

redirect [3] 3090/17 3090/19 3093/4

redo [1] 2928/20

3045/24 3048/17 3061/7 3080/15

2898/9 2898/23 2911/16 2955/12

raised [13] 2891/20 2891/21 2898/7

3016417, 3216/22, 3017/2, 3017/5, 3017/6 3016417, 3216/22, 3017/2, 3017/6 request [2] 2880/20 2953/19 requests [1] 2953/3 e1D #. 6681 Case 1:15-cr-00637-KAM Docu 3017/18 3017/23 3017/24 3018/1 reducing [1] 2904/11 3018/6 3018/10 3028/10 3089/24 require [1] 3122/10 reelection [1] 2985/25 release [8] 2977/24 3056/5 3057/9 required [4] 2916/19 2917/20 2924/21 refer [5] 2883/20 2941/4 2962/24 3068/23 3068/24 3069/19 3071/7 3098/6 3006/6 3086/7 3113/2 requirement [7] 2883/3 2932/8 2932/15 reference [22] 2898/10 2911/17 released [1] 2942/12 2957/1 2983/20 3063/11 3131/22 2912/11 2938/14 2942/16 2965/8 releases [3] 2942/8 2942/15 2975/21 requirements [5] 2925/23 2949/12 3011/20 3045/11 3058/2 3081/4 releasing [1] 2942/14 2966/18 2966/19 2966/23 3081/10 3090/25 3091/9 3092/9 3092/9 releasor [2] 3069/1 3069/6 research [9] 2960/8 2992/17 3032/7 3092/15 3100/24 3101/23 3103/6 releasors [1] 3069/10 3032/8 3032/11 3032/12 3032/14 3109/24 3119/18 3120/10 relevance [3] 2951/2 2951/3 3113/5 3032/23 3043/2 referenced [5] 2911/19 2950/6 2950/7 relevancy [1] 2986/13 reserves [1] 3108/21 2950/9 2955/17 relevant [13] 2951/18 2952/14 3015/14 resign [1] 2966/13 references [3] 2899/7 2912/6 3061/12 3016/6 3112/2 3135/22 3136/1 3136/3 resignation [2] 2966/15 2985/7 **referencing [1]** 2979/19 resigning [3] 2966/6 2982/19 2983/21 3136/13 3136/15 3136/19 3136/20 referrals [1] 3086/9 3138/21 resolution [1] 2901/1 referred [7] 2911/20 2911/21 2917/15 resolved [2] 2981/6 2981/14 relieved [1] 2976/10 3069/11 3092/20 3100/11 3100/12 rely [5] 3100/10 3105/3 3118/5 3124/22 resources [9] 2993/5 2993/14 3002/7 referring [25] 2883/16 2883/21 2889/13 3131/3 3005/24 3005/25 3008/15 3045/10 2889/18 2889/19 2899/7 2899/23 remain [3] 2885/15 2982/3 2985/24 3045/10 3045/12 2899/24 2917/12 2930/13 2930/20 respect [23] 2898/24 2904/2 2906/20 remainder [2] 2981/11 3134/22 2931/1 2939/7 2942/13 2943/9 2944/24 remained [1] 2969/5 2906/23 2907/11 2919/25 2928/24 2945/9 2945/10 2965/10 3020/15 remains [2] 3048/9 3134/17 2931/17 2935/4 2941/19 2945/8 3020/17 3020/19 3021/3 3021/16 2945/11 2951/15 2951/18 2959/1 remarks [1] 3084/15 3066/1 remember [58] 2916/1 2935/1 2990/20 2965/16 2966/4 2966/18 2980/15 refers [4] 3066/3 3066/5 3081/19 2997/1 3001/9 3002/15 3002/17 2985/14 2988/1 3015/4 3097/17 3081/21 3003/17 3004/20 3006/7 3009/23 respected [1] 3008/18 reflect [2] 2963/19 3124/13 3010/5 3011/15 3011/21 3011/22 respective [3] 2927/12 2927/14 reflection [1] 2892/4 3011/22 3011/23 3012/3 3020/2 3069/21 reflects [3] 2946/15 2946/16 3052/8 3024/11 3028/3 3030/14 3030/15 respond [6] 2883/10 2890/4 2892/6 refresh [8] 2942/4 2942/5 3013/8 3033/15 3033/23 3034/2 3034/3 3034/4 2897/4 2900/6 2901/19 3013/10 3013/14 3013/16 3014/2 3034/11 3034/16 3034/24 3043/5 responded [1] 3015/3 3052/25 3043/6 3043/20 3044/4 3044/6 3044/7 responding [3] 2890/10 2917/17 refreshes [3] 2941/5 2997/16 3025/4 3044/10 3045/6 3045/21 3045/23 3022/8 refunded [1] 2895/6 3046/1 3046/2 3047/15 3049/8 3049/9 response [32] 2883/8 2888/22 2890/13 regain [1] 2983/18 3049/10 3049/22 3054/12 3073/18 2890/19 2891/25 2892/9 2892/17 regard [4] 2951/25 3006/11 3058/24 3080/22 3082/12 3086/15 3089/17 2893/25 2896/11 2897/2 2897/7 2900/9 3073/25 3090/1 3092/15 3092/16 3133/10 2900/10 2901/8 2901/22 2901/23 regarded [1] 2904/6 reminded [1] 2935/19 2902/15 2923/19 2924/11 2924/11 regarding [21] 2879/15 2880/16 reminder [1] 2888/25 2933/19 2959/9 2981/20 2982/8 2881/14 2888/14 2895/1 2937/10 reminding [1] 2935/12 2988/17 2988/18 2997/3 2997/24 2941/14 2942/7 2947/8 2948/20 removal [4] 2981/6 2981/20 2982/14 3022/16 3023/2 3024/11 3122/10 2948/24 2951/19 2963/20 2966/5 2983/24 responsibilities [9] 2960/2 2962/20 2967/3 2976/11 2983/16 2983/24 remove [6] 2951/14 2969/2 2969/15 2993/1 2993/3 2993/11 2994/10 3124/13 3124/14 3137/12 2970/20 2984/22 3009/17 2995/19 2996/2 3110/18 Regards [1] 2924/10 removed [5] 2972/10 2972/16 2973/25 responsible [7] 2908/13 2908/17 regions [1] 2993/13 2974/6 2990/19 2993/12 2993/14 2993/16 2993/17 register [1] 3056/7 removing [3] 2972/5 2974/8 2979/2 3008/5 Registrar [1] 2880/19 rest [8] 2896/10 2916/8 2916/9 2924/13 **Repeat [2]** 3096/19 3131/9 registration [4] 2880/24 2904/22 repeatedly [3] 2899/3 3011/8 3136/11 2951/9 3022/19 3068/22 3138/20 3066/13 3066/15 rephrase [3] 2881/11 2990/15 3008/4 restate [1] 2916/19 registry [1] 2900/2 replace [2] 3042/17 3093/14 restated [1] 2935/17 regular [2] 2908/4 3024/18 replaces [1] 3039/4 restatement [3] 2918/6 2918/10 regularly [3] 2965/13 2996/12 2996/13 report [14] 3021/22 3022/17 3022/24 2918/21 regulatory [2] 2932/20 2932/20 3023/2 3023/8 3023/13 3023/24 3024/2 restaurant [1] 3003/18 rejections [1] 2942/9 3024/11 3025/7 3025/18 3074/7 restaurants [1] 3004/15 rekindle [1] 2988/16 3079/25 3081/15 restore [1] 3042/18 related [14] 2917/5 2921/4 2923/1 reported [2] 2980/14 2980/17 restricted [3] 2880/23 2881/1 2972/3 2947/19 2975/8 2991/9 2991/12 result [3] 2932/21 2953/19 2954/2 **Reporter [1]** 2877/22 2991/15 2991/18 3065/9 3065/12 reporting [2] 2916/21 2957/1 results [4] 2916/20 2980/22 3063/13 3065/15 3065/16 3133/3 reports [10] 3011/15 3011/17 3011/18 3074/5 relating [2] 2975/24 2977/4 3015/18 3017/18 3021/18 3024/6 resume [1] 3139/9 relation [3] 2921/11 2943/6 3052/9 3024/16 3063/12 3109/14 resumed [1] 2907/5 relations [3] 2977/22 2978/10 2993/17 represent [1] 2904/4 retainer [1] 2987/14 relationship [24] 2953/13 2953/18 represented [1] 2918/4 retaining [1] 2919/10 2960/23 2963/11 3011/7 3013/2 3014/9 represents [1] 3114/11 retaken [1] 2907/5 3014/18 3014/19 3015/11 3016/13

Case 1:15-cr-00637-KAM Docu 2888/9-2890/5-2893/2-2897/8-2900/6 2901/20 2913/21 2915/19 2923/14 retire [1] 3052/25 2927/17 2937/7 2942/4 2953/12 2955/3 retirement [1] 2999/9 2977/6 2980/7 2980/14 2980/17 Retrophin [168] 2879/5 2879/6 2879/8 2980/20 2990/5 2990/11 2997/12 2879/15 2880/16 2881/8 2881/14 2997/15 3020/2 3078/3 3090/14 2882/22 2883/5 2884/4 2885/12 3090/21 3091/10 3093/6 2885/16 2885/23 2889/9 2889/13 rid [2] 2968/8 3078/21 2889/19 2891/1 2891/5 2891/12 right-hand [1] 3051/8 2892/12 2892/16 2892/23 2894/1 rigor [2] 2923/7 2962/11 2894/16 2894/16 2894/19 2894/23 rigorous [1] 2930/15 2895/9 2895/14 2897/25 2898/6 Rise [1] 2878/1 2898/24 2902/12 2903/3 2903/13 rising [2] 3099/1 3099/2 2903/18 2903/23 2904/3 2904/20 risk [6] 2930/5 2931/25 2938/19 2939/1 2905/2 2905/7 2905/9 2905/10 2905/16 2939/3 2942/18 2905/18 2905/19 2906/9 2907/8 riskier [1] 2999/18 2907/11 2907/21 2911/5 2917/22 Rivka [1] 2877/22 2917/23 2918/3 2919/1 2920/11 2925/1 RivkaTeich [1] 2877/23 2925/8 2925/12 2925/18 2938/13 RMR [1] 2877/22 2938/19 2941/23 2947/1 2949/11 road [1] 3109/11 2949/12 2949/23 2950/8 2950/9 rock [1] 3019/3 2950/11 2951/11 2951/25 2952/11 rocky [1] 2985/4 2952/19 2953/3 2953/23 2953/25 Rodes [3] 2913/16 2914/1 3078/24 2956/11 2956/16 2960/11 2962/10 **ROHDE [1]** 2877/12 2962/12 2963/4 2964/25 2965/17 role [38] 2895/21 2900/4 2903/21 2967/3 2967/16 2975/24 2977/4 2905/10 2905/12 2906/24 2907/1 2978/17 2981/15 2982/15 2983/25 2907/4 2907/10 2924/19 2958/14 2984/11 2985/15 2986/5 2986/20 2958/25 2959/18 2959/19 2959/25 2987/11 2987/18 2987/20 2987/25 2964/7 2964/9 2964/21 2964/22 2990/19 2991/18 2992/1 2992/5 3033/3 2968/13 2969/3 2969/6 2969/16 3034/5 3034/21 3035/16 3035/21 2969/24 2969/25 2970/14 2970/20 3036/16 3036/22 3038/6 3043/11 2970/22 2979/2 2994/14 2995/22 3043/13 3043/15 3043/23 3044/12 3005/25 3009/25 3052/13 3059/3 3045/3 3045/5 3045/15 3045/25 3046/8 3059/7 3073/15 3088/5 3047/1 3047/14 3047/17 3047/22 roles [5] 2919/3 2963/14 2966/21 3048/14 3049/3 3049/19 3050/4 3066/6 3036/13 3043/19 3066/13 3067/17 3069/5 3069/10 rolled [2] 2907/6 2987/18 3069/16 3069/20 3070/18 3070/25 romantic [7] 3014/19 3016/8 3017/4 3071/8 3071/13 3074/9 3076/25 3077/5 3017/16 3017/23 3017/24 3018/1 3077/6 3077/7 3077/8 3077/9 3077/22 Ron [4] 2907/14 2907/15 2907/18 3077/22 3078/7 3079/20 3080/18 2919/3 3081/6 3081/24 3082/5 3082/7 3085/13 roof [3] 3000/7 3000/8 3002/18 3088/19 3089/9 3119/18 3120/10 room [3] 2933/23 2957/18 3052/25 3120/18 3120/23 3121/8 3121/11 rooms [1] 2926/11 3121/14 Rosenfeld [4] 2920/17 2920/20 3113/4 **Retrophin's [8]** 2879/10 2905/13 3113/21 2918/7 2952/25 2985/20 2987/6 Rosenman [1] 3084/25 3036/25 3076/20 Rosensaft [1] 2952/24 **Retrophin.com** [1] 2983/12 roughly [2] 2998/8 3053/2 return [3] 2936/6 2989/10 3037/8 route [2] 2905/22 2905/22 returned [1] 3125/4 **RPR [1]** 2877/22 returns [4] 2937/3 3107/19 3108/3 rule [2] 2951/17 2953/10 3109/22 ruling [1] 3138/16 reverse [6] 2879/13 2905/8 2905/23 run [7] 2963/24 2964/16 3046/19 3048/18 3048/20 3048/22 3046/20 3086/12 3129/13 3137/25 review [16] 2896/19 2896/24 2908/18 running [8] 2895/14 2964/23 3044/25 2908/21 2909/4 2911/7 2916/11 3045/3 3045/9 3045/13 3096/18 2923/10 2924/17 2945/12 2950/8 3096/20 2979/25 2989/7 3071/10 3104/19 3122/12 S reviewed [2] 2890/14 2897/2 **S1 [15]** 2899/24 2901/4 2901/9 2904/22 reviewing [6] 2915/10 2919/16 2941/8 2905/1 2905/5 3066/13 3066/15 3067/9 3074/4 3074/4 3067/17 3068/21 3070/21 3070/25 revised [3] 2905/5 3060/14 3122/9

revision [1] 2904/25

revisions [1] 2917/5

RICHARDSON [35] 2878/17 2879/3

2880/12 2882/9 2885/18 2885/25

3071/18 3071/19 3072/8

3031/24

3031/4 3031/8 3031/13 3031/23

salesman [2], 3094/17 3105/23 San [1] 2965/20 age ID #. 6682 Sarah [3] 2913/15 2913/25 3078/24 sarcolemma [1] 3042/11 sat [3] 2922/3 2935/9 3014/10 Save [1] 2888/17 saw [19] 2892/16 2893/19 2894/3 2919/23 2956/1 2956/14 2964/14 2973/15 3001/8 3062/18 3066/10 3066/11 3079/12 3080/3 3081/8 3086/9 3107/5 3123/17 3128/12 schedule [2] 2910/18 2948/15 scheme [1] 3135/22 science [2] 3042/22 3042/24 Sciences [1] 3114/9 scientific [2] 3036/8 3043/1 scope [1] 2950/8 score [2] 3119/2 3131/15 scratch [1] 2939/5 screen [7] 3042/4 3050/23 3054/13 3068/4 3072/12 3117/14 3130/12 scroll [4] 2893/18 2901/22 2911/15 2981/4 searching [1] 2938/20 seat [3] 2878/9 3054/1 3054/5 **SEC [43]** 2901/10 2916/14 2918/7 2932/19 2947/8 2947/18 2947/21 2948/1 2948/14 2948/15 2948/20 2949/14 2950/7 2951/3 2951/4 2951/5 2951/6 2951/16 2952/4 2952/5 2952/10 2952/16 2952/19 2952/23 2953/2 2953/20 2953/24 2955/4 2956/2 2958/11 2997/7 2997/21 3063/16 3070/21 3070/25 3072/2 3088/21 3088/24 3089/1 3089/4 3137/12 3137/14 3137/16 SEC's [1] 3063/18 second [22] 2884/17 2894/18 2899/2 2929/13 2976/17 2997/6 2997/11 2997/12 3003/4 3065/8 3067/6 3070/3 3073/21 3098/23 3106/5 3107/15 3107/16 3114/17 3120/6 3123/10 3128/4 3130/6 secondary [1] 3098/8 seconded [1] 2981/5 secondly [2] 2950/12 2971/6 secretary [7] 2935/14 2935/20 2958/15 2980/9 2980/11 2996/9 3085/10 section [14] 2894/11 2895/18 2896/13 2896/17 2912/1 2912/3 2913/2 2913/14 2930/5 2963/25 3070/19 3071/20 3072/9 3074/19 secure [5] 2899/19 2899/21 2925/17 2925/22 2925/23 secured [3] 2911/19 2928/2 2928/3 securing [1] 3050/15 securities [8] 2883/3 2932/22 2947/18 2997/1 3088/9 3097/3 3124/15 3127/19 see [87] 2878/20 2882/20 2889/10 2889/15 2892/21 2897/9 2898/3 2904/19 2910/20 2913/15 2913/16 2919/11 2927/19 2930/4 2932/23 2935/3 2938/7 2941/4 2941/17 2942/1 2962/13 2962/21 2981/8 2984/2 sales [9] 2960/5 3030/22 3031/2 3031/3 2993/10 3012/7 3020/6 3028/11

3028/16 3036/18 3039/2 3042/4

3050/23 3051/12 3052/6 3052/9

&ase 1:15-cr-00637-KAM_Doc September 10 [1] 3130/3 5/17 September 2011 [1] 31/9/1/17 2889/14/2889/18 2889/19 2889/19 2895/23 2896/6 2897/43 2897/193 see... [51] 3052/22 3054/25 3055/5 September 2012 [1] 3129/1 2897/25 2902/1 2902/6 2902/10 3055/8 3055/20 3058/17 3061/9 September 2013 [2] 2914/18 2914/23 2902/11 2902/12 2903/3 2904/2 2904/5 3061/13 3061/17 3063/2 3063/8 September 2014 [2] 2909/10 2985/15 2904/7 2904/9 2904/12 2905/2 2947/3 3063/25 3064/10 3064/19 3065/13 2987/25 2988/6 2988/7 3058/18 3059/2 September 28 [1] 3003/24 3065/20 3067/18 3068/3 3068/13 September 30 [4] 2979/10 2979/18 3059/6 3089/9 3068/20 3069/22 3072/5 3072/12 2984/25 2985/2 sharing [6] 2896/4 2982/6 3030/15 3074/16 3074/21 3075/5 3075/11 September 30th [1] 3073/4 3044/8 3045/12 3084/21 3075/12 3078/4 3078/9 3078/24 3079/3 September 9 [1] 2919/14 sharpening [1] 3005/13 3081/8 3081/20 3082/2 3092/7 3095/24 September 9th [5] 3054/11 3055/23 Shearson [3] 3094/18 3094/19 3094/21 3096/14 3096/15 3107/17 3109/1 shell [4] 3048/24 3048/25 3049/2 3059/10 3128/1 3129/19 3109/14 3109/22 3113/7 3114/18 SeraCare [5] 3111/24 3113/8 3114/9 3049/4 3119/1 3119/2 3119/15 3120/10 3114/10 3114/13 **shielded** [1] 3108/5 3122/14 3131/15 series [11] 2924/15 2962/7 2973/13 **shirt [2]** 3005/11 3096/4 seeing [8] 2889/24 2953/11 3001/9 2978/15 2981/19 3014/1 3020/7 SHKRELI [100] 2877/6 2879/9 2880/11 3011/22 3021/9 3039/22 3079/9 3065/10 3075/2 3116/25 3127/22 2882/11 2885/12 2886/16 2888/11 3079/10 serious [1] 2963/22 2888/14 2889/8 2890/10 2890/19 seek [1] 3107/18 seriously [2] 2906/1 2958/15 2892/6 2893/22 2893/25 2897/4 2897/8 seeking [1] 2948/6 seriousness [1] 2881/6 2898/22 2901/8 2901/19 2907/7 select [1] 2902/2 serve [1] 2981/2 2910/10 2922/6 2927/17 2938/5 selected [1] 2906/22 server [2] 2885/15 2885/16 2938/12 2939/6 2939/17 2939/20 self [2] 2932/20 3052/21 servers [6] 2885/12 2885/13 2885/23 2939/22 2940/13 2941/24 2942/6 self-afflicted [1] 3052/21 2886/16 2984/11 2984/23 2942/20 2943/12 2946/12 2946/23 self-regulatory [1] 2932/20 services [1] 2994/18 2947/13 2948/2 2948/25 2951/11 sell [6] 2881/8 2883/23 2985/8 2985/11 serving [1] 2987/6 2951/14 2951/23 2952/15 2953/13 3049/1 3050/10 2953/18 2953/22 2959/14 2959/17 session [10] 2929/24 2940/2 2940/5 **sellers [1]** 2881/5 2940/6 2940/10 2940/13 2944/17 2961/21 2963/7 2963/20 2967/3 2968/5 selling [4] 2881/14 2960/6 3095/3 2975/4 2977/3 2978/7 2980/15 2980/17 2945/2 2957/17 2959/2 3095/4 sessions [1] 2958/8 2980/20 2980/21 2981/2 2981/6 send [14] 2885/21 2891/9 2892/22 set [11] 2895/16 2924/15 2946/19 2981/10 2983/11 2983/15 2985/1 2904/25 2923/18 2953/3 3011/18 2962/15 2962/18 2963/20 2967/11 2985/5 3001/3 3015/21 3032/16 3011/19 3024/6 3024/21 3028/23 2969/1 2970/4 2978/11 2978/13 3035/24 3038/1 3054/18 3062/25 3090/12 3106/3 3111/17 setting [4] 2946/25 2985/9 3026/8 3069/1 3069/1 3069/6 3069/11 3069/15 sending [7] 2882/13 2963/7 2984/1 3097/6 3069/20 3072/19 3073/9 3073/12 3011/23 3022/16 3022/24 3024/20 3078/2 3082/11 3089/5 3092/4 3095/13 settle [4] 3065/10 3069/18 3075/2 sends [3] 2910/23 3023/8 3027/11 3075/10 3095/22 3095/24 3096/6 3102/12 senior [7] 2906/11 2942/23 2980/18 settlement [29] 2913/15 2916/19 3106/16 3116/6 3120/24 3126/4 2992/19 2992/21 2994/1 2994/9 2917/8 2917/21 2918/3 2918/6 2918/8 3128/18 3136/20 3137/20 3138/11 sense [4] 2904/14 3033/17 3098/23 2918/9 2918/12 2991/10 3066/8 Shkreli's [14] 2883/8 2888/22 2902/15 3104/25 3066/10 3066/11 3066/12 3068/22 2945/12 2953/19 2959/1 2965/16 sensitive [2] 2924/21 3057/5 3068/24 3071/2 3071/3 3071/7 3071/10 2980/16 2980/24 2981/20 2983/23 sent [40] 2882/17 2888/13 2890/10 3074/20 3075/9 3076/13 3077/12 2990/13 3041/8 3137/1 2890/18 2909/8 2919/18 2921/17 short [14] 2972/9 2973/6 2973/11 3077/13 3077/14 3077/18 3077/20 2921/20 2952/19 2988/10 3006/6 3078/23 2976/6 3030/22 3031/2 3031/3 3031/13 3012/2 3012/5 3024/2 3025/7 3055/10 settlements [2] 3078/14 3079/14 3031/23 3097/2 3097/4 3107/20 3108/7 3055/11 3055/16 3055/22 3059/9 3108/8 **setup [1]** 2964/15 3059/10 3061/24 3062/13 3071/25 seven [3] 2952/9 3057/11 3058/6 shorting [1] 3038/1 3077/16 3078/2 3105/19 3110/21 seven-page [1] 3058/6 shortly [1] 2943/8 3111/15 3113/2 3117/14 3122/5 3127/1 several [1] 3102/16 shorts [3] 3097/6 3097/7 3108/5 3127/3 3127/10 3127/16 3127/17 severe [2] 3006/24 3007/1 **show [13]** 2953/19 2997/15 3013/15 3128/13 3128/17 3130/19 3013/16 3020/5 3022/3 3025/3 3034/9 sexual [4] 3015/14 3016/5 3016/10 sentence [5] 2880/18 2896/12 2980/7 3017/6 3057/11 3062/23 3090/4 3136/1 3136/2 3109/16 3120/20 **shaping [1]** 3050/19 showed [2] 2895/23 3024/4 sentences [2] 2892/11 3108/19 share [12] 2902/20 2940/1 2940/4 showing [23] 2879/17 2881/16 2884/6 separate [10] 2898/23 2952/3 2972/13 2940/12 2940/19 2941/2 2945/7 2962/5 2892/25 2909/16 2915/2 2920/22 2972/14 2977/6 2986/15 2987/16 2977/24 2981/22 3009/19 3114/10 2923/11 2926/14 2937/14 2943/14 2987/24 3050/8 3124/8 **shared [10]** 2895/22 2901/6 2903/10 2945/18 2953/6 2979/4 2982/20 3091/5 separately [4] 2978/16 3022/18 3023/1 2904/4 2949/23 2966/7 2969/1 2982/7 3105/6 3106/19 3111/2 3115/10 3024/24 2984/4 3045/11 3121/16 3123/11 3125/22 **September [29]** 2909/9 2909/10 shareholder [7] 2930/25 2931/2 2931/6 **shown [1]** 3113/3 2914/18 2914/23 2919/14 2966/6 2931/22 2939/10 2957/2 2976/8 shows [1] 2952/24 2966/7 2966/14 2966/25 2967/2 shareholders [3] 2917/24 2957/5 shy [2] 2899/13 2899/14 2969/10 2970/5 2979/10 2979/18 3037/8 sick [4] 3008/22 3022/6 3022/6 3022/9 2984/25 2985/2 2985/15 3003/24 shareholding [1] 2883/4 side [9] 2890/23 2960/4 2963/18 3054/11 3055/23 3059/10 3059/16 3042/24 3051/7 3051/8 3108/4 3130/10 shares [36] 2880/23 2880/25 2882/17 3073/4 3080/6 3119/11 3128/1 3129/1 2883/7 2883/12 2883/22 2883/23 3130/10 3129/19 3130/3

standing [5] -2917/10 2917/12 2917/17 2988/11 300 //10 age ID #. 6684 3085/12 3101/16 3102/21 Sase 1:15-cr-00637-KAM Doc sometime [2] 2952/21 2958/14 sidebar [23] 2884/20 2887/11 2888/3 sometimes [5] 3005/3 3009/2 3010/21 stands [1] 2918/23 2950/17 2950/20 2954/10 2971/12 3011/3 3116/18 star [1] 3099/2 2971/15 2976/5 2976/21 3012/16 soon [5] 2937/2 2962/21 3012/7 3027/8 start [17] 2882/9 2888/9 2893/16 3012/20 3019/7 3040/9 3041/20 3027/19 2908/3 2914/6 2915/18 2959/7 2977/22 3099/12 3099/15 3103/22 3112/6 2977/23 2986/23 2989/10 3026/15 sophisticated [3] 2996/24 2997/2 3113/23 3131/25 3132/5 3138/18 2997/22 3026/19 3045/17 3045/18 3048/23 sidebars [1] 3015/25 sorely [1] 2889/2 3114/3 sign [11] 2882/24 2899/20 2899/22 sorry [21] 2879/19 2879/20 2913/11 start-up [5] 3026/15 3026/19 3045/17 2900/3 2900/23 2902/3 2904/22 2905/1 2915/18 2921/6 2942/3 2943/15 2944/9 3045/18 3048/23 2938/21 3115/24 3116/1 2952/23 3026/20 3032/8 3056/19 started [17] 2925/17 2925/19 2957/17 sign-off [1] 2938/21 3069/3 3077/4 3121/9 3126/25 3128/7 2959/4 2978/3 2978/3 2981/18 2982/17 signal [1] 2904/9 3129/19 3131/9 3131/10 3134/21 2984/11 2984/12 2995/21 3002/6 signature [4] 2899/19 2899/21 2946/1 sort [13] 2959/11 2967/7 2986/19 3002/8 3014/11 3030/17 3043/1 3070/15 2988/14 2996/20 3005/10 3026/8 3102/19 signed [4] 2891/2 2901/3 3075/17 starting [20] 2888/22 2893/5 2896/13 3026/13 3030/10 3035/16 3051/5 3115/14 3063/20 3090/25 2923/7 2923/18 2923/18 2929/17 significant [5] 2966/10 2993/20 sound [3] 3022/7 3085/17 3087/2 2947/2 2961/3 2961/3 2963/15 3004/6 2993/21 3039/19 3043/19 **Sounds [1]** 3044/11 3032/8 3034/14 3034/15 3036/12 significantly [1] 2890/14 sourcing [3] 2902/1 2902/5 2902/6 3038/22 3044/6 3048/4 3114/3 similar [2] 3039/6 3098/8 space [3] 2922/23 2957/10 3044/21 starts [4] 2881/24 2884/14 2897/7 similarly [1] 2903/21 speaking [10] 2908/7 2922/20 2937/8 3109/14 simple [1] 3097/15 2981/24 2996/7 3013/21 3022/25 state [9] 2895/13 2895/22 2905/13 simply [1] 2899/5 2911/10 2914/4 2932/21 2934/10 3047/5 3091/7 3091/8 sit [4] 2935/10 2958/7 3021/11 3104/22 **special [1]** 3010/13 2945/3 3093/17 sits [2] 2882/20 3065/25 statement [12] 2880/24 2905/5 3066/15 specializing [2] 3111/21 3114/6 Sitting [1] 3096/2 3109/20 3117/22 3117/25 3119/10 specific [18] 2890/2 2919/3 2950/5 situated [1] 2903/21 2956/13 2965/18 2965/24 2970/21 3120/4 3128/2 3128/21 3129/20 3130/4 situation [6] 2900/11 2924/23 2940/21 2974/23 2996/18 2997/8 3035/11 statements [18] 3066/13 3109/19 3082/14 3087/7 3089/16 3041/14 3066/1 3067/10 3071/20 3110/21 3110/21 3116/24 3117/6 six [6] 2892/12 2892/17 2992/11 3077/14 3080/14 3086/13 3118/2 3118/5 3118/8 3128/12 3128/19 3026/12 3078/8 3094/17 specifically [14] 2949/19 2967/6 3130/15 3130/19 3130/22 3131/3 sixthmanresearch.com [1] 2938/6 3014/17 3024/25 3032/13 3036/20 3131/8 3131/12 3133/5 size [5] 2939/2 2966/13 2970/16 3043/5 3062/16 3080/11 3080/24 states [18] 2877/1 2877/3 2877/3 3121/13 3127/18 3081/21 3082/12 3084/1 3124/13 2877/10 2877/13 2877/16 2881/4 sizeable [1] 2904/5 **specifics [3]** 2955/17 3002/14 3030/16 2888/25 2889/12 2889/14 2916/11 skimmed [3] 3056/1 3056/3 3056/6 speculating [1] 3095/3 2930/7 2932/17 2946/23 2946/24 skin [16] 3012/9 3013/20 3017/1 3018/8 spell [1] 3093/17 2993/13 2995/17 3107/22 3020/3 3020/11 3020/16 3020/19 Spencer [4] 2913/15 2913/25 3078/14 stations [1] 3026/12 3021/3 3021/15 3021/15 3090/22 3078/23 status [4] 2879/15 2907/25 2925/12 3091/9 3092/6 3092/18 3092/21 spend [1] 2999/2 2934/8 sleep [1] 3004/25 spending [1] 2914/9 stay [9] 2959/10 2968/14 2969/15 sleeping [4] 3004/25 3007/19 3030/10 Spielberg [4] 2913/15 2913/25 3078/14 2969/24 2969/25 2970/1 2970/22 3136/14 3078/24 2983/18 3127/7 slept [1] 3007/18 spirit [4] 2900/10 2939/8 2939/13 stayed [1] 2987/22 slightly [2] 2883/24 2883/25 3048/1 staying [1] 2988/15 slot [1] 2927/15 split [1] 2998/7 steeling [1] 2991/15 slowly [3] 2924/24 2924/24 3049/13 spoken [11] 2891/14 2895/1 2922/1 steer [2] 2965/5 2995/17 small [7] 2931/25 2948/7 3026/11 2933/9 2956/10 2971/5 2984/3 2999/20 stellar [1] 2938/24 3027/5 3043/14 3075/7 3127/13 3022/18 3080/23 3100/4 stenography [1] 2877/24 smaller [2] 2883/25 3127/23 step [7] 2891/12 2925/20 2965/24 squarely [1] 2974/9 **SMITH [2]** 2877/15 3138/18 **SR [1]** 2997/14 3049/24 3053/2 3067/1 3067/7 sneak [2] 3062/2 3062/6 Srini [1] 2929/9 stepped [1] 2933/24 snow [1] 2944/23 **Srinivas [2]** 2929/5 2929/6 steps [2] 3039/16 3053/5 social [4] 2935/9 2941/14 3001/14 **SRINIVASAN [2]** 2877/16 3140/6 Steve [38] 2907/1 2908/2 2920/16 3087/7 2925/9 2944/18 2944/21 2957/19 stability [2] 3042/12 3042/18 socializing [1] 3006/25 **stages [2]** 2900/15 2964/15 2957/21 2958/2 2958/24 2959/16 soft [10] 3012/9 3013/20 3017/1 3018/8 stake [2] 2896/7 2896/14 2959/19 2961/10 2961/21 2965/19 3020/3 3020/11 3021/3 3090/22 3091/8 **stakeholder** [1] 2963/25 2965/20 2966/2 2966/21 2968/23 3092/21 stance [3] 2982/17 2984/6 2984/8 2969/10 2969/11 2969/18 2970/3 sole [1] 2938/20 stand [8] 2878/16 2905/25 2990/5 2970/9 2978/14 2978/16 2979/3 solely [1] 2959/25 2990/6 3080/7 3093/10 3093/11 2983/12 2984/15 2984/18 2985/4 **solution [1]** 2899/18 3138/16 3050/25 3054/18 3062/24 3076/1 solutions [1] 2962/11 stand-alone [1] 2905/25 3076/5 3076/13 3078/2 someone [16] 2906/5 2907/15 2947/23 standard [3] 2880/19 2924/15 3124/18 **STEVEN [2]** 2878/17 2983/12 2952/4 3002/12 3010/1 3010/3 3010/6 standards [1] 3049/25 stick [7] 2984/5 3010/11 3027/17 3016/25 3036/4 3062/6 3080/19 3081/9

Ease 1:15-cr-00637-KAM Doci 2937/13 2940/25 2996/18 2920/23, 2923/12 2937/15, 2943/15 submission [2] 2924/212932/10 Page 2945/19 2961/6 2945/5 2982/2085 stick... [4] 3028/8 3041/17 3107/13 submit [3] 2882/15 2883/1 2893/21 3057/18 3064/15 3064/16 3074/12 3124/1 submitted [1] 2899/25 3074/13 3078/10 3105/9 3106/21 sticky [1] 2940/20 subscription [3] 3104/17 3106/7 3106/22 3106/24 3107/13 3111/3 still [20] 2878/20 2899/13 2918/16 3115/11 3117/13 3119/5 3120/1 3115/13 2925/3 2956/11 2956/12 2958/6 2966/2 subsequent [1] 2984/24 3121/18 3123/12 3123/25 3125/23 2968/11 2982/3 2985/20 2987/13 subsets [1] 2996/17 3127/24 3129/14 3129/25 2987/20 2988/6 2988/7 2988/18 2990/7 substance [1] 3088/14 Tab 31 [1] 3123/12 3036/11 3050/1 3095/8 Tab 54 [1] 3057/18 substantial [1] 3133/18 stimulating [1] 2995/14 substitute [1] 2885/8 tab 56 [2] 3064/15 3064/16 stipulate [1] 3096/3 succeeding [1] 3030/24 Tab 6 [2] 3121/18 3123/25 stock [61] 2880/1 2880/16 2880/20 success [3] 2960/18 3031/23 3035/5 Tab 61 [1] 2937/15 2881/8 2881/14 2882/16 2882/18 successful [1] 2994/6 **Tab 63 [1]** 2943/15 2882/19 2882/23 2883/5 2883/19 suffered [1] 3007/5 **Tab 64 [1]** 2945/19 2889/1 2889/15 2889/21 2889/24 suggest [3] 2924/19 3015/10 3102/23 **Tab 66 [1]** 2961/6 2891/3 2891/4 2891/5 2892/4 2892/15 suggested [2] 3014/8 3028/15 **Tab 7 [1]** 3125/23 2894/17 2894/23 2895/25 2898/20 suggesting [2] 3084/20 3137/21 Tab 8 [1] 3127/24 2899/2 2904/25 2971/7 2972/2 2972/18 suggestion [1] 2965/24 table [11] 2883/18 2890/17 2891/21 2973/20 2975/24 2976/6 2976/11 **suggests [1]** 3133/15 2892/5 2895/23 2904/19 2935/9 3034/3 2976/13 2977/4 2977/9 2980/21 sum [1] 3079/5 3050/22 3051/3 3052/20 2981/23 2983/21 2987/13 2987/13 summarized [1] 2980/20 tables [1] 3085/20 2987/14 2987/20 2991/4 2991/6 2992/2 summary [8] 2890/21 2894/15 2900/21 tabs [3] 2915/4 2926/15 3117/1 2992/5 3031/4 3031/5 3031/10 3058/19 talent [2] 2993/7 2993/15 2911/5 2926/24 3036/15 3037/4 3078/8 3059/3 3059/6 3066/16 3080/25 3081/5 summer [10] 2960/11 2960/22 2967/6 tally [1] 2895/10 3086/17 3089/10 3098/4 3114/10 2999/2 2999/2 3000/23 3030/20 tasks [1] 3105/24 3114/13 3030/21 3031/1 3032/2 tax [2] 3109/21 3109/22 stockholding [3] 2891/15 2893/6 summer/fall [1] 3032/2 teach [1] 2939/4 3081/3 Sunil [4] 2917/1 2922/8 3063/1 3072/20 team [12] 2882/16 2906/2 2926/5 stockholdings [2] 2891/23 2901/7 superior [2] 3107/18 3108/2 2931/5 2931/9 2935/8 2938/24 2942/23 stocks [3] 3028/24 3031/5 3038/1 supervise [1] 2992/22 2947/2 2994/20 2996/10 3088/19 stole [2] 2885/4 2951/12 supervising [1] 2993/3 team's [1] 2894/13 stood [1] 2894/14 supply [1] 3039/6 teams [1] 2994/11 stop [3] 2898/9 3038/1 3038/1 support [5] 2881/6 2962/8 2967/8 technical [1] 2983/19 stops [1] 3049/13 technology [2] 2984/22 3036/16 2996/23 3006/19 store [1] 3137/25 teeth [4] 3007/17 3007/19 3030/13 supporting [3] 2926/20 3060/9 3060/9 storm [1] 2944/23 supports [1] 3063/11 3030/14 story [1] 2982/7 supposed [1] 2908/11 Teich [1] 2877/22 straight [1] 2924/17 suppress [1] 2975/21 telephone [1] 3072/25 strained [2] 2960/23 2963/12 telephonic [3] 2908/8 2909/13 2914/25 Surepoint [1] 2895/3 strategic [5] 2892/19 2969/16 2980/19 surprised [7] 2889/25 2889/25 2892/20 ten [4] 2959/11 2996/11 3053/2 3116/25 3111/21 3114/6 2950/7 2973/5 2982/5 3017/13 term [5] 2975/1 2981/11 2983/19 **strategies** [1] 2995/6 surprises [2] 2949/18 2962/7 3111/21 3114/6 strategy [5] 2907/4 2914/7 2914/10 survey [2] 2964/1 2964/1 terminals [1] 3044/24 3048/15 3096/16 surveys [1] 2964/3 terminate [1] 2982/18 stream [1] 2960/14 sustain [2] 3082/19 3131/25 terminated [1] 2885/13 street [3] 2926/11 2968/17 3026/2 sustained [19] 2914/10 3010/18 terms [25] 2897/24 2954/4 2980/24 stricter [1] 2980/23 3012/11 3012/14 3023/12 3032/19 2995/13 3005/12 3009/13 3015/24 strike [3] 2891/6 3099/8 3100/23 3033/14 3037/3 3037/23 3039/11 3035/4 3036/5 3037/6 3037/18 3044/9 striking [1] 3103/21 3040/5 3062/5 3071/5 3076/4 3076/4 3044/11 3045/10 3050/1 3076/24 strong [2] 2922/2 2938/22 3082/1 3084/12 3084/12 3086/6 3086/16 3092/24 3096/13 3098/21 structure [3] 2967/15 2967/20 2996/7 sustaining [1] 2895/21 3098/22 3103/1 3103/1 3118/8 3136/5 struggling [1] 3048/11 swap [2] 2886/8 2887/7 terribly [1] 2899/14 stuck [1] 3016/23 swear [1] 2901/12 testified [10] 2878/18 2907/23 2953/23 studying [1] 3008/15 swing [3] 2972/9 2973/7 2973/11 3017/20 3026/3 3028/22 3028/23 stuff [2] 2945/7 3095/11 3044/15 3093/13 3100/2 swinging [1] 2976/6 stunned [2] 2967/23 2967/23 testify [2] 2885/18 3102/13 swings [1] 3108/6 **style [1]** 3096/15 Swiss [2] 3033/9 3033/12 testifying [3] 2952/5 3014/16 3092/10 Su [7] 2885/4 2885/9 2885/20 2885/20 testimony [11] 2922/25 2951/10 2973/1 switching [1] 3061/15 2886/10 2886/14 3088/18 sworn [2] 2878/18 3093/13 2990/20 3054/12 3079/8 3116/5 subgroups [1] 2996/21 sworn/affirmed [2] 2878/18 3093/13 3136/25 3137/12 3137/14 3137/16 subject [20] 2890/7 2890/9 2891/22 themselves [3] 2923/2 2940/7 3114/21 Syracuse [1] 3094/11 2899/24 2903/6 2932/18 2983/14 thereafter [2] 2943/8 3027/20 systematically [1] 2938/25 3023/6 3023/9 3023/16 3024/6 3027/23 therefore [1] 2902/3 3054/23 3077/13 3092/6 3108/20 thinking [1] 2906/5 3113/8 3114/15 3114/18 3131/23 tab [38] 2879/18 2879/20 2879/21 thinks [1] 3041/12 subjects [10] 2909/23 2915/9 2915/20 2881/17 2884/7 2893/1 2909/17 third [14] 2877/18 2895/1 2929/20 2926/23 2929/15 2930/17 2930/22

3125/16 tweeted [1] 297 Page ID #: 6686 Case 1:15-cr-00637-KAM_Doc 3078/24 Tiled 98/15/12/22 Pag third... [11] 2976/5 2976/17 2976/18 3104/10 3118/5 tweeting [14] 2972/15 2973/10 2974/14 2977/8 3026/25 3065/8 3070/6 3074/11 tracked [1] 2891/11 2974/17 2975/12 2975/14 2975/16 3074/14 3082/17 3106/9 tracks [3] 3045/6 3045/9 3045/12 2975/17 2975/20 2975/22 2976/2 Thirty [1] 2992/11 3083/21 3084/18 3084/19 trade [2] 2881/3 2971/8 Thirty-six years [1] 2992/11 traded [7] 2931/23 2957/2 2972/2 tweets [1] 3084/19 this -- this [1] 2963/6 2972/8 2973/20 2976/11 3095/1 twice [1] 3085/9 thoughts [3] 2888/17 2983/14 3017/22 trader [2] 3094/17 3103/12 Twitter [8] 2941/16 2941/23 2942/16 threatening [1] 3036/17 2974/21 3083/23 3083/24 3083/25 Traderexp [1] 3122/25 three [20] 2895/11 2908/2 2915/5 traders [1] 3094/25 3084/4 2938/21 2963/8 2968/25 2969/3 two [61] 2895/11 2898/4 2901/7 trades [2] 2931/10 2939/5 2970/21 2976/9 2977/6 2990/18 2906/16 2916/14 2922/7 2922/9 trading [36] 2880/23 2881/1 2930/24 2990/18 2995/4 3004/15 3004/18 2930/24 2930/24 2931/1 2931/5 2922/10 2924/1 2927/1 2928/3 2934/16 3011/24 3029/18 3105/9 3106/21 2940/20 2941/1 2941/12 2942/15 2931/10 2931/18 2932/19 2939/10 2939/12 2963/18 2967/14 2967/17 2942/15 2947/23 2950/6 2963/8 2964/2 throughout [3] 2977/14 3101/13 2971/4 2971/7 2971/9 2972/18 2973/15 2965/22 2966/20 2967/12 2968/25 3107/22 2975/8 2975/24 2976/6 2977/4 2980/21 2970/14 2976/4 2977/7 2978/14 thumb [1] 3058/7 2981/23 2981/25 2990/24 2991/1 2985/10 2985/11 2987/2 2987/12 tight [2] 2905/14 2914/7 2995/3 2995/4 2998/10 3001/2 3004/14 2991/3 2991/4 3095/2 3095/5 3095/8 Tilles [3] 2907/14 2907/18 2919/4 3095/12 3103/11 3004/18 3016/11 3016/11 3018/6 Tim [3] 2895/24 2896/2 2896/3 traditional [2] 2996/2 3008/12 3026/12 3026/19 3027/5 3027/15 timeline [3] 2904/17 2964/6 2964/8 traffic [1] 3085/13 3028/1 3028/16 3038/4 3044/9 3050/18 timing [4] 3044/7 3049/8 3130/14 3055/3 3057/23 3059/6 3061/2 3077/16 training [1] 2938/24 3130/21 3086/13 3111/19 3113/5 3117/24 trajectory [1] 2962/13 tips [1] 2953/15 transaction [1] 2899/16 3124/3 title [6] 2882/11 2963/3 2980/11 2993/8 type [14] 2919/2 2957/11 2970/17 transactions [1] 2896/20 3023/5 3056/5 2994/18 2997/7 2999/8 3039/8 3096/16 transcript [3] 2877/9 2877/24 3016/5 today [6] 2923/1 3021/11 3051/7 3096/17 3104/9 3110/18 3117/19 transcription [1] 2877/24 3095/24 3111/22 3114/7 transfer [5] 2880/18 2880/19 2891/14 3125/17 3125/18 today's [4] 2924/9 2924/20 2992/1 types [1] 3084/19 2892/14 3120/21 2992/5 transition [3] 2969/8 2980/18 2984/17 typical [1] 2994/15 together [24] 2902/22 2926/22 2928/17 transparent [2] 2901/9 2956/5 typically [1] 3036/4 2928/18 2934/25 2942/24 2945/17 transparently [1] 2957/5 2960/5 2962/11 2962/25 2963/1 2963/1 traumatic [1] 2968/18 2963/6 2969/21 2985/5 2993/9 2995/18 **U.S [1]** 3108/9 traveled [1] 2944/21 3001/10 3015/18 3016/23 3028/13 ultimately [5] 2904/22 2982/8 2982/11 travels [1] 2888/18 3130/13 3131/3 3137/25 tread [1] 3018/24 2986/1 3048/17 Tom [1] 2978/8 treated [2] 3020/14 3020/14 umbrella [1] 3124/21 tomorrow [5] 2899/20 2899/21 2901/10 treatment [3] 3037/18 3037/18 3049/15 unanimous [1] 2908/12 2901/10 2977/16 treck [1] 2944/19 unanimously [1] 2981/5 tonight [3] 2899/19 2977/16 3009/1 trial [10] 2877/9 2886/11 2973/1 unauthorized [3] 2975/19 2991/9 **Tony [3]** 3000/10 3000/13 3000/15 2991/12 2989/10 3011/25 3031/17 3050/1 took [19] 2883/13 2883/20 2885/24 uncle [1] 3038/9 3050/14 3101/13 3102/19 2896/16 2896/22 2930/2 2949/18 under [16] 2878/20 2913/5 2913/8 trials [1] 2933/17 2970/12 2981/22 2982/1 3016/22 2941/11 2942/1 2945/1 2962/7 2963/25 tried [3] 2899/5 2998/7 3028/13 3029/18 3061/4 3081/12 3095/8 2969/3 2990/7 2992/24 2997/18 3019/3 triggered [2] 3022/20 3088/13 3095/12 3127/17 3137/10 3137/20 trip [2] 2888/15 3029/20 3075/7 3133/25 3136/4 tool [4] 2938/24 2939/4 2939/5 2939/12 trips [1] 3029/17 underlying [1] 3139/4 top [17] 2889/5 2889/10 2899/13 underneath [3] 2889/17 2912/4 2930/7 trouble [1] 3003/11 2899/14 2900/22 2903/18 2903/19 understood [10] 2885/20 2935/15 true [3] 2886/18 3015/11 3045/8 2914/11 2918/21 2918/22 2944/6 2955/22 3013/23 3020/7 3043/10 Trump [1] 3084/9 2946/23 3080/25 3105/19 3111/15 trust [4] 2881/5 2901/25 2902/23 3077/8 3077/19 3083/6 3084/22 3129/17 3130/11 3006/16 undertaken [1] 2986/20 topped [1] 2899/15 undo [1] 2954/3 trusted [2] 3010/2 3042/25 topping [1] 3086/17 unduly [3] 2951/7 2952/14 2954/6 trusting [1] 2892/3 total [10] 2882/20 2889/12 2889/14 unfairly [2] 2973/25 2974/6 truth [1] 3119/22 2894/16 2895/14 2946/19 2987/12 unfortunately [6] 2927/23 2928/10 try [13] 2881/11 2897/22 3016/18 2987/14 3084/19 3089/12 3017/9 3022/14 3028/8 3033/12 2977/12 2978/1 2984/9 3098/2 totally [3] 2956/5 2985/16 3018/25 unique [1] 2938/17 3035/13 3045/24 3046/17 3096/16 touch [6] 2956/15 3012/9 3013/20 3125/20 3126/19 **UNITED [14]** 2877/1 2877/3 2877/3 3020/3 3020/11 3021/2 trying [13] 2882/20 2931/7 2940/21 2877/10 2877/13 2877/16 2993/13 touched [3] 2949/12 3092/21 3092/25 3007/24 3012/6 3018/5 3021/13 2995/8 2995/12 2995/16 2995/16 touching [3] 3017/1 3090/22 3091/8 2995/20 2996/3 3107/21 3037/10 3062/2 3062/6 3068/20 toward [3] 3078/13 3078/23 3083/20 units [3] 2889/13 3120/22 3120/22 3098/23 3125/16 towards [4] 2964/21 2967/5 3035/4 tune [1] 3082/7 University [1] 3094/11 3050/14 unpaid [1] 3065/18 turn [4] 2922/12 3058/22 3107/14 Trachtenberg [3] 2913/16 2914/1

very-well [1] 31,15/4 verted [3] 30,14/223014/253075/5Page Base 1:15-cr-00637-KAM Doci 2937/13,2940/17,2940/18,2942/23 2949/17 2973/13 2993/18 3003/13 unusable [1] 3042/14 vibes [1] 3006/5 3003/15 3015/13 3017/11 3022/22 unusual [1] 3130/14 Vice [2] 2992/19 2992/21 3022/23 3036/25 3066/7 3067/20 unveil [1] 3036/12 3069/25 3075/21 3076/23 3079/16 view [5] 2904/12 2993/14 3007/22 unveiled [1] 3035/16 3080/8 3081/11 3100/24 3109/10 3044/9 3045/9 up [77] 2878/3 2885/22 2892/15 viewed [3] 2904/8 3010/3 3047/13 wild [1] 3108/6 2893/18 2897/6 2899/13 2899/14 willing [7] 2904/13 2948/10 2969/2 Village [3] 3000/5 3002/18 3003/19 2899/15 2900/22 2901/22 2903/4 violation [1] 2932/21 2969/12 2988/19 2999/18 3000/1 2903/18 2903/19 2906/2 2906/3 virtually [2] 3085/14 3085/15 willingness [1] 3136/16 2910/23 2914/10 2922/5 2934/6 visible [1] 3043/22 winding [1] 2903/12 2938/18 2953/19 2956/4 2957/25 vision [4] 2900/11 2947/3 2995/24 window [3] 2960/22 2986/21 2991/5 2965/4 2966/6 2968/10 2970/4 2972/8 3052/8 windows [1] 2971/9 2972/15 2973/6 2973/13 2973/15 vital [1] 3042/12 winner [1] 2892/16 2978/11 2978/13 2985/9 2985/24 Vivo [4] 3045/21 3046/6 3047/6 winter [1] 2944/19 2995/10 2996/4 3000/1 3000/3 3003/6 3047/24 withdraw [2] 3102/17 3108/19 3005/22 3026/15 3026/19 3031/5 voice [1] 2994/12 withdrawals [1] 3108/17 3039/12 3043/3 3045/17 3045/18 volatile [1] 2982/19 withdrawn [2] 3084/13 3102/8 3046/9 3047/11 3047/18 3047/19 volatility [3] 3097/22 3107/20 3108/6 withdrew [4] 3101/19 3101/21 3102/15 3047/20 3048/14 3048/23 3050/19 volume [1] 2960/17 3103/2 3065/4 3065/10 3066/6 3068/2 3068/3 volumes [1] 2942/16 witness [39] 2878/13 2878/16 2878/16 3068/20 3073/21 3075/2 3076/17 voluntarily [1] 2947/21 2878/17 2937/3 2952/8 2953/9 2968/4 3078/20 3079/15 3080/25 3081/20 voted [1] 2965/6 2975/9 2976/1 2990/5 2990/6 3014/16 3086/17 3099/4 3102/3 3102/16 3127/2 3015/3 3015/10 3016/19 3017/9 3041/9 3133/8 3135/10 3053/5 3054/2 3066/25 3067/2 3067/9 update [5] 2910/18 2933/15 2933/17 wait [2] 2904/13 2904/16 3068/10 3090/17 3093/8 3093/11 2945/3 3024/24 waiting [3] 2891/24 2904/9 2984/2 3093/11 3093/12 3100/1 3113/5 updated [1] 3124/12 waive [3] 2885/7 2886/5 2888/3 3113/18 3134/21 3134/24 3136/3 updating [1] 3033/5 waiving [3] 2886/9 2886/24 3103/20 3136/7 3136/9 3136/18 3140/2 upset [2] 2903/9 2933/18 walk [1] 2959/5 witness's [1] 2973/1 upside [2] 2891/1 3108/4 walked [1] 3001/12 witnesses [6] 2974/25 3015/23 3102/13 urge [1] 3122/12 walking [2] 2958/6 2959/3 3136/12 3137/8 3137/15 urgency [1] 2882/16 Wall [1] 3026/2 woman [1] 3016/11 useful [1] 2939/12 wants [5] 2939/13 2941/19 3014/2 women [1] 3016/11 3014/2 3016/16 wondering [1] 3052/23 warned [2] 2974/16 2974/17 word [10] 2973/20 2986/10 2997/5 vacated [1] 2907/4 was -- it [1] 3121/3 2997/23 3009/11 3010/8 3010/20 vacation [4] 2965/11 2999/3 3028/6 was -- that [1] 2955/16 3037/17 3104/22 3104/22 3029/10 waste [1] 2928/21 words [5] 2900/14 3010/11 3013/5 vagrant [1] 3136/15 watching [1] 2885/21 3052/17 3105/2 vague [1] 2933/19 Water [2] 3004/11 3004/12 work.' [1] 3041/10 Vaino [2] 3043/21 3050/18 ways [4] 2930/16 2970/14 3005/18 works [2] 3041/15 3042/22 Valeur [6] 2909/1 2909/4 2979/24 3007/24 world [7] 2947/2 2992/13 2994/4 2980/8 2980/9 2985/18 weak [1] 2968/8 2995/16 3008/3 3107/22 3108/9 Valeur-Jensen [3] 2909/1 2979/24 wearing [1] 3096/4 Worldwide [1] 2995/8 2985/18 weather [1] 2944/19 worried [2] 2974/22 3131/1 valuable [1] 2970/2 website [2] 3063/18 3072/2 worry [1] 3076/1 valuation [2] 2895/16 2898/8 weed [1] 3034/5 worth [2] 2896/7 2896/15 valuations [1] 2898/6 week [14] 2910/18 2939/21 2944/16 worthwhile [4] 3031/10 3037/12 value [12] 2882/20 2891/23 2954/4 2944/17 2945/5 2945/9 2956/14 3038/18 3038/19 2987/14 2987/18 2992/1 2992/4 2992/5 2967/12 2969/9 2969/14 2984/1 2984/6 write [15] 2889/21 2891/17 2894/4 3031/25 3046/18 3124/23 3130/6 2984/9 2984/19 2894/11 2894/22 2895/5 2895/10 valued [1] 3052/13 weekend [3] 3014/16 3029/9 3029/19 2895/19 2902/18 2924/11 2944/16 various [6] 2889/9 2926/25 2944/11 weekends [1] 3029/8 3020/10 3090/7 3126/11 3126/13 2985/3 3030/22 3135/19 weeks [6] 2934/16 2967/12 2968/12 writes [6] 2889/17 2898/22 2910/17 vehicle [1] 2939/12 3027/10 3027/11 3027/16 2924/8 2938/12 2983/15 venture [11] 2905/22 3046/4 3046/7 weird [1] 3022/7 writing [6] 2887/6 2924/13 3051/14 3046/11 3046/14 3046/17 3046/24 Wells [1] 2992/18 3051/21 3078/16 3078/17 3047/1 3047/6 3047/24 3124/16 West [1] 3029/18 written [10] 2890/23 2892/21 2901/14 Ventures [2] 3045/21 3047/6 whatsoever [1] 2881/5 2908/12 2945/7 3031/22 3098/6 venue [2] 2926/10 2926/10 where/when [1] 2896/21 3108/25 3109/5 3137/18 verbal [2] 2883/17 2890/22 whereas [5] 3069/11 3069/13 3069/14 wrote [7] 2882/12 2896/4 3010/24 verbally [4] 2896/5 3021/9 3024/24 3069/15 3069/17 3011/2 3047/15 3126/14 3126/21 3051/19 whereby [1] 3065/16 version [7] 2886/7 2886/9 2886/22 wherewith [1] 3113/6 2886/25 2887/5 3064/3 3078/16 white [1] 3096/4 Yaffe [2] 2920/2 2920/14 versus [4] 3031/2 3031/23 3051/3 whole [27] 2889/6 2909/8 2918/3

3133/23

year [24] 2906/3 2906/17 2906/18

Kase 1:15-cr-00637-KAM Docu	ımont 215	Eilod 09/15/17	Dage 20	7 of 207 PagoID #	4. 6600
year [21] 2906/18 2908/3 2914/6	IIIIeIII 212	Filed 00/13/17	raye 29	11 01 291 PayelD +	+. 0000
2929/7 2945/25 2946/9 2946/17 2957/7					
2964/20 2983/3 2993/4 2999/21 3034/6					
3067/19 3067/21 3080/23 3094/9					
3095/11 3109/17 3109/19 3110/4					
year's [1] 2985/25					
year-and-a-half [1] 3095/11 years [17] 2992/11 2993/23 2998/22					
2998/22 2999/6 3002/13 3002/17					
3004/15 3005/9 3005/9 3017/13 3018/4					
3029/25 3060/12 3094/5 3094/22					
3095/9					
yesterday [20] 2879/5 2879/14 2895/2					
2999/12 2999/25 3002/23 3005/12					
3011/14 3017/17 3026/3 3028/22					
3031/19 3032/5 3035/5 3035/21 3036/2 3044/15 3045/5 3089/16 3100/21					
YORK [9] 2877/1 2877/4 2877/13					
2877/14 2877/19 2877/19 2924/14					
2998/9 3094/1					
young [6] 3008/17 3008/18 3026/19					
3027/5 3027/15 3049/12					
younger [4] 2941/18 3026/25 3084/6					
3084/10 yourself [12] 2880/12 2888/10 2922/6					
2944/12 2983/11 2997/19 3019/5					
3020/9 3022/10 3052/25 3092/4 3100/8					
Z					
ZELLAN [3] 2877/20 2944/10 3130/9 zero [1] 2891/1					
zoom [8] 2889/5 2910/22 2913/1					
3107/16 3111/19 3120/9 3124/6					
3130/10					